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SUMMARY
The Thl cytokines interleukin 12 (IL-12) and interleukin 18 (XL-18) are important 
mediators o f  the cell-mediated immune response. Separately, both cytokines act on T 
and natural killer (NK) cells and stimulate the production o f interferon gamma (IFNy). 
These molecules can also act synergistically on their effector cells to produce a 
dramatic IFNy response. IL-12 is important in the differentiation and proliferation o f  
T helper type 1 (Thl) cells, while IL-18 increases Thl proliferation and XL-12-driven 
Thl development. The role o f  these interleukins in the cellular immune pathway has 
led to their use as adjuvants to vaccines that require strong cell mediated immunity.
A previous vaccination trial investigated the use o f various feline cytokine constructs 
in their role as adjuvants to a DNA vaccine to feline leukaemia virus (FeLV) [Hanlon 
et a l  2001]. This study demonstrated that cytokine plasmid constructs encoding XL-12 
and XL-18, together elicited complete protection from viraemia and significant 
protection o f animals from latent proviral infection. In vitro analysis o f these cytokine 
constructs prior to use in vivo, failed to detect IL-18 protein expression by Western 
blot analysis. In addition, suitable assays for measurement o f in vitro bioactivity o f  
these constructs were not available at that time.
The preliminary work for this project focused on the development o f improved feline 
IL-12 and IL-18 constructs and demonstration o f in vitro expression and bioactivity. 
IL-12 may be administered using separate plasmids encoding the subunits p35 and 
p40, which can potentially lead to several problems. Firstly cells must take up both 
plasmids in order to produce bioactive IL-12 heterodimer. Also the overproduction o f  
p40 subunit is a potential risk, as p40 homodimer molecules can produce antagonism 
o f the heterodimer by binding to the IL-12 receptor and rendering it inactive. A new 
construct was therefore developed linking the cDNA o f each subunit by a synthetic 
linker sequence which overcomes these potential problems. The in vitro expression o f  
this feline flexi-IL-12 construct was demonstrated by Western blot analysis. Specific 
in vitro bioactivity was then shown using the dose dependent production o f IFNy from 
equine lymph node cells.
IL-18 is synthesised as a biologically inactive precursor molecule pro-IL-18, which is 
cleaved within the cell by the protease caspase-1 to produce bio active mature-IL-18. 
This molecule then possesses the natural signalling peptide required for extracellular 
secretion. Inoculation o f  pro-IL-18 plasmid therefore must rely on the presence o f  
endogenous caspase-1 for protein secretion. Immunisation with mature-IL-18 
produces protein that lacks a signalling peptide and is inefficiently secreted from the 
cell. For these reasons, a construct was produced which encoded feline mature-IL-18 
fused to a synthetic signal peptide IL-1(3 receptor antagonist protein (ILRAP). 
ILRAP-IL-18 in vitro protein expression was analysed by Western blot analysis. It 
was found that unlike pro- and mature-IL-18 constructs, the ILRAP signal peptide 
facilitated secretion from the cell and further, was associated with higher relative 
expression than the previously used IL-18 expression construct. Secreted ILRAP-IL- 
18 was also shown to be bioactive by measuring the specific dose dependent 
production o f  human IFNy from KG-1 cells. In addition, the feline IL-18 receptor was 
amplified from the total RNA o f MYA-1 cells. Development o f KG-1 cell lines 
expressing the feline IL-18 receptor should enable production o f a more sensitive 
feline IL-18 bioassay.
In order to establish the in vivo activity o f these new constructs, a vaccination trial 
was performed using an FeLV DNA vaccine. This vaccine consisted o f  two plasmids, 
one expressing gag/pol and the other expressing envA o f  FeLV and preliminary work 
confirmed their protein .expression by Western blot analysis and fixed cell 
immunofluorescence. Apart from new plasmid constructs, two main modifications to 
the previous trial were made. Firstly, a more natural oronasal FeLV-A/Glasgow-1 
viral challenge was used where previously the virus was administered into the 
peritoneum. Also, vaccine groups comprising the cytokines in combination and each 
alone were used in order to establish if  protection from viraemia was due to IL-12 and 
IL-18 acting in synergy or whether the effect was due to either interleukin alone. It 
was found that the vaccine with ILRAP-IL-18 and the vaccine group with both 
cytokines elicited complete protection against FeLV viraemia. Feline flexi-IL-12 
alone as an adjuvant was not found to be effective. The vaccine with ILRAP-IL-18 
alone also produced significant protection against latent infection. This suggests that.
IL-18 was acting as an effective adjuvant to the FeLV DNA vaccine and that IL-12 
was not an effective adjuvant and may even be producing an inhibitory effect.
Finally, four persistently viraemic animals from the control group were inoculated 
three times at weekly intervals with the DNA vaccine and ILRAP-IL-18. Periodic 
blood samples were taken in order to establish if  this vaccine combination would 
provide any immunotherapeutic effect in terms o f FeLV viral status and proviral load. 
The use o f this vaccine demonstrated no beneficial effects on the parameters 
measured.
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CHAPTER 1: INTRODUCTION
1 INTRODUCTION
1.1 DNA vaccination
1.1.1 Introduction
The development o f DNA vaccination originated from the discovery that injection o f  
DNA expression vectors into mouse skeletal muscle generated the expression o f  
protein without the requirement o f  a delivery system [W olff et a l  1990]. Long-term 
persistence o f  injected plasmid DNA in mouse muscle was subsequently 
demonstrated by quantitative PCR [W olff et a l  1992]. Soon after, it was found that 
plasmid DNA could be introduced into the skin o f mice, by propelling DNA-coated 
gold microprojectiles directly into murine skin cells using a gene gun. An immune 
response against the expressed protein was also detected [Tang et a l  1992]. 
Subsequently, protection against challenge with lethal influenza virus was 
demonstrated by injection o f chickens by intravenous (IV), intraperitoneal (IP) and 
subcutaneous (SC) injection with a haemagglutinin-expressing plasmid [Robinson et 
a l  1993]. Robinson et al. showed that two inoculations o f  lOOjag DNA plasmid 
injected 4 weeks apart was sufficient to induce protection against viral challenge. This 
was the first demonstration that an antigen-expressing plasmid could be used as a 
DNA vaccine.
This first trial led to further investigation into this new concept in vaccinology. 
Inoculation via parenteral, mucosal and gene gun delivery induced protection against 
influenza virus in chickens and mice [Fynan et a l  1993]. Also, stimulation o f strain- 
specific cytotoxic T lymphocytes (CTLs) to influenza A nucleoprotein DNA [Ulmer 
et a l. 1993] and production o f  anti-human immunodeficiency virus (HIV) 
neutralising antibody [Wang et a l  1993] were demonstrated in trials in mice. This 
confirmed that both branches o f the immune response may be stimulated by DNA  
vaccination.
This preliminary work has led to the development o f DNA vaccines encoding 
antigens against a wide range o f  pathogens, including viruses, bacteria and parasites.
Additionally, plasmids encoding tumour antigens have also shown potential in tumour 
immunotherapy.
Up to date information on genetic immunisation can be found on the DNA vaccine 
website. The address is http://www.dnavaccine.com/
1.1.2 Design of DNA vaccine plasmid vectors
1.1.2.1 Basic plasmid design
The basic plasmid design for a DNA vaccine is shown in figure 1.1. A DNA vaccine 
consists o f a plasmid that encodes an antigenic portion o f a pathogen. The backbone 
o f the plasmid is similar in structure to an in vitro expression vector. The basic 
elements that form this backbone may be split broadly into two groups. Firstly, 
replication and selection o f the plasmid during bacterial culture dictates that a 
bacterial origin o f replication and an antibiotic resistance gene are required. The 
second group consists o f  elements that assure efficient and maximal expression o f  
antigen. These consist o f a strong promoter suitable for expression in eukaryotic cells, 
a multicloning site for antigen cDNA insertion and a mammalian polyadenylation 
signal for efficient transcription termination. Also, the inclusion o f CpG motifs has 
been shown to enhance immunogenicity which will be described later in the section.
Figure 1-1 Basic design o f DNA vaccine plasmid
IN VITRO EXPRESSION VECTOR
Multicloning site Multicloning site
Promoter
Several promoters have been used to maximise the antigen expression o f  plasmid 
vectors. Reasonable expression has been shown using Simian virus 40 (SV40) 
[Moreau et a l  1981] and Rous sarcoma virus (RSV) [Gorman et a l  1982]. However, 
by far the highest gene expression has been demonstrated using the cytomegalovirus 
(CMV) immediate early gene promoter [Boshart et a l  1985]. The strength o f this 
promoter was further enhanced by the inclusion o f  the first intron (intron A) o f the 
immediate early gene [Chapman et a l  1991].
Polyadenylation signal
Two polyadenylation signals are used most frequently. These are the bovine growth 
hormone (BGH) and SV40 signals. A study has shown that BGH in combination with 
a CMV promoter and intron A elicited high expression o f influenza A haemagglutinin 
and nucleoprotein antigenic protein. When used in vivo this plasmid protected mice 
from lethal challenge [Montgomery et a l  1993].
1.1.2.2 Further development of DNA vaccine design
Following the basic plasmid design described above, recent work has identified new 
features o f  the plasmid that are able to enhance or customise antigen expression still 
further.
Multiple gene expression
In certain cases it is necessary to simultaneously express two genes within the same 
plasmid. This has been made possible using bicistronic vectors. These vectors 
incorporate an internal ribosome entry site (1RES) between the two genes [Clarke et 
a l  1997]. Co expression o f genes has also been investigated using the linear 
arrangement o f separate promoter, gene and polyadenylation sites within the same 
vector [Iwasaki et a l  1997]. In this case it was found that co expression o f B7-2 
enhanced the epitope-specific CTL response to a non-immunogenic influenza 
nucleoprotein-encoding vector.
Directing antigen processing
In the cellular processing o f an encoded protein, a limiting factor in the expression o f  
MHC I complexes is the peptide concentration in the endoplasmic reticulum 
[Ortmann et al. 1994]. The generation o f peptides for MHC I presentation takes place 
within the proteasome. Proteins can be targeted to the proteasome by a covalent link 
to the cellular protein ubiquitin. A study has shown that intracellular protein 
degradation o f a lymphocytic choriomeningitis virus nucleoprotein is enhanced by 
fusion with the gene encoding ubiquitin. Injection o f the DNA vaccine construct 
covalently linked to ubiquitin produced enhanced anti-viral CTL induction and 
protection, compared to nucleoprotein alone [Rodriguez et al. 1997].
Vaccines have also been designed where the antigen protein is directed towards sites 
o f  immune induction by fusion to certain ligands. In one example, two ligands were 
used, L-seleetin and cytotoxic T-lymphocyte antigen. These are concerned with 
initiating entry to lymph nodes and binding to antigen presenting cells (APCs) 
respectively. These enhanced cellular immune responses in mice and by directing 
antigens to APCs, hastened the appearance o f  an immune response [Boyle et al. 
1998].
Plasmids containing cDNA libraries
The concept o f DNA immunisation has been broadened by using cDNA library 
fragments [Barry et al. 1995]. A cDNA library preparation o f Mycoplasma pulmonis 
was found to confer protection in a mouse challenge model. It was postulated that 
approximately Ing o f DNA plasmid was required to elicit an immune response by 
genetic immunisation in mice. Each inoculation used l-4 |ig  o f DNA and libraries 
containing 10^ -10"^  members were used [Barry et al. 1995]. The advantage o f this type 
o f  approach is that an immune response may be elicited to a variety o f antigenic 
genes. It also affords a means o f  screening for antigens most effective in providing 
immune protection for a particular pathogen.
Cell specific promoters
The use o f promoters that direct the synthesis o f antigen protein in certain cells has 
been investigated [Xiang et al. 1997]. In this study, vectors were constructed 
expressing rabies virus glycoprotein under the control o f  MHC I and MHC II 
promoters. The MHC I promoter has broad tissue specificity and the antigen under 
control o f this promoter developed an immune response in mice comparable to a 
vector using SV40 promoter. The MHC II promoter restricts antigen expression to 
cells that express MHC II molecules such as dendritic cells (DCs), macrophages and 
B cells. Use o f this promoter resulted in a relatively weak immune response against 
the DNA vaccine concerned.
Cytokine enhancement o f DNA vaccines
Cytokines have been fused to antigens and have been incorporated into multigene 
expressing vectors. Depending on the cytokine used, this has been used to enhance or 
bias the immune response to the antigen [Iwasaki et al. 1997]. Use o f  cytokines as 
adjuvants to DNA vaccines will be discussed in subsequent chapters.
Use o f CpG motifs
Recent interest has been shown in the use o f immunostimulatory DNA sequences 
which may be used to enhance the performance o f DNA vaccines. This idea emerged 
from the report that bacterial DNA can activate NK cells and stimulate interferon 
(ÏFN) production and tumour regression in certain mouse models, whereas vertebrate 
DNA does not [Tokunaga et al. 1984]. Further work showed that in contrast to 
vertebrate DNA, bacterial DNA could also stimulate B cell proliferation and 
immunoglobulin secretion [Messina et al. 1991]. Cytosine-phosphate-guanine (CpG) 
dinucleotides appear in microbial DNA at the expected frequency o f 1 in 16, but are 
suppressed in the DNA o f vertebrates, being present four times less often than in a 
random mix o f bases. Also, CpG dinucleotides o f bacteria contain mostly 
unmethylated cytosine, whereas vertebrate CpG consists o f mainly methylated 
cytosine. A study using microbial DNA and synthetic oligodeoxynucleotides 
containing unmethylated CpG dinucleotides induced proliferation o f murine B cells 
and secretion o f  immunoglobulin [Krieg et a l  1995]. This effect was not seen in the
same oligonucleotides lacking CpG dinucleotides, or where the CpG contained 
methylated cytosine. B-cell activation was found to be optimal when the CpG 
dinucleotide was flanked by two 5' purines and two 3' pyrimidines and this pattern 
has been termed a “CpG motif.”
This has led to the theory that the immune system has evolved a way o f  detecting 
bacterial DNA and eliciting an appropriate immune response. The precise immune 
mechanisms against CpG DNA have since been explored. CpG DNA significantly up- 
regulates the expression o f  MHC II, CD86 (on circulating monocytes and activated B 
cells) and IL-12 in mouse DCs [Jakob et a l  1998]. This produces a corresponding 
enhancement o f B and T-cell stimulation against these motifs. CpG DNA activates 
several signalling pathways in B cells that amongst other effeets, induces secretion o f  
IL-6, IL-10 and immunoglobulin [Yi et a l  1996; Redford et a l  1998]. Also, CpG 
DNA stimulates the maturation and activation o f DCs and the conversion o f immature 
DCs into professional antigen presenting cells (APCs) [Sparwasser et a l  1998]. 
Similar effects have been demonstrated on monocytes, macrophages and NK cells. 
The CpG motif induces lytic activity o f  NK cells in mice both in vivo and in vitro and 
stimulates an interferon gamma (IFNy) response [Balias et a l  1996; Cowdery et a l  
1996]. The induction o f  lysis was found to be T and B cell independent and initiated 
indirectly by the secretion o f IL-12, IFNot and p, and tumour necrosis factor alpha 
(TNFa). More recently, a CpG pattern recognition receptor, toll-like receptor-9 
(TLR9) on DCs and other haematopoeitic cells has been identified [Hemmi et a l  
2000]. In this study, cells deficient in TLR9 were found to be unresponsive to CpG- 
containing DNA.
Having established that CpG DNA not only stimulates an immune response but biases 
the reaction towards Thl type immunity, these sequences have been found to be 
potentially beneficial in improving DNA vaccine efficacy. This was initially 
confirmed intradermally in mice using a kanamycin based P-galactosidase vector. 
Vectors containing CpG sequences induced a stronger antibody response than vectors 
deficient o f  CpG DNA [Sato et a l  1996]. The CpG containing vector was shown to 
transcribe large amounts o f IFNa, p, and IL-12 in vitro. Additionally, CpG sequence 
suppressed IgE synthesis and promoted IgG, IFNy and IL-18 production [Roman et
a l  1997]. Subsequently, CpG DNA has been shown to induce resistance to Listeria 
monocytogenes infection in BALB/c mice [Krieg et a l  1998]. The potential potency 
o f CpG DNA administered alone or in a DNA vaccine has also been demonstrated. 
Davis et a l  showed that in mice, CpG oligodeoxynucleotides enhanced by five-fold 
the antibody response to a recombinant hepatitis B vaccine compared with a 
conventional adjuvant aluminium hydroxide [Davis et a l  1998].
The use o f CpG motifs has been studied in various other species including primates. 
CpG DNA was used in combination with a commercial vaccine in an outbreak o f  
hepatitis B in orangutans. Orangutans are hypo-responsive to this vaccine, but 
addition o f CpG oligodeoxynucleotides greatly enhanced the seroconversion rate and 
antibody titres produced [Davis et a l  2000]. Also, eynomolgus monkeys 
intramuscularly injected with an HIV/SIV (SHIV) ^a^-expressing vector containing 
CpG sequences were protected against challenge with a highly pathogenic strain o f  
the virus. Interestingly, monkeys injected with a CpG containing vector alone were 
partially protected, showing positive virus isolation but negative virus replication 
[Cafaro et a l  2001].
Preliminary feline and canine studies using CpG have also demonstrated enhanced 
immune responses. Peripheral blood mononuclear cells (PBMCs), lymph node cells 
and spleen cells were taken from dogs and cats and exposed to CpG sequences. 
Lymphocyte proliferation was observed in both lymph node and spleen cells but not 
in PBMCs [Wemette et a l  2002]. Also, the use o f a CpG sequence in a minimalistic 
immunogenic defined gene expression vector (MIDGE) containing gp l40 o f FIV 
significantly reduced viraemia in cats compared to the use o f a gp 140 vector alone. 
This response corresponded with CTL activity as well as enhanced IL-12, IFNy and 
IL-10 from PBMCs taken from these cats [Leutenegger et a l  2000].
1.1.3 Delivery of DNA vaccines
1.1.3.1 Route of administration
A DNA vaccine may be administered in several ways and the route o f  delivery can 
have an important influence on the level and the type o f  immune response elicited. 
The three most common routes o f administration are intramuscular injection, 
intraepidermal delivery via a gene gun, and intradermal injection. Mucosal delivery 
via nasal, lingual, oral or vaginal routes has also been investigated as well as 
intrasplenic [Gerloni et a l  1997] and intrahepatic immunisation [W olff gf a/. 1997].
Needle injection and gene gun
Vaccines designed for hypodermic inoculation o f muscle or skin are usually 
suspended in saline or a saline mix containing a facilitator such as the anaesthetic 
bupivacaine, designed to increase uptake o f DNA. Davis et a l  showed that injection 
o f  DNA vaccine into muscle pre-treated with toxins or bupivacaine stimulated a 10- 
fold increase in antigen-expressing muscle cells and an enhanced immune response 
[Davis et a l  1995]. This mode o f  administration induced long-lasting immune 
responses without the requirement o f booster injections [Davis et a l  1996]. It is 
thought this may be because mature muscle fibres are post-mitotic, resulting in long­
term persistence and expression o f episomally situated DNA.
Gene gun inoculation is most commonly administered intradermally, although the 
intramuscular route has also been used. The gene gun uses plasmid-coated gold 
particles, which on penetration o f dermal cells allow solubilisation o f  plasmid DNA. 
This method o f delivery transfects 20% o f  cells in the target area o f the vaccine 
[Williams et a l  1991] and tissue stress resulting from inoculation possibly contributes 
to activation o f  DCs. It has been consistently shown that in comparison to needle 
injection, gene gun immunisation is more efficient, eliciting a comparable immune 
response with 100 to 5000-fold less DNA [Pertmer et a l  1995]. However, there is no 
empirical evidence to suggest that gene gun-based vaccination produces longer-term 
responses or superior protection against challenge than needle injection, even when 
larger doses o f DNA are used [Barry et a l  1997].
In terms o f  the practical application o f  these two routes o f  administration, needle 
injection provides a cheap, simple and effective way o f introducing the vaccine into 
the host. However, as previously mentioned, much larger amounts o f  DNA are 
required in order to induce a satisfactory level o f immune response. This may be 
because the needle introduces DNA into extracellular spaces exposing it to nucleases 
from the interstitial fluid. Alternatively, the increase in hydrostatic pressure in the 
muscle from intramuscular inoculation may result in DNA being driven out of 
protein-producing cells decreasing protein expression.
Conversely, the gene gun route is itself limited by the small amount o f DNA that can 
be introduced per inoculation. Administration o f any more than 2.5|Xg at once can 
produce clumping o f vaccine microparticles, which increases damage o f  the target 
tissue. Also the gene gun itself is expensive and requires inoculation into hairless skin 
that can lead to problems, especially in terms o f veterinary use. These issues are being 
addressed currently by development o f new generation guns.
Profound differences in the nature o f  immune responses elicited by gene gun and 
needle injection have been observed. Intramuscular injection tends to produce a 
mainly Thl type immune response, with a higher IgG2a:IgGl ratio, increased IFNy 
production and low IL-4 production. This route o f delivery therefore biases the 
immune system towards a cell-mediated response. Gene gun inoculation however 
tends to stimulate a Th2 orientated response and therefore humoral immunity, 
producing higher quantities o f IgG l, less IFNy and more IL-4 [Pertmer et al. 1996]. 
The gene gun can elicit a more Thl type response with the co administration o f  
cytokine genes such as IL-2, IL-7 and IL-12 [Prayaga et al. 1997]. In the case o f  
intradermal injection, both Thl and Th2 immune profiles have been reported [Pertmer 
et al. 1996; Raz <3/.  1996].
A possible reason for this variation may be due to the amounts o f DNA used in each 
case. Barry et al. 1997 demonstrated that when equal small amounts o f DNA are used 
for both routes o f administration, a predominantly Th2 response is elicited in both 
cases. When equal larger amounts were used as in intramuscular injection, the 
response shifted towards a Thl profile in both cases. However other studies conflict
with this observation, showing that even when 1-2 jig DNA was injected into muscle 
mostly IgG2a antibodies were induced, whilst the same quantity o f DNA stimulated 
IgGl antibodies when delivered using a gene gun [Feltquate et a l  1997].
Another explanation for these differences may lie in the way the DNA is delivered to 
host cells. Injection o f  vaccine tends to deliver plasmid DNA to extracellular spaces 
where it is taken up by a mechanism that has not been fully elucidated. Gene gun 
inoculation however delivers DNA directly into cells. This difference may alter the 
processing o f  the antigen, leading to induction o f different antibody responses.
Needle free jet
A new inoculation technique using the needle free jet device called Biojector™ has 
been used to administer DNA vaccines. It uses a CO2 cartridge to propel the vaccine 
subcutaneously or intradermally. When used in rabbits to deliver a malaria vaccine, 
the biojector elicited 10-50 fold higher antibody titres and an improved ability to 
prime the immune system than using intramuscular needle injection [Aguiar et a l  
2002].
Mucosal immunisation
There has also been recent interest in the delivery o f DNA vaccines to the mucosal 
tissues. The earliest study was by Fynan et a l  [1993], which showed that 2 intranasal 
inoculations o f plasmid encoding influenza haemaglutinin protein stimulated IgG 
antibodies and protected 76% of mice against challenge. Further studies have 
demonstrated that mucosal vaccination tends to elicit a high IgGl:IgG2a ratio and 
Th2 associated cytokines, eliciting a Th2 orientated response [Kuklin et a l  1997]. 
The development o f  immune responses at distant mucosal sites as well as systemic 
immunity may be particularly useful in the defence against pathogens such as HIV, 
herpes simplex virus and influenza, which gain entry to the host via the mucosa.
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1.1.3.2 DNA vaccine delivery systems
Lipopromoters
Incorporation o f DNA vaccines into microparticles consisting o f  the biodegradable 
polymer poly(lactide-co-glycoHde), allows the release o f entrapped vaccine over 
extended periods o f time and allows direct delivery o f  antigen into phagocytic APCs. 
This system was used by both intraperitoneal and mucosal delivery and successfully 
elicited IgG and IgM with the addition o f IgA when administered to the mucosa 
{SowQS et al. 1997].
A similar concept has combined DNA vaccines with cationic liposomes to form 
lipoplexes. Again this allows direct access to APCs by endocytosis, slow release o f  
vaccine locally and protection from nuclease degradation. Intramuscular injection o f  
lipoplexes containing DNA encoding hepatitis B surface antigen elicited stronger 
humoral and cellular immune responses than similar amounts o f  naked DNA [Perrie 
et al. 2001].
Live vectors
Live vector vaccines can be an effective way o f delivering DNA plasmids encoding 
antigenic proteins to cells. These consist o f attenuated strains o f bacteria or viruses, 
which act as an inherent adjuvant to the vaccine due to their high immunogenicity. 
Specific antigenic proteins are encoded within the genome o f  the vector and once 
delivered to the host, vectors undergo their normal life cycle. Upon host expression, 
the encoded antigenic proteins are also transcribed, translated and become exposed to 
the immune system. Studies have shown that generally this delivery system is poor at 
stimulating antibodies to the pathogen, but due to limited replication at target sites o f  
immunisation, they can be effective at inducing CD8^ T cell responses. Vectors that 
have commonly been used include strains o f  Salmonella [Pasetti et al. 2000], Shigella 
[Shata et al. 2001], and E. coli [Shiau et al. 2001].
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1.1.4 Safety issues concerning DNA vaccination
Following the promising results produced by DNA vaccination, clinical trials have 
been conducted on healthy volunteers to assess the clinical safety and efficacy o f  
plasmid DNA. There are several areas o f safety that have caused concern.
1.1.4.1 Potential for integration
One o f the main areas o f  concern is the possibility o f integration o f plasmid DNA into 
the host genome. Integration o f plasmid DNA can result in three possible outcomes. 
Firstly insertion o f DNA may have no effect on the host. If it produces disruption o f  a 
cellular gene, then this could potentially be mutagenic. Finally integration could 
inactivate a gene regulating cell division or activate an oncogene and the effect could, 
via a multistep process, be potentially carcinogenic [Amariglio et a l  1993].
DNA may be inserted into the host genome either by random or by homologous 
recombination. Homologous recombination is most likely to occur where there is 
simultaneous replication o f  both plasmid and host cells, and where homology exists 
between plasmid DNA and host DNA. In intramuscular DNA vaccination, the cells 
which process the plasmid are mainly non-dividing (myocytes and macrophages) 
[Mauro et a l  1969], the plasmids have very low sequence homology with mammalian 
DNA and plasmids do not contain a eukaryotic origin o f replication. Therefore in 
theory, the risk o f this type o f integration is low [Donnelly et a l  1997].
Recent studies have addressed the persistence and distribution o f  plasmid DNA on 
intramuscular injection. After a single inoculation o f a DNA malaria vaccine in mice, 
3-30 copies o f  plasmid were detected per 10  ^ muscle cells at up to 60 days post 
injection [Martin et a l  1999]. This study was unable to distinguish whether the 
plasmid was covalently linked to genomic DNA or merely adventitiously associated 
with it. However, assuming covalent linkage and that every integration resulted in 
mutation, this rate o f mutation would be 3000-fold less than the spontaneous rate for 
mammalian genomes. However, the validity o f  this comparison is questionable, as 
spontaneous mutation o f  a single base would be less deleterious than integration o f
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large inserts o f DNA. In addition, this study failed to monitor insertion o f shorter 
DNA fragments, which may also give rise to mutation [Smith and Klinman, 2001].
A study o f the tissue distribution o f a DNA vaccine detected plasmid DNA in all 
highly vascularised tissues for 2 days after intramuscular injection. After this time, 
plasmid could only be retrieved from the muscle at the site o f injection, where it 
persisted for up to 8 weeks [Parker et al. 1999]. Plasmid was detected initially in the 
gonads, giving rise to the risk o f heritable defects should integration take place. To 
date however, no further work has been published in this area. It should be noted that 
during these studies, no adverse effects were detected in any o f the clinical chemistry, 
haematology or histopathology o f these animals.
In conclusion, evidence suggests that o f the vaccines tested, integration is a rarity. To 
date, there is no proof that DNA vaccines can be carcinogenic or produce phenotypic 
mutation.
1.1.4.2 Autoimmunity
Another potential danger o f  DNA vaccination is the development o f  an immune 
response to host DNA. Studies have shown that the proportion o f myotubes 
transfected with plasmid DNA is only 1-5% [W olff et al. 1990]. Therefore it is 
unlikely that an immune response against these cells would be clinically significant.
O f the studies performed in which autoimmunity has been elicited, this has failed to 
produce autoimmune disease. Repeated immunisation o f mice with plasmid DNA  
brought about a 3 to 4-fold rise in B cells secreting anti-mammalian IgG antibodies. 
However, no disease was demonstrated in either normal mice or those prone to 
systemic lupus erythrematosus [Klinman et al. 1997; 2000].
1.1.4.3 Tolerance
It is theoretically possible that DNA vaccination could induce host tolerance to 
antigen rather than protective immunity. Generally, the amount o f antigenic protein 
synthesised is estimated to be small and this protein often persists for long periods o f
13
time, which makes immunotolérance a genuine concern. Studies have shown evidence 
o f  neonatal tolerance in mice immunised with a DNA vaccine for malaria. Mice 
immunised at 2-5 days o f  age failed to mount antibody, cytokine or cytotoxic 
responses on rechallenge with the vaccine [Mor et a l  1996]. This tolerance was found 
to persist for greater than a year and also interfered with immune responses to 
subsequent challenge. Susceptibility to tolerance was found to increase with higher 
doses and was not MHC restricted [Ichino et a l  1999].
In constrast, there is much work that demonstrates protective responses in neonates. A 
plasmid encoding lymphocytic choriomeningitis virus cDNA was found to induce 
long-term CD8^ and humoral responses when injected within hours or days o f birth 
[Hassett et a l  2000]. Also, neonatal mice injected with plasmids expressing influenza 
antigens were protected against lethal challenge whereas those injected with 
inactivated virus were not [Bot et a l  1998].
In conclusion, it is clear that the development o f tolerance to DNA vaccination 
requires further investigation, particularly in individuals that are most likely to be 
unresponsive such as the young.
1.1.4.4 CpG effect
In terms o f  safety, the major concern with CpG DNA is its ability to bias the cytokine 
response o f the host towards a Thl profile. This could increase the risk o f Thl- 
mediated organ-specific autoimmune diseases such as allergic encephalomyelitis or 
could increase susceptibility to infection requiring a strong Th2 response. There have 
been differing reports on this issue. Klinman et a l  have shown that repeated 
administration o f CpG DNA at least twice a month produced no adverse effects in 
mice [Klinman et a l  1999]. However CpG DNA stimulated quiescent myelin basic 
protein-specific T cells to become effector cells able to transfer experimental allergic 
encephalomyelitis [Segal et a l  1997]. Again, evidence suggests that the risk o f CpG 
DNA requires further investigation before concerns about safety can be fully 
answered.
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1.1.4.5 Development of anti-DNA antibodies
The stimulation o f antibodies against plasmid DNA itself is a potential problem, as 
this could theoretically contribute to the onset o f  certain autoimmune diseases such as 
systemic lupus erythematosus [Klinman et al. 1991]. Other important factors that 
predispose to this syndrome are genetic susceptibility and immune dysfunction.
It is, however, relatively difficult to induce antibodies to purified double stranded 
DNA (dsDNA). The DNA must first be denatured, complexed with methylated 
bovine serum albumin and co administered with complete Freund's adjuvant in order 
to stimulate this kind o f  response [Gilkeson et al. 1989]. Further studies analysed the 
immunisation o f mice with complexes o f E. coli dsDNA prepared in this way. Both 
normal and lupus-prone mice developed anti-dsDNA antibodies [Gilkeson et al.
1995]. However, survival o f these mice was actually increased compared to the 
controls, with immunised mice displaying less clinical expression o f the disease 
[Gilkeson et al. 1996]. Several studies using non-denatured, purified dsDNA as 
vaccines have failed to detect anti-DNA antibodies [Jiao et al. 1992]. One study 
detected a 35-60% rise in anti-DNA titres on DNA vaccination o f  normal and lupus- 
prone mice, but this had no effect on either the onset or the severity o f autoimmune 
disease [Klinman et al. 1997].
1.1.5 Mechanism of DNA vaccination
The process by which DNA vaccines exert their effect on the immune system has not 
yet been fully elucidated. Evidence gathered so far has led to theories regarding the 
probable processing pathways from host cell entry to immune cell activation.
1.1.5.1 Entry of DNA vaccine into host cell
Once administered to the host, plasmid DNA must gain access to host cells in order to 
produce expression o f  antigen. In contrast to viruses, naked DNA lacks the structural 
elements necessary for entry into cells. The precise mechanism o f cell entry remains 
unclear although it has been shown that cells can spontaneously take up nucleic acids. 
For example, myocytes have been shown to take up DNA, and initiate transcription
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and translation into protein [Davis et al. 1993]. It has been shown that DNA is 
internalised by muscle cells near the injection site within five minutes by muscle cells, 
with rapid dispersion through the muscle over the following few hours [Dupuis et al. 
2001]. Attempts have been made to enhance this uptake by the addition o f cationic 
lipids that are able to bind DNA and facilitate transport across the cell membrane 
[Feigner et al. 1987]. Alternatively, DNA may be administered directly into the cell 
by use o f a gene gun [Tang et al. 1992].
1.1.5.2 Antigen expression and uptake
Plasmid DNA is maintained episomally within host cells and the DNA is transcribed 
and translated into protein using the components o f the cell. This results in production 
o f vaccine-encoded antigenic protein, which may then be exposed to the immune 
system. Stimulation o f either humoral or cytotoxic immune responses require 
presentation o f  antigen protein to MHC class I or class II molecules respectively. The 
mechanism by which this occurs from intramuscular injection has led to three possible 
pathways which have been reviewed by Leitner et al. [2000a], and are summarised in 
figure 1.2.
Antigen is presented directly by transfected myocytes
It has been suggested that myocytes themselves may present antigen and elicit T cell 
responses directly. Evidence to support this demonstrates that T cells are able to 
recognise myocytes in certain myopathies [Hohlfeld et al. 1993] and also in response 
to DNA vaccination. Yokoyama et al. demonstrated an antigen-specific local 
inflammatory response at the intramuscular injection site o f a vaccine [Yokoyama et 
al. 1997]. Also a study has shown that where influenza nucleoprotein (NP) antigen 
production is restricted to C2C12 myoblasts, this is sufficient to induce a CTL 
response in C3H mice [Ulmer et al. 1996].
However it is the general view that in order to induce cytotoxic T-lymphocytes 
(CTLs), a cell requires at least two signals, an MHC I peptide complex and a co 
stimulatory molecule such as CD80 (B7.1) and CD86 (B7.2). Since expression o f
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both these molecules on myocytes is low, it is unlikely that muscle cells directly 
induce T cell responses.
Antigen is transfected into and presented by specialised bone marrow-derived 
antigen presenting cells (APCs)
A more likely mechanism o f antigen presentation is through DCs, which are able to 
function as APCs. These cells are known to express both MHC I and II, as well as co­
stimulatory molecules such as B7.1 and B7.2. This makes them highly efficient at 
presenting antigen to T lymphocytes. Various studies using chimeras have shown that 
CTL induction is restricted to MHC molecules o f  the bone marrow rather than the 
myocytes o f the host. This was the case for both intramuscular and gene gun 
vaccination [Corr et a l  1996; Doe et a l  1996; Iwasaki et a l  1997]. It has therefore 
been suggested that a small number o f  APCs may be transfected with plasmid DNA at 
the site o f  injection. In the case o f  intramuscular injection however, the relative 
scarcity o f  DCs and macrohages in muscle make this unlikely.
In intradermal inoculation, this hypothesis is more feasible due to the abundance o f  
APCs present in the dermis. Introduction o f plasmid DNA into the skin was shown to 
result in discrete foci o f epidermal and dermal cells. These included cells with 
dendritic morphology, which were found to contain the injected antigen [Raz et a l  
1994]. In fact Raz et a l  have suggested that the true effector cells involved in 
intramuscular injection may actually be within the skin through which the needle has 
passed.
Gene gun immunisation has been shown to directly transfect DCs that were recovered 
from lymph nodes draining the inoculation site. These cells were specifically 
identified using antibodies to an intact surface protein encoded by co transfected DNA  
[Porgador et a l  1998]. This has also been confirmed by demonstrating the presence o f  
DNA-coated gold particles in the cytoplasm o f DCs after gene gun inoculation 
{Conàon et a l  1996].
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Antigen is expressed in myocytes and presented by APCs (’’cross priming”)
A hypothesis that has gained popularity is that "cross priming" o f APCs occur, 
leading to antigen presentation. In this process, it is thought that the AFC is exposed 
to antigen manufactured by myocytes and acts as a "mediator cell" allowing antigen 
presentation to T lymphocytes. However, the way in which APCs apprehend the 
antigenic protein is still in debate. There are three possibilities. Firstly, the DC may be 
directly transfected with plasmid DNA as in the case o f gene gun immunisation 
described previously [Porgador et al. 1998]. Alternatively, soluble antigen secreted by 
myocytes may be taken up from interstitial spaces surrounding the APC. Finally, 
APCs may engulf cells that have been injured or killed by the vaccine or its function
Figure .1-2 Antigen expression o f DNA vaccine plasmid
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There has been much interest recently in the possible role o f apoptopic cell death in 
DNA vaccine efficacy, so this will be explained in more detail.
1.1.5.3 Signalling and activation of dendritic cells
It has been suggested that DC activation is dependent on recognition and binding to 
certain cellular signals. It has been found in a gene gun immunisation trial, that 
priming o f  specific CTLs is dependent on the co expression o f  antigen encoding DNA  
and the expression o f B7.2 antigen [Porgador et a l  1998]. Also a study has shown 
that DCs recognise antigen from cells undergoing apoptosis and subsequently induce 
class I-restricted CTLs [Albert et a l  1998]. Together, these ideas have led to the idea 
that cell death induced by transfection o f  host cells becomes a signal for activation o f  
DCs as they supply the necessary "danger signals" [Matzinger et a l  1998]. This cell 
death o f antigen-expressing myocytes on intramuscular injection o f DNA depends on 
MHC II restricted CD4^ activation o f  T cells, not MHC I or perforin-mediated lysis, 
and seems to be antibody mediated [Payette et a l  2001].
Destruction o f transfected cells tends to be restricted to those that harbour high copy 
numbers o f plasmid [Restifo et a l  2000]. This has been demonstrated by studies o f  
plasmid DNA vectors containing replicons which, when transfected into cells launch a 
self-replicating cycle o f the plasmid-encoded antigen. This vector was compared with 
a traditional DNA plasmid and was found to induce the same immune response and 
protection against tumour antigen with 100 to 1000-fold less replicon DNA. Neither 
vaccine produced higher antigen levels than the other; instead the effect was 
associated with caspase-dependent apoptopic death o f the host cells. This death 
facilitated antigen uptake by DCs, potentially enhancing the immunogenicity o f the 
vaccine [Ying et a l  1999; Leitner et a l  2000b], A theory has been put forward that 
low efficacy o f  conventional DNA vaccines may be due to a lack o f cell death, 
preventing exposure o f DCs to the "danger signals" required for activation.
Sasaki et a l  have deliberately used apoptopic death to enhance a DNA vaccine to 
influenza virus. They immunised mice with the vaccine and vectors expressing 
partially inactivated caspase-2 or the chimeric version o f caspase-2 grafted onto 
caspase-3. These enzymes mediate programmed cell death and mutated versions were
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used in order to allow antigen expression before apoptosis. They showed that the 
apoptopic bodies produced were engulfed by APCs and claim that the increased T cell 
response was the strongest vaccine adjuvant effect shown to date [Sasaki et a l  2001].
In conclusion, it is generally accepted that APCs provide the link between inoculation 
o f  antigen encoding DNA and exposure o f  antigenic protein to the cells o f the 
immune system. Whether this DNA is transfected directly into the APC and the 
protein synthesised, or whether the APC takes up protein synthesised elsewhere is 
unclear. Some studies have shown that a combination o f these two mechanisms take 
place. For example on intradermal injection o f a DNA vaccine, APCs were shown to 
process extracellular proteins, as well as directly transfected plasmid [Corr et a l
1999]. In addition, as mentioned in 1.1.2.2, fusion o f  antigenic cDNA to cytotoxic T- 
lymphocyte antigen encouraged binding o f  antigenic protein to APCs which was 
found to hasten and enhance the immune response elicited compared to unlinked 
vaccines [Boyle et a l  1998]. Whichever pathways occur however, antigens must then 
be processed and presented to immune cells to stimulate a protective immune 
response.
1.1.5.4 Presentation of antigen within the APC
Once exposed to environmental antigens, the APCs migrate to the draining lymph 
nodes where antigen presentation takes place. During this time, the APC undergoes a 
functional transition from antigen-uptake to presentation o f T-cell-stimulatory signals 
through MFIC I and MHC II complexes. DCs have been shown to have superior 
antigen-presenting capacity compared to other APCs during DNA vaccination. A  
possible explanation for this has been the discovery o f a DC-specific surface receptor 
called DC-SIGN (DC-specific ICAM-3 grabbing non-integrin) [Geijtenbeck et a l
2000]. These authors suggest that DC-SIGN interacts with ICAM-3 (CD50) on resting 
T-cells, which establishes initial contact with the T-cell and allows the T-cell receptor 
to scan the surface o f the DC for specific MHC complexes. This may be important in 
the adaptive immune response to DNA immunisation, where there may be very few 
antigen-presenting DCs available.
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Antigens encoded within DNA vaccines have the capability to induce both cell 
mediated and humoral immunity depending on factors such as the antigen concerned 
and the mode o f administration. These antigens are therefore able to enter both the 
MHC I and MHC II processing pathways o f the APC (figure 1.3).
Figure 1-3 Antigen presentation via the MHC I and MHC II oathwavs
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Antigenic protein entering the MHC II pathway may be endogenous within the APC 
[Oxenius et al. 1997] or taken up from the extracellular environment. It enters 
lysosomes where it is proteolysed to peptides, which then bind to MHC II molecules. 
These complexes are displayed on the cell surface where they are recognised by CD4^ 
T-helper cells [Male et al. 1996a]. T-helper cells are divided into 2 groups. Thl cells
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secrete IFNy, TNFa and IL-12, thereby promoting cellular immune responses. Th2 
cells secrete cytokines such as IL-4, IL-5 and IL-13, which stimulate the maturation 
o f humoral responses. CD4^ T cells act on mature and naive B cells, stimulating 
growth and clonal expansion when the cells come into contact with antigen. T-helper 
cells may also bring about class switching which involves changing the class o f  
antibody produced by the cell, from for example IgM to IgG. The precise role o f  
CD4^ cells in the generation o f CD8  ^ cytotoxic T-lymphocytes is at present unclear. 
However studies have shown that mice that lack CD4+ cells show relatively normal 
CD8  ^ CTL responses but impaired CTL memory. As a consequence o f  this, 
vaccination o f  CD4^ deficient mice is significantly less effective [Von Herrath et a l
1996].
The origin o f antigenic protein processed via the MHC I pathway is yet to be fully 
determined. Some believe the protein must be synthesised endogenously, others that 
"cross priming" occurs as explained above. Once inside the APC, antigenic protein is 
degraded to peptides within the proteasome. These peptides are transported to the 
endoplasmic reticulum by TAP transporters where they bind to MHC class I 
molecules and p2-microglobulin. These complexes are then displayed on the cell 
surface where they may be recognised by cytotoxic CD8^ T-cells [Male et a l  1996a]. 
These cells are able to lyse infected host cells which display antigen on their MHC I 
molecules, providing a crucial role in the spread o f  infection. There are various ways 
that lysis may take place. The cytotoxic T-cell may bind the target cell and release 
granules, which can non-specifically lyse the target cell in a Ca^ "*" dependent manner. 
In addition. Fas antigen, a 48kDa member o f the TNF receptor family, has been 
shown to be important. Fas ligand present on the cytotoxic T-cell can bind Fas antigen 
on the target cells. This complex can then bring about apoptosis o f the target cell 
[M aleeva/. 1996b].
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1.1.6 DNA vaccination of domestic animals
The concept o f  DNA vaccination has been explored in various species. The strength 
and type o f  immune response elicited, has varied with parameters such as the 
vaccination protocol, the amount o f vaccine used, route and timing o f  administration, 
type o f antigen and species concerned. Studies investigating genetic immunisation in 
feline (table 1.1) and canine (table 1.2) systems have been summarised below.
As shown in table 1.1, most studies o f  feline retrovirus DNA vaccines in vivo have 
used intramuscular inoculation o f plasmid vectors comprising one or more antigenic 
genes. These studies clearly show that the type o f immune response elicited can vary 
according to many parameters. In the case o f  FIV, injection with gp l20 cDNA  
induced a predominantly humoral response [Cuisinier et a l  1997], whereas 
inoculation with a defective mutant provirus induced antigen-specific CTLs and no 
humoral response [Hosie et a l  1998]. It could be concluded that the contrasting 
immune response may be due to the different FIV genes used, which stimulate 
different pathways in the immune system. However, when these two studies are 
compared, the immunisation protocol, dose o f vaccine and strain o f  virus used for 
challenge were different. All o f these parameters may have influenced the immune 
response elicited. As explained in 1.1.3, the way a DNA vaccine is administered can 
influence the response produced as much as the composition o f the vaccine itself. This 
highlights the empirical way in which the optimal conditions for a particular vaccine 
are defined. An additional problem, particularly relevant in human studies, is the use 
o f murine experimental systems to investigate vaccines for pathogens o f  other species. 
The response elicited by a vaccine in mice cannot necessarily be extrapolated to a 
different species, especially in the case o f DNA vaccination where immunisation 
parameters are so empirical.
As detailed in table 1.1, certain cytokines have been used as adjuvants to DNA  
vaccines for feline retroviruses. IFNy used as an adjuvant to an FIV DNA vaccine, 
increased the level o f protection to viral challenge [Hosie et a l  1998] and IL-12 
elicited a high degree o f  protection with a DNA vaccine to FIV delivered by gene gun 
[Leutenegger et a l  2000]. IL-18 was also shown to enhance FIV-specific CTL 
responses when used in combination with a DNA vaccine [Dunham et a l  2002]. The
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efficacy o f  IL-12 and IL-18 as vaccine adjuvants are described in chapters 3 and 4 
respectively. Some studies have shown that a DNA vaccine that is not protective 
alone can provide complete protection against challenge when accompanied by these 
adjuvants. Hanlon et a l  demonstrated that IL-12 and IL-18 together with a DNA  
vaccine encoding FeLV-A gag/pol and env genes, produced complete protection from 
FeLV challenge which was not induced by vaccine alone [Hanlon et a l  2001]. The 
effect was found to be associated with an increase in antigen-specific CTLs [Flynn et 
a l  2000a]. This shows that IL-12 and IL-18 biased the immune response towards cell- 
mediated immunity, which allowed a more effective immune response to viral 
challenge. The work in this thesis further investigates the adjuvant role o f  these feline 
cytokines either alone or combination, to a FeLV DNA vaccine in vivo.
Table 1-1 Feline DNA vaccination studies
*F1PV = Feline infectious peritonitis virus
Pathogen Route Antigen cDNA Delivery/
adjuvant
Immune response Study
FeLV IM gag/pol + envA Plasmid vector, 
IL-12 + IL-18
T virus-specific effector CTL, gag/pol 
recognition > envA 
No antiviral antibodies produced Significant 
protection in vaccine + IL-12 + IL-18
Hanlon et al. 2001 ; 
Flynn et al. 2000a
FlV IM FIV gpI20 and pIO Plasmid vector gp 120 induced humoral response and some 
maintained low proviral load and controlled 
replication 
gpI2G + pIO: complete humoral response 
and transient drop in proviral load
Cuisinier ef a/. 1997
FIV IM env (wild-type + 
mutated gene
Plasmid vector Enhanced infection 
low anti-env antibodies
Richardson e/ a/. 1997
FIV IM defective mutant 
provirus
Plasmid vector, 
IFNy
Vaccine alone: CTL to FIV gag  and env, i  
viral loads, No antiviral antibodies 
Vacc + IFNy; T protection
Hosie ef u/. 1998
FIV IM + 
Mucosal
Nucleocapsid FIV DNA as 
adjuvant to 
gpI20 protein
FIV DNA f  viral load and I  anti-FIV 
humoral response o f  protein vaccine
Cuisinier ef cj/. 1999
FIV IM defective mutant 
provirus o f  FIV 
petaluma strain and 
Glasgow-8
Plasmid vector Some protection o f petaluma strain, no effect 
on more virulent Glasgow-8 strain
Hosie et al. 2000
FIV IM provirus with 
deletion in accessory 
gene v if
Plasmid vector Protection with low CTL response, high anti- 
env antibodies, no anti-gog antibodies
Lockridge et al. 2000
FIV Gene gun FIV gpI40 MIDGE vector, 
IL-12, IL-I6, 
CpG motif
No protection with vaccine alone, high 
protection with either o f  3 adjuvants. Weak 
CTL response. No FIV specific antibodies. 
Moderate cytokine response
Leutenegger et al. 2000
FIV IM replication defective 
provirus
Plasmid vector 
with CMV or 
5'LTR 
promoters, IFNy
Vaccine alone: significant protection 
Vaccine + IFNy: highest virus-specific lysis 
with CMV promoter, highest protection with 
5'LTR promoter
Flynn et al. 2000b
FIV IM replication defective 
Reverse 
Transcriptase and 
Integrase genes
Plasmid vector, 
IL-12 and IL-18
7/30 animals remained virus free.
IL-18 cDNA : more consistent CTL response 
IL-12 cDNA: no enhancement o f  immune 
response
Dunham et al. 2002
Rabies
virus
IM + ID glycoprotein G Plasmid vector VNA level ID > IM Osorio e /a /, 1999
FIPV* 2 X 1D + 
2 x I M
membrane and 
nucleocapsid
Plasmid vector, 
IL-12
No protection elicited by DNA vaccine 
IL-12 increased susceptibility o f animals to 
virus
Glansbeek et al. 2002
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Table. 1-2 Canine DNA vaccination studies
Pathogen Route Antigen cDNA Delivery/
adjuvant
Immune response Study
canine
distemper
virus
(CDV)
IM + gene gun Haemagglutinin 
and ftision protein
Plasmid vector IM; lgG2a antibody (Ab) 
gene gun: haemagglutinin produced 
IgG I . Fusion produce mixed Ab 
response. Both produced class I-CTL 
and protection from challenge
Sixt et al. 1998
CDV IM Nucleocapsid, 
fusion, and 
attachment protein
Plasmid vector Positive virus neutralising antibodies 
and protection from challenge
Cherpillod et al. 2000
CDV IM Nucleocapsid o f  
CDV
Plasmid vector Positive specific IgG response, with no 
IgM antibody peak, Lower response 
than conventional protein vaccine
Griot-Wenk et al. 2001
Rabies
virus
IM PV strain 
glycoprotein
Plasmid vector Positive virus neutralising antibodies 
and protection from challenge
Perrin et al. 2000
Rabies
virus
IM + ID glycoprotein G Plasmid vector VNA level IM > ID Osorio et al. 1999
canine
parvovirus
IM VP I gene Plasmid vector Increase in IgG titres and complete 
protection from virus
Jiang g/ a/. 1998
canine oral 
papilloma 
virus
mucosa via 
Powerject 
device
LI gene particle 
mediated DNA  
delivery
Complete protection from challenge. 
Cell mediated lymphoproliferative and 
humoral responses observed
Stanley et al. 2001
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1.2 Feline Leukaemia Virus
1.2.1 introduction
Feline leukaemia virus (FeLV) was originally identified by William Jarrett in 1964 
[Jarrett et al. 1964a; Jarrett et al. 1964b]. In this work, a cell-free extract was prepared 
from a naturally occurring lymphosarcoma in the mediastinum o f a cat and was 
injected into four kittens within 12 hours o f birth. These animals were then reared in 
isolation and subjected to frequent clinical examination. Within six months o f  
injection, enlarged superficial lymph nodes could be detected and several cats had 
developed splenomegaly. Within eighteen months all o f the cats had either died or had 
to be euthanased, having developed signs associated with leukaemia or 
lymphosarcoma. Post mortem examination confirmed that all cats demonstrated 
leukaemic disease based on gross and histologic diagnosis [Jarrett et a l  1964a].
The hypothesis that the lymphosarcoma induced by the inoculation o f the tumour 
extract contained some kind o f infectious agent was tested by electron microscopic 
examination o f the mass. The cells examined contained highly vesiculated areas and 
virus-like particles were identified within the vesicles and in the intercellular spaces. 
These particles comprised an electron-dense nucleoid enclosed in a densely stained 
double membrane. Large numbers o f  similar particles were detectable in short-term 
cell cultures o f  the tumour cells. This virus was designated "feline leukaemia" virus 
due to its strong structural similarity to murine leukaemia virus (MuLY) [Jarrett et a l  
1964b].
The isolation o f FeLV also led to the identification o f feline sarcoma virus (FeSV) by 
Snyder and Theilen who found that naturally occurring fibrosarcoma could be 
reproduced by inoculating experimental cats, in a similar way to FeLV [Snyder and 
Theilen, 1969]. Further work demonstrated that FeSVs arise from recombination 
between FeLV and cellular proto-oncogenes, but are not transmitted from cat to cat in 
nature.
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1.2.2 Structure of FeLV
FeLV is a spherical enveloped virus, lOOnm in diameter (figure 1.4). The structure o f  
the virus is reviewed by Granoff and Webster [1999], and Fields and Knipe [1990].
Figure 1-4 Diagram representing the structure o f feline leukaemia virus
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The FeLV viral genome comprises two linear 8.3kb positive-sense single stranded 
RNA molecules linked together to form a dimer. As shown in figure 1.5, the encoded 
gene order from 5' to 3' is gag/pol/env and as in cellular RNA, the genome has a 5' 
cap and 3' polyadenylation signal. Encoded in the viral RNA is reverse transcriptase, 
which on infection o f the cell reverse transcribes the genome into DNA. This then 
becomes stably integrated into the host DNA to form a provirus.
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The FeLV genome also contains U3, U5 and R sequences situated at the 5' and 3' 
ends o f the genome. These are copied to form the proviral long terminal repeat (LTR) 
sequences and function in the initiation o f transcription, polyadenylation o f viral RNA 
and promotion o f  viral transcription. The 5' LTR acts to initiate transcription o f the 
provirus, whereas the 3' LTR functions mainly as an RNA processing signal. On 
replication o f the host cell, copies o f  the viral protein and DNA are manufactured by 
the machinery o f  the cell to form complete viral particles, which are then released.
Figure 1-5 Diagram o f FeLV genome
^  LTR — ► LTR — ►
The proteins plO, pi 5, pl5E, p27 and gp70 produced from gag, po l and env o f the 
FeLV genome were named according to their sizes in kilodaltons. However recently 
the nomenclature o f these proteins has changed to NC, MA, TM, CA and SU 
respectively. The gag  gene encodes polyprotein precursors o f  internal non­
glycosylated core proteins. The major capsid protein (CA) forms the icosahedral core 
particle. The matrix protein (MA) forms an outer layer on the capsid and the 
nucleocapsid protein (NC) is associated with the virion RNA.
Proteins encoded by the env gene are required for the adsorption and entry o f  
retroviral particles. These proteins are not necessary for virion assembly or budding as 
normal appearing virions can be made and released in their absence [Dickson et al. 
1982]. The envelope o f the virus is formed from the budding process as the virus 
leaves the host cell and consists o f phospholipid bilayer derived from the plasma 
membrane. This envelope is studded with complexes o f  two euv-coded proteins: 
surface glycoprotein (SU) and the transmembrane anchor protein (TM) which form 
trimers on the envelope surface [Hunter et al. 1990]. Variations in the SU protein 
separate FeLV into subgroups, FeLV-A, FeLV-B and FeLV-C [Sarma and Log, 1973; 
Russell and Jarrett, 1976] and FeLV-T [Rohn et al. 1998].
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The virion enzymes protease, reverse transcriptase (RT) and integrase (IN) are 
encoded by the p o l or polymerase gene o f  the genome. This arises from a gag-pol 
precursor, which is produced due to suppression o f the gag  termination codon.
1.2.3 Replication of FeLV
All retroviruses follow a similar replication cycle which is summarised in a diagram 
at the end o f this section (figure 1.6).
1.2.3.1 Attachment of the virus to a specific ceii-surface receptor
The initiation o f replication takes place by the binding o f the SU protein on the viral 
envelope to a specific receptor found on the host cell surface. Interference studies o f  
FeLV-A, -B, -C and -T have suggested that each subgroup uses a specific receptor in 
order to infect a host cell. As yet, a receptor for FeLV-A has not been found. FeLV-B 
and -T use feline Pit 1 as a receptor, FeLV-T requiring a cofactor called FeLlX, an 
endogenous protein highly related to the N-terminal portion o f FeLV envelope protein 
[Takeuchi et al. 1992; Anderson et al. 2000]. Pit 1, also the receptor for gibbon ape 
leukaemia virus, is a multiple membrane spanning protein with a sodium-dependent 
phosphate transporter function [Kavanaugh et al. 1994]. In addition, some FeLV-B 
isolates have been shown to use feline Pit 2 as a receptor as well as Pit 1. Feline Pit 2 
is a phosphate transporter protein related to Pit 1, with approximately 53% homology 
at the amino acid level. This finding has led to the suggestion that subsequent 
evolution o f FeLV-B by recombination may lead to this dual receptor use, facilitating 
viral entry and replication [Anderson et al. 2001]. Recently, the receptor for FeLV-C 
has been cloned and found to be a member o f  the major-facilitator superfamily o f  
transporters, possibly transporting an organic anion [Quigley et a l  2000; Tailor et al.
1999]. Studies have shown that cells otherwise resistant to FeLV-C may become 
infected with the virus if  the receptor to FeLV-C is over expressed [Tailor et al.
2000].
29
1.2.3.2 Penetration and uncoating
The way in which the retroviral particle enters the cell is not well understood. It is 
generally thought that after binding, the viral envelope and the cell membrane fuse to 
release the virion core into the cytoplasm. Two distinct processes have been put 
forward for the way in which this occurs. Evidence suggests that in the case o f  HIV, 
fusion probably occurs immediately after binding as cells expressing HIV Env protein 
fuse directly to uninfected cells expressing its receptor [Lifson et a l  1986]. Other 
retroviruses, however, are possibly internalised due to receptor-mediated endocytosis 
with subsequent fusion o f  the viral envelope and endosomal membrane.
1.2.3.3 Reverse transcription of genome RNA into DNA
Once the retroviral core has gained access to the cell, the virion reverse transcriptase 
makes use o f  a proline tRNA primer to initiate DNA synthesis [Baltimore, 1970]. 
Firstly, a negative-strand DNA molecule is transcribed which is then used to derive 
the positive-strand DNA. The reverse transcriptase also carries a ribonuclease H 
function which produces degradation o f the virion RNA and removal o f  the tRNA 
primer. Generation o f the LTRs occurs by duplication o f sequences at the 3' (U3) and 
5' (U5) poles o f the RNA genome [Fields et a l  1990].
It has been suggested that DNA synthesis takes place in a structure derived from the 
viral capsid [Bowerman et a l  1989], and that a p27 and viral DNA complex is 
important in DNA integration [Brown et a l  1987]. Whilst the cellular location o f  
DNA synthesis has yet to be fully clarified, cell fractionation studies suggest that it 
takes place within the soluble cytoplasmic fraction [Varmus et a l  1982].
Once cDNA o f the viral genome has been synthesised, it becomes closely bound to or 
contained within the nucleus. As well as the linear form, there is also circular viral 
DNA produced from either ligation o f  the linear form or defective DNA generated in 
the replication process.
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1.2.3.4 Integration
Integration involves the insertion o f  newly synthesised linear viral cDNA into host 
DNA. During the integration process, both the viral DNA and the host DNA undergo 
characteristic modifications, consisting o f various base deletions and duplications, 
which have been found to be virtually universal in this family o f viruses.
The mechanism o f this process has been studied using avian leukosis virus (ALV) and 
MuLV. Data from these studies suggest that integration is mediated by a 
ribonucleoprotein complex derived from the viral core [Bowerman et a l  1989]. These 
complexes have been found to contain linear and circular forms o f  DNA. In the case 
o f MuLV, low levels o f circular DNA produced from pro virus integrating to itself or 
LTR circles have been detected in vitro and have also been detected to a lesser extent 
in vivo [Shoemaker et a l  1980].
Experiments in vitro show that the 3' viral DNA adjoins the 5" cellular DNA while 
the 5' viral DNA remains unattached. This is strong evidence that a linear integration 
intermediate is formed as opposed to circular DNA containing two LTR sequences 
[Fujiwara et a l  1988]. Ligation o f  the 5' viral DNA is completed by cell repair 
mechanisms.
Experiments on MuLV show that integration does not require the use o f ATP [Brown 
et a l  1987]. This suggests the possibility o f topoisomerase catalyst type reaction 
rather than cleavage and ligation. The catalyst o f  the integration reaction is integrase 
protein encoded by the p o l gene. In the case o f FeLV, this enzyme produces a 
staggered cut in the host DNA and a four base pair duplication at the insertion site.
Upon integration the 5' and 3' ends o f retroviral DNA are always 5'-TG.........CA-3'
which implies that these dinucleotides are somehow crucial to the integration process 
[Colicelli et a l  1988]. The location at which the viral DNA inserts into the cellular 
DNA appears to be a more random process. Certain studies show no strong sequence 
similarity around areas o f  integration [Robinson et a l  1986], whereas others suggest 
more specificity. For example a study o f integration sites o f  ALV into avian cell DNA  
demonstrated that 20% o f integrations inserted into one o f around a thousand sites
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[Shih et al. 1988]. Other work has suggested that integration frequency is higher in 
transcriptionally active areas that have an "open" chromatin structure, thereby being 
more accessible [Rohdewohld et a l  1987].
Once the provirus has been integrated it is then stable from excision or translocation. 
Any loss or destruction o f provirus is due to random cellular processes or 
recombination, often between the LTRs o f the pro virus.
1.2.3.5 Proviral expression
The subsequent transcription and translation o f  the provirus is carried out entirely by 
cellular mechanisms. The LTR sequences provide signals to the cellular machinery to 
encourage efficient expression. As with cellular mRNA, retroviral genomes are 
synthesised by RNA polymerase II. In FeLV, full-length virion RNA produced 
functions as mRNA for the production o f gag  and p o l gene products, whereas Env 
proteins are translated from a 3kb spliced sub-genomic RNA.
During translation, the full length mRNA is responsible for the production o f two 
main products, a Gag precursor protein and a Gag/Pol precursor. Similarly, an Env 
precursor protein is synthesised from the spliced fragment o f  genomic RNA. These 
protein products make up the entire structure o f  the virion. In addition, the gag  gene is 
also expressed in a different glycosylated form and is both released from the cell and 
found on the cell surface. This protein is not required for in vitro viral expression and 
its function is as yet unknown. However, some have suggested that it plays a role in 
immunoevasion by inducing immunotolérance o f  the host to Gag proteins [Jarrett, 
1999].
1.2.3.6 Virion assembly and budding
Once the mature components o f the virion have been produced, they are assembled at 
the host cell membrane where budding o f  the virus particles takes place. The envelope 
o f  the virion consists o f  host-cell membrane studded with virus-coded surface spikes 
composed o f gp70 and p l5E  proteins. Just beneath the cell surface the capsid is 
assembled and rearranged to a condensed form just before budding takes place.
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During the budding process, virion aspartyl protease cleaves Gag and Gag/Pol 
precursors into the mature Gag and Pol proteins. Similarly, the Env precursor protein 
is cleaved at budding to yield the mature proteins gp70 and pl5E. Finally the virus 
particle is released from the cell by a process which is usually non-cytopathic.
Figure 1-6 Replication o f  feline leukaemia virus
This diagram shows the replication o f  FeLV. The virus first binds to a specific cell- 
surface receptor on an FeLV susceptible cell (1). The virus is transported across the 
cell membrane where uncoating takes place (2). The single stranded RNA genome is 
reverse transcribed into double stranded DNA (3), and integrated into the cellular 
genome to become a provirus (4). The provirus is expressed using cellular 
mechanisms (5) and the virus is assembled close to the cell membrane. Budding then 
takes place where the envelope o f  the virus is derived from the cell membrane (6).
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1.2.4 Classification of FeLV
FeLV is a member o f the Retroviridae family o f viruses. This family consists o f  
Alpha-, Beta-, Gamma-, Delta- and Epsilonretroviruses as well as Lentiviruses and 
Spumavimses. FeLV is classified as a Gammaretrovims. An older classification 
system is based on viral morphology where retroviruses may be distinguished by 
differences in core structure and surrounding membrane [Bernhard et al. 1958]. In this 
case, FeLV is classified as a C-type retrovirus.
FeLV consists o f  three major subgroups, FeLV-A, FeLV-B and FeLV-C. 
Classification o f  these groups is reviewed by Sparkes [1997]. The subgroups were 
distinguished originally by studies o f viral interference patterns and neutralisation 
tests [Sarma and Log, 1973]. In feline fibroblast cells in vitro, different virus 
subgroups prevent superinfection with other viruses o f the same subgroup. 
Subsequent studies have shown that subgroups may be distinguished by env 
sequences, which encode the N-terminal region o f gp70 surface glycoprotein [Riedel 
et al. 1988; Mullins et al. 1990]. More recently, another subgroup, FeLV-T, has been 
isolated which also has unique interference properties and is T-cell tropic, infection 
being limited to feline T-cells and feline fibroblasts [Moser et al. 1998; Rohn et al. 
1998].
All cats naturally infected with FeLV harbour FeLV-A, the dominant subgroup 
[Jarrett et al. 1978a]. It has been reported that 50% o f naturally infected cats are 
infected with FeLV-A alone, 49% with FeLV-A and B and 1% with any combination 
containing FeLV-C [Jarrett et al. 1978a; Rojko and Hardy, 1994].
FeLV-A has been shown to be readily transmissible, although the proportion o f cats 
becoming viraemic is age-dependent. Of the three subgroups FeLV-A is the least 
pathogenic, being slow to cause disease and frequently resulting in latent infection 
[Hoover et al. 1991; Rojko and Kociba, 1991]. The sequence o f the FeLV-A genome 
is highly conserved [Donahue et al. 1988], and the protein structure o f FeLV-A Env 
protein is similar for all FeLV-A isolates. Virus neutralising antibodies to FeLV-A 
gp70 (SU) are therefore cross-reactive across the subgroup [Russell and Jarrett, 
1978a; Donahue et al. 1988]. The presence o f  such antibodies in an infected cat
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con'elates highly with an absence o f  active viraemia with FeLV [Russell and Jarrett, 
1978b].
FeLV-B arises by recombination between FeLV-A sequences and endogenous FeLV- 
related sequences (enFeLV). enFeLV are incomplete proviral retrovirus sequences 
which occur in all domestic cats [Soe et al. 1985; Rojko and Hardy, 1994]. Studies 
suggest that FeLV-C is derived from FeLV-A by mutation, although recombination 
remains a possibility [Rigby et al. 1992]. This recombination hypothesis came from 
studies using specific probes from the env genes o f the FeLV subgroups as most 
sequence differences were found here. Probes o f  FeLV-A env detected FeLV-A and C 
isolates, and probes o f FeLV-B detected independent FeLV-B isolates and 
endogenous FeLV-related sequences [Stewart et al. 1986].
FeLV-B and -C  subgroups possess variants, which may be replication-competent or 
replication-defective. Replication-defective viruses require the additional presence o f  
FeLV-A in order to provide functions that have been lost through mutation or 
recombination [Stewart et aL 1986; Overbaugh et al. 1988]. It is thought that these 
subgroups rely on phenotypic mixing with FeLV-A where FeLV-B or -C are 
encapsulated in FeLV-A envelope, facilitating spread o f the less transmissible 
subgroups [Jarrett et al. 1973; Rigby et al. 1992; Rojko and Hardy, 1994]. The fact 
that FeLV-B and -C arise from mutation or recombination events o f  FeLV-A and may 
rely on FeLV-A for replication, is consistent with the fact that FeLV-A can always be 
isolated from individuals infected with subgroups B and C [Rojko and Hardy, 1994]. 
Subgroups B and C have not been shown to transmit horizontally on their own. It is 
likely that co inoculation with FeLV-A would be necessary for successful infection 
[Jarrett et al. 1978; Jarrett et al. 1984; Hoover et al. 1991].
A recent study has suggested that FeLV-B may inhibit FeLV-A infection possibly due 
to an immune mediated mechanism. The proportion o f cats developing chronic 
viraemia from inoculation with FeLV-A alone was decreased with co inoculation with 
FeLV-B virus [Phipps et al. 2000].
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1.2.5 Transmission of FeLV
Cats infected with FeLV excrete the virus mainly via the saliva and nasal secretions. 
FeLV has also been found to replicate in the mucosal epithelium o f the intestine and 
urinary bladder, but this is not a major source o f  infection, as the virus does not live 
long in the urine or faeces [Hoover et a l  1977]. FeLV is therefore transmitted through 
socialising o f  infected cats with susceptible individuals [Hardy et a i  1973a; Jarrett et 
a l  1973]. Persistently infected cats secrete high titres o f  infective virus in the saliva 
generally five times that found in the plasma, although survival time outwith the cat is 
less than two hours [Francis et a l  1977]. Therefore FeLV is transmitted most 
effectively by direct contact or communal feeding or watering. Indirect contact such 
as aerosol or infection from the surrounding environment has not been found to be 
important [Hoover et a l  1977; Francis and Essex, 1980].
Venereal transmission o f  FeLV may occur as the virus has been detected both in the 
epithelium o f  the urogenital tract, semen, vaginal fluids and the virus has also been 
shown to be transmitted to the foetus across the placenta [Hardy et a l  1973a; Rojko et 
a l  1979a]. One study indicated that exposure through the milk is a higher risk. 
Progeny o f  an infected cat were shown to contract the virus from 45 days after birth 
when FeLV neutralising antibodies could no longer be isolated from the milk. FeLV 
antigen and virus were detected in the milk, making it likely that transmission was via 
this route [Pacitti et a l  1986].
1.2.6 Pathogenesis of FeLV
The outcome o f infection with FeLV depends on the ability o f the host to mount an 
effective immune response. There are various possible disease states that may occur 
from infection with this virus: acute infection, transient viraemia without latent 
infection, transient viraemia with latent infection, atypical infection and persistent 
viraemia. These outcomes are summarised by Sparkes [1997], and Hoover and 
Mullins [1991] (figure 1.7).
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1.2.6.1 Acute infection
Oronasal exposure to FeLV allows infection o f  B and T lymphocytes and 
macrophages present in lymphoid tissue, primarily the tonsils. The virus may 
subsequently infect myeloid and erythroid haematopoietic progenitor cells in the bone 
marrow bringing about a cell associated viraemia [Rojko et a l  1979a; Hoover et a l  
1980; Rojko and Kociba, 1991].
1.2.6.2 Transient viraemia without latency
Most adult cats exposed to FeLV undergo transient viraemia that lasts up to 12 weeks 
whereby virus replicates and is shed. If these cats develop an immune response before 
infection becomes established in the bone marrow, then the virus is eliminated and no 
latent infection occurs. Virus neutralising antibodies can usually be detected in the 
blood in these individuals [Madewell et a l  1983]. Susceptibility o f  adult cats to FeLV 
may be enhanced if  the immune system is compromised, for example in treatment 
with adrenal corticosteroids [Rojko et a l  1979b].
1.2.6.3 Transient viraemia with latent infection
In some cats, protective immunity occurs after the virus has reached the bone marrow. 
This results in a transient infection lasting several weeks with the subsequent 
development o f immunity. However in 30 - 70% o f cats, latent provirus persists in the 
bone marrow, being held in check by the immune response [Post and Warren 1980]. It 
is thought that animals at this point do not shed virus, as cats exposed to latently 
infected individuals fail to show signs o f  exposure [Madewell et a l  1983]. Most 
latently infected cats have been found to completely eliminate provirus from the bone 
marrow within 30 months o f exposure to FeLV [Pedersen et a l  1984]. However 
studies have shown that a small proportion, around 10%, maintains latency for a 
prolonged period o f time. Loss o f latent virus is thought to occur because the infected 
immature marrow cells eventually differentiate to extinction, or are removed by the 
immune response [Pacitti et a l  1985]. Those cats that do remain latently infected are 
at risk o f reactivation o f infection if  their immune system is sufficiently compromised, 
such as administration o f adrenal corticosteroid hormones [Rojko et a l  1979b].
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However it is unlikely that latent infection plays a significant role in pathogenesis 
since it has been shown that cats who recover from natural FeLV exposure have a 
similar fatality rate to those who have never been exposed to the virus [McClelland et 
a l  1980].
1.2.6.4 Atypical infection
Atypical infection occurs in less than 5-10 % o f cats exposed to virus. In these cases, 
neither virus nor antigen can be detected in the blood, but FeLV can be found 
sequestered at various sites. These individuals can exhibit intermittent clinical signs o f  
infection and subsequently either eliminate the virus or become persistently infected 
in the future [Hayes et a l  1989; Rojko and Hardy, 1994].
1.2.6.5 Persistent viraemia
After the initial acute infection, the infected cat may become viraemic depending on 
whether an immune response can control and eliminate the virus. If the response is 
insufficient to prevent the virus becoming established in the bone marrow, then 
persistent viraemia will occur. Bone marrow infection generally occurs two to six 
weeks after viral exposure. At this point provirus becomes integrated into cells o f the 
bone marrow and viral replication takes place. On dissemination by the blood, the 
virus replicates in cells undergoing cell division producing localisation in mucosal 
and glandular epithelial cells o f  the pharynx, nasal passages, trachea, eosophagus, 
urinary bladder, intestines, salivary glands and pancreas [Rojko et a l  1979a]. 
Persistently infected cats are highly contagious and virus is released from the 
epithelium in large quantities into the local environment [Hardy et a l  1973a; Jarrett et 
a l  1973].
Viral replication in cells o f  the bone marrow over long periods, will give rise to 
multiple integration o f provirus into host cells [Mullins et a l  1980]. Continual 
replication in haemolymphatic tissues brings about depletion in lymphoid and 
myeloid cells and gradual immunosuppression. In time, malignant cell transformation 
may eventually occur [Hoover et a l  1980; Neil et a l  1987; Mullins et a l  1990]. The
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generation o f more pathogenic FeLV variants FeLV-B and FeLV-C may also occur at 
this point [Neil et a l  1987; Mullins et a l  1990].
The clinical signs o f disease are often not displayed in persistently infected 
individuals for periods o f months to years. During this time they remain viraemic and 
infectious to other cats. Persistent infection is rarely reversed and almost all cats will 
eventually succumb to FeLV-associated diseases later in life, often around 2-4 years 
o f  age [Hoover et a l  1991]. It is presumed that most cats succumb to disease at this 
age, because animals are most susceptible to infection in the early months o f  life and 
the sequence o f events from infection to clinical disease requires an approximate 2-4 
year incubation period.
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Figure 1-7 Outcome o f  FeLV infection THpover and Mullins. 19911.
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1.2.6.6 Susceptibility of the host to FeLV infection
The most crucial factor affecting susceptibility to FeLV infection is the potency o f the 
immune system. Also important is the viral dose, the duration o f exposure, the strain 
o f virus and the age o f the cat. Increasing maturity has shown to correlate with 
increased resistance to FeLV, cats up to 12 weeks o f age being highly susceptible to 
infection [Hoover et al. 1976]. Once the mature immune system has developed, cats
40
tend to recover from transient viraemia and by the age o f 16 weeks they are difficult 
to experimentally infect. As already explained, compromising the immune system 
with steroid treatment can break down this resistance and leave individuals 
susceptible to infection [Rojko et a l  1979b]. It is a strong possibility that genetics 
affect susceptibility to FeLV, particularly the type o f histocompatibilty complex 
inherited, but this has yet to be proven [Winkler et a l  1989].
1.2.7 Diseases associated with FeLV infection
The clinical consequences o f  FeLV infection can be broadly split into two categories: 
acute and chronie. Cats that contract the virus early in life may develop viraemia 
followed by an acute immunodeficiency syndrome with possible mortality within a 
year. Those cats that are asymptomatic during a prolonged incubation period o f  
months to years may develop a chronic immunodeficiency syndrome. These cats will 
have an increased risk o f tumour development.
1.2.7.1 Acute FeLV infection in the young cat
Studies o f  cats neonatally infected with FeLV have shown an impeded growth rate 
and higher death rate than control kittens, many dying between 8-12 weeks o f age. On 
necropsy, thymic atrophy and lymphoid depletion are usually present. Other 
infections may be evident which may have been a consequence o f FeLV infection. 
Some may also develop alimentary lymphosarcoma or lymphoblastic leukaemia 
[Anderson et a l  1971]. One group has shown what they describe as an acute feline 
immunodefieiency syndrome, eharaeterised by a survival period o f less than 180 days 
in cats inoculated at less than 8  weeks o f  age [Hoover et a l  1987]. In this syndrome a 
short asymptomatic period o f 2 - 1 0  weeks was followed by the onset o f disease: 
progressive lymphocytopenia, decreased lymphocyte blastogenesis, loss o f weight 
resulting in emaciation, persistent diarrhoea and opportunistic infections. Infections 
included bacterial rhinitis, pneumonia and necrotising stomatitis.
41
1.2.7.2 Diseases associated with chronic FeLV infection
These diseases are summarised by Hoover and Mullins [1991]. They consist o f  
cytoproliferative diseases including lymphosarcoma and FeLV-negative 
lymphosarcoma, leukaemia, myeloproliferative disorders, fibrosarcomas, 
immunosuppressive disease, myelosuppression, anaemia, and leucopenia. Less 
prevalent are enteropathy, infertility syndrome and neurologie disorders.
Lymphosarcoma
Lymphosarcoma is the most common form o f neoplasia associated with FeLV [Hardy 
et a l  1976] and it is likely that in time, all FeLV isolates would induce this disease 
provided another fatal FeLV-associated disease did not occur first. There are a 
significant proportion o f cats with lymphosarcoma where FeLV cannot be isolated, 
although in these cases there is a correlation o f  FeLV exposure, suggesting it could be 
the aetiological agent [Hardy et al. 1980].
Although in many cases the molecular basis for the induction o f  lymphosarcoma is 
unknown, two modes o f genetic mutation have been identified: transduction and 
insertional mutagenesis. Transduction is a process o f recombination between 
retroviral DNA and cellular oncogenes to produce an oncogenic variant. Diseases 
caused by recombinant viruses tend to be restricted to a single host probably due to a 
"swamping” effect by high titres o f FeLV virus in the host. Many cellular genes have 
been shown to be transduced by FeLV including abl, sis, kit and myc genes.
Neil et al. [1987], has reviewed the role o f  FeLV in naturally oecurring leukaemias. 
Several isolates o f FeLV/v-myc provirus were found originating from a recombination 
event between viral and cellular genes [Neil et al. 1987]. In one study, transduetion 
with c-myc gene was responsible for 21% o f 63 lymphoid tumours and was the most 
frequently mutated gene (32%) [Tsatsanis et al. 1994].
Secondly, proviral insertional mutagenesis can bring about the onset o f  neoplasia in 
FeLV. In the case o f lymphoma, several oneogenes and integration loci have been 
described 'mQlvLdingfit-l, flvi-1 , flvi-2, c-myc and pim-1. Tsatsanis et al. described the 
frequency o f proviral insertion as Jlvi-2 (24%), c-myc {\\Vo), fit-1  (8 %), and pim-1
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(5%). O f the tumours examined, 19% were mutated at two sites, and 5% at three o f  
the sites mentioned [Tsatsanis et a l  1994].
In addition, mutation within the LTR region has been detected in thymic 
lymphosarcomas where duplications o f  sequence in the core enhancer domain often 
occur [Granoff and Webster 1999].
Three anatomic groups o f feline lymphosarcoma have been found [Mackey et a l  
1972a; Mackey et a l  1972b]. In thymic lymphosarcoma the mass is found in the 
cranial mediastinum and is often associated with an effusion o f neoplastic cells in the 
thorax, which may cause dyspnoea. The neoplasia is usually solitary and tends to 
occur in cats under 3 years o f age. Multicentric lymphosarcoma lesions occur in the 
lymph nodes and other organs. The clinical signs associated with this are morbidity, 
anaemia, anorexia and debilitation as well as signs relating to space occupying 
lesions. Lastly, alimentary lymphosarcoma exhibits lesions in the intestines, 
mesenteric lymph nodes, kidneys and liver. Clinieal signs demonstrated here are 
usually connected with the intestines and renal function. In addition, lymphosarcoma 
cases often show immune dysfunction prior to neoplasia [Perryman et a l  1972].
Leukaemia and myeloproliferative disorders
Leukaemia occurs through the transformation o f  haemopoietic cells in the bone 
marrow, which are then released into the circulation. This may produce an increase in 
total leukocyte count. The clinical signs associated with leukaemia include weight 
loss, lethargy, pallor, listlessness, anaemia, intestinal disruption, hepatosplenomegaly 
and opportunistic infections. The most common leukaemias o f eats are erythroid and 
myelomonocytic leukaemia [Fraser et a l  1974; Faeklam and Kociba, 1986].
Myeloproliferative disorders display an abnormal growth and differentiation o f  
haemopoietic cells within the bone marrow. It is similar to a subleukaemic stage o f 
leukaemia. The clinical signs are similar to leukaemia, but animals also have a 
nonregenerative, macrocytic anaemia [Ward et a l  1969; Blue et a l  1988].
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Fibrosarcoma
Multicentric fibrosarcomas in young cats may be caused by feline sarcoma viruses 
(FeSV) whieh are reeombinants between FeLV and cellular proto-oncogenes. During 
this process some o f the viral genome is lost, so FeSV must be complemented by a 
concomitant FeLV-A infection in order to replicate [Besmer et al. 1983]. The 
neoplasia may be lethal or may regress completely over time.
Immunosuppressive disease
It has been shown that all FeLV subtypes cause dysfunction o f the immune system 
due to the development o f T- and B-cell deficits [Cockerell et al. 1976; Trainin et al. 
1983], which usually begin within the first two months after infection. Specific FeLV 
subtypes tend to display similar patterns o f  progressive immunosuppression. FeLV-A 
causes a slow gradual deficiency, which may suddenly worsen with the development 
o f variants such as FeLV-C [Jarrett et al. 1984; Mullins et al. 1991].
Studies have shown that some variant viruses are more acutely pathogenie than 
others. It has been demonstrated that small genetic substitutions in env gene o f one 
isolate in a family o f variants caused changes in function, structure and antigenicity o f  
SU and TM protein which is responsible for its increased T-cell cytopathogenicity 
[Overbaugh et al. 1988; Poss et al. 1989]. In addition, some groups have shown that 
the TM protein itself may have an immunosuppressive effect [Mathes et al. 1979].
Suppression o f the haemopoietic system
Suppression o f the haemopoietic system brings about a group o f diseases depending 
on the cell type affected, including myelosuppression, anaemia and leucopenia. 
Myelosuppression, or suppression o f  cells o f  the bone marrow, may produce clinical 
signs such as weight loss, anorexia, anaemia and secondary infection. If the erythroid 
cells are predominantly affected, then anaemia and its associated clinical signs will 
prevail, as will leucopenia if  leucocyte suppression is the major effeet.
It is thought that the virus genotype or mix o f genotypes will dictate the degree o f  
myeloid versus erythroid suppression involved. The most specific link between FeLV
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subtype and disease is FeLV-C and pure red cell aplasia [Jarrett et a l  1984; Domsife 
et a l  1989]. The anaemia associated with FeLV-C is usually nonregenerative, 
normocytic and normochromic with no significant reticulocytosis, whereas the more 
general anaemia produced by other subtypes is often more varied [Cotter et a l  1979; 
Weiser and Kociba, 1983].
Studies have shown that the anaemogenicity o f FeLV-C Sarma is localised to the N- 
terminus o f  SU protein [Riedel et a l  1986; Riedel et a l  1988;]. Other work has 
demonstrated that FeLV-C infects marrow erythroid progenitor cells preventing 
proliferation and differentiation, leading to impaired red blood cell production [Boyce 
et a l  1981; Abkowitz e/a/. 1987].
Enteropathy
FeLV can infect the crypt cells o f the intestinal mucosa causing chronic diarrhoea and 
weight loss. This is characterised histologically by crypt cell damage and villus 
atrophy and fusion [Reinaeher et a l  1987].
Foetal resorption
Infertility relating to foetal resorption has been shown to occur where conception and 
implantation occurs in viraemic animals, but within the first month o f gestation the 
foetuses die and beeome autolysed. Sometimes, the foetus may be carried to term and 
persistently infected kittens are bom [Cotter et a l  1975; Hoover et a l  1983].
Neurologic disease
A small number o f FeLV infeeted cats develop neurological dysfunction such as 
polyneuropathy, locomotory disorders and lower motor neurone paralysis [Haffer et 
a l  1987; Mitchell et a l  1997].
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1.2.8 Immune response to FeLV
The mechanism by which immunity to FeLV is achieved has yet to be fully 
elucidated, but work has concentrated on virus neutralising antibodies (VNAb), 
antibody to other viral antigens, anti-feline oncornavirus associated cell membrane 
antigen (FOCMA) antibodies and cell mediated immunity.
1.2.8.1 Virus neutralising antibodies and antibodies to other antigens
Virus neutralising antibodies to FeLV are directed at the envelope proteins o f the 
virus. Immune cats produce a strong antibody response to SU and TM envelope 
protein preventing attachment and binding o f  the virus to the cell specific receptor o f  
the host [Lutz et al. 1979; Rojko and Olsen, 1984; Rojko and Kociba, 1991]. There is 
a strong correlation between these high VNAb titres and resistance to infection. 
Immune cats do not normally produce antibodies to Gag proteins. It has been 
suggested that naturally infeeted cats are transiently anergic to these proteins. Since 
cats that are inoculated with recombinant protein produce anti-Gag antibodies 
[Charreyre and Pedersen, 1991], a theory has been proposed that FeLV has evolved a 
way o f  inducing anergy to prevent a CTL response to Gag-expressing cells [Jarrett, 
1999]. This may be due to the way in which Gag proteins are glycosylated.
The active development o f VNAb has been shown to be associated with resistance to 
FeLV infection [Hardy et a l  1976]. It has also been shown that passive transfer o f  
VNAb from the milk o f  the dam to her offspring will protect the kittens from 
infection [Jarrett et al. 1977]. However, VNAb are not essential for protection against 
FeLV and VNAb may be found in persistently viraemic cats [Charreyre and Pedersen, 
1991; Rojko and Hardy, 1994]. This has led to investigation into antibodies that are 
produced to other proteins such as NC, MA, TM, CA and other SU antibodies [Lutz et 
a l  1980; Snyder et al. 1985]. These studies suggest that antibodies other than VNAb 
are found at a higher level in resistant individuals than those persistently viraemic, 
suggesting a possible role in immunity against FeLV.
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1.2.8.2 Anti-FOCMA antibodies
Feline oncornavirus-associated cell membrane antigen (FOCMA) is a protein which is 
expressed on all cells that have been infected with FeLV. Antibodies to FOCMA have 
been shown to be cross-reactive with antibodies to the SU protein o f FeLV-C/Sarma 
[Vebrat et a l  1983]. This has led to the hypothesis that FOCMA may be endogenous 
FeLV-related sequences expressed as an antigen on the cell surface. Some studies 
have shown that the occurrence o f anti-FOCMA antibodies is associated with 
protection against some FeLV-induced neoplasia [Rojko and Kociba, 1991; Rojko 
and Hardy, 1994]. Cats with leukaemia or lymphosareoma have been shown to have 
negligible or low anti-FOCMA antibody titres, whereas cats with high titres appear to 
be protected even though they are viraemie [Cotter et a l  1974; Essex et a l  1976]. The 
mechanism by which this occurs may be associated with a complement-dependent 
reaction to transformed cells bringing about lysis [Grant et a l  1979].
1.2.8.3 Cell-mediated immunity
As VNAb have been shown not to be essential for protection against FeLV, this has 
led to the idea that cell mediated immunity may play an important role in resistanee 
[Jarrett, 2001]. This hypothesis is supported by work showing that a DNA vaccine to 
FeLV demonstrated a high degree o f  protection without the detection o f anti-FeLV 
antibodies following immunisation [Hanlon et a l  2001]. Those cats protected in this 
study were shown to have higher FeLV-speeific CTL responses in blood and 
lymphoid organs than those who were not vaccine immune [Flynn et a l  2000a]. 
Further to this, CTLs were shown to appear before VNAb in recovering cats whereas 
those with persistent viraemia displayed a silencing o f FeLV-specific humoral and 
CTL responses [Flynn et a l  2002].
1.2.9 Diagnosis of FeLV infection
In persistent viraemia, virus may be detected in sites o f replication such as the bone 
marrow and saliva, as well as in plasma and neutrophils o f the blood [Hoover et aL 
1977]. The blood may be used as an indicator o f infection in several ways. Plasma can
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be used for virus isolation (VI), or a blood smear can be used to detect p27 antigen in 
neutrophils by immunofluorescence [Hardy et al. 1973b]. Studies have shown that a 
persistently infected cat will give a positive result for both o f these techniques [Jarrett 
e ta l. 1982].
In addition, during viraemia infected cells produce large amounts o f p27 antigen 
which is released into the plasma. This has allowed the use o f  a capture enzyme- 
linked immunosorbent assay (ELISA) for p27 detection in plasma. The first 
commercial ELISA came on the market in 1979 (Leukassay F; Pitman-Moore) 
[Hartmann et al. 1973]. This was a sensitive detection system, but not very specific 
and has since been improved. There are many "in practice" detection kits for p27 also 
available which are based on ELISA or rapid immunomigration (RIM) [Hartmann et 
al. 2001]. Some studies have compared the use o f  RIM and p27 ELISA and found 
discrepancies due to differential sensitivity and specificity. Thus, it is usually 
recommended that these tests are confirmed by VI or immunofluorescence [Robinson 
eta l. 1998].
In addition, "discordant" cats are positive for FeLV antigen by ELISA but are 
negative by VI [Jarrett et a l  1991]. Up to 10% o f  cat plasma samples that are antigen- 
positive do not contain infectious virus. Virtually all these cats were from households 
with FeLV infection so it is possible that cats were sampled at the beginning or the 
end o f an infection. In some, however, this discordant state persisted for a long period 
o f time. It has been suggested that these individuals eould have had focal or atypical 
infection, which releases antigen but not virus into the blood. Cats in this state tended 
to eventually become seronegative to both tests, but some reverted to viraemia even 
after long periods, so these individuals should probably be considered a risk o f  
infection to other cats.
On rare occasions cats have been found to be negative for p27 antigen but positive for 
virus isolation [Jarrett, 1991]. This situation could be due to a mutant FeLV that either 
fails to release high levels o f p27 into the plasma or produces a mutant p27 molecule 
that cannot be detected by the monoclonal antibody used to capture p27 in the ELISA.
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1.2.10 Control of FeLV infection
In order to control the spread o f  FeLV in a household, persistently infected cats must 
be identified and separated from FeLV negative cats. The household must then be 
quarantined and no cats may be taken into or out o f the area. All equipment associated 
with the cats should be disinfected with diluted household bleach to kill the virus. It is 
recommended that all cats be re-tested after twelve weeks. The reason for this is to 
ensure that the positive cats are persistently viraemic rather than undergoing transient 
infection and also to ensure that virus negative cats were not incubating infection at 
the time o f testing. The negative cats at this point are considered FeLV free and 
should be re-tested every six to twelve months. Quarantine is then terminated, but any 
cats brought into this environment should be tested beforehand and kept in isolation 
until the test twelve weeks later has proven to be negative. In the case o f positive cats, 
these should either be euthanased or kept in isolation. These animals should not be 
used for breeding, as it is likely that all progeny will be FeLV positive [Hardy et a l  
1976].
49
CHAPTER 2: MATERIALS AND METHODS
2 MATERIALS AND METHODS
2.1 Materials
Any materials spécifié to given chapters are described in the relevant sections.
2.1.1 General
2.1.1.1 Major equipment
Sequencing apparatus and appliances; Licor 4000 (Licor Incorporated, USA), 
ABI Prism 3100 genetic analyzer (Applied Biosystems, Warrington, UK).
- Ultraviolet camera system: Photometries GmbH Sensys, A2S / Leica system 
(Munich, Germany).
Benehtop orbital shaker S03 (Stuart Scientific, UK).
C25 incubator shaker (New Brunswick Scientific, USA).
Cell freezer: Model Cryo 10 Series II (Planer products Ltd., UK).
Gel doeumentation system: (Ultraviolet products Inc., USA).
Centrifuges
Mierofuge 5415C (Eppendorf GMBH, Germany).
Benehtop centrifuge GS-6 R (Beckman Instruments Inc., USA).
Ultracentrifuge J2-21 (Beckman Instruments Inc., USA).
CO2 incubators for tissue culture (Leec Ltd., UK and Sanyo, UK).
Pipetteman (PIO, P20, P I00, P200, P I000): (Gilson Medical Electronics, France). 
Spectrophotometer model DU640 (Beckman Instruments Inc., USA).
Thermal Cyclers: GeneAmp 9600 (The Perkin Elmer Corporation, USA), PCR 
Express (Hybaid Limited, Middlesex, UK).
ABI Prism 7700 sequence detection system (Applied Biosystems, Warrington, 
UK).
Vacuum Dessicator (Jencons-PLS, UK).
- Water baths (Grant Instruments Ltd., UK).
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2.1.1.2 Consumables
Falcon tubes: 15 and 50 ml (Coming Incorporated, USA).
Screw top and flip top 1.5 ml Eppendorf and 0.5 ml tubes (Treff LAB, 
Switzerland).
- Pipette tips, yellow (200 |il) and blue (1000 pi) (Sarsteds, Germany). 
Endotoxin-free Rainin Greenpak filter tip pipette tips 20, 200 and 1000 pi 
(Anachem, UK).
- 0.2ml PCR tubes (The Perkin Elmer Corporation, USA).
Syringes o f  1, 2, 5, 10, 20 and 50 ml (Becton Dickinson Labware, UK).
Needles: 18, 21, 23 and 25 gauge (Becton Dickinson, UK).
Single use syringe filter, 0.2 and 0.45 pm (Sartorius, Germany).
Disposable, sterile scalpels (Swann Morton, UK).
Tissue culture disposables: Costar flasks (TRP, Switzerland), multiwell plates and 
pipettes (Coming Incorporated, USA).
Cell scrapers (Greiner Labortechnik Ltd., UK).
Petri dishes, bijoux and universals (Greiner Labortechnik Ltd., UK).
Lab Tek II chamber slide system - 8 well (Scientific Laboratory supplies, UK). 
Endotoxin-free Eppendorf tubes (Fisher Scientific, UK).
- 2 ml Cryogenic vials (Coming Incorporated, USA).
- Blood tubes: Heparin 2ml, EDTA 2ml, plain 2ml and sodium citrate 2ml
(Sarstedt, Germany).
2.1.1.3 Complete kits and specialist reagents
- PCR-Script Cloning Kit (Stratagene, Netherlands).
- Qiaprep Miniprep Kit (Qiagen, West Sussex, UK) was used to isolate up to 20 pg
o f plasmid DNA from 3 ml LB bacterial culture.
Qiagen plasmid Mega Kit (Qiagen, West Sussex, UK) was used to prepare up to 
2.5 mg o f  plasmid DNA from 500 ml LB bacterial culture.
Qiagen plasmid Endofree Giga Kit (Qiagen, West Sussex, UK) was used to isolate 
up to 10 mg o f  high-copy plasmid DNA using 2.5 1 LB bacterial culture.
QIAquick gel extraction kit (Qiagen, West Sussex, UK) for purification o f  DNA  
and extraction o f DNA from agarose gel.
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QIAamp DNA blood mini kit (Qiagen) for the preparation o f  up to 120 pg DNA  
from buffy coat or lymphocyte samples.
- TOPO TA Cloning Kit (Invitrogen Life Technologies, Paisley, UK) for the 
cloning o f PCR products with A overhangs, generated by Taq polymerase.
Centra Pureseript RNA isolation kit (Flowgen, Leicestershire, UK ).
- Access RT-PCR System (Promega, UK) for reverse transcription and PCR 
amplification o f specific target RNA from total RNA.
- ABI Prism BigDye Terminator Cyele Sequencing Ready Reaction Kits (Applied 
Biosystems, Warrington, UK).
Performa DTR gel filtration cartridge kit (Edge Biosystems, USA).
Quantikine human IFNy kit (R + D Systems, USA).
ECL+ PLUS Western blotting detection system and ECL Hyperfilm (Amersham 
Pharmacia, UK).
LipofectAMINE Reagent (Invitrogen Life Technologies, UK).
2.1.1.4 DNA plasmid vectors
- PCR-Script Amp SK(+) cloning vector (Stratagene, UK) is derived from 
pBluescript II SK(+) phagemid. This plasmid contains an ampicillin resistance 
gene, a lac promoter, T3 and T7 RNA polymerase promoters and a multicloning 
site, which includes S rfl restriction site.
pCI-neo Mammalian Expression Vector (Promega, USA).
- pCR®2.1 TA cloning vector (Invitrogen Life Technologies, Paisley, UK) as part 
o f the TOPO TA cloning kit, supplied as linearised DNA with 3 ’ T overhangs. 
pCR®3.1 Eukaryotic TA Cloning® Kit cloning vector (Invitrogen Life 
Technologies, Paisley, UK).
- pUSEL , from a mammalian expression series constructed from pCI-neo 
(Promega), by Dr Derek Bain.
- pEGFP-Cl vector (Clontech Laboratories Inc., UK) containing GFPmutl variant 
used to monitor transfection efficiency.
52
2.1.1.5 Enzymes
Restriction enzymes and buffers were supplied by New England Biolabs (Herts, 
UK), Invitrogen (Paisley, UK), or Stratagene (UK).
~ PURESCRIPT DNAse I (Gentra systems, USA ).
- Pfu DNA polymerase (Promega, USA) for proof reading polymerase function.
Taq DNA polymerase (Qiagen).
T4 DNA ligase (New England Biolabs, USA).
Thermosequenase DNA polymerase supplied as a component o f the cycle 
sequencing kit (Amersham Pharmacia, UK).
Human recombinant caspase I (Calbiochem, UK).
2.1.1.6 Reagents and solutions
Water
Water for the preparation o f media and general solutions was purified using a 
Millipore ROlO system. Ultrapure water for work using recombinant DNA and 
protein was purified by a Millipore Q50 water purifieation system (Millipore (UK) 
Ltd., Watford, UK). Tissue culture grade distilled water was supplied by Invitrogen 
Life Technologies, UK. For any work using RNA, DEPC treated water was used. This 
was prepared by treating dH2 0  with 0.05% diethyl pyroearbonate overnight at room 
temperature. This was then autoclaved for 30 minutes at 120°C to remove DEPC. 
Endotoxin free water for DNA vaccine preparation was supplied by Sigma and PCR 
grade water by Invitrogen Life Technologies, UK.
Chemicals
All general chemicals used were o f analytical (Analar) or ultra pure grade, supplied 
by Sigma Chemical Company, (Dorset, UK) or BDH Ltd., (Poole, UK), unless 
otherwise specified.
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Phosphate buffered saline
Phosphate buffered saline (1 x PBS): 140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HP0 4 , 1.8 mM KH2PO4 (pH 7.3).
Endotoxin-free PBS (Biowhittaker UK Ltd.).
2.1.1.7 Oligonucleotides
All oligonucleotides were synthesised and supplied freeze dried by the manufacturer 
MWG-Biotech and were then resuspended in dIÎ2 0  for use. Sequencing primers for 
Licor model 4000 were modified by IRD 800 labelling. Sequencing primers for ABI 
Prism 7700 system were unmodified. Spécifié primer sequences are detailed in the 
appropriate chapters.
2.1.1.8 ELiSA
Coupling buffer: 10 mM sodium bicarbonate, 1 mM EGTA, pH 9.5, Made at 10 x 
concentrated and stored at 4^C.
TBS-T: 20 mM Tris, 140 mM sodium chloride, 0.1% Tween-20, pH 7.6, stored at 
room temperature.
TMB liquid substrate system (Sigma, UK).
2.1.1.9 Experimental animals
Specific pathogen free (SPF) cats were purchased from a commercial breeding unit 
and housed at the isolation unit at The University o f Glasgow. They were fed a 
commercial diet and all procedures were performed according to Home Office 
regulations.
54
2.1.2 DNA and protein analysis
2.1.2.1 DNA purification
STET: 8 % sucrose, 50 mM Tris-HCl pH 8 , 50 mM EDTA pH 8 , 5% triton x 100 
in dH2 0 , filtered (0 .2 2  pm), stored at room temperature.
- lysozyme (Sigma, UK).
2.1.2.2 Molecular size standards for DNA and protein
DNA: 1 kb DNA ladder (size range 100 base pairs (bp) to 12 kb) (Invitrogen Life 
Technologies, Paisley, UK).
PROTEIN: Kaleidoscope Pre-stained Markers wide range (6.7-205 kDa) (Bio- 
Rad, Herts, UK).
- Perfect protein HRP conjugate Western blot marker (15kDa - 150kDa) (Novagen, 
Germany).
2.1.2.3 DNA agarose gel reagents
- DNA loading buffer: 50% glycerol, 0.5% bromophenol blue, 0.5% xylene cyanol,
100 mM EDTA in dH2 0 . Stored at room temperature and used at a dilution o f
1: 10.
Ethidium bromide: 10 mg/ml stock in dH2 0 , working solution at 3 mg/ml with 
dH2 0 , stored away from light.
2.1.2.4 SDS-PAGE reagents
SDS-PAGE denaturing loading buffer: 62.5 mM Tris-HCl, pH 6 .8 , 20% glycerol, 
2 % SDS, 5% p-mereaptoethanol, stored at 4°C.
10 X SDS-PAGE Running Buffer: Tris base 30 g, glycine 144 g, SDS 10 g in 1 
litre dH2Û.
- Polyacrylamide solution: Acrylamide/Bis acrylamide stock solution. 30% (w/v)
acrylamide, 1.579% (w/v) bis acrylamide, ratio 19:1 (Severn Biotech Ltd.); stored
in the dark at 4”C.
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1 M Tris HCl: 121 g Tris base in 800 ml dH2 0  adjusted to pH 6 .8  with 
concentrated HCl and made up to 1 litre with dH2 0 .
1.5 M Tris: 181.5 g Tris base in 800 ml dH2 0  adjusted to pH 8 .8  with sodium 
hydroxide and made up to 1 litre with dH2 0 .
- Towbin transfer buffer: 25 mM Tris, 137 mM glycine, 20% methanol to 500 ml 
with dH2 0 .
10 X  Tris Buffered Saline (TBS): Tris base 24.2 g, NaCl 80.0 g, HCl 38.0 ml pH 
7.6, dH2 0  to 1 litre.
TBS-T: 20 mM Tris, 140 mM sodium chloride, 0.1% Tween-20, pH 7.6, stored at 
room temperature.
- TBE (10 x): 0.9 M Tris-HCl, 0.9 M Boric acid, 25 mM EDTA pH 8.3 diluted to 1 
X with dH2 0 .
2.1.3 Bacteria
2.1.3.1 Bacterial strains
Epicurian Coli XL-10-Gold Kan ultracompetent cells (Stratagene, UK).
MAX Efficiency STBL2 competent eells (Invitrogen Life Technologies, UK).
TOP 10 cells comprising One Shot chemically competent E. coli (Invitrogen Life 
Technologies, Paisley, UK).
2.1.3.2 Bacterial media and supplements
Ampicillin: 100 mg/ml in dH2 0 . Filtered through a 0.22pm filter, aliquoted and 
stored at -20®C.
SOC Medium: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2j. 10 mM MgS0 4 , 20 mM glucose.
Luria-Bertani (LB) medium: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% 
(w/v) sodium chloride in dH2 0 , autoclaved and stored at room temperature.
- LB-agar: LB medium containing 1.5% (w/v) agar.
X-gal solution: prepared as 40 mg/ml stock in dimethylfbrmamide, stored at 
-20°C.
56
Isopropyl p-D-l-thiogalactopyranoside (IPTG): 10 mM in dH2 0 , stored at -20°C.
2.1.4 Cell culture
2.1.4.1 Cell lines
293T cells were kindly supplied by Celia Cannon (Retrovirus Research 
Laboratories, University o f Glasgow).
FEA and FeLV-A cells were a kind donation from Mathew Golder (Feline Virus 
Unit, University o f Glasgow).
Lec8  (CHO) and KG-1 cells were purchased from American Type Culture 
Collection (ATCC).
MYA-1 cells were kindly supplied by Hayley Haining (Retrovirus Research 
Laboratories, University o f Glasgow).
2.1.4.2 Media
- All media and supplements were purchased from Invitrogen Life Technologies 
unless otherwise stated.
FEA and 293T cells: Dulbecco s Modified Eagle Medium (DMEM) with sodium 
pyruvate, with 1 0 0 0  mg/1 glucose, with pyridoxine.
LN156 cells: RPMI 1640 medium with L-glutamine.
MYA-1 cells: RPMI 1640 medium without L-glutamine.
KG-1 cells: Iscove's Modified Dulbecco's medium with L-glutamine.
Lec8  cells: Nutrient mixture F-12 (HAM) with L-glutamine.
Leibovitz medium
2.1.4.3 Supplements
- Foetal Calf Serum (FCS), (TCS Biologicals LTD., Buckingham, UK): heat 
inactivated, virus screened, mycoplasma screened.
- Horse Serum heat inactivated at 56°C for 1 hour (Invitrogen, UK).
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Peniciilin/streptomycin: supplied as a 100 x stock solution o f 10,000 units 
penicillin and 1 0 ,0 0 0  pg streptomycin per millilitre, used at a final concentration 
o f 100 lU penicillin and 100 pg streptomycin per ml (1 x 
Penicillin/Streptomycin). Stored at 4°C.
L-glutamine: supplied 200 mM (100 x) stock solution stored at 4°C.
Gentamicin: 10 mg/ml in dH2 0 .
Trypsin-EDTA (1 x) in HESS W /0  CA + MG W/EDTA 4NA. Stored at 4°C. 
p-Mercaptoethanol (2-ME) 14.3 M, DNase, RNase and protease free (Sigma, 
UK).
Cell lysis buffer for SDS-PAGE: 100 mM Tris HCl pH 6 .8 , 2% SDS, 20% 
glycerol in dH2 0  with protease inhibitors.
Polybrene: registered trademark for hexadimethrine, (Abbott laboratories, USA). 
Hydrocortisone succinate (Sigma, UK).
10% dimethyl sulphoxide (DMSO) (Analar, BDH Ltd).
Caspase buffer: 100 mM NaCl, 50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10% 
glycerol, 0.1% CHAPS, pH 7.4.
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2.2 METHODS  
2.2.1 Plasmid DNA production from bacteria
Bacterial cultures for isolation o f  plasmid DNA were prepared in LB growth medium, 
while single colonies o f bacteria were grown on agar. LB-agar plates were made by 
filling a 100 mm Petri dish with approximately 15 ml agar. The presence o f  an 
ampicillin resistance gene in all plasmids used allowed selective growth o f plasmid 
containing bacteria. Ampicillin was added to both growth media and agar to a final 
concentration o f 1 0 0  pg/ml.
For small scale DNA preparation, single colonies o f  bacteria were selected using a 
sterile 200 pi pipette tip and transferred to a bijoux containing 3 ml o f  LB culture 
medium. These were incubated overnight at 37°C in an orbital incubator.
For large scale DNA preparation, a single colony was transferred into either 3 ml o f  
LB medium (Qiagen Mega kit) or 8  ml LB medium (Qiagen Endofree Giga kit) and 
incubated for 6 - 8  hours at 37°C in an orbital incubator. The culture was then added to 
the appropriate volume o f LB medium and incubated in an orbital incubator overnight 
at 37"C.
Bacterial cultures were preserved for further use by making glycerols from large-scale 
DNA preparations. A volume o f 200 pi o f  80% glycerol was added to 800 pi o f fresh 
culture, vortexed briefly and then stored at -70°C. To recover the bacteria from 
glycerol stocks, the glycerols were thawed, streaked out onto an LB-agar plate using a 
sterilised platinum wire and incubated overnight at 37°C.
2.2.2 Purification of minipreparations of DNA
The STET method was used to obtain DNA from small-scale preparations. A 3 ml 
bacterial culture was grown overnight and 1.5 ml was pelleted by centrifugation at 
14000 rpm for 2 minutes. The supernatant was removed using a pipette and the
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bacterial pellet was resuspended in 85 pi o f STET. 35 pi o f 10 mg/ml lysozyme in 
STET was then added and gently mixed. This was boiled at lOO^C for 45 seconds and 
centrifuged for 15 minutes at 14000 rpm. Precipitated DNA was removed using a 
wooden toothpick, 120 pi o f propan-2-ol added and the sample placed at -70°C for 15 
minutes. The DNA was harvested by centrifugation at 14000 rpm for 15 minutes, 
drying o f the pellet using a vacuum pump and elution in 20 pi dHiO. The DNA was 
stored at -20°C until further use.
High quality small scale DNA preparations required for cloning or sequencing were 
made using QIAprep Miniprep kit (Qiagen), according to the manufacturer's 
instructions. This procedure involves alkaline lysis o f bacterial cells followed by 
adsorption o f DNA onto a silica-gel membrane. The membrane is washed o f  
endonucleases and salts and then eluted in 50 pi dH2 0 .
2.2.3 Large scale DNA preparation
Larger quantities o f DNA were prepared using Qiagen plasmid Mega Kit and Qiagen 
plasmid Endofree Giga Kit (Qiagen, West Sussex, UK) for up to 2.5 mg and 10 mg o f  
plasmid DNA respectively. Both kits consist o f  a scaled up version o f  the QIAprep 
Miniprep kit (Qiagen).
2.2.4 Digestion of DNA with restriction enzymes
Restriction endonucleases were used for analysis and manipulation o f DNA. 
Typically, 1-2 pg o f  DNA was digested with 5 units/pg o f  the appropriate restriction 
enzyme. 1 0  x enzyme reaction buffer was used at 1 0 % total volume and the reaction 
was made up to 20 pi in dH2 0 . The reactions were incubated at 37°C for at least 1 
hour unless otherwise stated.
For preparation o f  DNA fragments for use in ligation reactions, between 5 and 20 pg 
o f DNA was digested overnight with the appropriate enzyme and reaction buffer to a 
final volume o f 2 0 0  pi in dH2 0 .
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2.2.5 DNA electrophoresis
Typically, 0.8-1.5% agarose gels were prepared as this produced efficient separation 
o f DNA fragments between 800 and 1500 bp. The agarose gel was made using 1 x 
TBE and ethidium bromide was added at 0.25 pg/ml. The gels were submerged in 
perspex tanks using 1 x TBE and the comb removed. Samples mixed with DNA  
loading buffer were loaded onto the gel alongside 1 kb marker. Gels were run 
between 80-100 volts for 30-90 minutes and bands visualised using a short wave UV  
transilluminator. Images were then captured using a gel documentation system.
2.2.6 DNA fragment purification
DNA fragments used for ligation reactions were initially visualised on an agarose gel 
and excised using a sterile scalpel. DNA purification was performed using QIAquick 
gel extraction kit, (Qiagen, West Sussex, UK) according to the manufacturer's 
instructions. The DNA was generally eluted in 50 pi o f  dH2 0 .
2.2.7 Ligation of DNA
In general, 100-200 ng o f vector DNA was used per reaction and insert DNA  
calculated to a molar ratio o f 1:9, vector: insert. A ligation mix was prepared along 
with the DNA using 3 units (3 pi) o f DNA ligase, 4 pi o f 5 x ligation buffer and dH2 0  
to a final volume o f 20 pi. The reaction was incubated overnight at a temperature o f  
14°C, which maintains a good balance between annealing o f ends o f  DNA and 
activity o f  the enzyme. Ligations performed using commercial kits (e.g. pCR-Script 
(Stratagene)) were carried out according to the manufacturer's instructions.
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2.2.8 Quantification of nucleic acid concentration
2.2.8.1 Spectrophotometer
The spectrophotometer was firstly zeroed by measuring the optical density (OD) o f  
DNA diluent at 260 nm. The DNA was diluted in the appropriate diluent at a 1:100 
dilution, transferred to a cuvette and an OD reading taken at 260 nm. The 
concentration o f  nucleic acid (NA) in the sample was calculated using the following 
formula:
[NA] pg/pl = OD260X NAF X DF/1000,
In this formula, NAF (nucleic acid factor) is 50 for DNA, 40 for RNA and 20 for 
oligonucleotides. The DF (dilution factor) in this case was 100 [Sambrook et a l  
1989]. For DNA samples prepared as described, the concentration o f  nucleic acid in 
pg/pl was 5 X  OD260.
2.2.B.2 Agarose gel
Alternatively, DNA amounts could be estimated by running the sample on an agarose 
gel. The sample band was compared to bands o f a known quantity o f  1 kb DNA  
marker following staining with ethidium bromide and UV transillumination.
2.2.9 Bacterial transformation
Transformation o f bacteria was performed using commercial kits according to the 
manufacturer's instructions. Any modifications to the manufacturer's protocol are 
listed in the appropriate chapters. Volumes o f 50 and 100 pi o f  transformation were 
plated onto LB-agar plates containing 100 pg/ml ampicillin. The plates were 
incubated overnight at 37^C and colonies were selected and cultured as described 
previously.
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Where cloning vectors contained a lac promoter, application o f 25 pi o f X-gal to agar 
plates 30 minutes prior to coating with bacterial culture allowed blue/white colony 
selection. Cloning into the multicloning sites o f these vectors causes disruption o f  
lacZa expression and these constructs remain white, whilst vectors without insert 
appear blue on the plate.
2.2.10 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE gels consist o f a stacking buffer that initially concentrates the protein into 
a narrow band and a separating gel, which separates the proteins according to 
molecular size. The composition o f separating gel is determined by the molecular size 
o f the protein to be separated. Higher percentages separate smaller sized proteins. To 
detect flexi-IL-12 (75kDa), a 12% gel was used whereas a 15% separating gel was 
used to detect ILRAP-IL-18 (18kDa). Recipes for stacking and separating gels are 
described by Sambrook et al. [1989].
2 glass plates (10 x 7.3 cm and 10 x 8.3 cm) were separated by 0.75 mm spacers and 
assembled in a casting stand. The separating gel was poured between the plates to a 
depth o f  around 5 cm and was overlaid with Tris-saturated butanol to allow the gel to 
polymerise with a straight edge. Once polymerised, the butanol was removed, the 
stacking gel poured and a ten well comb was inserted into the top o f  the gel. Once 
completely polymerised, the gel was run on the Mini-PROTEAN II electrophoresis 
system. The gel plates were attached to the gel holder and transferred to the 
electrophoresis tank. The holder was immersed in 1 x SDS-PAGE running buffer, the 
comb was withdrawn and the wells were flushed with running buffer to remove any 
excess gel fragments.
Most protein samples consisted o f transfection products and initially 20 jil o f  either 
supernatant or cell lysate were used for each well. These samples were diluted 
appropriately depending on the visibility bands produced upon immunodetection. A 
suitable volume (5 pi) o f  5 x protein sample loading buffer was added to each sample 
and they were incubated at 100°C for 5 minutes. The loading buffer contains SDS and 
p-mercaptoethanol, which reduces proteins to their subunits by reducing disulfide
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bonds. The samples were then loaded into the wells alongside a molecular size 
marker. The gel was electrophoresed at 150 V for 70 to 80 minutes until the 
bromophenol blue had reached the bottom o f the glass plates. The gel was removed 
from the plates and the stacking gel excised with a sterile scalpel and discarded.
2.2.11 Immunodetection of proteins
This technique involves the electrophoretic transfer o f protein onto a membrane, in 
this work either nitrocellulose or PVDF, using a semidry immunoblotter. The protein 
is then bound to the membrane and can be probed using immunodetection reagents. 
The membrane is probed firstly with primary antibody and then secondary anti-IgG 
antibody, which is coupled with horseradish peroxidase. These protein-antibody 
complexes are then detected using ECL+ PLUS reagents (Amersham Pharmacia, 
UK). This system relies on the emission o f  light due to oxidation o f luminol by 
horseradish peroxidase. This light is then detected by a short exposure to blue-light 
Hyperfilm ECL (Amersham Pharmacia, UK).
Following electrophoresis, the gel was submerged in Towbin transfer buffer along 
with two similarly sized sheets o f extra thiek filter paper (Whatman international Ltd., 
England). A suitably sized Hybond-ECL PVDF or nitrocellulose membrane was pre­
wetted in 100% methanol before being submerged in Towbin buffer. A filter 
paper/membrane/gel/fllter paper sandwich was made and air bubbles removed by 
gentle pressure. This sandwich was then placed in a semi-dry electroblotting system  
(Transblot SD- Biorad). The electroblotter was run at 15 V for 30 minutes allowing 
protein from the gel to be transferred to the membrane.
The non-specific binding sites o f  the membrane were blocked by washing overnight 
in 10% low fat dried milk (Marvel-Premier beverages, Stafford, UK) diluted in 0.1% 
Tween in Tris buffered saline (TBS-T) on an orbital shaker at room temperature. The 
membrane was washed in TBS-T once for 15 minutes and twice for 5 minutes on the 
orbital shaker at room temperature. Primary antibody was delivered to the membrane 
in 5% Marvel in TBS-T and incubated at room temperature for 1 hour with gentle 
shaking. The primary antibodies used in this work were generally used at a
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concentration between 1:2000 and 1:80. The membrane was washed in TBS-T for 30 
minutes and two more washes o f 15 minutes, on the orbital shaker at room 
temperature. The HRP labelled secondary antibody used at dilutions o f  between 
1:2000 and 1:200, was delivered in 5% Marvel in TBS-T for 1 hour also shaking at 
room temperature. This was followed by a final set o f washes in TBS-T, one for 30 
minutes and two for 15 minutes.
The membrane was placed on cling film, protein side up, and protein was deteeted 
using ECL+ PLUS reagents (Amersham Pharmacia, UK) using the instructions o f  the 
manufacturer. The membrane was placed between cling film in a film cassette and a 
piece o f  Hyperfilm-ECL was placed into the eassette and exposed for 1 to 30 seconds 
under dark conditions. The film was then developed using an automated processor. 
Longer exposures o f between 2 and 30 minutes were also taken depending on the 
result o f the first film.
2.2.12 Polymerase chain reaction (PCR)
2.2.12.1 Primer design
In primer design, eertain specific parameters were followed to encourage efficient 
annealing and amplification. Primers used were between 18 and 25 nucleotides in 
length, with a G/C concentration o f  50-60% where possible. Also primer-dimer 
formation was minimised by avoidance o f complementarity between primer pairs and 
within the primer itself. In terms o f the gene used as template in the primer design, 
G/C rich areas were avoided due to secondary structure. Wherever possible, primer 
pairs with similar melting temperatures were used to ensure similar annealing 
temperatures for both primers.
2.2.12.2 Master mixes
Master mixes were mainly prepared in bulk in a designated “PCR clean area” within 
the department. Precautions were taken to prevent contamination o f the reactions or 
the surrounding area, which included the use o f  protective clothing, filter pipette tips, 
gloves and sterile tubes. PCR o f p35 and p40 fragments for flexi-IL-12 used the
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commercial kit Pfu polymerase isolated from Pyrococcus furiosus (Promega, USA). 
This kit contained master mixes that were prepared according to the instructions of 
the manufacturer, aliquoted into 0.2 ml PCR tubes (Perkin Elmer, USA) and stored at 
-20°C. These master mixes consisted o f  optimised proportions o f Pfu DNA  
polymerase enzyme, enzyme buffer, dNTPs and nuclease free dHaO. This 
optimisation is to achieve a balance between specificity and quantity o f product 
amplified. DNA template and primer pairs were added to the master mix in the "PCR 
clean area" and the reactions were carried out using GeneAmp 9600 cycler (Perkin 
Elmer, USA). Specific reaction amounts and cycling conditions are described in more 
detail in the relevant chapters.
2.2.13 Reverse Transcriptase- PCR
RT-PCR was carried out using total RNA prepared from MYA-1 cells using the 
Gentra Purescript RNA isolation kit according to the manufacturer's instructions. The 
Access RT-PCR system (Promega, USA) is a one-tube, two-enzyme kit which uses 
Avian Myeloblastosis Virus (AMV) reverse transcriptase for first strand DNA  
synthesis, and thermostable Tfl DNA polymerase from Thermus flavus for second 
strand cDNA synthesis and DNA amplification. Master mixes for this system were 
prepared as for PCR described above. In addition, all plasticware was RNase free and 
DEPC treated water was used.
Reaction mixes comprised: 0.2 mM dNTP mix, 1 pM o f both upstream and 
downstream primer, 1 mM MgS0 4 , 0.1 p/pl AMV Reverse Transcriptase, 0.1 p/pl Tfl 
DNA Polymerase, and 20% total volume with 1 x P^MSflTfl Reaction Buffer. 1 pg -  1 
pg total RNA was used and the reaction was made up to 50 pi with Nuclease - Free 
Water.
The cycling conditions used were as follows: First Strand cDNA Synthesis: Reverse 
Transcription step; 48°C for 45 minutes, AMV RT inactivation and 
RNA/cDNA/primer dénaturation; 94°C for 5 minutes. Second Strand cDNA Synthesis 
and PCR amplification: Dénaturation; 94°C for 30 seconds, Annealing; 45°C for 30 
seconds. Extension; 68°C for 1 minute. 40 cycles o f this was completed. The final
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extension was ll^ C  for 10 minutes and the soaking step was 1 cycle at 4°C. In order 
to establish the most suitable annealing temperature, reactions were often set up with 
a temperature gradient between 37°C to 66^C.
2.2.14 Sequencing
Two methods o f  sequencing were undertaken in this project. Initially sequencing was 
performed using the Li-Cor 4000 model. This was subsequently replaced by the ABI 
Prism technique as this method produced more accurate, reliable data, particularly in 
G/C rich sequences.
2.2.14.1 Li-Cor 4000 model
This technique required the use o f IRDSOO-labelled primers (MWG-Biotech) and the 
ThermoSequenase Fluorescent Labelled Primer Cycle Sequencing Kit with 7-deaza- 
dGTP (Amersham Pharmacia, UK). Cycle sequencing is based on the chain 
termination method [Sanger et al. 1977], with use o f  a thermostable DNA polymerase 
that allows multiple rounds o f  high temperature DNA synthesis.
A reaction mix o f  500 ng plasmid DNA, 1 pmol o f  IRD800 labelled primer and 2 pi 
o f  reaction mix containing 45 mM o f dGTP, dATP, dTTP and dCTP, reaction buffer 
and thermostable DNA polymerase was prepared in a 0.2 ml reaction tube and dH20 
was added to a volume o f  8 pi. Cycling conditions used were as follows: 95^C for 5 
minutes followed by 25 cycles o f  95°C for 30 seconds, 50-60®C for 30 seconds and 
72°C for 30 seconds. The annealing temperature was usually 2°C below the melting 
temperature o f the primer used. Once this reaction was completed, 4 pi o f formamide 
loading buffer provided with the kit was added to each reaction and the samples were 
ready to be loaded.
Gel plates were thoroughly cleaned and polished with isopropanol, and then 
assembled in the casting stand with spacers. The gel was prepared using 7.2 ml 10 x 
TBE, 25.2 g urea, and 4.8 ml Sequagel XR ultra pure concentrate (National 
Diagnostics) and made up to a total volume o f  60 ml with dH20. A volume o f 400 pi
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o f 10% APS was added and 3 ml o f this mix was removed and placed in a bijou. A 
32 pi volume o f 10% APS and 4 pi N'-tetramethyl-ethylenediamine (TEMED) was 
added and the mix was injected at the bottom o f  the glass plates and allowed to 
polymerise to form a plug. A volume o f 36 pi o f  TEMED was added to the remaining 
gel mix and the gel was poured. The comb was placed in the top o f the gel and the gel 
was allowed to polymerise for approximately 90 minutes. The gel was then inserted 
into the Li-Cor 4000 system with 1 x TBE added to buffer tanks. The comb was 
removed, the wells flushed with buffer and a pre-electrophoresis step performed 
focussing o f the microscope and adjustment o f gain controls. Reaction samples were 
denatured for 3 minutes at 95°C and then around 1-1.5 pi was loaded into each well. 
The gel was electrophoresed and sequence data was recorded, one run typically 
producing 800 bp o f sequence. The data was analysed using the GCG package 
(Wisconsin Package Version 9.1, Genetics Computer Group (GCG), Madison, 
Wisconsin).
2.2.14.2 ABI Prism Technique
Cycle sequencing reactions were prepared in 0.2 ml PCR tubes using a ready made 
BigDye Terminator RR master mix (Applied Biosystems, Warrington, UK). This 
consisted o f  dNTPs, dye terminators, magnesium chloride, buffer, AmpliTb^ DNA  
polymerase and FS, which is a variant o f Thermus aquaticus DNA polymerase. In 
general, around 500 ng o f high-quality double stranded DNA template was included 
in the cycling reaction (200-500 ng). 3.2 pmol o f  forward and reverse primers were 
included. The reactions were made up to a total volume o f 20 pi with dH20.
The cycle sequencing reaction was carried out under the following conditions: 25 
cycles o f  the following; rapid thermal ramp to 96°C, 96°C for 10 seconds, rapid 
thermal ramp to 50°C, 50°C for 5 seconds, rapid thermal ramp to 60°C, 60°C for 4 
minutes and rapid thermal ramp to 4°C and held until collection.
Reactions were purified by spin column using Performa DTR gel filtration cartridge 
kit (Edge Biosystems, USA). A fresh spin column was centrifuged at 750 g for 2 
minutes to remove interstitial fluid. The column was removed from the wash tube and
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placed in a new collection tube and the cycle sequencing reaction was applied to the 
centre o f the binding column and centrifuged for 2 minutes at 750 g. The binding 
column was then removed, the DNA pellet dried for 15 minutes using a vacuum pump 
and the pellet was resuspended in 20 pi Hi Di Formamide (Applied Biosystems, UK). 
The samples were loaded onto a 96 well plate and electrophoresed on an ABI Prism 
3100 Genetic Analyser. The chromatogram was studied by eye and also analysed in 
the GCG package as described above.
2.2.15 Eukaryotic cell culture
2.2.15.1 Maintenance of ceiis
All cell lines were maintained in plastic tissue flasks in an incubator at 37®C with 5% 
CO2. 5 ml o f  medium was used in 25 cm  ^flasks, 20 ml o f medium in 75 cm  ^ flasks, 
and 35 ml used in 175 cm  ^flasks.
293T cell line
293T cells are highly transformed human renal epithelial cell line, which expresses 
SV40 large T antigen [DuBridge et al. 1987]. They were maintained as a monolayer 
in Dulbecco's MOD Eagle medium (DMEM), 400 lU/ml penicillin/streptomycin, 
2 mM L-Glutamine, 10% FCS and 400 pg/ml G418 (gentamycin). Transfections for 
use in KG-1 bioassays were maintained in G418 free culture medium. They were split 
1:8 every 3-4 days when confluent, using trypsin as described below.
FEA and FeLV-A cell line
FEA cells are fibroblasts derived from whole feline embryos [Jarrett et al. 1973]. 
FeLV-A cells are FEA cells infected with FeLV-A virus. These cells were maintained 
as a monolayer in Dulbecco's MOD Eagle medium (DMEM), 1 x 
penicillin/streptomycin, 2 mM L-Glutamine and 10% FCS. They were split 1:4 every 
3-4 days when confluent, using trypsin as described below.
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C H O  (L ec8) cell line
These are Chinese hamster ovary epithelial cells derived from a parental CHO Pro-5 
clone (ATCC). They were maintained as a monolayer in Nutrient mixture F-12 
(HAM) with L-Glutamine, 1 x penicillin/streptomycin and 10% FCS. They were split 
1:10 every 3-4 days when confluent, using trypsin as described below.
MYA-1 cell line
These are pathogen-free feline T lymphoblast cells derived from the peripheral blood. 
They were maintained in a 7 x 10  ^cell/ml suspension o f RPMI 1640 medium with no 
L-Glutamine, 10% FCS, 1 x penicillin/streptomycin, 5 x 10'  ^ M o f 2-ME and 1:50 
dilution o f interleukin-2 (IL-2). They were centrifuged and split into fresh medium 
every 3 days.
KG-1 cell line
KG-1 cells are bone marrow myoblast cells from acute myelogenous leukaemia. They 
were maintained in cell suspension at a density o f  between 1 x 1 0 ^  and 2 x 1 0 ^  
cells/ml. They were split every 7 days into fresh medium o f Iscove's Modified 
Dulbecco's medium, 20% FCS, 1 x penicillin/streptomycin and 2 mM L-Glutamine.
LN156 cell line
These are mononuclear cells recovered from equine lymph nodes from fresh post 
mortem cases. They were dispersed through gauze and re suspended in RPMI 1640 
with gentamycin. The cells were layered over Histopaque 1083 (Sigma, UK) and 
centrifuged for 15 minutes at 1000 rpm. The cell band interface was taken off, washed 
in RPMI 1640, resuspended in freezing medium as described below and stored in 
liquid nitrogen [McMonagle et al. 2001]. On revival o f  the cells for bio assay, cells 
were maintained in RPMI 1640 with no glutamine, 4 mM L-Glutamine, 1 x 
penicillin/streptomycin, 10% horse serum, 57.2 |iM 2-ME and 20 pg/ml gentamicin.
70
Q N IO  cell line
This monolayer cell line is derived from an AH927 feline fibroblast clone containing 
the provirus o f  Moloney murine sarcoma virus [Jarrett and Ganiere, 1996]. They were 
usually split 1:5 every 3-4 days using Dulbecco's MEM containing 25 mM N-2- 
hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES) buffer, 10% FCS, 1% 
100 mM sodium pyruvate, 1% 200 mM L-Glutamine and 400 lU/ml 
peni cill in/streptomycin.
2.2.15.2 Seeding of cell lines
When seeding cells, the culture medium was removed and 4 ml trypsin-EDTA was 
added to 175 cm  ^ flasks, 2 ml to 75 cm  ^ flasks and 1 ml to 25 cm  ^ flasks. The cells 
were incubated at 37°C until the cells had detached from the flask bottom. Two 
volumes o f appropriate medium were added to neutralise the trypsin and the cells 
were centrifuged at 1000 rpm for 5 minutes. The cells were resuspended in fresh 
medium at the required cell density and were maintained in new flasks as before.
2.2.15.3 Counting cells
Total live cell count was performed using trypan blue which stains dead cells dark 
blue. 10 pi o f cell suspension was added to 90 pi o f  trypan blue (Invitrogen, UK). 10 
pi was loaded onto a haemocytometer with a cover slip added. The number o f  cells in 
each o f the 4 open squares was counted under the 10 x objective and a mean o f these 
was taken. This mean multiplied by 10  ^represented the number o f cells per ml.
2.2.15.4 Storing and reviving cells
Cells to be frozen down for future use were trypsinised and pelleted as described 
above. The cells were counted and resuspended at approximately 1 x 1 0 ^  cells/ml in 
freeze medium containing 90% FCS and 10% DMSO. This was aliquoted into 2 ml 
cryogenic vials and placed at -70°C overnight. The following day the tubes were 
placed in liquid nitrogen until future use.
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On revival, cells were quickly thawed using a water bath at 37°C. Fresh culture 
medium was added to the cells and centrifuged for 5 minutes at 1000 rpm. The cells 
were resuspended in medium, transferred to a flask and maintained as before.
2.2.15.5 Transfection of cells
Cells were transfected 24 hours after seeding when they were approximately 40% 
confluent. Transfections were performed using Lipo feet AMINE Reagent (Invitrogen 
Life Technologies, UK) according to the instructions o f the manufacturer. 3 pg DNA  
was used for 25 cm  ^ flasks, 10 pg for 75 cm  ^ flasks and 20 pg for 175 cm  ^ flasks. In 
order to monitor the efficiency o f  the procedure, a transfection using pEGFP-Cl 
plasmid DNA was carried out alongside the other transfections. This was viewed 
using the ultraviolet camera (Photometries GmbH Sensys, A2S / Leica system 
(Munich, Germany) and the proportion o f  cells displaying fluorescence was 
estimated. Following the transfection procedure, cells were incubated at 37°C with 
5% CO2 in their appropriate medium for 48 hours. Cells undergoing 
immunofluorescence were harvested using trypsin. Those used to demonstrate protein 
expression were removed from the flask using a cell scraper and lysed using either 
cell lysis buffer or a freeze/thaw protocol. These are explained further in the relevant 
chapters.
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CHAPTER 3: INTERLEUKIN 12
3 INTERLEUKIN-12
3.1 INTRODUCTION
3.1.1 Structure of IL-12
Interleukin-12 (IL-12), formerly known as natural killer cell stimulatory factor and 
cytotoxic lymphocyte maturation factor, is a heterodimeric cytokine consisting o f  two 
subunits, p40 and p35, linked by a di sulphide bond. Human IL-12 was first isolated 
from a B cell line RPMI 8866 [Kobayashi et a l  1989]. The cDNA o f each subunit o f  
IL-12 was cloned and cotransfection o f vectors containing each subunit was found to 
yield a 70-90kDa biologically active molecule [W olf et a l  1991]. The subunit p40 is 
306 amino acids (aa) in size with 10 cysteine residues and four potential N-linked 
glycosylation sites. The p35 subunit consists o f 197 aa with 7 cysteine residues and 3 
potential N-linked glycosylation sites [Gubler et a l  1991; W olf et a l  1991; Podlaski 
et a l  1992]. These subunits are encoded by distinct mRNA products [Gubler et a l  
1991] and it was found using rodent-human hybrids that the genes were located on 
separate chromosomes, p40 located at 5q31-q33 and p35 found at 3pI2-3ql3.2  
[Sieburth et a l  1992]. Similarly, the p35 and p40 subunits o f murine IL-12 have been 
located at chromosomes 3 and 11 respectively [Tone et a l  1996]. Coexpression o f  
both subunits is required for secretion o f  a bioactive IL-12 molecule [Gubler et a l  
1991].
Feline IL-12 was fully sequenced by Schijns et a l  [1997], and Hanlon [1999], by 
reverse transcription o f mRNA extracted from lipopolysaccharide (LPS) stimulated 
PBMCs. The p35 subunit consisted o f 685 bp and shared 91%, 82%, 85% and 55% 
identity with the canine, bovine, human and murine sequence respectively at amino 
acid level. The p40 subunit was 1006 bp and shared 92%, 85%, 84% and 68% identity 
respectively, also at amino acid level. The full-length cDNA was subsequently cloned 
into separate plasmids and bioactivity confirmed using CTL enhancement by human 
PBMCs [Imamura et a l  2000].
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IL-12 p35 and p40 subunits have no sequence homology, nor are they structurally 
related. The p35 subunit is 35kDa in size and its structure, as in the case o f most 
cytokines, is alpha helix rich. In terms o f sequence, p35 shows homology with IL-6 
and granulocyte-colony stimulating factor (G-CSF) [Merberg et a l  1992]. In contrast, 
the 40kDa p40 subunit shows no homology with other cytokines and is related to the 
haemopoietin family o f receptors. O f this group, p40 correlates most with the 
extracellular domain o f the a-subunit o f IL-6 receptor and the ciliary neurotrophic 
factor receptor [Gearing and Cosman, 1991; Schoenhaut et a l  1992].
3.1.2 Antagonism of p40 homodimer to heterodimeric IL-12
Production o f  p40 subunit has been shown to result not only in p40 monomer, but also 
a disulphide-linked p40 homodimer [Gillessen et a l  1995]. It has been demonstrated 
that lymphoblastoid cell lines produce in the region o f  5-500 fold excess p40 
compared to heterodimeric IL-12 [D'Andrea et a l  1992; Podlaski et a l  1992]. Of 
circulating p40, about 20-40% consists o f  p40 homodimer in endotoxaemic murine 
serum [Heinzel et a l  1997].
Supernatant from p40 transfections have been shown to antagonise IL-12 
heterodimer, inhibiting proliferation and IFNy production by mouse splenocytes and 
inhibition o f  the effect o f  IL-12 on differentiated T helper 1 cells [Mattner et a l 
1993]. The p40 homodimer is 25-50 fold more effective than the monomer at 
producing specific inhibition o f  IL-12 function [Gillessen et a l  1995]. Work has 
shown that this antagonism is due to the ability o f the homodimer to bind the IL-12 
receptor without eliciting biological activity [Ling et a l  1995]. It is therefore 
important that this potential for antagonism is addressed in the design o f constructs 
encoding IL-12.
Some work has suggested that p40 alone may play a role in some immune responses. 
Allografted p35 deficient mice were shown to have higher Thl responses than p40 
deficient mice. Thl enhancement was then suppressed by treatment with anti-p40 
monoclonal antibody [Piccotti et a l  1998].
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3.1.3 IL-12 receptor
Both human and murine IL-12 receptor cDNA has been cloned and the receptor 
consists o f two subunits, IL-12Rpl and IL-12Rp2 [Chua et a l  1994; Presky et a l  
1996]. IL-12Rpl subunit is a 662 aa (lOOkDa) type 1 transmembrane protein, which 
has a cytoplasmic domain o f  91 aa and an extracellular domain o f 516 aa. IL-12RP2 
subunit is also a type 1 transmembrane protein o f 862 aa (130kDa) with cytoplasmic 
and extracellular domains o f 216 and 595 aa respectively. Both are members o f the 
cytokine receptor superfamily and have closest homology to gpl30 P-type cytokine 
receptor, leukaemia-inhibitory factor and granulocyte-colony-stimulating factor 
receptors. [Chua et a/. 1994; Presky et a l  1996].
Recombinant IL-I2Rpi and IL-12Rp2 exist as disulphide-linked dimers or 
oligomers on the cell surface. When these subunits are expressed individually, they 
each bind IL-12 with only low affinity. High affinity binding occurs with 
coexpression o f  both subunits [Chua et a l  1994; Presky et a l  1996]. The murine IL- 
12 receptor subunits show similar structural homology to their human counterparts. 
Differences however have been found in the formation o f high and low affinity 
receptors for murine IL-12 [Chua et a l  1994; Presky et a l  1996]. In both species 
however, it appears that the IL-12P2 subunit acts as the signal-transducing element 
o f the high affinity receptor formation [Presky et al. 1996; Zou et al. 1997].
The IL-12 receptor is expressed mainly on Thl cells such as T and NK cells [Desai 
et a l  1992]. The receptor may be found on resting NK cells but only on activated T 
cells such as those treated with mitogens or alloantigens to produce receptor 
upregulation [Desai et a l  1992]. IL-2 and IL-12 can also activate NK cells bringing 
about upregulation o f  IL-12 receptor and IL-4 and IL-12 act synergistically to 
upregulate receptor expression [Desai et a l  1992; Naume et a l  1993]. The fact that 
expression o f IL-12Rp2 subunit is mainly restricted to Thl cells has led to the 
suggestion that it is this subunit that brings about sensitivity to IL-12 [Rogge et al. 
1997; Szabo et al. 1997]. These studies also showed that Th2 cells express IL- 
12Rpi subunit but not IL-12Rp2 and it has been suggested that upregulation o f this
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subunit on Th2 cells may play a role other than formation o f the high affinity IL-12 
receptor complex [Gately et al. 1998],
In terms o f signal transduction, it has been established that the IL-12 receptor brings 
about activation o f  signal transducers and activators o f transcription 3 (ST AT 3) and 
ST AT 4 [Jacobson et al. 1995]. Evidence suggests that IL-12Rpi interacts with 
Janus-family kinase 2 (JAK2) whereas IL-12Rp2 uses TYK2, STAT3 and STAT4 in 
signal transduction [Lamont and Adorini, 1996]. As will be explained later, this 
signal transduction mechanism is distinct from that o f IL-18 and it is activation o f  
separate pathways that explains the synergistic effect o f  these cytokines on target 
cells.
3.1.4 Production of IL-12
Human IL-12 was first isolated from an EBV-transformed human B cell line RPMI 
8866 [Kobayashi et a l  1989]. This cytokine is produced mainly by monocytes, 
macrophages and B cells [D'Andrea et a l  1992]. PBMCs also produce IL-12 in 
response to various stimulatory factors such as LPS, Staphylococcus aureus and 
Mycobacterium tuberculosis [D'Andrea et a l  1992; Baron et a l  1993]. It is thought 
that IL-12 production is brought about by interaction o f the CD40 ligand (CD40L) 
o f  activated T cells with CD40 present on cells such as monocytes [Shu et a l  1995].
Other cells have also been shown to exhibit low levels o f  IL-12 production such as 
Langerhans cells, follicular dendritic cells [Trinchieri, 1994] and also LPS and 
IFNy-stimulated granulocytes [Cassatella et al. 1995]. Various studies have 
demonstrated the in vivo production o f IL-12 by human kératinocytes when contact 
allergen was applied to the skin, implying a possible role o f IL-12 in dermal immune 
responses [Muller et a l  1994]. In other studies, these cells demonstrated constitutive 
p40 mRNA expression while requiring phorbol ester stimulation to induce p35 
mRNA expression [Aragane et al. 1994].
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3.1.5 Regulation of IL-12 production
3.1.5.1 Stimulation of production
Three major factors are thought to be involved in the upregulation o f IL-12 
production (figure 3.1). These are 1) cytokines such as IFNy, 2) induction o f IL-12 
by bacteria and certain microorganisms, 3) costimulation o f  IL-12 by CD40/CD40L 
interaction [M'^Dyer et al. 1998].
1 ) It has been demonstrated that pretreatment o f  monocytes with IFNy primes the 
cells, stimulating enhancement o f p35 and p40 mRNA expression on exposure to 
LPS [Hayes et al. 1995]. In addition a study has suggested that mycobacteria- 
induced p40 induction from bone marrow-derived macrophages depends on the 
presence o f tumour necrosis factor- alpha (TNF-a) and IFNy [Flesch et al. 1995]. 
Work has shown that the stimulatory effect o f  IFNy arises from its ability to enhance 
the expression o f  CD40 on monocytes [Alderson et al. 1993].
Evidence suggests, however, that the presence o f IFNy is not always essential for the 
stimulation o f IL-12 production. IFNy-deficient mice infected with Toxoplasma 
gondii or Listeria monocytogenes have been shown to produce p40 subunit after 
stimulation in vitro implying that there are other stimulatory factors involved in 
IL-12 expression [Scharton-Kersten e? <?/. 1996; Szalay 1996].
Although IFNy is recognised as the major cytokine in upregulation o f IL-12, other 
molecules such as granulocyte macrophage-colony stimulating factor (GM-CSF) 
have also been found to have a role [Kubin et al. 1994].
2) Infection o f  cells with T. gondii can induce the production o f IL-12 in the absence 
o f both IFNy and CD40L [Sousa et al. 1997]. This demonstrates an alternative 
pathway by which IL-12 may be stimulated, where APCs directly produce IL-12 in 
response to exposure to antigenic material.
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3) As mentioned previously, T cell activation stimulates CD40L expression, which 
on interaction with CD40 present on APCs induces IL-12 production [Shu et a l 
1995]. IL-12 production by PBMCs stimulated with phytohaemaglutinin (PHA) was 
completely suppressed by anti-CD40L antibody implying that in this case, 
CD40/CD40L interaction was vital for the production o f IL-12 protein [McDyer et 
a l  1998].
3.1.5.2 Inhibition of IL-12 production
Various factors are known to inhibit IL-12 production. The most widely studied is 
IL-10, which has been shown to inhibit human lymphocyte IFNy production by 
suppressing the synthesis o f  IL-12 in accessory cells [D'Andrea et a l  1993].
Prostaglandin E2 has also been shown to have an inhibitory effect on IL-12 
production in LPS-stimulated human peripheral blood cells [van der Pouw Kraan et 
a l  1995], as has IL-4, IL-13 and tumour growth factor-P (TGF-P) [D'Andrea et a l  
1995]. Certain pathogens have also shown an ability to suppress the production o f IL- 
12. For example, exposure o f S. aureus or IFNy-stimulated monocytes to measles 
virus reduced IL-12 protein production, and cross-linkage with the CD46 measles 
receptor produced the same effect [Karp et a l  1996].
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Figure 3-1 Stimulation and inhibition o f  IL-12
B a c te ria  and  L P S
P a th o g e n s
VA n tig e n  p resen tin g  cell
C D 4 0
ligand _______
m o n o cy te , 
C D 4 0  j  m a c ro p h a g e  
o r B cell V%
e  g T o x o p la s m a  
® ®®
S-S
Inhibition o f IL -1 2  p roduction  
by IL -1 0 , p ro stag lan d in  E 2 , 
IL -1 4 . IL -1 3  an d  T G F -p
IL -1 2  h e te ro d im e r
79
3.1.6 Biological activities of IL-12
Interleukin-12 has been shown to exhibit several biological functions that make this 
cytokine crucial in the immune response to pathogens. A diagram showing the 
functions o f this cytokine is shown at the end o f this section (figure 3.2). Firstly IL-12 
activates and stimulates the proliferation o f T and NK cells which contribute to the 
first line o f  defence against pathogenic microorganisms. In addition, IL-12 has been 
shown to encourage the development o f  T helper type 1 responses and also the 
differentiation o f CTLs. IL-12 therefore promotes cell-mediated immune responses to 
infection and is particularly important in combating intracellular organisms such as 
viruses.
3.1.6.1 Cytotoxicity of NK cells
IL-12 has been shown to enhance the in vitro cytotoxicity o f T cells [Kobayashi et al. 
1989] and NK cells [Robertson et al. 1992]. Increased lysis o f  HIV-infected target 
cells and antibody-coated target cells was shown by NK cells treated with IL-12 
[Chehimi et al. 1993]. This effect o f IL-12 corresponded to enhanced binding and 
increased granularity o f  the NK cells [Cesano et al. 1993; Chehimi et al. 1993], which 
was associated with an upregulation o f  a variety o f  cell adhesion molecules and 
activation markers such as CD2, GDI la, CD25, CD56, CD54, CD69, CD71 
[Rabinowich et al. 1993]. IL-12 also increases the frequency o f  NK cell interaction 
with its target cells by enhancing the migratory activity [Rabinowich et al. 1993], and 
stimulating chemotaxis o f NK cells [Allavena et al. 1994]. The increase in the 
granular nature o f NK cells after IL-12 treatment is due to increased protein and 
mRNA expression o f cytotoxicity-related proteins, enhancing the cytolytic ability o f  
these cells still further [Aste-Amezaga et al. 1994].
When the optimal cytotoxic effect o f IL-12 is compared with other cytokines with the 
same ability such as IFNy and IL-2, IL-12 produces a lower response in NK cells. 
However, the lowest concentration required to increase cytotoxicity was found to be 
3-fold higher for IFNy and IL-2 than for IL-12, suggesting that NK cells may be more 
sensitive to IL-12 [Kobayashi et al. 1989].
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IL-12 may play a role in the formation o f  lymphokine activated killer (LAK) cells. 
These cells arise when lymphocytes are cultured in vitro with cytokines such as IL-2 
and exhibit MHC-unrestricted killing properties. It is unclear whether these cells also 
occur in vivo, or whether they are a result o f  exposure to high cytokine concentrations 
in vitro [Male et al. 1996a]. It has been found that the formation o f LAK cells by IL-2 
was decreased when incubated with an anti-IL-12 antibody, implying that IL-12 may 
be involved in the generation o f these cells [Gately et al. 1992].
3.1.6.2 Cytotoxicity of T cells
IL-12 also increases the cytotoxicity mediated by T cells. Peripheral blood T cells 
were found to lyse Fc-receptor-positive target cells coated with anti-CD3 antibody 
after treatment with IL-12 [Chehimi et al. 1993]. IL-12 has also been shown to bring 
about a 10-20 fold increase in CTL production from CD8^ cells specific for anti-CD3 
hybridoma target cells [Mehrotra et al. 1993]. Studies suggest that IL-12 enhances 
both the generation and activity o f  CTLs as the increased generation o f allospecific 
murine CTL from leukocyte cultures was comparable when IL-12 was used at the 
beginning or the end o f leukocyte incubation [Bloom et al. 1994].
3.1.6.3 T and NKceii proliferation
In order to induce proliferation o f T and NK cells in culture, both must first be 
preactivated with a stimulant such as PHA [Desai et al. 1992]. Upon activation, IL-12 
has been found to induce the proliferation o f both T and NK cells [W olf et al. 1991]. 
This mitogenic effect is observed in preactivated CD4^ and CD8^ T and NK 
lymphoblasts, but in NK and T lymphoblasts with T cell receptor (TCR)-gamma 
deltaT, IL-12 can significantly inhibit proliferation [Perussia et a l  1992]. This is 
thought to be due to IL-12-dependent TNF production, as treatment o f  cells with 
antibody to TNF re-established 70% of the inhibited proliferation. This proliferative 
effect has been found to coincide with IL-12 receptor expression o f  these cells [Desai 
et al. 1992].
It has also been demonstrated that IL-12 alone does not induce proliferation o f  
PBMCs, but on pretreatment with low doses o f IL-2, enhancement o f proliferation is
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observed [Gately et al. 1991]. This is a consequence o f  IL-2-induced IL-12 receptor 
expression stimulated by IL-2 [Desai et al. 1992].
Both human CTL and T helper type 1 (Thl) cells have been shown to proliferate in 
response to IL-12 under certain parameters. CTLs require preactivation by anti-CD3 
antibodies to induce proliferation [Bertagnolli et al. 1992], whereas Thl cells required 
stimulation with antigen, anti-CD3 antibodies or mitogens [Trinchieri et al. 1994].
In general, the presence o f IL-2 is not required to produce the proliferative effect by 
IL-12 [Gately et al. 1991]. In addition, IL-4, CD28-ligand and B7.1 molecules can 
also under certain circumstances, augment IL-12-mediated proliferation. IL-4 and IL- 
12 have a synergistic effect on CD56^ NK cell proliferation [Naume et al. 1993]. IL- 
12 and B7/CD28 interaction produces a strong synergistic effect in stimulating 
cytokine production and proliferation o f  peripheral blood T cells [Kubin et al. 1994].
3.1.6.4 Regulation of Th1 and Th2 cells
Naive CD4^ T cells have the ability to differentiate into either Thl or Th2 cells. Thl 
cells promote cell-mediated immunity by the production o f IL-2 and IFNy. 
Conversely, Th2 cells encourage humoral immunity by the production o f IL-4, IL-5, 
IL-6, IL-10 and IL-13 [Scott et al. 1993; Paul and Seder, 1994]. An important 
function o f IL-12 is its ability to promote the in vitro production o f T helper 1 
responses, which have been shown in both humans [Manetti et al. 1993] and mice 
[Hsieh et al. 1993]. This has also been demonstrated in vivo [Magram et al. 1996], 
where IL-12 deficient mice displayed impaired Thl responses measured by the IFNy 
response to endotoxin administration.
IL-12 influences Thl cell development and function in several ways. Firstly it is 
required for the differentiation o f  naive T cells into Thl cells on activation by an 
antigen [Schmitt et al. 1994]. IL-12 also acts as a costimulant in inducing the 
production o f IFNy from stimulated Thl cells treated with B7 [Murphy et al. 1994]. 
Finally, memory T cells previously exposed to antigen can be stimulated to
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differentiate into IFNy-producing Thl cells by incubation with IL-12 [Marshall et al. 
1995].
The IL-12 related promotion o f Thl immune responses are inhibited in some cases by 
anti-IFNy antibody [Schmitt et al. 1994]. However, some Thl responses could not be 
inhibited in this way. For example the effect o f IL-12 on cytokine secretion by 
Dermatophagoides pteronyssinus group 1 (Derp 1)-specific T cells was not prevented 
by the use o f anti-IFNy [Manetti et al. 1993]. IFNy is incapable o f  inducing Thl cell 
development alone, instead acting as a costimulator o f IL-12 as previously described 
[Wenner et al. 1996]. Also, the Thl response induced by IL-12 does not stimulate the 
production o f  the other major Thl related cytokine, IL-2 [Magram et al. 1996].
IL-12 also inhibits the production o f IL-4 from antigen specific T cell lines. IL-4 can 
induce the development o f Th2 cells from CD4^ T cells and is the dominant influence 
over CD4^ cells when both IL-12 and IL-4 are present [Hsieh et al. 1993]. Incubation 
o f  T cells specific for Der p 1 with IL-12 demonstrated increased IFNy stimulation 
and inhibition o f IL-4 production. This cytokine profile represents a predominance o f  
Thl rather than Th2 clones [Manetti et al. 1993]. This experimental system was 
further used to show that IL-12 probably increases Thl responses by priming clone 
progenitors to differentiate into Thl cells rather than selecting precommitted T cell 
precursors [Manetti et al. 1994].
The bias o f IL-12 towards a Thl type response however is not ubiquitous, and under 
certain conditions IL-12 may produce Th2 responses in cells. For example, in IFNy 
knockout mice, IL-12 induced Th2-dependent granuloma formation and increased IgE 
levels. The induction o f  IFNy by IL-12 therefore appears to be responsible for the IL- 
12 induced suppression o f Th2 responses [Wynn et al. 1995].
3.1.6.5 Cytokine production and regulation by IL-12
Although IFNy is the main cytokine induced by IL-12, several others may be induced 
in smaller amounts such as TNFa, IL-2 [Perussia et a l  1992], GM-CSF, [Aste- 
Amezaga et al. 1994] and lL-10 [Gerosa et a l  1996]. This is interesting as IL-10 is a
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cytokine that stimulates Th2 responses. IL-10 is able to inhibit both the synthesis and 
action o f IL-12, possibly acting as a negative feedback mechanism on the cytokine 
[D'Andrea et a l  1993; Tripp et a l  1993]. IL-12 has also been shown to inhibit the 
production o f  transforming growth factor P (TGFp) [Marth et a l  1997].
IL-12 can function in synergy with several other cytokines in the production o f IFNy 
such as TNFa [Aste-Amezaga et a l  1994], IL-2 [Tripp et a l  1993], and IL-1 [Wu et 
a l  1993]. Conversely IL-12 related IFNy production can be inhibited in the presence 
o f other cytokines such as IL-10 [Tripp et a l  1993], TGpp [Hunter et a l  1995] and 
IL-4 [K iniwae/a/. 1992].
3.1.6.6 Effect of IL-12 on humoral Immunity
In mice, Thl type antibody responses tend to be associated with the secretion o f  
IgG2a, IgG2b and IgG3 antibodies [Finkelman et a l  1990]. IL-12 has been shown to 
upregulate these antibody isotypes in mice in vivo [Germann et a l  1995], and 
suppress Th2 associated IgGl responses after primary IL-12 immunisation [McKnight 
et al. 1994; Buchanan et a l  1995]. Successive exposure to IL-12 however has been 
shown to enhance IgGl levels [Buchanan et a l  1995] and in this study, treatment with 
anti-IFNy antibody eliminated the initial IgGl suppression but had no effect on the 
increased IgG2a levels demonstrated. This suggests that the antibody responses 
stimulated by IL-12 are influenced by the lL-12-induced IFNy, although other factors 
or cytokines are probably also involved.
IL-12 has also been shown to influence IgE antibody responses. The in vitro synthesis 
of IgE is suppressed in IL-4 treated lymphocytes by IL-12 [Kiniwa et a l  1992], 
whereas in some cases IL-12 may significantly enhance IgE secretion [Wynn et a l  
1995]. It is likely in this case that IgE is produced in response to IL-4 stimulation by 
IL-12, which takes place under certain experimental circumstances as described 
previously.
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Figure 3-2 Biological functions o f  IL-12
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3.1.7 Potential clinical role of IL-12
The important role that IL-12 plays in the immune response has led to investigation 
into its potential therapeutic value. Studies have demonstrated the use o f IL-12 in the 
treatment o f infectious disease such as Toxoplasma gondii [Khan et al. 1994], 
Mycobacterium tuberculosis [Cooper et al. 1995], Leishmania major [Heinzel et al. 
1991; 1993], and also tumours [Brunda et al. 1993; Rakhmilevich et al. 1996]. IL-12
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has been shown to play a role in immune-related diseases and treatment to decrease 
IL-12 levels have been found to be beneficial. Examples o f these include 
experimental autoimmune encephalomyelitis [Issazadeh et al. 1995; Gately et al. 
1998], and collagen-induced arthritis [McIntyre et al. 1996]. O f direct relevance to 
this project is the potential use o f IL-12 as an adjuvant to vaccination.
3.1.7.1 IL-12 as a vaccine adjuvant
The stimulation o f Thl responses and consequent promotion o f cell mediated 
immunity by IL-12, has led to its use in vaccinology where cell mediated responses 
against the pathogen would be beneficial.
Coadministration o f Thl promoting cytokines with DNA vaccination can increase 
Thl cells and CTL activity, while suppressing Th2 responses [Chow et al. 1998]. It is 
well documented that CTL activity is crucial for the clearance o f intracellular 
pathogens, particularly viruses. Expression vectors encoding IL-12 have been used as 
adjuvants to DNA vaccines to human immunodeficiency virus-1 (HIV-1). The use o f  
an IL-12 plasmid significantly increased the specific CTL response to a variety o f
HIV-1 DNA vaccines [Kim et al. 1997]. This CTL response was associated with an
increase in IFNy production, an effect that was abrogated by the use o f anti-IFNy 
antibody [Tsuji et al. 1997]. This shift towards cell-mediated immunity was in 
contrast to some studies that showed that IL-12 increased only the magnitude o f  the 
immune response to an HIV env DNA vaccine rather than the nature o f  the response 
[Moore et al. 2002].
This type o f vaccine can also be administered by topical application involving prior 
removal o f kératinocytes by fast-acting adhesive [Liu et al. 2002]. In this case, 
coadministration o f IL-12 vector resulted in enhancement o f CTL response and the 
delayed-type hypersensitivity response (DTH).
The adjuvant effect o f  IL-12 on DNA vaccines has been studied using a variety o f  
other viruses. One study investigated the immunisation o f mice with a DNA vaccine 
to hepatitis B virus with IL-12 or IFNy genes. DNA vaccination corresponded with 
increased Thl cells, CTL activity and IgG2a antibody production, with inhibition o f
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Th2 cells and IgGl antibody. In contrast, coadministration with the Th2 cytokine IL-4 
stimulated the opposite effect [Chow et a i  1998]. In addition, coinjection o f an IL-12 
vector with a herpes simplex virus-2 vaccine, decreased morbidity and mortality o f 
mice. This was due to increased Thl type CD4^ T cell responses producing an 
increase in IL-2 and IFNy levels and inhibition o f IL-4 and IL-10 [Sin et al. 1999].
IL-12 has been used as an adjuvant to vaccines for both parasitic and bacterial 
pathogens, BALB/c mice vaccinated with soluble leishmanial antigen alone or IL-12 
plasmid alone failed to protect mice from disease. However coadministration 
produced complete protection and long-term immunity along with enhanced antigen- 
specific IFNy production. This effect was abrogated by the use o f anti-IL-12 or anti- 
IFNy antibody [Yamakami et al. 2001]. Also, coimmunisation o f a DNA vaccine to 
Mycobacterium tuberculosis with IL-12 demonstrated increased protection from 
challenge and increased both the specific lymphocyte proliferative response and level 
o f IFNy producing T cells [Palendira et al. 2002].
In several studies, IL-12 had a negative adjuvant effect on DNA vaccination. IL-12- 
expressing plasmid suppressed the protective immunity o f  a DNA vaccine to Japanese 
encephalitis virus. This was associated with reduced specific T cell proliferation and 
antibody responses and the effect was dependent on endogenous IFNy production 
[Chen et al. 2001]. Finally, adverse effects o f a feline IL-12 plasmid were 
demonstrated in DNA vaccination against feline infectious peritonitis virus (FIPV). 
Coinoculation in this case enhanced susceptibility to challenge with the virus 
[Glansbeek et al. 2002].
3.1.7.2 The role of IL-12 as an adjuvant to feline retrovirus DNA vaccines
DNA vaccination against feline retroviruses has demonstrated some success when 
used in conjunction with IL-12 plasmid vectors. A vaccine for FeLV coinjected with 
IL-12 and IL-18 expression vectors elicited complete protection against both transient 
and persistent viraemia and protected five o f  six kittens from latent viraemia [Hanlon 
et al. 2001]. These protected cats were found to have higher levels o f  virus-specific
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CTLs in peripheral blood and lymphoid organs than unprotected control cats [Flynn et 
a l  2000a].
In contrast, when IL-12 vector was used in conjunction with DNA vaccines to feline 
immunodeficiency virus (FIV) and IL-18 vector, this had either no effect on 
protection against reverse transcriptase defective FIV cDNA and actually decreased 
protection induced by an integrase defective FIV cDNA. When virus-specific CTL 
responses were measured, IL-12 elicited no enhancement o f the former vaccine and a 
decrease in CTL level for the latter vaccine [Dunham et a l  2002]. However in a 
different study, a DNA vaccine to FIV gpl40 protein in combination with IL-12 
expression vector demonstrated significant immune protection [Leutenegger et a l  
2000].
3.1.8 Structural conformation of IL-12 constructs
The heterodimeric structure o f  IL-12 has presented some problems in the 
development o f  IL-12 plasmid constructs. As mentioned previously, p40 monomer 
has been shown to form a disulphide-linked homodimer, which is able to bind the IL- 
12 receptor without evoking biological activity [Ling et a l  1995]. The homo dimer 
therefore acts as a physiological antagonist to IL-12 heterodimer by suppression o f  the 
biological effect o f the functional molecule [Mattner et a l  1993]. It is therefore 
important that the production o f p40 homo dimer is minimised in the construction o f a 
vector for IL-12.
IL-12 DNA may be administered by the inoculation o f  separate plasmid vectors 
encoding p35 and p40 subunits [Hanlon et al. 2001]. The potential disadvantages o f  
this are that it relies on the transfection o f  each host cell with both plasmids in order 
to produce IL-12 protein. In addition, there is potential for excess production o f p40 
which theoretically may lead to antagonism problems (figure 3.3 top).
Figure 3-3 Comparison o f  separate IL-12 subunit plasmids with flexi-IL-12
p 4 0 + p 35
IL -1 2  H E T E R O D IM E R
IL -1 2  H O M O D IM E R
IN A C T  V E ACTIVE
F L E X I- IL -1 2  M O L E C U L E
A
Several IL-12 constructs have since been designed in an attempt to overcome these 
problems and are listed as follows:
1) A single plasmid vector containing both p35 and p40 subunit DNA in tandem 
either under the same promoter [Yamakami et al. 2001], or separate promoters [Tsuji 
et al. 1997].
2) An internal ribosome entry site sequence (1RES) o f encephalomyocarditis virus 
between the coding sequences o f  each subunit [Zitvogel et al. 1994].
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3) IL-12 subunits linked by cDNA encoding the foot and mouth disease virus self­
cleaving peptide, 2A. This sequence produces protease cleavage o f  the polypeptide 
into separate subunits on translation [Kokuho et a l  1999].
4) Fusion o f p35 and p40 subunits with a 45 base pair synthetic linker sequence to 
produce a single chain fusion construct [Anderson et a i  1997],
The single plasmid expressing both subunits in tandem still has the potential for p40 
overexpression and IL-12 antagonism. In plasmids where the subunits are under the 
control o f  a single promoter, the subunit downstream in these constructs has a 
tendency to be expressed at a lower level. Subunits controlled by separate identical 
promoters are more likely to express similar levels o f subunit. Although the 1RES 
construct increases expression o f the subunit downstream, there is still a tendency for 
the 3' protein to be expressed at a lower level and equimolar concentrations o f p35 
and p40 are not guaranteed. Both IL-12 protease cleavage construct and the single 
chain fusion construct guarantee comparable protein expression o f  each subunit, 
although the cleavage construct allows production o f free p40 which could form p40 
homodimer.
The single chain fusion construct uses a synthetic polypeptide linker based on a 
system used previously to construct single chain antibodies [Huston et a l  1993]. The 
linker consists o f a chain o f  Gly-Gly-Gly-Gly-Ser repeated three times followed by 
the subunit downstream minus its leader sequence [Anderson et a l  1997]. On 
translation, this fusion protein mimics the biological functions o f recombinant IL-12 
(figure 3.3 bottom) such as activated T cell proliferation, production o f  IFNy from 
activated T cells, activation o f  NK cells and phosphorylation o f the same intracellular 
signal transduction proteins as rIL-12 [Anderson et al. 1997]. An equine form o f IL- 
12 fusion protein has since been cloned and bioactivity confirmed by means o f  an 
IFNy induction assay [McMonagle et a l  2001]. In addition, the use o f a murine fusion 
protein construct in vivo has demonstrated protection when used in tumour 
immunotherapy [Lode et a l  1998].
The bioactivities o f several IL-12 constructs were compared by cloning both murine 
and human constructs into a retroviral vector [Lieschke et al. 1997]. Separate
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plasmids encoding p40 and p35 were used along with 1RES and single chain fusion 
IL-12, In the case o f the latter two constructs, subunits were arranged in both 5'- 
p40/p35-3' and 5'-p35/p40-3' orientations. O f all the constructs, the single chain 
fusion IL-12 plasmid with 5'-p40/p35-3' orientation showed the highest level o f IL- 
12 in the bioassay and showed the highest relative specific activity. The human IL-12 
fusion construct was also found to be bioactive with high specific activity. It was on 
the basis o f these results that this fusion protein was selected for use in our work.
3.1.9 Aim of work
Given the recent development o f a murine IL-12 fusion construct which expresses p40 
and p35 linked by a synthetic polypeptide linker sequence [Anderson et a l  1997], this 
chapter describes the cloning o f an equivalent feline fusion construct (flexi-IL-12) and 
demonstrates its in vitro expression and bioactivity. This flexi-IL-12 structure 
overcomes the major potential disadvantages existing in other constructs by ensuring 
cotransfection and equimolar levels o f  expression o f both p35 and p40 subunits. In 
vitro expression o f feline flexi-IL-12 protein was performed by Western blot analysis. 
In vitro bioactivity was demonstrated using an assay that measures the dose dependent 
production o f equine IFNy from equine lymph node cells when exposed to feline IL- 
12 protein.
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3.2 MATERIALS AND METHODS
3.2.1 Cloning strategy of flexi-IL-12
Flexi-IL-12 consists o f the two subunits o f  IL-12, p40 and p35, linked by a synthetic 
"flexi" linker sequence. As bioactivity o f murine flexi-IL-12 was found to be maximal 
when p40 was situated at the 5' end o f the construct [Lieschke et a l  1997], a similar 
strategy was adopted to generate feline flexi-IL-12. Thus an intact p40 subunit cDNA  
was linked to signal peptide deleted p35 subunit cDNA (Ap35), through a glycine- 
serine rich peptide sequence [Anderson et a l  1997].
The cloning strategy o f this construct was based on the separate PCR o f  each subunit, 
using primers that encoded 5' and 3' subunit sequence o f feline IL-12 [Hanlon, 1999]. 
The 3' p40 primer encoded a portion o f  the flexi sequence with a Nar I restriction site 
at the 3' end and the 5' Ap35 primer encoded a Nar I site with the 3' portion o f the 
linker sequence. This restriction site was then used to unite the two linker sequences 
to produce the complete flexi-IL-12 cDNA sequence. Other restriction sites were 
included in the primers to allow excision o f the flexi-IL-12 cDNA from the 
intermediate vector into the expression vector (pCI-neo, Promega). This cloning 
strategy is summarised in figure 3.4.
Mapping o f primers
5'p40 primer
5 ' -GCGGTTAACGTCG AC ACGCCACG ATGG ATCCTC AG-3 '
< Hpal X  Sail > < KOZAK > M G P Q
3'p40 primer
5'GTGTCCTGCAGTGGTGGCGGTGGCTCGGGCGGTGGTGGATCGGGCGCCGCG-3' 
V S C S < ....................................... linker - -    >< Narl >
5'p35 primer
5’-GCGGGCGCCGGTGGCGGATCTAGGAACCTCCCCACAC-3'
< Narl > <  linker > R N L P
3’p35 primer
5’-CTGAATGCTTCCTAAGCGGCCGCGTTAACGAGCTCGC-3'
L N A S < Not I >< Hpal >< Sad >
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Figure 3-4 Diagram depicting feline flexi-IL-12 cloning strategy
1 ) P C R  a m p lific a tio n
N a r  IS a l I N a r  I N o t I
2 )  L ig a tio n  in to  p C R -S c r ip t  
S e q u e n c in g  o f  c lo n e s
N a rS a l I N a r  I N o t
3 )  N a r  I /  S a l I d ig e s t  
P u rific a tio n  o f  D N A  
fra g m e n ts
p C R -S c n p t
N a r  IS a l I
S a l I
N a r  I N o t  I
4 )  L igation  o f D N A  fra g m e n ts p C R -S c r ip t
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3.2.2 PCR of 5'/p40-lînker/3' and 5'/linker-Ap35/3' fragments
Initially both Taq DNA polymerase and Pfu polymerase methods were attempted. 
However although Taq DNA polymerase produced successful amplification, the 
requirement o f  a polishing step to allow ligation o f the Taq polymerase fragments into 
pCR-Script (Stratagene) greatly lowered the efficiency o f ligation. Also, the potential 
for misincorporation o f  nucleotides o f  Taq enzyme led to the decision to pursue the 
Pfu polymerase reactions in the PCR o f these fragments.
Template DNA encoding feline p40 and p35 sequence consisted o f a pCI-neo plasmid 
containing both feline subunits under separate CMV promoters (RP31) which was 
kindly provided by Samantha Taylor (Retrovirus Research Laboratories, University o f  
Glasgow). RP31 was cloned by the excision o f  a DNA fragment encoding a 
CMV/p40/poly A from an intermediate eloning vector using a DrallVAfllW  digest 
which was then filled in. A pCI-neo/CMV/p3 5/polyA construct was digested using 
RsrlVDralW  and ligation produced the final RP31 construct. The RP31 DNA template 
was diluted to a concentration o f 100 ng/p.1 in dHzO and 100 ng was used in the 
reaction.
Master mix reactions were prepared in 0.2 ml PCR reaction tubes on ice according to 
the instructions o f the manufacturer. PCR reactions for both 5Vp40-linker/3' and 
5Vlinker-Ap35/3' were performed in a Perkin Elmer 9600 thermal cycler under the 
following conditions: 94°C for 45 seconds, 30 cycles o f 94®C for 45 seconds, 40°C 
(annealing temperature) for 45 seconds, and 72°C for 2 minutes. This was terminated 
with a single cycle o f  72°C for 10 minutes and reactions were maintained at 4®C. PCR 
products were visualised on a 0.8% ethidium bromide agarose gel using 10 pi o f 
reaction per well diluted to 20 pi with dHzO and 5 pi o f DNA loading buffer.
Under these conditions, a fragment o f the correct size (692 bp) was produced for 
5Vlinker-Ap35/3'. However there was no amplification o f 57p40-linker/3'. Therefore 
reaction conditions were varied by altering the p40 primer levels and the amount o f  
DNA template as follows:
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Table 3-1 Range o f  reaction conditions used for amplification o f  57p40-linker/3
Reaction Primer (|iM) DNA (ng)
i iOO 100
2 75 100
3 25 100
4 100 25
5 75 25
6 25 25
A primer concentration o f 25 pM and a DNA level o f  25 ng produced successful 
amplification o f  a DNA fragment o f  the appropriate size (1053 bp) on UV  
visualisation o f a 0.8% agarose gel.
3.2.3 Cloning of PCR fragments Into the intermediate pCR-Script 
vector
The pCR-Script Amp Cloning Kit (Stratagene) was used to clone PCR fragments 
according to the manufacturer's instructions. A purification step separated the PCR 
products from primers, enzymes, buffer and unincorporated nucleotides associated 
with the PCR reaction. Purification used a microspin cup containing silica-based 
matrix that binds DNA. The DNA was washed and eluted in low-ionic strength buffer 
and 8 pi o f  the purified PCR product was used in the ligation into the vector.
The ligation was prepared in a 0.5ml microfuge tube by mixing reagents in the 
following order: 10 ng pPCR-Script vector, 1 x reaction buffer, 5 x 10'  ^ pM rATP, 
8 pi (around 200 ng) PCR product, 5 U S rf I restriction enzyme and 4 U T4 DNA  
ligase made up to a final volume o f 10 pi with dH20. The use o f Srf I enzyme in the 
ligation preserves a high concentration o f digested vector, increasing the efficiency o f  
the reaction. The ligation was incubated at room temperature for 1 hour, 65°C for 10 
minutes and then stored on ice until the transformation reaction.
The ligation product was transformed into Epicurian Coli XL 10-Gold Kan 
ultracompetent cells according to the manufacturer's instructions. Blue/white colour 
screening was performed as described in 2.2.9. Colonies were selected and
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minipreparations o f DNA were prepared. 5'/linker-Ap35/3' (sense) clones were 
identified using a BamH I restriction digest and 5'/p40-linker/3' (non-sense) clones 
were identified with an AflWISacW double restriction digest. These digested reactions 
were visualised on a 0.8% agarose gel stained with ethidium bromide.
3.2.3.1 Sequencing of positive clones
Positive clones were subcultured overnight at 37°C by seeding 30 pi cultured broth 
into 3 ml LB medium containing 100 pg/ml ampicillin. High-quality DNA for 
sequencing was prepared using Qiaprep Miniprep Kit (Qiagen). The DNA was 
quantified on a 0.8% agarose gel with ethidium bromide and cycle sequencing 
reactions were prepared using 500 ng DNA per reaction. T7 and Ml 3-Reverse 
primers situated at the 5' and 3' ends o f  the insertion site for pCR-Script were used to 
sequence vector inserts.
Primer Sequence ( 5 - 3 )
T7 TAATACGACTCACTATAGGG
M 13-Reverse GGATAACAATTTCACACAGG
The Li-Cor 4000 model was initially used for flexi-IL-12 sequencing, but G/C rich 
regions o f  the gene yielded inaccurate sequence data. The ABI Prism technique was 
therefore used in these problem areas. Consensus sequences were produced for each 
clone and compared with the source IL-12 sequence to detect any ambiguities. A 
pCR-Script/5Vlinker-Ap35/3 ' clone and a pCR-Script/5'/p40-linker/3' clone with no 
ambiguities were then used for ligation to produce pCR-Script/flexi-IL-12.
3.2.4 Ligation of 5'/p40-linker/3' and pCR-Script/5'/iinker-Ap35/3'
5'/p40-linker/3' fragment was excised from the pCR-Script vector using a bulk digest 
o f Nar MSal I. In addition, a Nar MSaî I bulk digest o f pCR-Script/5'/linker-Ap35/3' 
excised a 54 bp fragment and opened the plasmid at the 5 '/linker area to allow 
ligation with 5'/p40-linker/3'. Fragments were purified and ligated as described in
2.2.6 and 2.2.7. The ligation reaction was transformed into Epicurian Coli XL 10-Gold
96
Kan ultracompetent cells according to the instructions o f the manufacturer. Colonies 
were selected and minipreparations o f DNA were prepared as described in 2.2.2. 
Positive pCR-Script/flexi-IL-12 clones were identified using Not USal I, Bgl II and 
Pvu VNde I digests.
3.2.5 Ligation of fiexi-iL-12 into pCI-neo
A glycerol stock o f a pCR-Script/flexi-IL-12 positive clone was prepared, streaked 
out onto an LB agar plate using a sterile wire loop and incubated overnight at 37°C. A 
single colony was selected and DNA was prepared as detailed in 2.2.1. Not VSal I 
bulk digests o f  pCR-Script/flexi-IL-12 and pCI-neo allowed flexi-IL-12 and linearised 
pCI-neo fragments to be isolated and purified as described in 2.2.6. A  ligation 
reaction was performed and transformed into Epicurian Coli XLl0-Gold Kan 
ultracompetent cells according to the instructions o f the manufacturer. Single colonies 
were selected and minipreparations o f DNA were prepared. Positive clones were 
confirmed using Bgl II digest. DNA was prepared from a positive clone using Qiagen 
plasmid Mega Kit (Qiagen) following the instructions o f  the manufacturer and 
glycerol stocks o f the final construct were prepared and stored at -70°C.
3.2.5.1 Sequencing of pCI-neo/flexi-IL-12
Sequencing o f  the final flexi-IL-12 eonstruct was performed using the ABI Prism 
technique following the protocol described in 2.2.14.2. T7 and T3 primers 
incorporated in the pCI-neo plasmid were used to sequence the 5' and 3' ends o f the 
construct and specific primers were designed within the flexi-IL-12 sequence (figure 
3.5).
Primer Sequence (5'-3')
T7 TAATACGACTCACTATAGGG
T3 CTTCCCTTTAGTGAGGGTTAAT
The data was analysed using the GCG package (Wisconsin Package Version 9.1, 
Genetics Computer Group (GCG), Madison, Wisconsin). Authentic sequence o f  pCI- 
neo/flexi-IL-12 was further confirmed by analysing the chromatogram by eye.
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Figure 3-5 Sequence o f  flexi-IL-12 and position o f sequencing primers 
Red text - primer derived sequence Black text - feline p40
Blue text - glycine-serine linker sequence (ire> text -fe line A p35
C reen  text - forward primers P urp le  text - reverse primers
1 g c g g t t a a c g  t c g a c a c g c c  a c g a t g g a t c  c t c a g c a g c t  g g t c a t c g c c
51 t g g t t t t c c c  t g g t t t t g c t  g g c a c c t c c c  c t c a t g g c c a  t a t g g g a a c t
101  g g a g a a a a a c  g t t t a t g t t g  t a g a g t t g g a  c t g g c a c c c t  g a tg c c c c c g
151  g a g a a a t g g t  g g t c c t c a c c  t g c a a t a c t c  c tg a a g a a g a  t g a c a t c a c c
2 01  t g g a c c t c t g  a c c a g a g c a g  t g a a g t c c t a  g g c t c t g g t a  a a a c t c t g a c
251  c a t c c a a g t c  a a a g a a t t t g  c a g a tg c t g g  c c a g t a t a c c  t g t c a t a a a g
301  g a g g c g a g g t  t c t g a g c c a t  t c g t t c c t c c  t g a t a c a c a a  a a a g g a a g a t
351  g g a a t t t g g t  c c a c t g a t a t  c t t a a g g g a a  c a g a a a g a a t  c c a a a a a t a a
401  g a t c t t t c t a  a a a tg t g a g g  c a a a g a a t t a  t t c t g g a c g t  t t c a c c t g c t
4 51 g g tg g c tg a c  g g c a a t c a g t  a c c g a t t t g a  a a t t c a c t g t  c a a a a g c a g c
501 a g a g g c tc c t  c tg a c c c c c a  a g g g g tg a c t  t g tg g a g c a g  c g a c a c t c t c
551 a g c a g a g a a g  g t c a g a g t g g  a c a a c a g g g a  t t a t a a g a a  g t a c a c a g tg g
601 a g tg t c a g g a  g g g c a g tg c c  t g c c c g g c t g  c c g a g g a g a g  c c t a c c c a t t
651 g a a g t c g t g g  t g g a c g c t a t  t c a c a a g c t c  a a g t a c g a a a  a c t a c a c c a g
701  c a g c t t c t t c  a tc a g g g a c a  t c a t c a a a c c  g g a c c c a c c c  a a g a a c c tg c
751  a a c tg a a g c c  a t t a a a a a a t  t c t c g g c a t g  t g g a a g t g a g  c tg g g a a t a c
801 c c t g a c a c c t  g g a g c a c c c c  a c a t t c c t a c  t t c t c c t t a a  c a t t t g g c g t
851 a c a g g tc c a g  g g c a a g a a c a  a c a g a g a a a a  g a a a g a c a g a  c tc tc c g C g g
901  a c a a g a c c t c  a g c c a a g g tc  g t g t g c c a c a  a g g a tg c c a a  g a tc c g c g t g
951  c a a g c c a g a g  a c c g c t a c t a  t a g c t c a t c c  t g g a g c a a c t  g g g c a t c c g t
1 0 0 1  g t c c t g c a g t  g g tg g c g g tg  g c tc g g g c g g  t g g t g g a t c g  g g c g c c g g tg
1051  g c g g a t c t a g  g a a c c t c c c c  a c a c c c a c a c  c a a g c c c a g g  a a t g t t c c a g
1 1 0 1  t g c c t c a a c c  a c t c c c a a a c  c c t g c t g c g a  g c c a tc a g c a  a c a c g c t t c a
1151  g a a g g c c a g a  c a a a c t c t a g  a a t t t t a c t c  c t g c a c t t c c  g a a g a g a t t g
120 1  a t c a t g a a g a  t a t c a c a a a a  g a ta a a a c c a  g c a c a g tg g a  g g c c t g c t t a
1251  c c a c t g g a a t  t a a c c a t g a a  t g a g a g t t g c  c t g g c t t c c a  g a g a g a tc t c
1301  t c t g a t a a c t  a a t g g g a g t t  g c c t g g c c t c  c a g a a a g a c c  t c t t t t a t g a
1351  c g a c c c t g tg  c c t t a g c a g t  a t c t a t g a g g  a c t t g a a g a t  g t a c c a g g t g
1401  g a g t t c a a g g  c t a t g a a t g c  a a a g c t g t t a  a t g g a t c c t a  a a a g g c a g a t
1451  c t t t c t g g a t  c a a a a c a t g c  t g a c a g c t a t  t g a t g a g c t g  t t a c a g g c c c
1501  t g a a t g t c a a  c a g t g t g a c t  g tg c c a c a g a  a c t c c t c c c t  g g a a g a a c c a
1551  g a t t t t t a t a  a a a c t a a a a t  c a a g c t c t g c  a t a c t t c t t c  a t g c t t t c a g
1601  a a t t c g t g c a  g t g a c c a t c a  a t a g a a t g a t  g a g c t a t c t g  a a t g c t t c c t
1651  a a g c g g c c g c  g t t a a c g a g c  t c
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3.2.6 In vitro expression of flexi-IL-12 protein
3.2.6.1 Transfection of flexi-IL-12 into 293T ceii line
In order to demonstrate in vitro expression o f the flexi-IL-12 plasmid, transfections 
were performed using 293T cells. Several other constructs were transfected alongside 
flexi-IL-12 as detailed in the table below. The cloning o f RP31 is described in 3.2.2.
Table 3-2 Feline IL-12 nlasmic constructs used for in vitro expression
Constnict Description Plasmid Promoter(s) Source
flexi-IL-12 Feline p40 + Ap35 linked by a 
glycine-serine rich coding region
pCI-neo CMV + intron Constructed as 
previously described
RP31 Feline p40 and p35 pCl-neo p35: CMV + intron 
p40: CMV
S. Taylor*
pCI-
neo/p40
Feline p40 subunit pCl-neo CMV + intron L. Hanlon**
pCI-
neo/p35
Feline p35 subunit pCI-neo CMV + intron L. Hanlon**
* Retrovirus Research Laboratories, University o f  Glasgow.
** Molecular Oncology Laboratories, University o f  Glasgow.
10 fig each o f  flexi-IL-12, RP31, pCI-neo/p40, pCI-neo and 5 fig each o f pCI-neo/p35 
and pCI-neo/p40 DNA were transfected using 75 cm  ^ flasks as described in 2.2.15.5. 
A negative control consisting o f cells transfected with empty pCI-neo plasmid was 
prepared alongside. Cells were transfected using LipofectAMINE Reagent (Invitrogen 
Life Technologies, UK) using the protocol given by the manufacturer. They were then 
incubated for 72 hours at 37'^C with 5% CO2 .
Supernatant and cell lysate were then harvested from each transfection. Supernatant 
was removed from the cells, centrifuged at 1000 rpm for 5 minutes to remove any 
cellular debris, aliquoted and stored at -20‘^ C until further use. The cells were washed 
with 1 X PBS and incubated at 37°C in 4 ml trypsin-EDTA until they had detached 
from the flask bottom. A volume o f 8 ml o f  fresh medium was added and the cells 
were centrifuged for 5 minutes at 1000 rpm. The pellet was resuspended in 2 ml 1 x 
PBS with protease inhibitors (1 mM AEBSF and 10 fig/ml Leupeptin). Cells were
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then frozen and thawed three times using a dry ice/ethanol mix in order to rupture the 
cell membranes and release the protein into the surrounding buffer. This cell lysate 
was centrifuged for 30 seconds at 14000 rpm to pellet cell debris and the lysate was 
removed and stored at -20^C until further use.
3.2.6.2 Expression of flexi-IL-12 protein using Western blot analysis
In vitro protein expression o f  flexi-IL-12 in cell lysate and supernatant o f transfected 
293T cells was investigated using Western blot analysis. The primary antibody used 
for this procedure was a rabbit anti-feline p40 peptide antibody (Intervet 
International) delivered at a dilution o f 1:1500. This antibody was generated to a 
peptide derived from a 17 amino acid region o f  feline p40 sequence. The secondary 
antibody was anti-rabbit HRP conjugate (Sigma), which was used at a dilution o f 
1:3000.
A 12% SDS-PAGE gel was prepared under denaturing conditions as described in 
2.2.10. A volume o f 20 pi each o f flexi-IL-12, pCI-neo, RP31 and pCI-neo/p40 
supernatant and cell lysate were prepared as described. The positive control o f equine 
flexi-IL-12 supernatant was used, which demonstrates protein o f the same expected 
size as the feline flexi protein. Feline flexi IL-12 supernatant was concentrated 10 fold 
as protein bands were only just within the detectable limits o f  this system. This was 
performed using a centrifugal filter technique (Centriplus) to remove proteins greater 
than lOOKDa and was carried out according to the instructions o f the manufacturer.
3.2.7 In vitro bioactivity of flexi-IL-12 using IL-12 bioassay
3.2.7.1 Preparation of assay plate
This bioassay was originally developed by Sam Taylor (Retrovirus Research 
Laboratories, University o f  Glasgow), for assessing the bioactivity o f  equine flexi-IL- 
12 [McMonagle et a l  2001] but was also found to be sensitive to feline IL-12 protein. 
LN156 cells were recovered from equine lymph nodes and placed in liquid nitrogen 
as described in 2.2.15.4. Feline cells were not used in this assay because feline lymph
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nodes were difficult to obtain and produced low yields o f lymphocyte populations 
compared to equine lymph nodes.
On revival, the cells were thawed quickly in a water bath at 37“C, slowly resuspended 
in 10 ml culture medium and centrifuged at 1000 rpm with low brake for 5 minutes. 
The cells were slowly resuspended in 10 ml growth medium and counted using a 
haemocytometer. Cell density was adjusted to 1 x 10^/ml and supplemented with 1 p 
g/ml o f  PHA-L (Sigma, UK), and human IL-2 (T. Dunsford, Retrovirus Research 
Laboratories, Department o f Veterinary Pathology, University o f Glasgow). 100 pi o f 
cell suspension was administered to each well o f a 96 well plate and this was 
incubated for 24 hours at 37°C with 5% CO2.
Ten fold dilutions o f  flexi-IL-12, RP31, pCI-neop35/p40 and pCI-neo 293T 
transfection supernatants were made in LN156 medium (RPMI 1640 with no 
glutamine, 4 mM L-Glutamine, 1 x penicillin/streptomycin, 10% horse serum, 57.2 p 
M 2-ME and 20 pg/ml gentamicin) from 10'  ^ to 10' .^ In addition, another two sets o f  
dilutions o f Flexi-IL-12, RP31 and pCI-neop35/p40 were prepared alongside. Added 
to one set was a feline IL-12 cross reactive monoclonal antibody (C8.6 IgGi mouse 
anti-human IL-12 p40/p70 (BD PharMingen)) added to each dilution at a level o f 10 
ng/ml. With the other set o f dilutions was incubated a negative control antibody 
(mouse monoclonal IgG; anti-protein A  antibody (Sigma)) also added at a 
concentration o f 10 ng/ml. As a negative control, pCI-neo transfection was prepared 
alongside at the same dilutions. These dilutions were incubated for 2 hours at 37°C 
with 5% CO2 and 100 pi o f each dilution was added to wells in triplicate and mixed 
gently. LN156 cells were incubated for 72 hours at 37°C with 5% CO2 and amounts o f 
IFNy produced by each sample was measured using an IFNy sandwich ELISA.
3 .2 .7 .2  IF N y  sandwich E L IS A
Three antibodies were used in this procedure. The capture SE3 antibody was an 
affinity purified sheep polyclonal antibody, raised to recombinant equine IFNy. 
Primary R1053E2 antibody was a rabbit polyclonal raised to bacterially produced
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recombinant equine IFNy. The secondary antibody was goat anti-rabbit HRP 
conjugate (Sigma).
A high binding 96 well plate (Coming Incorporated) was incubated for 24 hours at 
room temperature with SE3 capture antibody. The antibody was diluted 1:500 in 
coupling buffer and 100 pi was added per well. Wells were blocked for 20 minutes 
with 200 pi o f 0.1% casein in TBS-T buffer, on a shaking platform at room 
temperature. Each well was washed twice with TBS-T and 100 pi o f samples, 
including zeroes and standards, were added and incubated for 2 hours, shaking at 
room temperature. Standards consisted o f  recombinant equine IFNy diluted 1:2 from
15.6 ng/ml to 0.122 ng/ml in LN156 culture medium. The plate was washed four 
times as before and then incubated for 2 hours with 1:1000 dilution o f primary 
antibody, shaking at room temperature. After washing four times, the secondary 
antibody was added at a dilution o f 1:1000 for 1 hour, with gentle shaking at room 
temperature. The washing was repeated and 100 pi TMB liquid substrate was added 
to each well and incubated for 30 minutes at room temperature. The plates were read 
using a spectrometer at 620 nm and the results were analysed using a Microsoft Excel 
worksheet.
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3.3 RESULTS
3.3.1 Amplification of 57Ap35-linker/3'
The PCR reaction using Pfu reagents for Ap35 amplification was run on a 0.8% 
agarose gel and displayed a band o f  the expected size (692 bp) (figure 3.6). The 
fragment was cloned into pCR-Script and sequenced. No mutations were found in the 
plasmid, so this clone was used in the subsequent ligation with 5'/p40-linker/3'/PCR- 
Script.
3.3.2 Amplification of 5'/linker-p40/3'
O f the 6 reactions with variable primer and DNA template concentrations, it was 
found that a primer concentration o f 25 pM and a DNA concentration o f 25 ng/pl 
produced successful amplification o f a DNA fragment o f  the appropriate size (1053 
bp) (figure 3.6). The fragment was successfully cloned into pCR-Script and 
sequenced. O f two clones sequenced, one had a substitution mutation and was 
abandoned. The other was free o f  ambiguities and was subsequently used in the 
ligation to produce the full-length flexi-IL-12 sequence.
3.3.3 Ligation of flexi-IL-12 and cloning of flexi-IL-12 into pCI-neo
Restriction digests Bgl II and Pvu VNde I were used to identify positive flexi-IL- 
12/PCR-Script clones as shown in figure 3.6. Positive flexi-IL-12/pCI-neo clones 
were detected using Bgl II restriction digests (figure 3.6) and a single positive clone 
was sequenced using internal primers (figure 3.5). Plasmid DNA was prepared from 
this clone and used in subsequent transfections to show in vitro expression.
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Figure 3-6 Gels o f  feline flexi-IL-12 cloning strategy
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3.3.4 In vitro expression of flexi-IL-12
Supernatants and cell lysates o f flexi-IL-12, RP31 and pCI-neo/p40 transfections were 
analysed on a 12% SDS-PAGE gel (figure 3.7).
Figure 3-7 SDS-PAGE gel o f feline flexi-IL-12 protein
75kDa
40kDa
L an e  n u m b e r 1 10
This is an autoradiograph o f a 12% SDS-PAGE gel depicting feline IL-12 p40 subunit 
and feline flexi-IL-12 protein. Each lane contains 20 pi o f the following: 
lane 1: kaleidoscope protein marker, lane 2: equine flexi-IL-12 supernatant, lane 3: 
pCI-neo supernatant, lane 4: pCI-neo cell lysate, lane 5: feline flexi-IL-12 
supernatant 10 x concentrate, lane 6: feline flexi-IL-12 cell lysate, lane 7: RP31 
supernatant, lane 8: RP31 cell lysate, lane 9: feline p40 supernatant, lane 10: feline 
p40 cell lysate.
Flexi-IL-12 supernatant contained a protein o f  approximately 75 kDa corresponding 
to the expected size o f p40 (40 kDa) linked to p35 (35 kDa) via a synthetic linker 
sequence. This protein product was a similar size to that seen in the equine flexi-IL-12 
supernatant positive control [McMonagle et al. 2001]. There was no evidence o f a 
protein product o f  40 kDa, suggesting that the fusion protein was stable and there was 
no breakdown into the separate subunits.
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The supernatant o f RP31 plasmid transfection contained a double protein band at 
approximately 40 kDa with no evidence o f full length IL-12 protein at 75 kDa. As 
explained previously, the primary antibody would not have detected any p35 protein 
expressed by this plasmid. A similar p40 protein band 40 kDa in size was evident in 
the feline p40 supernatant.
There were no bands evident in the cell lysate o f feline flexi-IL-12. Only faint 40 kDa 
bands were evident in RP31 and feline p40 plasmid cell lysates, implying that IL-12 
related protein is secreted and not retained within the cell from which it is expressed.
3.3.5 !n vitro bioactivity of flexi-IL-12/pCI-neo using IL-12 bioassay
The bioactivity o f transfection supernatants was analysed using a bioassay that 
measures the amount o f  equine IFNy produced in response to IL-12 by LN156 cells 
isolated from equine lymph nodes. The assay was performed using ten fold dilutions 
o f protein and IFNy produced was quantified by capture ELISA. The CD o f samples 
and human IFNy standards were measured using a spectrophotometer.
Analysis o f flexi-IL-12, RP31, pCI-neo/p40/p35 and pCI-neo transfections were 
carried out using this assay. In addition, to confirm that IFNy stimulation was specific 
to IL-12 expression, dilutions o f supernatant produced from 293T cells transfected 
with each construct were incubated with an anti-human IL-12 antibody. This study 
demonstrated that anti-human IL-12 antibody induced suppression o f  IFNy production 
suggesting cross-reactivity with feline IL-12. Anti-protein A, a negative antibody non­
specific to IL-12 was used as a negative control.
A standard curve was constructed o f  human IFNy (ng/ml) against OD using the 
sample standards performed on the capture ELISA plate. Graphs were then 
constructed o f IFNy against dilution o f protein for flexi-IL-12, RP31, pCI- 
neo/p40/p35 transfections and their associated control data (figure 3.8).
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Figure 3-8 Graphs o f  IL-12 bioassav
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The quantity o f  IFNy produced by LN156 cells decreased as the dilution o f  feline 
flexi-IL-12 protein increased, producing an S-shaped dose response curve. In contrast, 
pCI-neo transfection supernatant stimulated undetectable levels o f IFNy production. 
When flexi-IL-12 protein was preincubated with anti-human IL-12, this significantly 
reduced the level o f  IFNy induction, confirming that the antibody recognised feline 
IL-12 and that bioactivity was specific to IL-12 protein present in the transfection 
supernatant. The negative control anti-protein A antibody had no significant effect on 
the bioactivity o f  flexi-IL-12. This indicates that suppression o f IFNy induction by the 
anti-human antibody was due to binding and inactivation o f IL-12 rather than non­
specific antibody neutralisation. A similar level o f  bioactivity and suppression by anti­
human antibody was also demonstrated in both RP31 and p40/p35 transfection 
supernatants as shown in the appropriate graphs.
It has been shown that IL-12 p35 is constitutively expressed in many cells in the 
absence o f  p40 [D'Andrea et a l  1992; Schoenhaut et a l  1992]. Levels o f  
endogenously generated p35 could not be quantified in these experiments, as there 
was no p35 antibody available. It is therefore a theoretical possibility that the protein 
expressed from transfected p40 cDNA could complex with endogenous p35 to 
produce functional IL-12 affecting IFNy levels stimulated by the bioassay. Although 
not conducted here, this possibility was investigated in the equivalent equine IL-12 
bioassay where equine p40 transfection supernatants were associated with only 
background IFNy levels. This suggests that endogenous p35 does not contribute to IL- 
12 detected by this bioassay system.
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3.4 DISCUSSION
This chapter presents the cloning, in vitro expression and confirmation o f bioactivity 
o f feline flexi-IL-12 expressed in mammalian expression vector pCI-neo. PCR 
fragments encoding feline p40 and p35 subunits o f IL-12 were linked using a 
synthetic linker sequence built into specifically designed primers. Restriction sites 
included in primers allowed ligation to form the flexi-IL-12 fragment, which was 
subsequently cloned into pCI-neo.
Western blot analysis using a rabbit anti-feline p40 peptide antibody, demonstrated in 
vitro expression o f a 75 kDa sized protein molecule. In order to investigate in vitro 
bioactivity o f this protein, a bioassay previously used to study equine IL-12 constructs 
was used [McMonagle et ah 2001]. Flexi-IL-12 protein expressed in transfected cells 
was shown to be bioactive and exhibit similar levels o f  IFNy induction in equine 
lymph node derived cells as naturally formed IL-12 protein.
3.4.1 Cloning of flexl-IL-12/pCI-neo
The use o f a polypeptide synthetic linker to unite p40 and p35 subunits o f IL-12 
originated from Lieschke et al. [1997] and Anderson et a l  [1997]. In these studies, 
IL-12 fusion protein was expressed using a linker previously used to connect subunits 
o f antibody molecules [Huston et a l  1988]. Lieschke et a l  found that murine fusion 
protein was bioactive in vitro, having a specific activity equivalent to that o f native 
and recombinant IL-12 [Lieschke et a l  1997]. Anderson et a l  confirmed that the 
human fusion protein retained all the biological characteristics o f recombinant IL-12 
[Anderson et a l  1997].
A comparison o f the bioactivity o f  different murine IL-12 constructs was also made 
by assaying the bioactive IL-12 produced by CMS-5 tumour cells infected with 
protein from different IL-12 construct transfections [Lieschke et a l  1997]. Various 
IL-12 constructs were cloned into retroviral vectors including separate p35 and p40 
plasmids, 1RES constructs and flexi-IL-12 constructs. Of these, the flexi-IL-12 
plasmid with 5'p40 showed the highest level o f  IL-12 in the bioassay and the highest
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relative specific activity. The feline flexi-IL-12 plasmid was therefore designed on the 
basis o f these results.
One o f  the major difficulties encountered in this cloning strategy involved the 
application o f PCR to amplify 57p40-linker/3' and 5Vlinker-p35/3' fragments. 
Initially PCR reactions were performed using Taq DNA polymerase and Pfu 
polymerase alongside one another.
Taq DNA polmerase reactions yielded immediate amplification o f the appropriately 
sized DNA fragments. However, this method was ultimately rejected for several 
reasons. Firstly, as Taq tends to add non-template nucleotides to the 3' end o f DNA  
fragments, a polishing step using Pfu polymerase was required to clone fragments into 
PCR-Script. This polishing step was found to greatly decrease the efficiency o f  
ligation, with bacterial transformations yielding predominantly plasmid vector 
without insert. In addition, Taq DNA polymerase is a low fidelity enzyme with a 
higher error rate than Pfu  ^ estmated to be 2 x 10'  ^ [Lundberg et a l  1991]. This error 
rate may also increase if  cycling conditions are not optimal for the enzyme. This has 
led to the recommendation that between three and six amplified fragments are 
required to establish a consensus sequence [Ennis et a l  1990]. This, along with low  
Taq ligation efficiency resulted in the subsequent pursuit o f fragments amplified using 
Pfu polymerase. This enzyme produces 11-12-fold greater replication fidelity than 
Taq, with an error rate o f 1.6 x 10"^  [Lundberg et a l  1991] and produces blunt ended 
fragments that do not require a polishing step prior to ligation.
Pfu DNA polymerase produced successful amplification o f 571inker-p35/3' clone 
containing no sequence ambiguities. However manipulation o f  both primer and DNA  
template concentrations were required in order to amplify 57p40-linker/3' fragment. 
A primer concentration o f  25 p,M and a DNA concentration o f 25 ng/pl resulted in 
production o f  a 57p40-linker/3' clone which was used to generate full-length flexi-IL- 
12.
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3.4.2 In vitro expression of flexi-IL-12 protein
pCI-neo plasmid encoding flexi-IL-12 was transfected into 293T cells and the protein 
detected under denaturing conditions by Western blot using a rabbit anti-feline 
peptide antibody raised to p40. A 75 kDa band was detected in the cell supernatant 
but not in the cell lysate. This suggests that once synthesised, IL-12 protein is rapidly 
secreted from the cell into its surroundings. Any protein present within the cells is in 
insufficient quantities to be detected by this method. No p40 subunit protein was 
detected in flexi-IL-12 supernatant. This suggests that flexi-IL-12 is stable under 
denaturing conditions with no breakdown into separate subunits.
The 75kDa band in the neat flexi-IL-12 supernatant was almost undetectable and 
required concentration by ten-fold in order to detect the protein adequately on 
immunoblot. In comparison, feline p40 expressed by both RP31 and feline p40 
supernatants was detectable without concentration. The reason for this may be that the 
flexi-IL-12 is glycosylated differentially from the native molecule which may affect 
binding o f  the primary antibody. Alternatively flexi-IL-12 may be less stable in vitro 
or be expressed in lower quantities than the p40 subunit.
As mentioned, the supernatants o f both RP31 and feline p40 contained detectable 
levels o f  p40. Faint bands were also detected in the cell lysates o f  each transfection, 
perhaps due to the high degree o f  cellular expression o f this protein. There was no 
evidence o f  disulphide linked IL-12 in the RP31 supernatant. This is to be expected, 
as denaturing conditions would cleave the protein into separate subunits. However, 
unlike feline flexi-IL-12 supernatant, protein in the RP31 supernatant was not 
concentrated further, so there is the possibility that the levels o f protein in the neat 
supernatant were too low to be detected. This gel was repeated under non-denaturing 
conditions but no IL-12 was detected, possibly due to larger size and secondary 
structure o f IL-12 as mentioned above.
I l l
3.4.3 Bioactivity of flexi-IL-12 protein
A bioassay performed previously to analyse bioactivity o f  equine IL-12 [McMonagle 
et al. 2001] was found to be sensitive to feline protein. Flexi-IL-12, RP31 and 
p40/p35 supernatants showed significant titration o f LN156 IFNy induction between 
10'  ^ and 10'  ^ dilutions. Suppression o f  IFNy production was elicited when IL-12 
supernatants were incubated with anti-human IL-18 antibody which suggests that this 
antibody binds to and neutralises feline IL-18. In this assay, flexi-IL-12 supernatant 
was found to stimulate equivalent levels o f  IFNy from LN156 cells as RP31 
supernatant, where subunits synthesised separately became linked by a disulphide 
bond. However, a direct comparison between the bioactivity o f  flexi-IL-12 and 
disulphide linked IL-12 cannot be made for several reasons. Firstly, di sulphide-linked 
IL-12 from RP31 could not be detected on Western blot which prevented comparison 
o f relative amounts o f  flexi-IL-12 and RP31 IL-12 in transfections. In addition, free 
p40 present in RP31 supernatant may have induced an inhibitory effect on the IL-12 
protein present, preventing a fair comparison o f  bioactivity o f  each molecule. The 
detection o f bioactivity o f flexi-IL-12 does however confirm that the synthetic 
polypeptide linker allows correct alignment o f  subunits and its structure does not 
abrogate the biological function o f the molecule.
3.4.4 Advantages of flexi-IL-12 fusion protein
There are several reasons why flexi-IL-12 may be favoured over other IL-12 
constructs. Firstly the use o f  a linker sequence reduces the size o f the construct. This 
is particularly advantageous if  used in viral vectors where construct size may be 
restricted.
In addition, use o f the flexi-IL-12 construct ensures the equimolar production o f both 
p35 and p40 within the same cell. The exposure o f cells to p35 and p40 DNA in 
separate plasmids or 1RES constructs does not guarantee equimolar subunit 
concentrations. In both cases, differential expression o f  IL-12 subunits has the 
potential to lead to decreased IL-12 protein production.
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By linking p35 and p40 subunits in this way, the production o f  p40 homodimer is 
prevented. As previously mentioned, certain cells such as stimulated PBMCs, 
neutrophils and EBV transformed cell lines have been shown to express between 10- 
50 times the amount o f free p40 as p70 heterodimer [D'Andrea et al. 1992]. This p40 
has been shown to form disulphide linked homo dimers which can act as specific 
antagonists to heterodimeric IL-12 by binding to the IL-12 receptor [Ling et al. 1995]. 
In addition, culture supernatants containing murine p40 were found to inhibit the 
biological activity o f IL-12 demonstrated in in vitro assays [Mattner et al. 1993]. The 
use o f  constructs that allow synthesis o f  separate IL-12 subunits could potentially 
elicit inhibition o f  IL-12 function by overproduction o f p40, whereas the structure 
flexi-IL-12 prevents this from occurring. To date however there is no in vitro 
evidence to demonstrate this.
3.4.5 Applications of flexi-IL-12
Since the development o f flexi-IL-12 fusion protein [Anderson et al. 1997; Lieschke 
et al. 1997], this construct has been cloned in other species and used effectively in 
vitro and in vivo.
In the mouse, flexi-IL-12 has been used to prevent the development o f métastasés in a 
poorly immunogenic murine neuroblastoma model. NXS2 neuroblastoma cells were 
genetically engineered to produce flexi-IL-12 and were injected into mice. On 
boosting with a low dose o f  IL-2 fusion protein and tumor-specific antibody followed 
by challenge with a lethal dose o f  NXS2 cells, five out o f six mice were protected 
from metastasis. Injection with fiexi-IL-12-expressing cells was associated with a 
partially protective CD8  ^ T cell response, which was further enhanced by the booster 
described above [Lode et al. 1998; Lode et al. 1999]. Additional studies using the 
same fiexi-IL-12-expressing NXS2 cells demonstrated complete protection from liver 
and bone marrow métastasés without additional boost o f  the cellular immune response 
[Balicki et a l  2000].
Porcine flexi-IL-12 has also been cloned and oral inoculation in vivo was shown to 
increase antigen-specific IgA and IgG in jejunal mucus. This construct was expressed
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as recombinant protein and found to be bioactive by lymphoblast proliferation and 
IFNy production. This bioactivity was not inhibited by the coadministration o f  p40 
subunit [Foss et a i  1999]. Porcine flexi-IL-12 was also found to act synergistically 
with human IL-12 in the induction o f  IFNy from T and NK cells in vitro [Domeika et 
a i  2002].
Transfections o f equine flexi-IL-12 cloned into pCI-neo, produced dose dependent 
IFNy stimulation in cells recovered from  equine lymph nodes. IFNy production was 
suppressed using anti-p40 monoclonal antibody showing that the response was 
specific to flexi-IL-12 fusion protein [McMonagle et al. 2001].
There are several studies describing the use o f flexi-IL-12 fused with proteins to 
target cytokine delivery to tumour cells. Murine flexi-IL-12 was fused to a tumour- 
specific antibody anti-Her2/«ew to allow selective targeting to this tumour antigen. 
This preparation was shown to elicit antitumour activity in vivo [Peng et al. 1999]. A 
similar method was used to target a marker o f angiogenesis B-Fibronectin which 
accumulates around the vasculature o f  proliferating tumours. An antibody to this 
marker was fused to murine flexi-IL-12 and displayed antitumour activity and 
infiltration o f the tumour with immune cells [Halin et al. 2002],
Finally other IL-12 fusion constructs have been developed to ensure delivery o f  
equimolar concentrations o f each subunit to target cells. For example, a linker 
sequence encoding a cleavage site for furin, a Golgi expressed endoprotease, was 
included between IL-12 subunits in a single expression cassette. This construct was 
shown to be secreted from cells and to be bio active by the stimulation o f human T cell 
proliferation [Gâken et al. 2000].
A construct has also been designed which ensures equimolar levels o f p35 and p40 
protein by expression o f bovine IL-12 as a self-processing 2 A polypeptide [Chaplin et 
al. 1999]. 2A polypeptide is a 19 amino acid sequence derived from foot-and-mouth 
disease virus, which produces cleavage o f  the two subunits. This construct was 
subsequently shown to act as an adjuvant to a DNA vaccine for Mycobacterium  
tuberculosis [Palendira et al. 2002].
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3.5 CONCLUSION
Recent work has shown the potential use o f  IL-12 DNA constructs in the treatment o f  
cancer, immunotherapy and as adjuvants to vaccines. The requirement for the 
expression o f two protein subunits from separate genes and the potential inhibition o f 
IL-12 heterodimer by p40 homodimer, has recently led to the design o f  various new 
IL-12 plasmid constructs. Flexi-IL-12 has shown advantages over other constructs in 
that the subunits are fused, ensuring equimolar subunit expression and prevention o f  
p40 homodimer inhibition. This chapter has described the cloning o f  feline flexi-IL- 
12 and in vitro expression and specific bioactivity o f feline flexi-IL-12 protein. 
Overall this data supports the future use o f  this IL-12 fusion plasmid in vivo.
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CHAPTER 4: INTERLEUKIN 18
4 INTERLEUKIN 18
4.1 INTRODUCTION
4.1.1 Isolation of interleukin-18
This cytokine was first discovered in 1989 when induction o f  IFNy from mouse 
spleen cells was demonstrated by endotoxin-induced serum on costimulation with 
IL-2 and mitogens [Nakamura et a i 1989]. Neutralising antibodies to IL-1, IL-4, IL- 
5, IL-6 and TNF failed to suppress the activity o f post-endotoxin mouse serum, which 
suggested that this effect was produced by a distinct factor [Nakamura et al. 1993]. 
This molecule, named IFNy-inducing-factor (IGIF), was purified to homogeneity 
from mouse livers treated with Propionibacterium acnes and found to have a 
molecular mass o f  18-19 kDa. IGIF was shown to augment T cell proliferation and 
NK cell activity in murine spleen cells in a similar way to IL-12 [Okamura et al. 
1995b].
4.1.2 Molecular cloning of IGIF
The nucleotide sequence o f murine IGIF was elucidated and the gene was shown to 
encode a precursor protein 192 aa in size and a mature protein o f  157 aa [Okamura et 
al. 1995a]. Anti-IGIF antibodies were shown to prevent liver damage induced by LPS 
in P. acnes pre-conditioned mice [Okamura et al. 1995b].
The same group then cloned human IGIF cDNA from normal human liver cDNA  
libraries using murine IGIF cDNA as a probe. This encoded a 193 aa precursor 
peptide with 65% identity with murine IGIF at the amino acid level. The properties 
demonstrated by this peptide led to the proposal that IGIF be designated "interleukin- 
18" [Ushio et al. 1996]. The human interleukin-18 gene was shown to map to 
chromosome 1 Iq22.2-q22.3, closely linked to the DRD2 gene locus [Nolan et al.
1998].
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Full length canine IL-18 was shown to have 84% and 74% sequence homology to the 
human and mouse sequence respectively at nucleotide level [Argyle et a l  1999]. The 
bioactivity o f  a similar clone was confirmed by the induction o f canine IFNy from 
canine lymphocytes [Okano et a l  1999]. Feline IL-18 was cloned and found to be 192 
aa in length with 77%, 85% and 63% identity at the amino acid level to human, canine 
and murine sequences respectively [Hanlon, 1999; Ishizaka et a l  2001].
4.1.3 Structure and processing of interleukin-18
Interleukin-18 is synthesised as a non-glycosylated biologically inactive precursor 
peptide called pro-IL-18, which is 24 kDa in size and lacks a conventional signal 
sequence [Okamura et a l  1995]. This molecule possesses similar structural homology 
to IL-lp both o f which are members o f  the IL-1 family [Bazan et a l  1996].
Pro-IL-18 is cleaved at Asp^  ^in mice to produce the mature protein, which suggested 
that an aspartic acid-specific protease was involved [Okamura et a l  1995; Ushio et a l  
1996]. It was found that interleukin-Ip converting enzyme (ICE or caspase-1) brought 
about cleavage o f pro-IL-18 to mature IL-18 [Gu et a l  1997]. ICE is an intracellular 
cysteine protease, which is expressed by B cells, neutrophils and macrophages 
[Cerretti et al. 1992; Singer et al. 1995]. It is produced as a 45 kDa proenzyme which 
is cleaved to active ICE consisting o f equal amounts o f plO and p20 subunits [Singer 
et a l  1995]. The proenzyme is cleaved into its mature form by either autoproteolytic 
conversion [Ramage et al. 1995], or by caspase-11 [Wang et a l  1998].
Caspase-3, also known as CPP32 is also able to cleave pro-IL-18 at Asp^  ^ and Asp^  ^
producing biologically inactive peptide molecules [Akita et al. 1997] and a recent 
report has suggested that proteinase 3 may be an alternative enzyme for processing o f  
IL-18 into its bioactive form [Sugawara et al. 2001].
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4.1.4 Regulation of the IL-18 gene
The structure o f the murine IL-18 gene has been elucidated and found to consist o f 7 
exons distributed over 26 kb (figure 4.1). Exons 1 and 2, situated at the 5' end are 
noncoding and distinct regions upstream from each noncoding exon show high 
promoter activity [Tone et al. 1997]. Each promoter is TATA-less and not G+C rich. 
The promoter upstream o f exon 1 is inactive under normal conditions, being 
upregulated by activated macrophage and T cell lines, whereas the promoter upstream 
o f exon 2 acts constitutively [Tone et al. 1997]. These promoters are used by many 
cell types, which may explain why IL-18 is expressed in both immune and non- 
immune cells [Nakanishi et al. 2001a]. The regulatory components o f each promoter 
were examined and the promoter upstream o f exon 1 required a binding site for the 
IFN consensus sequence binding protein (ICSBP), which is a member o f the family o f  
interferon regulatory factors, the binding o f which was increased by LPS [Kim et al. 
1999]. The expression o f ICSBP has been shown to be upregulated by IFNy [Wu et al. 
1999]. A binding site for PU .l, a transcription factor that can also be upregulated by 
IFNy as well as LPS [Shackelford et al. 1995], was found to be important for the 
activity o f the promoter upstream o f exon 2 [Kim et al. 1999].
Figure 4-1 Regulation o f IL-18 gene
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Once IL-18 protein is synthesised in cells it is stored as the inactive precursor pro-IL- 
18 [Gu et al. 1997]. This is in contrast to many other cytokines, which tend to have 
only a short half-life in the cell due to the processing o f mRNA by RNA-destabilising 
elements [Cosman, 1987]. It has been suggested that the lack o f  RNA-destabilising 
elements allows storage o f pro-IL-18 within these cells and that the active molecule is 
secreted via processing o f this protein store [Nakanishi et al. 2001a].
4.1.5 Production of IL-18
IL-18 is produced by cells o f the immune system and also non-immune cells. Certain 
cells require stimulation in order to produce expression o f  IL-18 protein. These 
include macrophages such as Kupffer cells [Okamura et al. 1995b], macrophages 
[Bohn et al. 1998], astrocytes and microglia [Conti et al. 1999] and kératinocytes in 
response to contact allergens [Stoll et al. 1997].
Other cells are able to secrete IL-18 in their normal functioning environment without 
stimulation. Enriched Langerhans cells and bone marrow-derived dendritic cell 
release functional IL-18 protein [Stoll et al. 1998], and human pro-IL-18 has been 
expressed constitutively in PBMCs from fresh whole blood [Puren et al. 1999].
4.1.6 IL-18 receptor
4.1.6.1 Structure
The receptor o f  IL-18 consists o f  a ligand-binding subunit termed IL-18Ra and a 
signal transduction unit called IL-18Rp. Human IL-18Rot was identified using the 
Hodgkin's disease cell line L428 which was shown by binding assays to express high 
levels o f IL-18 receptor [Torigoe et al. 1997]. The nucleotide sequence o f  the receptor 
was identical to human IL-1 receptor-related protein (IL-lRrp) cDNA, a member o f 
the IL-1 receptor (IL-IR) family which, when isolated, was found not to bind any o f  
the known IL-1 ligands. The gene encoding human IL-18Ra was found to be on 
chromosome 2ql2-13, in a different location to IL-18 [Pamet et al. 1996; Nolan et al.
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1998]. When a comparison o f human and murine IL-18Ra was made the overall 
amino acid identity was 65% [Pamet et a i  1996].
IL-18Rp subunit is also a member o f  the IL-IR family, previously called IL-IR- 
accessory protein- like protein (AcPL) due to its similarity to IL-IR acessory protein. 
In a study, human IL-lRrp and AcPL together were required to induce the IL-18 
signalling pathway and AcPL alone was unable to bind IL-18, suggesting that AcPL 
was required for signal transduction whereas ILlRrp was necessary for binding o f the 
cytokine [Bom et al. 1998].
4.1.6.2 IL-18 binding protein
Recently, a protein called IL-18 binding protein (IL-18BP) was isolated from human 
urine and was found to bind IL-18 and prevent IFNy production in murine splenocytes 
[Novick et al. 1999]. This protein exists in 6  naturally occurring isoforms, four human 
and two murine forms, brought about by splicing o f mRNA [Kim et al. 2000]. This 
protein functions as an inhibitor o f  the Thl immune response and appears to show no 
species specificity, as human IL-18BP is able to bind murine IL-18 [Novick et al.
1999]. Work has shown that IL-18BP may be induced by IFNy, which in tum limits 
the biological function o f IL-18 [Paulukat et al. 2001].
4.1.6.3 Expression of IL-18 receptor
IL-18Ra mRNA is expressed in lung, liver, heart, gut, prostate, placenta and thymus 
but not in brain, skeletal muscle, kidney and pancreas [Pamet et al. 1996]. The 
receptor has also been found in monocytic, erythroid, megakaryocytic, and myeloid 
cell lines [Nakamura et al. 2000].
IL-18Ra has been shown to play a role in the synergism o f IFNy induction by IL-12 
and IL-18. Treatment o f  T and B cells with IL-12 increased their responsiveness to 
IL-18. These cells were shown to demonstrate increased IL-18Ra mRNA expression, 
particularly in T cells [Yoshimoto et al. 1998]. This increased responsiveness to IL-18
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also increased the responsiveness to IL-12 by producing upregulation o f IL-12R|32 
[Chang et al. 2000].
Different subsets o f T cells demonstrate different levels o f IL-18 receptor. In one 
study CD4^ T cells were shown to express marginal IL-18 receptor expression 
whereas CD8  ^ T cells expressed higher levels, producing more IFNy in response to 
IL-18 than CD4^ cells [Tomura et al. 1998a]. One study showed that T and B cells 
express both high and low affinity IL-18 receptors, which produce IFNy in response 
to IL-18 [Yoshimoto et al. 1998]. A recent study suggested that IL-1R(3 is required for 
the production o f high affinity receptors for IL-18 [Debets et al. 2000] and this 
receptor subunit is present on Thl cells but not Th2 cells, which instead express 
T1/ST2, a member o f the IL-IR family [Lohning et al. 1998].
4.1.6.4 Signalling pathway of IL-18 receptor
The cytoplasmic domains o f IL-1 and IL-18 receptors are homologous to Toll, a type 
I transmembrane receptor isolated from the Drosophila fly [O'Neill and Greene,
1998]. They are therefore both members o f  the IL-lR/toll-like receptor superfamily 
(IL-IR/TLR) [O'Neill and Dinarello, 2000]. The signalling pathway o f IL-1 and IL- 
18 receptors involves recruitment o f an adaptor molecule called MyD8 8 , which 
initiates the IL-1 receptor-associated kinase pathway (IRAK) [Robinson et al. 1997; 
Takeuchi et al. 2000]. This pathway through tumour necrosis factor receptor- 
associated factor- 6  (TRAF6 ) then leads to the activation o f  NFkB, which is 
translocated to the nucleus [Robinson et al. 1997; Kojima et al. 1998] (figure 4.2).
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Figure 4-2 IL-18 signalling pathway
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4.1.7 Biological functions of IL-18
Studies o f the biological effect o f IL-18 have shown that the cytokine has multiple 
functions in the immune response. It induces IFNy production from Thl and NK cells 
[Okamura ef al. 1995], particularly in combination with IL-12. However, as well as 
encouraging a Thl biased response, under certain circumstances it can stimulate T 
and NK cells to produce Th2 cytokines.
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4.1.7.1 Functions of IL-18 relating to Thl response
IL-18 induces dose dependent proliferation o f T cells, which is not inhibited by 
treatment with antibodies against IFNy [Micallef et a l  1996]. IL-18 also synergises 
with IL-12 in the production o f  IFNy from Thl cells [Ahn et a l  1997]. In this study, 
in an IL-12 responsive T cell line, IL-18 stimulated only marginal IFNy production in 
cell deprived o f IL-12, but markedly enhanced production when both cytokines were 
present.
In contrast to IL-12, IL-18 alone is incapable o f producing differentiation o f naive T 
cells into Thl cells. However, the presence o f IL-18 accelerates IL-12-driven Thl 
development [Robinson et a l  1997]. Also, mice deficient in IL-18 demonstrate fewer 
defects in Thl function than IL-12-deficient mice [Takeda et a l  1998].
In addition to inducing IFNy production, IL-18 also selectively enhances the Fas 
ligand-(FasL) mediated cytotoxicity o f  murine Thl cells [Dao et a l  1996]. Fas ligand 
is expressed on activated or cytotoxic T cells and on engagement o f this 
transmembrane protein with Fas on the target cell induces apoptosis. IL-18 does not 
enhance FasL on Th2 cells or naive T cells [Dao et a l  1996].
IL-18 acts as a costimulant with factors such as IL-2 and Con A to augment the 
production o f IL-2 and GM-CSF from Thl clones. This cytokine also induces 
proliferation o f populations o f  Thl clones. However, IL-18 induces little effect on the 
proliferation or cytokine production o f Th2 cells [Micallef et a l  1996; Kohno et a l
1997].
4.1.7.2 Biological action of IL-18 on NK and CD8* cells
As well as stimulating the cytotoxicity o f  Thl cells, IL-18 also influences the 
cytotoxic effect o f NK and CD8  ^ cells. These cells exert their cytotoxic function by 
apoptosis using perforin [Dao et a l  1998], FasL [Tsutsui et a l  1996] and TNF-related 
apoptosis-inducing ligand (TRAIL) [Wiley et a l  1995]. Cloned NK cells were shown 
to constitutively express FasL and kill target cells expressing Fas. This killing activity 
was upregulated by IL-18 but not IL-12 [Tsutsui et a l  1996]. On the other hand, IL-
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18 does not to induce expression o f  TRAIL on activated NK cells [Kayagaki et al.
1999].
Experiments with IL-18 deficient mice showed that IL-18 is also important in the 
activity o f NK cells. Impaired NK cell activity was demonstrated in both IL-18- 
deficient and IL-12-deficient mice. Administration o f exogenous IL-12 or IL-18 
restored NK cell activity in both IL-12 and IL-18 deficient mice which implies that 
each cytokine exerts its effect on NK cells independently o f the other [Takeda et al.
1998].
4.1.7.3 IFNy stimulation of other cells by IL-18
Cell types other than T and NK cells have been shown to respond to IL-18. Murine 
bone marrow-derived macrophages secrete high levels o f IFNy in response to IL-12 
and IL-18, which neither cytokine stimulates alone [Munder et al. 1998]. IL-18 also 
augments the IFNy production o f  murine splenic dendritic cells by IL-12 [Fukao et al.
2000] and microglia have been shown to express elements o f the IL-18 receptor 
system and demonstrate expression o f  IRAK and TRAP 6  [Prinz and Hanisch, 1999].
Under certain circumstances B cells are able to respond to IL-18. When B cells are 
stimulated with anti-CD40 and IL-4 they produce IgGl and IgE antibody. However 
when stimulated in this way in the presence o f  IL-12 and IL-18, there is inhibition o f  
IgGl and IgE with stimulation o f  IgG2a, and a rise in production o f IFNy [Yoshimoto 
et al. 1997].
4.1.7.4 Synergistic action of IL-18 and IL-12 on IFNy production
IL-18 and IL-12 act synergistically to stimulate IFNy production from T cells and NK 
cells [Ahn et al. 1997; Lauwerys et al. 1999]. This synergism occurs because each 
cytokine activates the IFNy promoter by a separate pathway. The receptor for IL-12 
activates STAT 4 [Jacobsen et al. 1995; Xu et al. 1996] as well as AP-1. The IFNy 
promoter contains a binding site for both STAT 4 and AP-1, both o f  which are 
required for IL-12-dependent IFNy promoter activity [Barbulescu et al. 1998]. IL-18
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however functions via the IRAK-TRAF 6  pathway and the activation o f NF-kB 
[Robinson et al. 1997; Kojima et al. 1998].
These separate signalling pathways produce synergy o f IL-12 and IL-18 in the 
induction o f IFNy transcription o f  T cells and this pathway functions independently o f  
T cell receptor (TCR) signalling [Yang et al. 1999]. However anti-CD3 stimulation is 
required for the formation o f Thl cells from T cells in the presence o f  IL-12 and IL- 
18 showing that TCR is essential for T cell differentiation [Yoshimoto et al. 1998].
IL-12 and IL-18 have been shown to have a differential effect on CD8  ^ effector T 
cells. IL-12 alone was shown to decrease the CD8^/CD4^ ratios, IFNy production and 
CTL activity o f mixed lymphocyte cultures whereas IL-18 alone increased these 
levels but did not induce CD8  ^ effector cells. Together however, the two cytokines 
acted synergistically to produce CD8  ^ effector cells from mixed lymphocyte cultures 
[Okamoto et al. 1999]. This synergy has also been seen in the proliferation, activity 
and IFNy production o f NK cells [Tomura et al. 1998].
4.1.7.5 Induction of Th2 cytokines by IL-18
Although the stimulation o f  IFNy is the main cytokine induced by IL-18 in the 
immune pathway, IL-18 can also stimulate Th2 cytokine expression by T and NK  
cells. IL-18 in combination with IL-2 induced strong production o f IL-13 mRNA and 
protein from T and NK cells and enhanced the level o f IL-13 induced by IL-2 alone 
[Hoshino et al. 1999]. This expression o f IL-13 protein was increased in IFNy 
knockout mice, implying that IFNy plays a role in the regulation o f  IL-18-induced IL- 
13 production.
Also, naive CD4^ T cells treated with IL-18 and IL-2 showed TCR-independent 
production o f IL-13, CD40L and IL-4 [Yoshimoto et al. 2000]. Stimulation o f these 
cells with TCR stimulated further Th2 cytokine stimulation. Recent evidence shows 
that IL-18 is able to induce the development o f Th2 cells from naive CD4^ T cells in 
the presence o f IL-4, but these cells develop into Thl cells if  treated with anti-IL-4 
antibody [Nakanishi et al. 2001b].
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IL-18 in conjunction with IL-3 also induces expression o f IL-18Ra on basophils and 
mast cells and stimulates the production o f IL-4 and IL-13 from basophils. This Th2 
cytokine production is inhibited by treatment with a combination o f  IL-12 and IL-18 
[Yoshimoto et al. 1999].
4.1.8 Role of IL-18 In defence against pathogens
The function o f IL-18 in promoting cell-mediated immunity has led to studies o f its 
role in defence against pathogens such as bacteria, viruses and fungal infection. One 
study showed that mice demonstrated protection against Listeria monocytogenes 
when injected with recombinant murine IL-18. Enhanced bacterial clearance occurred 
even when functional IFNy was eliminated using an anti-IFNy monoclonal antibody. 
The cytokine was shown to affect the innate immune response by production o f  TNF 
from macrophages, as well as stimulating antigen-specific T cells [Neighbors et a l  
2001]. Caspase-1 deficient mice were shown to have impaired Thl resistance to 
infection with Candida albicans. This corresponded with low IL-18, IL-12 and IFNy 
levels. Thl resistance was restored when mice were treated with exogenous IL-18 
[Mencacci et al. 2000]. The role o f IL-18 in anti-viral therapy has also been 
investigated. One study has shown that when recombinant murine IL-18 was 
administered to mice along with vaccinia virus, the clinical signs o f  disease were 
suppressed. This corresponded with an increase in NK and CTL activity. The 
beneficial effect was nullified by the use o f anti-IFNy antibody, showing that in this 
case, the role o f IL-18 in IFNy stimulation was obviously important [Tanaka-Kataoka 
et al. 1998].
4.1.8.1 Role of IL-18 in tumour therapy
The ability o f IL-18 to promote NK, Thl, CD8  ^ cell cytotoxicity and T cell 
proliferation has been shown to be useful in stimulating a response against tumour 
antigens. Recombinant murine IL-18 suppressed over 75% primary tumour growth in 
murine T241 fibrosarcoma o f SCID mice when administered intratumorally and 
systemically [Cao et al. 1999]. This study also showed that IL-18 suppressed tumour
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angiogenesis shown by a significant decrease in blood vessel density in IL-18-treated 
mice compared to control animals.
In another experiment, a human parathyroid hormone leader sequence was fused to 
mature murine IL-18 and transfected into recombinant adenoviral vectors. Direct 
injection into established MCA205 murine fibrosarcoma cured all animals and 
produced protective immunity against the tumour. A synergistic effect was induced by 
simultaneous systemic IL-12 therapy with no side effects [Osaki et a l  1999]. The 
synergistic effect o f  IL-12 and IL-18 in tumour immunotherapy was also shown by 
the coadministration o f  murine IL-12, pro-IL-18 and caspase-1 cDNA by gene gun. 
This treatment suppressed the growth o f  murine mammary adenocarcinoma tumours 
implanted into the skin [Oshikawa et a l  1999].
4.1.8.2 Role of IL-18 as a vaccine adjuvant
O f particular relevance to this project is the great potential that IL-18 has shown as an 
adjuvant to vaccination. Several studies have been performed where IL-18 is 
delivered as an adjuvant in order to modulate the immune response towards cell 
mediated immunity. This shows particular promise with intracellular viruses such as 
HIV-1 where cell mediated immunity is important in viral clearance. In one study, the 
coinjection o f  IL-18 encoded DNA with an HIV-1 nef DNA prime/protein boost 
vaccine shifted the specific immune response towards Thl cell mediated immunity 
[Billaut-Mulot et a l  2001a]. Similarly, the inclusion o f murine plasmid IL-18 was 
used to modulate the response to a multiepitopic DNA vaccine for HIV-L The 
vaccine constituted constructs encoding gag, tat and nef and the IL-18 gene decreased 
by 2 weeks the time taken to induce CTLs and increased the level o f IL-2 and IFNy 
induced by the antigen. Antibody titres against the viral proteins were deereased in 
this case [Billaut-Mulot et a l  2001b].
Studies have analysed the use o f  IL-18 as an adjuvant to DNA vaccines for feline 
retroviruses. A plasmid encoding feline mature IL-18 with an immunoglobulin 
secretory signal sequence derived from PsecI plasmid (Invitrogen Life Technologies), 
was used in vivo with an integrase deleted FIV DNA vaccine. The virus-specific CTL 
responses using IL-18 as an adjuvant were more consistent than using the DNA
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vaccine alone. The efficacy o f this vaccine was not improved by the inclusion o f a 
plasmid encoding feline IL-12 [Dunham et a l  2002]. Of these cats, 33% 
demonstrated protection against FIV challenge.
The same IL-18 expression vector was used with an IL-12 plasmid as adjuvants to a 
DNA vaccine to FeLV. This combination produced complete protection against 
transient and persistent viraemia and 5 o f  6  cats from latent infection [Hanlon et a l
2001]. Cats protected using these vaccines were shown to have higher FeLV-specific 
CTL responses in blood and lymphoid organs than control cats [Flynn et a l  2000a].
4.1.9 Design of IL-18 constructs
Experimental studies have used various forms o f IL-18-encoding plasmid including 
pro-IL-18 cDNA alone [Oshikawa et a l  1999], pro-IL-18 coinoculated with IL-ip  
converting enzyme (ICE) cDNA [Oshikawa et a l  1999] and mature-IL-18 cDNA  
[Giavedoni et a l  2001] (figure 4.3). On transcription and translation within the cell, 
both pro- and mature-IL-18 produced from these vectors pose problems in terms o f  
secretion across the cell membrane.
As mentioned previously, IL-18 is synthesised within the cell as pro-IL-18, a 
biological precursor molecule that lacks a signalling peptide. Pro-IL-18 requires 
cleavage by ICE or caspase-1 to produce the biologically active mature-IL-18, which 
contains the natural signal for secretion across the cell membrane [Okamura et a l  
1995; Gu et a l  1997]. Cells transfected directly with pro-IL-18 must therefore rely on 
natural ICE present within the cell to allow secretion o f bioactive mature-IL-18. Cells 
transfected with mature-IL-18 cDNA are unable to secrete IL-18 protein as they lack 
a natural signalling peptide. Therefore protein can only be released during apoptosis 
or cell injury. The coinoculation o f pro-IL-18 and ICE cDNA partially addresses this 
problem [Oshikawa et a l  1999], but in this case the use o f separate plasmids for each 
construct does not guarantee the production o f  both IL-18 and ICE protein in one cell.
For these reasons several groups have investigated the use o f cDNA encoding signal 
peptides fused to the mature-IL-18 gene to encourage secretion from transfected cells.
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One study demonstrated antitumour activity o f  a vector encoding the prepro leader 
sequence o f human parathyroid hormone fused to mature murine IL-18 [Osaki et al.
1999]. Others have shown resistance to Mycobacterium avium using murine mature- 
IL-18 fused to the human immunoglobulin kappa leader sequence [Kim et al. 2001].
Figure 4-3 IL-18 DNA vaccine constructs and their potential secretion
1) Inoculation of p ro -IL -18  plasm id: secretion  o f m a tu re -IL -1 8  with natural signalling peptide
only in the  p resence  o f natural caspase-1
2) Inoculation of m atu re -IL -1 8  plasm id: no secretion  o f m atu re -IL -1 8  as  no signalling peptide
3) ILR A P  signal protein c leaved  in the endoplasm ic reticulum: secretion  of m ature IL -18
4.1.10 In vitro measurement of bioactivity of IL-18
Since its isolation, the standard assay used to measure the in vitro bioactivity o f IL-18 
has been the production o f IFNy from fresh PBMC populations [Ushio et al. 1996]. 
These cells were cultured in the presence o f IL-18 samples and the supernatants were 
measured for human IFNy production by specific ELISA. This system presents
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several disadvantages. Firstly the preparation o f PBMC cells is laborious and cell 
responses vary between blood donors. In addition, PBMC cells under certain 
conditions are able to produce IFNy in response to other cytokines such as IL-12, 
which decreases the specificity o f  the assay [McDyer et a l  1998].
These disadvantages led to the development o f  a new bioassay based on IFNy 
production from KG-1 cells. This is a human myelomonocytic cell line that produces 
human IFNy (hlFNy) in response to IL-18 without the requirement o f a costimulatory 
signal [Konishi et a l  1997]. A study o f this cell line showed that an NF-kB binding 
site was stimulated at the regulatory region o f  the IFNy gene in response to human IL- 
18 [Kojima et al. 1999]. Konishi et a l  developed this bioassay by incubating test 
samples in a KG-1 cell suspension o f  3 x 10  ^ cells/ml for 24 hours. The level o f  
hlFNy produced from samples and human IFNy standards was measured using a 
specific ELISA. Human IL-18 was detected in a dose dependent manner, which was 
suppressed by the addition o f  human serum. Background levels o f hlFNy were 
produced when cells were incubated with human IL-12, confirming the specificity o f  
this assay to IL-18.
Konishi et a l  demonstrated detection o f murine IL-18 using this assay, but at 100- 
fold lower sensitivity. With the aim o f improving the sensitivity to murine protein, 
they produced a stable cell line o f  KG-1 cells expressing murine IL-18 receptor. This 
modified cell line was shown to express large amounts o f hlFNy in response to both 
human and murine IL-18 in a dose dependent manner, increasing significantly the 
sensitivity o f  this assay to murine IL-18 [Taniguchi et a l  1998].
4.1.11 Aim of work
The aim o f this work was to analyse the level o f  expression and bioactivity o f  several 
feline IL-18 constructs in vitro. A feline signal IL-18 construct, PsecI-IL-18 was 
cloned previously using a PsecI plasmid, a vector derived from pCI-neo (Promega) 
containing a synthetic immunoglobulin secretory component [Hanlon, 1999]. This 
construct was used in vivo with IL-12 as a vaccine adjuvant to a DNA vaccine for 
FeLV [Hanlon et al. 2001] and a DNA vaccine to FIV [Dunham et a l  2002].
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However, the in vitro expression and bioactivity o f  PsecI-IL-18 had not been 
confirmed.
This work involved the development o f a new feline signal IL-18, ILRAP-IL-18. This 
construct consisted o f feline mature-IL-18 fused to the human signal sequence for IL- 
ip  receptor antagonist protein (ILRAP) [Wingren et a l  1996]. In vitro experiments 
demonstrated protein expression and a KG-1 bioassay was developed to detect feline 
IL-18 protein in vitro. This system was used to measure the bioactivity o f pro-, 
mature-, PsecI- and ILRAP-IL-18 supernatants and cell lysates from cell 
transfections. In addition the feline IL-18Rot was cloned. This receptor may be used to 
produce a stable cell line o f KG-1 cells to further increase the sensitivity o f  the KG-1 
assay to feline IL-18.
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4.2 MATERIALS AND METHODS
4.2.1 Cloning of feline pro-, mature- and PsecI-IL-18 constructs
Feline pro-IL-18 and mature-IL-18 were a kind donation from Dr Linda Hanlon 
(Molecular Oncology Laboratories, University o f Glasgow). cDNA encoding pro-IL- 
18 was isolated by RT-PCR o f mRNA from LPS-stimulated feline alveolar 
macrophages [Hanlon, 1999]. This fragment was cloned into pCI-neo expression 
vector (Promega).
Mature-IL-18 was amplified from the pro-IL-18/pCI-neo construct by PCR using 
specific primers and also cloned into pCI-neo expression vector [Hanlon, 1999].
L. Hanlon performed the cloning o f PsecI-IL-18. Specific primers were designed to 
amplify mature-IL-18 with restriction sites encoded at the 5' and 3' end. These sites 
were used to clone the mature-IL-18 fragment into PsecI expression vector [Hanlon,
1999].
4.2.1.1 Cloning of feline ILRAP-IL-18 construct
ILRAP-IL-18 was cloned by L. McMonagle, Retrovirus Research Laboratories, 
University o f Glasgow. The DNA template used for PCR amplification was feline 
mature-IL-18 [Hanlon, 1999]. Two sets o f  specific primers were designed to amplify 
mature-IL-18 with ILRAP-encoding sequence at the 5' end o f the fragment. The 
primary PCR used the following primers with Tag DNA polymerase:
Primary 5' primer: 5' -CGC AGT CAC CTA ATC ACT CTC CTC CTC TTC CTG 
TTC CTG TTC CAT TCA GAG ACG ATC TGC TAC TTT GGC A AG CTT G -3'
Primary 3' primer: 5' -GCG CGT CGA CCT AAT TCT TGT TTT GAA CAG TG- 3'
This 5' primer encoded half o f the ILRAP sequence followed by feline mature-IL-18 
sequence. The 3' primer encoded the 3' feline mature-IL-18 sequence. A secondary
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PCR was used to amplify a full length ILRAP-IL-18 fragment from the 1° PCR. The 
same 3' primer was used in combination with the following 5' primer:
Secondary 5' primer: 5' - GGC AGA ATT CGC CAT GAA ATC TGC AGA GGC 
CTC CGC AGT CAC CTA ATC AC - 3'
This produced a full length ILRAP-IL-18 construct which was cloned into pCR3.1 
vector (Invitrogen Life Technologies). The fragment was excised from pCR3.1 using 
an EcoR 1/ Sal I restriction digest and cloned into similarly digested pCI-neo 
expression vector (Promega).
4.2.2 Transfection of IL-18 constructs into CHO cell line
DNA for transfection o f  pro-IL-18, mature-IL-18, ILRAP-IL-18 and pCI-neo 
expression vector was prepared using Qiagen plasmid Mega Kit (Qiagen) and stored 
at -20°C until further use. CHO cells were maintained in 175 em  ^ culture flasks and 
20 |Lig o f  DNA was used for each transfection. All transfections were carried out under 
the same conditions using LipofectAMINE Reagent (Invitrogen Life Technologies) 
according to the instructions o f  the manufacturer. The transfections were incubated 
for 48 hours in an incubator at 37°C with 5% COg.
In a separate experiment, transfections o f  feline PsecI-IL-18, ILRAP-IL-18 and pCI- 
neo vector were performed in parallel, in order to compare the levels o f  protein 
expression and secretion o f  feline signal-IL-18 constructs.
The supernatants and cell lysates were then harvested for analysis. The supernatant 
was removed from each transfection and any cellular debris eliminated by 
centrifugation at 1000 rpm for 5 minutes. The supernatant was then aliquoted and 
stored at -20°C until further use. The cells were detached from each flask using a cell 
scraper and the cells from each transfection were harvested in the appropriate buffer 
amounts. These amounts were based on observed expression levels between the 
different IL-18 constructs; constructs eliciting the highest protein expression were 
diluted in larger buffer volumes. As a result, cells from the pro-IL-18 transfection
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were harvested in separate 4 ml PBS and 4 ml caspase buffer (CB) aliquots, mature- 
IL-18 in 4 ml PBS, ILRAP-IL-18 and PsecI-IL-18 in 2 ml PBS and pCI-neo in 1 ml 
PBS and 1 ml CB. Pro-IL-18 caspase buffer cell lysate was included in order to allow 
digestion o f pro-IL-18 with caspase-1 to produce bio active mature-IL-18. These cells 
were then frozen and thawed three times in a dry ice ethanol bath and 37°C water hath 
respectively, in order to rupture cell membranes. Cell lysate debris was pelleted by 
centrifugation at 14000 rpm for 30 seconds and the supernatant was aliquoted and 
stored at -20°C until later use. Prior to storage, pro-IL-18 cell lysate was digested to 
produce mature-IL-18 as described below.
4.2.2.1 Preparation of bioactive mature-IL-18 from pro-IL-18 cell lysate
Pro-IL-18 cell lysate in caspase buffer produced from CHO cell transfections was 
incubated overnight at room temperature with human recombinant caspase- 1 
(Calbiochem, UK) at a concentration o f 2500 U/ml. This sample was then stored at - 
2 0 °<C until further use.
4.2.3 In vitro expression of IL-18 protein products using Western 
blot analysis
Expression o f  pro-IL-18, mature-IL-18, ILRAP-IL-18 and pCI-neo transfection 
products were analysed using SDS-PAGE and immunodetection. The primary 
antibody was a sheep anti-feline IL-18 polyclonal antibody, a kind donation from Dr 
Norman Flynn (Retrovirus Research Laboratories, University o f Glasgow), used at a 
1:2000 dilution. The secondary antibody was anti-sheep IgG peroxidase conjugate, 
delivered at a dilution o f 1 :2 0 0 0 .
Before separation on a gel, each IL-18 cell lysate sample was diluted appropriately in 
dHiO in order to balance the protein level in each sample. A volume o f 20 pi o f  
undiluted supernatant sample with 5 pi protein loading buffer was used per well. The 
protein samples were separated on a 15% SDS-PAGE gel under denaturing conditions 
as outlined in 2.2.10. In addition, 3.2 ng o f recombinant equine IL-18 was run
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alongside as a positive control. The gel was transferred to a PVDF membrane and 
probed as described in 2 .2 . 1 1  using the antibody concentrations described above.
Samples o f feline ILRAP-IL-18, PsecI-IL-18 and pCI-neo cell lysate and supernatant 
were also compared on an SDS-PAGE gel prepared as described previously. 18 pi o f  
sample was used in each well with 5 pi protein loading buffer. This gel was to allow 
comparison o f  protein expression and secretion o f  signal-IL-18 constructs. Equine 
ILRAP and PsecI-IL-18 constructs were also analysed by Western blot analysis. All 
samples were exposed to a primary antibody o f  rabbit anti-equine polyclonal antibody 
(prepared in our laboratories) at a concentration o f 1:4000 and a secondary antibody 
o f  anti-rabbit IgG peroxidase conjugate at a dilution o f  1:2000. This rabbit anti-equine 
polyclonal antibody was found to be cross-reactive with feline IL-18 protein.
4.2.4 In vitro bioactivity of iL-18 protein products
The bioactivity o f  caspase-1 digested pro-IL-18, mature-IL-18, ILRAP-IL-18, PsecI- 
IL-18 and pCI-neo transfection products were analysed using a KG-1 bioassay 
system, which measures the level o f  hlFNy production by this cell line in response to 
IL-18. [Konishi etal. 1997].
4.2.4.1 IL-18 bioassay samples
O f the supernatant samples, neither pro-IL-18 nor mature-IL-18 displayed detectable 
levels o f protein secretion from the cell in either Western blot or previous bioassays 
and were therefore excluded from this experiment. However comparison o f ILRAP- 
IL-18 and PsecI-IL-18 supernatants was performed along with pCI-neo supernatant as 
a negative control.
The following cell lysate samples diluted in PBS were used: pro-IL-18, mature-IL-18, 
ILRAP-IL-18, PsecI-IL-18 and pCI-neo as a negative control. Lysate samples diluted 
in caspase buffer were prepared as follows: pro-IL-18 digested with caspase and pCI- 
neo digested with caspase as a negative control; caspase-digested pro-IL-18 with 
sheep anti-feline IL-18 polyclonal antibody (34ng/|al) and caspase digested pCI-neo
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also with antibody as a negative control. In addition a negative control for the 
antibody itself was included by using caspase-digested pro-IL-18 with FeLV rabbit 
polyclonal antibody at a similar concentration. The inclusion o f an IL-18 specific 
neutralising antibody allows binding and inactivation o f the bioactive IL-18 molecule 
verifying specificity o f  the hlFNy production to IL-18 protein.
4.2.4.2 IL-18 bioassay
A 1:2 titration o f each sample was made in KG-1 medium (Iscove's Modified 
Dulbecco's medium, 20% FCS, 1 x Penicillin/Streptomycin and 2 mM L-Glutamine) 
and 150 |ul o f  each dilution was added to a fiat-bottom 96 well plate. The higher 
protein expression o f  pro-IL-18 transfeetion required larger dilution factors than either 
mature-IL-18 or ILRAP-IL-18. As a result, titrations from 1:1250 to 1:20000 were 
used for pro-IL-18 and 1:32 to 1: 1024 were used for mature-IL-18, ILRAP-IL-18 and 
PsecI-IL-18. This plate was then incubated at 4°C for 24 hours on a shaking platform.
After 24 hours, 100 jil o f  each sample was aliquoted onto a fresh 96 well plate. KG-1 
cells were suspended at a eell density o f  3 x 10  ^cells/ml in fresh culture medium and 
human recombinant TNFa was added to a concentration o f 10 ng/ml. 100 |il (3x10^  
cells) was added to each protein sample and mixed gently. The plate was then 
incubated for 24 hours at 37°C with 5% COo.
The cells were pelleted by centrifugation o f  the plate at 1000 rpm for 5 minutes and 
the amount o f  IFNy in the supernatant was measured using the Quantikine human IFN 
y kit (R + D Systems) under the manufacturer's instructions. This system consists o f a 
quantitative sandwich enzyme immunoassay using an ELISA plate pre-coated with an 
IFNy-specific polyclonal antibody. 100 \i\ sample was added to 100 pi assay diluent 
and incubated for 2 hours at room temperature. Standard samples o f human IFNy 
were completed alongside at concentrations o f  1000-15.6 pg/ml. Any hlFNy present 
in the transfection sample became bound to the plate and unbound substances were 
removed by washing the plate 4 times in wash buffer. Each well was then incubated 
for 2 hours with 200 pi conjugate containing an anti-IFNy polyclonal antibody 
conjugated to horseradish peroxidase. The washing step was repeated and a substrate
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was added to each well, which develops colour in proportion to the level o f IFNy 
bound to each well. The substrate was incubated on the plate in the dark for 30 
minutes at room temperature. The colour development was stopped by adding 50 pi 
o f stop solution, and the intensity o f  colour measured using a spectrophotometer at 
560 nm.
4.2.5 Cloning of feline IL-18 receptor
4.2.5.1 Design of primers
Primers for the amplification o f ligand binding subunit o f  the feline IL-18 receptor 
(FIL-18Ra) were designed using a consensus sequence o f  human IL-18Ra [Torigoe 
et al. 1997] and murine IL-18Ra [Taniguchi et al. 1998]. Focus was placed on areas 
o f sequence which would require primers o f  low degeneracy. This involved locating 
blocks o f amino acids that were conserved between species. In addition, low  
degeneracy primers were favoured in areas o f  amino acids encoded by only one 
possible codon sequence rather than several codons. The sequence o f oligonucleotides 
tended to be based on the human IL-18Ra sequence because in general, human 
sequences display greater homology with feline than murine sequences. All primer 
positions are demonstrated in figure 4.4.
An initial set o f  primers was designed to amplify preliminary fragments o f  IL-18Ra. 
The sequence data produced from these fragments facilitated the design o f  subsequent 
primers internal to the known sequence and at the start and stop codon, again using 
the published human receptor sequence as reference. These primers were then used in 
combination to amplify the fragments upstream and downstream from the original 
isolated fragments to obtain the full receptor sequence.
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Primer Sequence (5'-3')
Initial primers
F9a CCTCATTGTATAARAAYTGCAA
F9b CCTCATTGTATAARAAYTGTAA
F9s ACATCATTGTATAAGAACTG
R6 GTAAAGAAGGTTYTTCCARAA
R8 CTGGCCACAGTRCARTTRTA
R8s TCCCGTGCTGGCCACAGTGC
Subsequent primers
Fid GCGAAGCAGAATCCAAANNATG
RIO AATATCCCTGATCTTCAAACTC
F ll CTTGAAAGTGGACTCCATGAAGC
R12 TTAAGACTCGGAAAGAACAG
N = A/G/C/T H -A /C /T  R = A/G Y = C/T
Fragments attained from these reactions resulted in a full preliminary FIL-18Ra 
sequence with a small area o f primer-derived sequence at both 5' and 3' ends. Primers 
F id  and R12 were then modified and extended using exact FIL-18Ra sequence to 
produce 3DN and 12NL respectively. These were used in combination with both 
existing primers and new primers, F I3 and F I5 derived from human and equine IL- 
18Ra sequence, to amplify more fragments. Additional sequence information was 
gained by using F9SF which was a primer based on F9s using exact feline IL-18 
receptor sequence, and R16SF and R17SF which were reverse primers o f  exact feline 
sequence situated close to 12NL primer.
F eline IL-18R a primers
Name o f  primer Sequence (5'-3')
3DN ATGCGTCATATAGAACTGCTCTTAACG
12NL GTTAAGACTCGGAAAGAACAGGAAAGACTTCAGATT
F13 GTGTTGGAGAAACATTTTGG
F15 ATCCACTCACTGATAGAGAA
9SF ACTTCACTGTATAAGAACTG
R16SF GCAGGCATCAGGTACAGAAG
R17SF CAGATTCAGTTCCACGAGGC
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4.2.5.2 Isolation of MYA-1 cell RNA
The MYA-1 cell line was maintained as described in 2.2.15.1. Total RNA was 
obtained from 2 x 10  ^ cell aliquots using the Centra Purescript RNA isolation kit 
(Flowgen) according to the manufacturer's instructions. This kit lyses cells in the 
presence o f an RNA preservative using an anionic detergent which solubilises the 
cellular components. The RNA preservative limits the activity o f  RNases that are 
present in the cell and elsewhere in the environment. The contaminating DNA and 
proteins are then removed by salt precipitation.
RNA from each cell aliquot was resuspended in 200 pi DEPC-treated water and 
treated with DNase. Purescript DNAse I (Centra systems) was used with 1 x reaction 
buffer at a concentration o f 0.017 U/pl. This reaction was incubated at 37°C for 
1 hour and the DNase was inactivated at 65°C for 10 minutes. The RNA was 
aliquoted and stored at -20°C until further use.
4.2.5.3 Reverse trancription-PCR of feline IL-18Ra
Total RNA was reverse transcribed and PCR fragments amplified using the Access 
RT-PCR System (Promega). Basic reaction concentrations and conditions are 
described in 2.2.13. Aimealing temperatures were selected according to the melting 
temperatures o f each primer combination used. The use o f PCR Express machines 
(Hybaid Limited) allowed a range o f  annealing temperatures to be used 
simultaneously, permitting efficient identification o f optimal PCR conditions.
Fragments o f  expected sizes were cloned into pCR-2.1-TOPO cloning vector using 
the TOPO TA cloning kit (Invitrogen Life Technologies) under the instructions o f  the 
manufacturer. TOPO cloning reactions were transformed into One Shot Chemically 
Competent E. colt (Invitrogen Life Technologies) and minipreparations o f plasmid 
DNA made from the colonies produced. Plasmid DNA was digested with appropriate 
enzymes within the cloning vector to excise the insert. These fragments were 
visualised on a 0 .8 % agarose gel stained with ethidium bromide.
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Confirmation o f positive clones was carried out by sequencing using the ABI Prism 
system. Forward and reverse primers featured in the cloning vector were used to 
verify both forward and reverse sequence. This data was analysed using the GCG 
package (Wisconsin Package Version 9.1, Genetics Computer Group (GCG), 
Madison, Wisconsin), and by visualisation o f the chromatogram. A consensus 
nucleotide sequence o f  feline IL-18Ra was produced which was extrapolated to 
establish the amino acid sequence o f  the receptor.
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Figure 4-4 Consensus sequence o f  human and murine IL-18a
Key
Red text 
Blue text 
Green text 
Purple text
-initial set o f primers 
-subsequent primers 
-modified primers
-degenerate primers derived from equine and human IL-18Ra 
sequence
Degeneracy sequences
R -A /G  
Y -C /T  
N -A/G/C/T  
H -A /C/T
F3DN ATGCG TCATATAGAA
Fid GCGA AGCAGAATCC AAANNATG
hillSr   -GCCATTTGA AGCAGAATCC AAACCATGAA TTGTAGAGAA
mill8r AAACAAGAGA TACCATTCAA AGTGGAAGCC TAAACATGCA TCATGAAGAA
Con ------------------ — CCATT--A AG--GAA-CC -AA-CATG-A T— T— AGAA
CTGCTCTTAA CG
hillSr TTACCCTTGA CCCTTTGGGT GCTTATATCT GTAAGCACTG CAGAATCTTG
millSr TTAATCTTGA CACTCTGCAT TCTCATTGTT AAAAGTGCCT CAAAAAGTTG
Con TTA--CTTGA C -C T -T G --T  -CT-AT T — A A G --C -- CA-AA--TTG
101 150
hillSr TACTTCACGT CCCCACATTA CTGTGGTTGA AGGGGAACCT TTCTATCTGA
millSr TATTCACCGA TCACAAATTC ATGTGGTAGA GGGAGAACCT TTTTATCTGA
Con TA-T CG- -C-CA-ATT- -TGTGGT-GA -GG-GAACCT TT-TATCTGA
151 200
hillSr A...ACATTG CTCGTGTTCA CTTGCACATG AGATTGAAAC AACCACCAAA
millSr AGCCATGTGG CATATCTGCA CCAGTGCACA GGAATGAAAC AGCCACCATG
Con A A --T -G  C T-T-CA C --G --C A --  -GA-TGAAAC A-CCACCA--
201 250
hillSr AGCTGGTACA AAAGCAGTGG ATCACAGGAA CATGTGGAGC TGAACCCAAG
millSr AGATGGTTCA AAGGCAGTGC TTCACATGAG TATAGAGAGC TGAACAACAG
Con AG-TGGT-CA AA-GCAGTG- -TCACA-GA- -AT GAGC TGAAC AG
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251 300
hillSr GAGTTCCTCG AGAATTGCTT TGCATGATTG TGTTTTGGAG TTTTGGCCAG
millSr AAGCTCGCCC AGAGTCACTT TTCATGATCA CACCTTGGAA TTCTGGCCAG
Con -A G -T C --C - AGA-T--CTT T-CATGAT----------TTGGA- TT-TGGCCAG
301 350
hillSr TTGAGTTGAA TGACACAGGA TCTTACTTTT TCCAAATGAA AAATTATACT
millSr TTGAGATGGA GGATGAGGGA ACGTACATTT CTCAAGTCGG AAATGATCGT
Con TTGAG-TG-A -GA GGA -C-TAC-TTT --C A A -T   AAAT-AT--T
351 400
hillSr CAGAAATGGA AATTAAATGT CATCAGAAGA AATAAACACA GCTGTTTCAC
millSr CGCAATTGGA CCTTAAATGT CACCAAAAGA AACAAACACA GCTGTTTCTC
Con C— AA-TGGA — TTAAATGT CA CA AAGA AA AAACACA GCTGTTTC-C
401 450
hillSr TGAAAGACAA GTAACTAGTA AAATTGTGGA AGTTAAAAAA TTTTTTCAGA
millSr TGACAAGCTC GTGACAAGCA GAGATGTTGA AGTTAACAAA TCTCTGCATA
Con T G A -A --C -- GT-AC-AG-A -A--TGT-GA AGTTAA AAA T -T-T -C A -A
F9b CCTCATTG 
F9s F9a CCTCATTG
hillSr TAACCTGTGA AAACAGTTAC TATCAAACAC TGGTCAACAG CACATCATTG
millSr TCACTTGTAA GAATCCTAAC TATGAAGAGC TGATCCAGGA CACATGGCTG
Con T-AC-TGT-A AA T-AC TAT-AA C TG-TC-A CACAT TG
TATAARAAYT GTAA
TATAARAAYT GCAA
hillSr TATAAGAACT GTAAAAAGCT ACTACTGGAG AACAATAAAA ACCCAACGAT
millSr TATAAGAACT GTAA............ GGAA ATATCCAAAA CCCCAAGGAT
Con TATAAGAACT GTAA  GGA- A AAAA -CCCAA-GAT
551 RIO 600
hillSr AAAGAAGAAC GCCGAGTTTG AAGATCAGGG GTATTACTCC TGCGTGCATT
millSr CCTGAAGGAT GCCGAGTTTG GAGATGAGGG CTACTACTCC TGCGTGTTTT
Con -----GAAG-A- GCCGAGTTTG -AGAT-AGGG -TA-TACTCC TGCGTG— TT
601 650
hillSr TCCTTCATCA TAATGGAAAA CTATTTAATA TCACCAAAAC CTTCAATATA
millSr CTGTCCACCA TAATGGGACA CGGTACAACA TCACCAAGAC TGTCAATATA
Con -----T-CA-CA TAATGG-A-A C— T— AA A TCACCAA-AC — TCAATATA
651 700
hillSr ACAATAGTGG AAGATCGCAG TAATATAGTT CCGGTTCTTC TTGGACCAAA
millSr ACAGTTATTG AAGGAAGGAG TAAAGTAACT CCAGCTATTT TAGGACCAAA
Con A CA -T--T-G  AAG G-AG T A A --TA --T  C C -G -T -T T- T-GGACCAAA
701 750
hillSr GCTTAACCAT GTTGCAGTGG AATTAGGAAA AAACGTAAGG CTCAACTGCT
millSr GTGTGAGAAG GTTGGTGTAG AACTAGGAAA GGATGTGGAG TTGAACTGCA
Con G --T -A --A -  GTTG--GT-G AA TAGGAAA --A -G T  G -T-AACTGC-
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751 800
hillSr CTGCTTTGCT GAATGAAGAG GATGTAATTT ATTGGATGTT CGGGGAAGAA
millSr GTGCTTCATT GAATAAAGAC GATCTGTTTT ATTGGAGCAT CAGGAAAGAG
Con -TGCTT T GAAT-AAGA- GAT-T— TTT ATTGGA T C-GG-AAGA-
SOl S50
hillSr AATGGATCGG ATCCTAATAT ACATGAAGA. ..GAAAGAAA TGAGAATTAT
millSr GACAGCTCAG ACCCTAATGT GCAAGAAGAC AGGAAGGAGA CGACAACATG
Con A— G-TC-G A-CCTAAT-T CA GAAGA — GAA GA A GA AA--------
S51 900
hillSr GACTCCAGAA GGCAAATGGC ATGCTTCAAA AGTATTGAGA ATTGAAAATA
millSr GATTTCTGAA GGCAAACTGC ATGCTTCAAA AATACTGAGA TTTCAGAAAA
Con GA-T-C-GAA GGCAAA--GC ATGCTTCAAA A-TA-TGAGA TT A AA A
RS TARA ARTGRACTGT GOCCAG RSs
hillSr TTGGTGAAAG CAATCTAAAT GTTTTATATA ATTGCACTGT GOCCAGCACG
millSr TTACTGAAAA CTATCTCAAT GTTTTATATA ATTGCACCGT GGCCAACGAA
Con TT— TGAAA C-ATCT-AAT GTTTTATATA ATTGCAC-GT GGCCA-C-----------
951 1000
hillSr GGAGGCACAG ACACCAAAAG CTTCATCTTG GTGAGAAAAG CAGACATGGC
millSr GAAGCCATAG ACACCAAGAG CTTCGTCTTG GTGAGAAA.. .AGAAATACC
Con G-AG-CA-AG ACACCAA AG CTTC-TCTTG GTGAGAAA-- AGA AT— C
1001 1050
hillSr TGATATCCCA GGCCACGTCT TCACAAGAGG AATGATCATA GCTGTTTTGA
millSr TGATATCCCA GGCCATGTCT TTACAGGAGG AGTAACTGTG CTTGTTCTCG
Con TGATATCCCA GGCCA-GTCT T-ACA-GAGG A T A  T - --T G T T -T --
1051 1100
hillSr TCTTGGTGGC AGTAGTGTGC CTAGTGACTG TGTGTGTCAT TTATAGAGTT
millSr CCTCTGTGGC AGCAGTGTGT ATAGTGATTT TGTGTGTCAT TTATAAAGTT
Con -CT--GTGGC AG-AGTGTG- -TAGTGA-T- TGTGTGTCAT TTATA-AGTT
1101 1150
hillSr GACTTGGTTC TATTTTATAG ACATTTAACG AGAAGAGATG AAACATTAAC
millSr GACTTGGTTC TGTTCTATAG GCGCATAGCG GAAAGAGACG AGACACTAAC
Con GACTTGGTTC T-TT-TATAG -C  TA-CG — AAGAGA G A ACA TAAC
1151 1200
hillSr AGATGGAAAA ACATATGATG CTTTTGTGTC TTACCTAAAA GAATGCCGAC
millSr AGATGGTAAA ACATATGATG CCTTTGTGTC TTACCTGAAA GAGTGTCATC
Con AGATGG AAA ACATATGATG C-TTTGTGTC TTACCT-AAA GA-TG-C-C
FI3 GTG
hillSr CTGAAAATGG AGAGGAGCAC ACCTTTGCTG TGGAGATTTT GCCCAGGGTG
millSr CTGAGAATAA AGAAGAGTAT ACTTTTGCTG TGGAGACGTT ACCCAGGGTC
Con CTGA-AAT-- AGA GAG A AC-TTTGCTG TGGAGA— TT -CCCAGGGT-
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TTGGAGAABC ADTTDGG
hillSr TTGGAGAAAC ATTTTGGGTA TAAGTTATGC ATATTTGAAA GGGATGTAGT
millSr CTGGAGAAAC AGTTTGGGTA TAAGTTATGC ATATTTGAAA GAGATGTGGT
Con -TGGAGAAAC A-TTTGGGTA TAAGTTATGC ATATTTGAAA G-GATGT-GT
FI5 ATCCA CTCACTGATH GABAA
hillSr GCCTGGAGGA GCTGTTGTTG ATGAAATCCA CTCACTGATA GAGAAAAGCC
millSr GCCTGGCGGA GCTGTTGTCG AGGAGATCCA TTCACTGATA GAGAAAAGCC
Con GCCTGG-GGA GCTGTTGT-G A-GA-ATCCA -TCACTGATA GAGAAAAGCC
1351 1400
hillSr GAAGACTAAT CATTGTCCTA AGTAAAAGTT ATATGTCTAA TGAGGTCAGG
millSr GGAGGCTAAT CATCGTTCTC AGCCAGAGTT ACCTGACTAA CGGAGCCAGG
Con G-AG-CTAAT CAT-GT-CT- AG--A-AGTT A--TG-CTAA -G--G-CAGO
Fll GCCTTG AAAGTGGACT CCATGAAG
hillSr TATGAACTTG AAAGTGGACT CCATGAAGCA TTGGTGGAAA GAAAAATTAA
millSr CGTGAGCTCG AGAGTGGACT CCACGAAGCA CTGGTAGAGA GGAAGATTAA
Con — TGA-CT-G A-AGTGGACT CCA-GAAGCA -TGGT-GA-A G AA ATTAA
1451 1500
hillSr AATAATCTTA ATTGAATTTA CACCTGTTAC TGACTTCACA TTCTTGCCCC 
millSr GATCATCTTA ATTGAGTTTA CTCCAGCCAG CAACATCACC TTTCTCCCCC
Con -AT-ATCTTA ATTGA-TTTA C-CC-G— A — AC-TCAC- TT--T-CCCC
1501 1550
hillSr AATCACTAAA GCTTTTGAAA TCTCACAGAG TTCTGAAGTG GAAGGCCGAT
millSr CGTCGCTGAA ACTCCTGAAG TCCTACAGAG TTCTAAAATG GAGGGCTGAC
Con — TC-CT-AA -C T— TGAA- TC--ACAGAG TTCT-AA-TG GA-GGC-GA-
R6 TTRTGG AAYAACCTTC TTTAC
hillSr AAATCTCTTT CTTATAACTC AAGGTTCTGG AAGAACCTTC TTTACTTAAT
millSr A...GTCCCT CCATGAACTC AAGGTTCTGG AAGAATCTTG TTTACCTGAT
Con A T C --T  C AACTC AAGGTTCTGG AAGAA-CTT- TTTAC-T-AT
R12NL GAATCTGAA GTCTTTCCTG
R12 CTG
hillSr GCCTGCAAAA ACAGTCAAGC CAGGTAGAGA CGAACCGGAA GTCTTGCCTG
millSr GCCCGCAAAA GCCGTCAAGC CATGGAGAGA GGAGTCGGAG GCGCGGTCTG
Con GCC-GCAAAA -C-GTCAAGC CA-G-AGAGA -GA--CGGA- G G-CTG
TTCTTTCCGAGTCTTAAC 
TTCTTTCCGA GTCTTAACGC
hillSr TTCTTTCCGA GTCTTAATCT TCAGAAACAG TGAACGCCAA AAAGAACTCA
millSr TTCTCTCAGC ACCTTGAGCT CCAGACGAGC TTGATGTCAA AAGCAAGTGA
Con TTCT-TC-G- — CTT-A-CT CAGA  T--A-G-CAA AA AA T A
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4.3 RESULTS
4.3.1 In vitro expression of feline IL-18 protein products
Feline pro-IL-18, mature-IL-18, ILRAP-IL-18, and pCI-neo were transfected into 
CHO cells and supernatants and cell lysates harvested. A 15% SDS-PAGE gel was 
prepared using various dilutions o f the feline IL-18 protein constructs (figure 4.5).
Figure 4-5 SDS-PAGE gel o f feline pro-, mature- and ILRAP-IL-18 protein
25kDa
18kDa
Lane number 1 2 3 4 5 6 7 8 9 10 11 12 13
This is an autoradiograph o f a 15% SDS-PAGE gel showing feline IL-18 protein 
constructs.
Lanes are as follows: lane 1: kaleidoscope protein marker, lane 2: Novagen Perfect 
Protein marker.CELL LYSATES: lane 3: pro-IL-18 in PBS (1:40), lane 4: pro-IL- 
18 in caspase buffer (1:40), lane 5: pro-IL 18 caspase buffer digested with human 
recombinant caspase-1 (1:40), lane 7: ILRAP-IL-18, lane 9: mature-IL-18 (1:2), lane 
12: pCI-neo. SUPERNATANTS: lane 6: pro-IL-18, lane 8: ILRAP-IL-18, lane 10: 
mature-IL-18, lane 13: pCI-neo, lane 11: recombinant bacterial equine IL-18 (1.6ng).
The Western blot demonstrates expression o f uncleaved pro-IL-18 protein 24 kDa in 
size (lanes 3 and 4), and mature cleaved IL-18 protein, 18 kDa in size (lane 5). In 
addition, 18 kDa recombinant equine IL-18 protein was used as a positive control 
(lane 11).
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IL-18 was detected in cell lysates o f undigested and digested pro-IL-18, mature-IL-18 
and ILRAP-IL-18 transfections. In order to load equivalent amounts o f protein, each 
cell lysate was diluted appropriately prior to running on the gel. From these dilutions 
it can be estimated that expression o f pro-IL-18 is approximately 40-fold greater than 
ILRAP-IL-18 and mature-IL-18 is approximately twice that o f  ILRAP-IL-18 protein 
expression.
Pro-IL-18 and mature-IL-18 were not detected in transfection supernatants (lanes 6  
and 10 respectively). In contrast, ILRAP-IL-18 was detected in the supernatant (lane 
8 ). This suggests that detectable secretion o f  IL-18 protein occurs in cells transfected 
with the ILRAP-IL-18 construct but not in cells transfected with pro- or mature-IL- 
18.
4.3.2 In vitro expression of ILRAP-IL-18 and PsecI-IL-18
Parallel transfections o f  feline ILRAP-IL-18, PsecI-IL-18 and pCI-neo constructs 
were performed and cell lysates and supernatants were run on a Western blot (figure 
4.6). ILRAP-IL-18 protein is clearly detected both in the cell lysate and in the 
transfection supernatant as shown by the large 18 kDa band. A much fainter, similarly 
sized band can be visualised in the PsecI-IL-18 cell lysate, but no band is visible in 
the transfection supernatant.
For reference, figure 4.7 shows a similar pattern in the expression o f  equine ILRAP- 
IL-18 and PsecI-IL-18. 18 kDa bands are evident in the ILRAP-IL-18 lysate and 
supernatant, but there is no protein detectable in either PsecI-IL-18 lysate or 
supernatant suggesting much lower or maybe even non-existent expression o f this 
signal protein.
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Figure 4-6 SDS-PAGE gel o f  feline ILRAP-IL-18 and PsecI-IL-18 protein
18kDa
Lane 1 2 3 4  5 6
Autoradiograph o f a 15% SDS-PAGE gel showing ILRAP-IL-18 and PsecI-IL-18 
protein from transfections. Lanes are as follows: lane 1: pCI-neo cell lysate, lane 2: 
pCI-neo supernatant, lane 3: ILRAP-IL-18 cell lysate, lane 4: ILRAP-IL-18 
supernatant, lane 5: PsecI-IL-18 cell lysate, lane 6: PsecI-IL-18 supernatant.
Figure 4-7 SDS-PAGE gel o f equine ILRAP-IL-18 and PsecI-IL-18 protein
18kD a-
Lane
Autoradiograph o f a 15% SDS-PAGE gel showing ILRAP-IL-18 and PsecI-IL-18 
protein from transfections. Lanes are as follows: lane 1: pCI-neo cell lysate, lane 2: 
pCI-neo supernatant, lane 3: ILRAP-IL-18 cell lysate, lane 4: ILRAP-IL-18 
supernatant, lane 5: PsecI-IL-18 cell lysate, lane 6: PsecI-IL-18 supernatant.
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4.3.3 In vitro bioactivity of feline IL-18 protein using KG-1 bioassay
The KG-1 bioassay measures the level o f human IFNy production produced by KG-1 
cells on exposure to a given dilution o f  IL-18 protein. It should be noted here that 
these bioassay data were produced from a series o f bioassay experiments used to 
establish suitable sample dilutions and antibody levels. In producing preliminary data 
for this final experiment, the bioassay was found to be a robust and repeatable assay 
for the detection o f bioactivity in feline IL-18 protein samples.
4.3.3.1 Negative control samples
Both caspase-digested pCI-neo cell lysate in CB (figure 4.8) and pCI-neo cell lysate 
and supernatant in PBS (figure 4.9) demonstrated background levels o f hlFNy 
production. In addition, caspase-digested pCI-neo incubated with feline IL-18 specific 
antibody (figure 4.8) elicited background levels o f  IFNy stimulation.
4.3.3.2 IL-18 transfection samples
Cell lysates o f all feline IL-18 transfections apart from PsecI-IL-18 demonstrated the 
dose dependent production o f human IFNy using this system. Cell lysate dilution 
ranges were selected for each IL-18 construct according to where background levels 
of bioactivity were reached. Assays were therefore performed for mature-IL-18, 
ILRAP-IL-18 and PsecI-IL-18 at a dilution range o f  1:1024 to 1:32 (figure 4.9) and 
graphs for pro-IL-18 at a range o f  1:20000 to 1:1250 (figure 4.8).
Caspase-digested pro-IL-18, mature IL-18 and ILRAP-IL-18 cell lysates 
demonstrated dose dependent production o f  IFNy from KG-1 cells whereas non­
digested pro-IL-18 stimulated background levels o f hlFNy production. Assuming 
different IL-18 proteins were comparable in terms o f  KG-1 IL-18 receptor binding, 
the fact that similar hlFNy levels were produced at these dilutions again suggests that 
pro-IL-18 protein expression is approximately 20-fold greater than ILRAP- and 
mature-IL-18 expression. Additionally, mature-IL-18 cell lysate demonstrates 
approximately half the level o f hlFNy production than ILRAP-IL-18 cell lysate at a
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given dilution. PsecI-IL-18 protein exhibited almost background levels o f  IFNy 
production at all dilutions.
Figure 4.8 also shows that the hlFNy elicited by caspase-digested pro-IL-18 cell lysate 
was suppressed by incubation with a feline IL-18-specific polyclonal antibody. 
Incubation with a non-specific FeLV rabbit polyclonal antibody produced no 
suppression o f bioactivity. Suppression o f this bioactivity by an IL-18-neutralising 
antibody suggests that IFNy stimulation is specific to IL-18 protein present in the 
sample.
As previously stated, pro-IL-18 and mature-IL-18 supernatants demonstrated 
background levels o f  bioactivity and were not included in this experiment. However, 
comparisons o f transfection supernatants were performed for ILRAP-IL-18 and PsecI- 
IL-18. ILRAP-IL-18 supernatant demonstrated dose dependent IFNy production 
whereas PsecI-IL-18 supernatant elicited background levels o f IFNy from KG-1 cells 
(figure 4.9).
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Figure 4-8 KG-1 assay o f  pro-IL-18 with antibodies and controls
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Figure 4-9 KG-1 assay o f  mature-IL-18. PsecI-IL-18 and ILRAP-IL-18
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4.3.4 Amplification of the feline IL-18 receptor
The initial set o f  IL-18 receptor primers yielded several fragments o f  F9 x R8 and also 
an F9 x R6 fragment using an annealing temperature o f 45°C. Confirmation o f  
positive clones using the ABI Prism system allowed design o f subsequent primers 
based on exact feline sequence. These primers, used in combination with degenerate 
primers based around the start and stop codon sequences, amplified FI I x R12 and 
F id  X RIO fragments at annealing temperatures as shown in figure 4.10.
Confirmed feline IL-18Rot sequence at the start and stop codon allowed redesign o f  
F id  and R12 primers to produce F3DN and R12NL respectively. Combinations o f  
these and new primers yielded F3DN x R8s, F13 x R12NL and FI 5 x R12NL, F9SF x 
R16 and F9SF x R17 fragments. As shown in figure 4.11, this resulted in a series o f  
IL-18R fragments across the 1650 base pair sequence. The final feline IL-I8Ra  
sequence was confirmed by producing a consensus o f  sequences produced from each 
of these fragments using the GCG package (Wisconsin Package Version 9.1, Genetics 
Computer Group (GCG), Madison, Wisconsin) and the encoding amino acid sequence 
was elucidated (figure 4.12). The sequence was assigned a GenBank Accession 
number AY 160954.
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Figure 4-10 PCR fragments o f  feline IL-18 receptor
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1OOObp 918bp
F 3 D N x R 8 s  6 6 ”C  6 2 ”C  5 8 ”C  54"C  50"C  4 4 ”C
500bp 420bp
F 1 3 x R 1 2 N L  6 6 “C  6 0 ”C  56°C  50"C  46"C
400bp 342bp
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Figure 4-11 Diagram showing feline IL-18 receptor fragments
0 100 200 300 400 500 600 700 800 900 1000 I 100 1200 1300 1400 1500 1600 1700
 1 I I I I I I I I I I I I I I I I 1
9 s  X 6
154
F ig u re  4 -12  F eline  lL -1 8 R g  n u c leo tid e  an d  am ino  ac id  sequence
atgcgtcatatagaactgctcttaacgcttttggcacttatgtttacaagcacctcagaa 60 
M R H I E L L L T L L A L M F T S T S E  
acatgtatttcacgtcatagcatcactgcagtggaaggggaatttttctatctgagatac 12 0 
T C I S R H S I T A V E G E F F Y L R Y  
tgctcatcagcatctgagcacgatagtgaaaaaaacagcataaaatggtacaagagcagt 180 
C S S A S E H D S E K N S I K W Y K S S  
gggtcacatggacgcattgagctaaactcaagcagttcccccagaattactttgcacgat 240 
G S H G R I E L N S S S S P R I T L H D  
tatgttttggagttttggccagttgagttggaggacagtggatcttactttttccaaatg 3 00 
Y V L E F W P V E L E D S G S Y F F Q M  
ggaaatgatactcgtaaatggaaattaaatgtcattggaagaagtaaaagcagctgtttt 360 
G N D T R K W K L N V I G R S K S S C F  
gttgaaaaactactaactagtaaaactgtagaagttcagaaatctttgcacgtagcctgt 420 
V E K L L T S K T V E V Q K S L H V A C  
aaacatgactactttcaaccattggccaatagaacttcactgtataagaactgtgaaaag 480 
K H D Y F Q P L A N R T S L Y K N C E K  
ataaacaatggtacaaacccagttttacagaagaatgcagagtttgaagatcagggatat 540 
I N N G T N P V L Q K N A E F E D Q G Y  
tacacctgtgtgttttccatccctcataatggaaaactatttaatgtcaccaaaaccatc 600 
Y T C V F S I P H N G K L F N V T K T I  
aacgtaacaatcgttggagatcgcagtaaaataattcctgttcttcttggaccaaagctt 660 
N V T I V G D R S K I I P V L L G P K L  
aaccgtgtgaaggtggaattaggaaaagatgtaaacctcaattgctctgctttggcgaat 720 
N R V K V E L G K D V N L N C S A L A N  
gaaaaggatcagatttattggaacttgtgggatgaaaatggaaaggagcccaatgtacat 7 80 
E K D Q I Y W N L W D E N G K E P N V H  
gaagagaacgtaaaaaaaaataggactctggatggcaaattgtatgtgtcaagaatgttg 840 
E E N V K K N R T L D G K L Y V S R M L  
aaaatcgagaatattaatgcaaaaaatctaaaattttcatataattgcactgtggccagt 900 
K I E N I N A K N L K F S Y N C T V A S  
gagggaggcacagacaccataaacttcgtcttgttgaaaaaagaagatatggctgatatc 960 
E G G T D T I N F V L L K K E D M A D I
ccaggctacatcttcaccagaggaatgattgtggctgttttgatctcagtggtagttgtg 102 0 
P G Y I F T R G M I V A V L I S V V V V
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tgcctagtgataatgggtgtcatttatagagttgacttggctctattttatagacatttc 1080 
C L V I M G V I Y R V D L A L F Y R H P  
acgagaaaagatgaaacattaacagatgggaaaacatacgacgcttttgtgtcttaccta 1140 
T R K D E T L T D G K T Y D A F V S Y L  
aaagaatgtggacccgaaaatggagaggagcacacctttgctgtggagattttgcccaag 1200 
K E C G P E N G E E H T F A V E I L P K  
gtgttggagaaacactttgggtataagttatgcatatatgaaagggatgtagtgcctgga 1260 
V L E K H F G Y K L C I Y E R D V V P G  
ggagctattgttgatgaaatccactcattgatagagaaaagccgaagactgatcattgtc 1320 
G A I V D E I H S L I E K S R R L I I V  
ctaagtaaaagctacatgtctaatgaagtcaggtatgaacttgaaagtggactccatgaa 13 80 
L S K S Y M S N E V R Y E L E S G L H E  
gctctggtagaaaggaaaattaaaatcatcttaattgaatttacacctgtcagtgacttc 1440 
A L V E R K I K I I L I E F T P V S D F  
acattcttcccccaatcactaaagcttttgaaatctcacagagttctgaagtggaacgct 1500 
T F F P Q S L K L L K S H R V L K W N A  
gataaacctctgtcgtataactcaaggttctggaagaatcttctgtacctgatgcctgca 1560 
D K P L S Y N S R F W K N L L Y L M P A  
aaagtggtcaagcctcgtggaactgaatctgaagtctttcctgttctttccgagtcttaa 1620 
K V V K P R G T E S E V F P V L S E S *
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4.4 DISCUSSION
Since its isolation, the biological significance o f IL-18 in stimulation o f the immune 
response has led to its use in vivo as an immunotherapeutic against pathogens such as 
bacteria [Neighbors et a l  2001], viruses [Tanaka-Kataoka et a l  1998] and fungi 
[Menacci et a l  2000]. In addition, IL-18 has been adopted as a potent 
immunotherapeutic agent against tumours. In this case IL-18 has been used alone and 
as an adjuvant to other types o f  tumour therapy by several different methods o f  
delivery [Cao et a l  1999; Osaki et a l  1999]. IL-18 has also been utilised as an 
adjuvant to vaccination, making use o f  its ability to modulate the immune response 
towards cell mediated immunity [Billaut-Mulot et a l  2001; Hanlon et a l  2001].
However, the synthesis and secretion o f native IL-18 within the cell poses certain 
challenges to researchers in this field. As mentioned in 4.1.3, IL-18 is synthesised as a 
biologically inactive precursor molecule pro-IL-18 [Okamura et a l  1995], which is 
cleaved by ICE or caspase-1 to the active molecule, mature IL-18. Mature-IL-18 then 
carries the natural signal required for secretion across the cell membrane [Gu et a l
1997]. Both mature-IL-18 cDNA [Giavedoni et al. 2001] and pro-IL-18 cDNA  
[Oshikawa et a l  1999] constructs have been studied. However there are potential 
processing problems with each o f these constructs. Researchers using pro-IL-18 
cDNA depend on the presence o f  caspase-1 producing transfected cells for 
endogenous cleavage and secretion o f the bio active mature molecule. Those utilising 
mature-IL-18 cDNA rely on the release o f  the molecule from injured cells or those 
undergoing apoptosis as this molecule lacks a natural signalling peptide. In an attempt 
to overcome these problems, studies have been carried out using mature-IL-18 cDNA  
fused to signalling peptides to encourage the secretion o f the molecule without the 
requirement for caspase-1 cleavage [Osaki et a l  1999; Hanlon et a l  2001; Kim et a l  
2001].
The purpose o f this work was to analyse the in vitro expression o f  feline pro- and 
mature-IL-18 and to establish whether the use o f  two synthetic signal sequences 
ILRAP and PsecI demonstrated intracellular expression o f  protein and successful
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protein secretion. Additionally, a system analysing the in vitro bioactivity o f  these 
constructs was used to investigate activity and IL-18 secretion o f  these constructs.
4.4.1 In vitro protein expression of feline IL-18 constructs
Western blot analysis o f  transfections o f feline IL-18 plasmids demonstrated in vitro 
protein expression o f  pro-, mature-, and ILRAP-IL-18. This experiment demonstrated 
that feline pro-IL-18 was strongly expressed in CHO cells and was successfully 
cleaved to mature-IL-18 using a recombinant caspase-1 enzyme. The lack o f mature- 
IL-18 in the pro-IL-18 supernatant suggests that CHO cells do not naturally produce 
high levels o f  caspase-1, thereby preventing secretion o f  the bioactive molecule. 
Mature-IL-18 construct demonstrated expression o f  protein in the cell lysate without 
release into the supernatant which confirms that the molecule lacks the signalling 
sequence required to allow secretion from the cell.
In contrast, ILRAP-IL-18 protein was detectable both in the transfection cell lysate 
and supernatant, which shows that this signal protein is synthesised and successfully 
secreted from the cells into which it is transfected. This indicates that when fused with 
feline mature-IL-18, ILRAP provides a suitable signal sequence for IL-18 protein 
expression and secretion from transfected cells.
4.4.2 Comparison of ILRAP-IL-18 and Psecl-IL-18 in vitro 
expression
To compare their relative levels o f protein expression, parallel transfections o f  
ILRAP-IL-18, PsecI-IL-18 and pCI-neo were performed along with a pCI-neo 
negative control. Again, the feline ILRAP signal construct displayed strong protein 
expression in the cell lysate o f transfected cells. The expression exhibited by feline 
PsecI-IL-18 in the cell lysate was minimal, only just within the detection limits o f this 
protein detection system. This is indicative o f  a lower level o f  PsecI-IL-18 protein 
expression relative to ILRAP-IL-18, but further work would be required to 
definitively confirm the low protein expression o f  this construct. This relative 
difference in protein expression between ILRAP and PsecI signal protein was also
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seen in the equine IL-18 constructs, where there was no evidence o f  PsecI-IL-18 
protein expression in either o f the transfection products.
When the levels o f IL-18 signal protein in transfection supernatants were analysed, 
ILRAP-IL-18 demonstrated similar levels o f IL-18 protein expression in the 
supernatant relative to the cell lysate. However, PsecI-IL-18 showed no evidence o f  
IL-18 in the supernatant even though a low level was present within the cell. If both 
signal constructs secreted protein to the same level, then the relative proportions o f  
IL-18 in supernatant compared to cell lysate would presumably be similar. This 
therefore implies that ILRAP signal is more effective at bringing about cell secretion 
than PsecI signal. However it is difficult to make a fair comparison o f the protein 
expression o f each supernatant as expression levels o f PsecI-IL-18 were so low.
There are several reasons why IL-18 protein expression o f ILRAP-IL-18 transfection 
products may have appeared higher than those o f  PsecI-IL-18. PsecI-IL-18 protein or 
mRNA may have expressed at a similar level but have been unstable, degraded within 
the cell and therefore undetectable using this system. Another possibility is that the 
PsecI signal peptide was not cleaved by signal peptidase from the primary translation 
product which may have altered the structure o f the IL-18 molecule, preventing 
binding o f the primary antibody. It is possible that lower PsecI-IL-18 expression may 
be a reflection o f low transfection efficiency in this particular experiment. However, 
in producing this data at least three separate transfections were performed, all o f  
which demonstrated low protein expression.
It should be noted here that the feline PsecI-IL-18 construct was shown in vivo to act 
in combination with IL-12 as an effective adjuvant for a DNA vaccine to FeLV 
[Hanlon et al. 2001]. In cats inoculated with DNA vaccine and IL-12 plasmid, three o f  
six cats were viraemic and four were latently infected at 15 weeks post challenge. 
With the coadministration o f PsecI-IL-18 plasmid, no cats were viraemic and only 
one was latently infected at this time. This study implies that the PsecI-IL-18 
expression vector must be expressed and secreted at least to some extent in host cells 
to exert its effect, although it is possible that in vivo this protein was released from 
injured cells or those undergoing apoptosis rather than being secreted using the
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synthetic signal. The actual process o f intramuscular injection o f this type o f  vaccine 
may provide the necessary cell death to encourage the release o f protein in this way.
In conclusion, this work shows that feline ILRAP-IL-18 signal protein shows a high 
level o f protein expression relative to PsecI-IL-18 in this in vitro expression system. It 
also confirms that ILRAP-IL-18 protein is effectively secreted out o f  transfected cells, 
in contrast to pro-IL-18 and mature-IL-18 constructs.
4.4.3 In vitro bioactivity of feline IL-18 constructs
Several negative control transfection samples were used in this experiment including 
pCI-neo cell lysate and supernatant and caspase-digested pCI-neo cell lysate. The 
purpose o f  these samples was to establish whether cell lysates or supernatants o f  
transfected cells contained any components other than IL-18 protein, which directly or 
indirectly induced detectable levels o f IFNy. In addition, a sample o f caspase-digested 
pCI-neo incubated with feline IL-18 specific antibody was also used to establish 
whether this antibody preparation influenced the level o f IFNy production by KG-1 
cells. In all cases, background levels o f IFNy were elicited, confirming that o f IFNy 
induction by IL-18 samples was due to IL-18 protein rather than any other 
codelivered transfection products.
When pro-IL-18 cell lysate was used directly in this assay without prior caspase-1 
digestion, background levels o f  activity were detected, whereas digestion with 
caspase-1 induced dose dependent production o f  IFNy from KG-1 cells. This shows 
that in order to demonstrate bioactivity, the inactive pro-IL-18 precursor must first be 
cleaved by caspase-1 to release the bioactive mature molecule. This protease cleavage 
process was confirmed in Western blot analysis, where undigested pro-IL-18 
demonstrated a protein band approximately 24 kDa in size, which on caspase-1 
digestion displayed an 18 kDa band.
Previous assays detected no activity in transfection supernatants o f pro-IL-18 and 
mature-IL-18, which were therefore excluded from the present experiment. This 
confirms the Western analysis that showed that neither protein was secreted from the
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transfected cell. The cell lysate o f pro-IL-18 induced dose dependent IFNy production 
at approximately 20-fold higher dilutions than mature-IL-18, which confirms the 
previous in vitro data that required a 1:20 dilution to demonstrate comparable protein 
bands on the Western blot. As cleavage o f  pro-IL-18 produces the same mature 
polypeptide as expressed in a mature-IL-18 transfection, the difference in IFNy 
production must be reflective o f  the relative expression or processing o f pro- and 
mature-IL-18 in transfected cells. This difference may be because in vivo IL-18 
protein is stored as the pro-IL-18 precursor, which is subsequently processed to allow 
secretion o f  bioactive mature-IL-18 [Gu et a l  1997; Nakanishi et a l  2001a]. 
Therefore mature-IL-18 synthesised from the mature-IL-18 transfection may be 
unstable and only have a short half-life in the cell.
To confirm specificity o f  this response to IL-18 activity, this sample was pre­
incubated with a sheep anti-feline polyclonal antibody at a dilution o f 34 ng/|il. This 
suppressed hlFNy production to approximately half its original level. This antibody 
must therefore recognise regions o f IL-18 responsible for attachment o f IL-18 to the 
receptor on the KG-1 cell. The antibody therefore neutralises IL-18 by obstructing 
receptor binding, preventing the signalling pathway required for IFNy production.
It is possible however that incubation with the antibody preparation itself could elicit 
suppression o f IL-18 bio activity. For example the medium used to elute the antibody, 
or the antibody itself could have an inhibitory effect on the KG-1 cells. Therefore a 
non-specific polyclonal antibody prepared in the same way was incubated with 
digested pro-IL-18 cell lysate. This produced no inhibition o f IFNy production; in fact 
it produced a mild stimulatory effect on IFNy production in this system. However, the 
level o f activity demonstrated by the inclusion o f the negative antibody was so small 
that this was not found to be significant. These data therefore suggest that the 
suppression by the sheep anti-feline antibody was due to the neutralising effect o f  the 
antibody rather than any inhibitory effect o f the antibody preparation.
A comparison o f  the bioactivity o f  cell lysates and supernatants o f the two IL-18 
signal constructs ILRAP- and PsecI-IL-18 were made. Both lysate and supernatant o f  
PsecI-IL-18 transfection failed to elicit IFNy stimulation from KG-1 cells. The most
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likely explanation for this would be a low level o f protein expression, which was 
reflected in the Western blot analysis o f this construct. However, the transfections 
used to compare the bioactivity o f  these signal constructs were different to those used 
for Western blot analysis which prevents a direct comparison o f  Western blot and 
KG-1 bioassay data. It was therefore not possible to establish whether the lack o f  
activity o f  PsecI-IL-18 transfection samples was due to low levels o f protein present, 
or to a lack o f production o f bioactive protein in the sample.
ILRAP-IL-18 cell lysates and supernatants displayed dose dependent induction o f  
hlFNy from KG-1 cells. This confirms the Western blot data, suggesting that feline 
ILRAP-IL-18 protein was expressed and readily secreted from transfected cells. In 
addition it shows that ILRAP-IL-18 produces a protein that is able to bind its 
associated receptor and stimulate the signalling pathway required to carry out its 
biological function on target cells.
In conclusion, this in vitro information suggests that signal ILRAP-IL-18 holds 
advantages over all other feline IL-18 constructs studied in this chapter. Firstly the 
level o f  bioactive protein expression within the cell appears to be superior to the other 
signal construct PsecI-IL-18. Additionally this construct displays activity in 
transfection supernatant, which was not detected in any other feline IL-18 construct. 
This synthetic signal overcomes the problems experienced using a mature-IL-18 
construct, which lacks a natural signal peptide to allow secretion, and the pro-IL-18 
construct, which relies on endogenous caspase-1 for cleavage to produce the bioactive 
molecule. ILRAP-IL-18 was therefore selected as the most appropriate feline IL-18 
construct for use in vivo as an adjuvant to a DNA vaccine for FeLV described in 
chapter 5.
Studies using other synthetic signal sequences for IL-18 have also shown success in 
terms o f bioactivity and cell secretion. The fusion o f mature-IL-18 to the prepro 
sequence o f  human parathyroid hormone produced a construct whose transfection 
supernatant stimulated IFNy production in cocultured splenocytes. This confirmed 
both cell secretion and bioactivity o f this construct, which was then used in a 
recombinant adenoviral vector to induce tumour regression in a murine fibrosarcoma
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model [Osaki et al. 1999]. Also, the fusion o f mature-IL-18 to the human 
immunoglobulin kappa leader sequence produced a signal construct which was 
transfected into COS-7 cells. Secretion o f this construct across the cell membrane was 
confirmed by Western blot analysis o f transfection supernatant [Kim et al. 2001]. 
Collectively then, these studies, along with the data produced in this chapter, show 
that bioactive IL-18 protein can be effectively synthesised and secreted in an in vitro 
expression system by fusion to conventional signal sequences.
4.4.4 Feline IL-18 receptor
Total RNA extracted from MYA-1 cells, a feline T lymphoblast cell line derived from 
peripheral blood, was used to amplify the feline IL-18Ra receptor sequence. The RT- 
PCR amplification system used a Taq DNA polymerase enzyme which is a low  
fidelity enzyme with a higher error rate than proof reading enzymes, estimated to be 2 
X 10'  ^ [Lundberg et al. 1991]. As stated in Chapter 3, this rate o f  error may increase if  
cycling conditions are not optimal for the enzyme. It is therefore recommended that 
between three and six amplified fragments are required to establish a consensus 
sequence [Ennis et al. 1990]. In this case, three separate PCR fragments were 
amplified for each area o f the gene to produce a consensus nucleotide and amino acid 
sequence o f  the receptor.
The feline IL-18Ra receptor was 1620bp in length and contained an open reading 
frame o f 540 amino acids (figure 4.12) (GenBank Accession number; AY 160954). 
Comparison o f the feline IL-18Ra sequence with published sequences shows 83%, 
81% and 70% identity with human, porcine and murine sequence at the nucleotide 
level, and 72%, 76% and 61% at the amino acid level respectively
The nucleotide sequence o f human IL-18Ra was found to be identical to human IL-1 
receptor-related protein (IL-lRrp) cDNA, a member o f the IL-1 receptor (IL-IR) 
family [Torigoe et al. 1997]. IL-lRrp, like all members o f its family is predicted to 
comprise a signal peptide, an extracellular region which consists o f three 
immunoglobulin like domains, a transmembrane region and a cytoplasmic region 
[Parnet et al. 1995; Vigers et al. 1997]. The amino acid sequence o f feline IL-18Ra
1 6 3
was compared with IL-18Ra o f other species using the Pileup program o f  GCG 
package (Wisconsin Package Version 9.1, Genetics Computer Group (GCG), 
Madison, Wisconsin) as shown in figure 4.13. The areas o f homology are shown by 
the consensus sequence in bold type. The predicted signal peptide, transmembrane 
region, extracellular and intracellular domains were extrapolated from human and 
murine predictions [Pamet et a l  1995]. The asterisks indicate the positions o f  
conserved cysteine residues which are thought to form the typical intradomain 
disulphide bonds o f  the three Ig domains o f the extracellular region [Pamet et a l  
1995; Vigers et a l  1997]. Using the GCG package Peptidestructure and Plotstructure 
programs, the areas o f hydrophilicity and hydrophobicity o f feline IL-18Ra were 
established. Hydrophobic areas were found between amino acids 1 and 20 and amino 
acids 325 and 355 (data not shown). These areas corresponded to the predicted signal 
peptide and transmembrane domains respectively.
The purpose o f  amplification o f the IL-18Ra receptor was to investigate its ability to 
increase the sensitivity o f the KG-1 bioassay system. Human KG-1 cells were shown 
to respond to human IL-18 by the dose dependent production o f  human IFNy [Konishi 
et a l  1997]. This assay also detected murine IL-18, but at sensitivity o f 100-fold less 
than human protein. It was found that transfection o f KG-1 cells with cDNA encoding 
murine IL-18Ra, produced a stable cell line which when used in the bioassay, 
significantly increased the sensitivity o f the system to murine protein [Taniguchi et a l
1998].
It was therefore postulated that if  a stable cell line o f  feline IL-18Ra-transfected KG- 
1 cells was used in this assay, they may demonstrate an increased sensitivity towards 
feline IL-18 protein. This work could therefore be extended in the future by cloning 
the full length feline IL-I8Ra sequence into a single expression vector. This would 
require either amplification o f full sequence using specific primers, or the use o f  
restriction enzyme sites in the sequence to allow ligation o f fragments. This construct 
could then be used to produce a stable KG-1 cell line expressing the feline IL-18Ra 
receptor in a similar way to the murine IL-18Ra cell line produced by Taniguchi et a l  
[1998]. Parallel bioassays using untransfected KG-1 cells and the feline receptor
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transfected cell line would establish whether KG-1 cells expressing feline IL-18Ra 
were more sensitive to feline IL-18 protein than untransfected cells.
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Figure 4-13 Consensus o f  IL-18Ra sequences and predicted domains
Red text -signal peptide
Blue text -extracellular regions
Green text -transmembrane region
Purple text -cytoplasmic domain
Asterisks* -cysteines predicted to form intradomain disulphide bonds o f Ig
domains o f  the extracellular region
1 * 50
fillSr MRHIELLLTL LALMTTSTS. ETCISRHSIT AVEGEFFYLR YCS. SASEHD
pillSr MHCGELPLTL LILMFISTSE EICISRHHIT AVEGEPFYLK CCP.SSSEHK
hillSr MNCRELPLTL WVLISVSTA. ESCTSRPHIT WEGEPFYLK HCS.CSLAHE
millSr MHHEELILTL CILI.VKSAS KSCIHRSQIH WEGEPFYLK PCGISAPVHR
Con M— — — EL — LTL — — L— — — — — — — ——C ——R —— I — —VEGE —FYL— —C —— — — — —H —
51
fillSr SEKNSIKWYK SSGSHGRIEL NSSSSPRZTL HDYVLEFWPV ELEDSGSYFF
pillSr NKTTTIKWYK NE.SHGPTEL RSGGSPRIIL HDYVLEFWPV EMDDSGSYSC
hillSr lETTTKSWYK SSGSQEHVEL NPRSSSRIAL HDCVLEFWPV ELNDTGSYFF
mill8r NETATMRWFK GSASHEYREL NNRSSPRVTF HDHTLEFWPV EMEDEGTYIS
Con — — — — — ——W—K — — — S —— ——EL — — ——S —R — — — HD——LEI^TPV E——D—G—Y——
101 * 150
filler QNGNDTRKWK LNVZGRSKSS CFVEKLLTSK TVEVQKSLHV ACKHDYFQPL
pillSr RMGNDTQAWK LNVIRRSKNS WFTEKQVISK WEVKKTLQV PCENNYFQNL
hillSr QMKNYTQKWK LNVIRRNKHS CFTERQVTSK IVEVKKFFQI TCENSYYQTL
millSr QVGNDRRNWT LNVTKRNKHS CFSDKLVTSR DVEVNKSLHI TCKNPNYEEL
Con —“ “N~“ “ LN V --R -K -S _F -----------S - —VEV—K———— -C -------------L
151 * 200
filler ANRTSLYKNC E K .. INNGTN PVLQKNAEFE DQGYYTCVFS ZPHNGKLFNV
pillSr ANRTSLYKDC EK..IDFNFN LNLKKIAEFK DGGYYTCVFF LHHAGKLFNV
hillSr VNSTSLYKNC KKLLLENNKN PTIKKNAEFE DQGYYSCVHF LHHNGKLFNI
millSr IQDTWLYKNC KEI....SKT PRILKDAEFG DEGYYSCVFS VHHNGTRYNI
Con -----T-LYK-C ------------------- ————K—AEF— D-GYY-CV— ——H—O———N—
201 « 250
filler TKTINVTIVG DRSKZZPVLL GPKLNRVKVE LGKDVNLNCS ALANEKDQIY
pillSr TKTFNITIIG DHSSIIPALL GPKLTQVKVE LGKDTQLNCS ALLNEKDWY
hillSr TKTFNITIVE DRSNIVPVLL GPKLNHVAVE LGKNVRLNCS ALLNEEDVIY
millSr TKTVNITVIE GRSKVTPAIL GPKCEKVGVE LGKDVELNCS ASLNKDDLFY
Con TKT-N-T----- ——S— ——P ——L GPK-----V-VE LGK———LNCS A——N——D——Y
251 300
fillSr WNLWDENGKE PNVHEE. NVK KNRTLDGKLY VSRMLKZENZ NAKNLKFSYN
pillSr WNTWRENGSD PNVHEE.EGT RIRTPDGKWL ASKTLRIENV NEKNLNFLYN
hillSr WMFGEENGSD PNIHEE.KEM RIMTPEGKWH ASKVLRIENI GESNLNVLYN
millSr WSIRKEDSSD PNVQEDRKET TTWISEGKLH ASKILRFQKI TENYLNVLYN
Con W-------E------- P N --E ---------
. 350
fillSr CTVASEGGTD TINFVLLKKE DMADIPGYZF TRGMIVAVLI SWWCLVIM
pillSr CTVASKGGTD TKSFILLRKE DMADIPGHVF TRGMIVAALI SVSIVCLVIM
hillSr CTVASTGGTD TKSFILVRKA DMADIPGHVF TRGMIIAVLI LVAWCLVTV
millSr CTVANEEAID TKSFVLVRKE .IPDIPGHVF TGGVTVLVLA SVAAVCIVIL
Con CTVA---------D T——F —L——K— ———DIPG— F T—G — — — ——L— -V --V C -V —
fillSr
pillSr
hillSr
millSr
Con
351
GVIYRVDLAL
GVIYRVDLAL
CVIYRVDLVL
CVIYKVDLVL
-VIY-VDL-L
FYRHFTRKDE 
FYRHFTGRDE 
FYRHLTRRDE 
FYRRIAERDE 
FYR— — — — — DE
TLTDGKTYDA
TLTDGKTYDA
TLTDGKTYDA
TLTDGKTYDA
TLTDGKTYDA
FVSYLKECGP
FVSYLKECRP
FVSYLKECRP
FVSYLKECHP
FVSYLKEC-P
400
ENGEEHTFAV
ENGEEYTFAV
ENGEEHTFAV
ENKEEYTFAV
EN-EE-TFAV
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40 1  45 0
fillSr EILPKVLEKH FGYKLCIYER DWPGGAIVD EIHSLIEKSR RLIIVLSKSY
pillSr EILPRVLEKH FGYKLCIFER DWPGRAWE EIHSLIEKSR RLIIVLSKSY
hillSr EILPRVLEKH FGYKLCIFER DWPGGAWD EIHSLIEKSR RLIIVLSKSY
millSr ETLPRVLEKQ FGYKLCIFER DWPGGAWE EIHSLIEKSR RLIIVLSQSY
Con E-LP-VLEK- FGYKLCI-ER DW PG -A-V- EIHSLIEKSR RLIIVLS-SY
4 5 1  500
fillSr MSNEVRYELE SGLHEALVER K IK IIL IE F T  PVSDFTFFPQ SLKLLKSHRV
pillSr MSNEVRYELE SGLHEALVER KIKIILIEFT PVGDFTFLPQ SLKLLKSHRV
hillSr MSNEVRYELE SGLHEALVER KIKIILIEFT PVTDFTFLPQ SLKLLKSHRV
millSr LTNGARRELE SGLHEALVER KIKIILIEFT PASNITFLPP SLKLLKSYRV
Con — N— R-ELE SGLHEALVER K IK IIL IE F T  P  T F -P -  SLKLLKS-RV
501 545
fillSr LKWNADKPLS YNSRFWKNLL YLMPAKWKP RGTESEVFPV LSES *
pillSr LKWKAEKSLS YNSRFWKNLR YLMPAKTVKP CGDESEVLPV LSQA-
hillSr LKWKADKSLS YNSRFWKNLL YLMPAKTVKP GRDEPEVLPV LSES*
millSr LKWRADSP.S MNSRFWKNLV YLMPAKAVKP WREESEARSV LSAP*
Con LKW—A—“ “ “ S “NSRFWKNL” YLMPAK~VKP — — —E—E—“ “V LS" — —
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4.5 CONCLUSION
The purpose o f this work was to design a signal-IL-18 construct and analyse its 
expression and bio activity in comparison to pre-existing constructs cloned in our 
laboratories. We cloned mature-IL-18 fused to a signal sequence o f  the human IL-1 (3 
gene called IL-lp receptor antagonist protein (ILRAP). This construct was found to 
be expressed within transfected cells and to be readily secreted across the cell 
membrane. Protein secretion could not be detected in any other feline IL-18 
constructs. In addition, our group applied a KG-1 bioassay previously used to detect 
human IL-18 in the detection o f feline IL-18 protein [Konishi et a l  1997]. This assay 
confirmed in vitro bioactivity o f feline IL-18 constructs and demonstrated bioactivity 
o f ILRAP-IL-18 transfection supernatant. Finally, the feline IL-18Ra receptor 
sequence was established which may be used in future work to increase the IL-18 
bioassay sensitivity to feline IL-18 protein.
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CHAPTER 5: DNA VACCINATION TRIAL
5 DNA VACCINATION TRIAL
5.1 INTRODUCTION
5.1.1 Types of viral vaccine
Several categories o f FeLV vaccines are either commercially available or have been 
studied experimentally in vivo. These include attenuated virus, inactivated whole 
virus, subunit vaccines, live vector vaccines and DNA vaccines. All o f these 
preparations have their own advantages and disadvantages. Live vaccines, similar to a 
pathogen in vivo, are able to stimulate both cellular and humoral immunity, providing 
strong protection. However, these vaccines have the potential to revert to virulence, 
causing infection in some animals and may be pathogenic in pregnant or 
immunosuppressed individuals. Inactivated whole virus vaccines are considered safer 
but also have the potential to cause disease if  the inactivation process is not complete. 
Inactivated whole virus vaccines expose the host to all antigens present on the whole 
pathogen but do not tend to stimulate CD8  ^CTLs from MHC I association as they are 
not synthesised as endogenous antigen in the APC. They are also expensive to 
produce and require adjuvants.
Viral subunit vaccines may be extracted from native virus or may be recombinant 
preparations. These vaccines are generally classed as safe, as the host is only exposed 
to the antigenic part o f the pathogen. However, the inclusion o f  only certain antigens 
limit the immune response compared to live and inactivated whole virus vaccines, 
which expose the host to all antigenic proteins. As described above, these subunits are 
also unable to stimulate CTLs unless administered with adjuvants.
Live vector vaccines consist o f attenuated strains o f bacteria or viruses, which encode 
specific antigenic proteins o f a pathogen. Once inoculated, these vectors undergo their 
normal life cycle and are able to stimulate both CD8  ^ and CD4^ immune cells. The 
vector carrier itself also acts as an inherent adjuvant to the vaccine due to its high 
immunogenicity. However, questions have arisen over the repeated use o f these 
vectors in the host and as in subunit vaccines only certain antigens are delivered,
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which limits the capacity o f  the immune response. Again, reversion to pathogenicity 
is a potential risk using these vectors and vaccination could lead to infection in 
immunocompromised individuals.
The potential advantages o f DNA immunisation have been explained in detail in the 
main introduction. These advantages include induction o f  both cellular and humoral 
immunity and no reversion to virulence due to inclusion o f  only partial genomic 
sequence. In addition, this type o f vaccine is heat stable and easy and inexpensive to 
prepare and purify. As mentioned previously, however, the use o f selected antigens 
limits the immune response compared to exposure to the whole pathogen.
5.1.2 Efficacy of FeLV vaccination
In a FeLV vaccination study, there are two basic parameters by which the efficacy o f  
a vaccine is assessed. Firstly, the level o f resistance o f vaccinates to live viral 
challenge must be established. The second parameter that must be assessed is the 
proportion o f persistently infected animals in the vaccinated group compared to the 
control animals.
Experimental parameters vary widely between studies such as strain o f virus, age o f  
cats, time o f challenge, definition o f  persistent viraemia and method o f  FeLV 
challenge used. This experimental variation between FeLV studies is summarised in 
table 5.1. It is clear that this variation presents difficulties when comparing the 
efficacy o f vaccines. Table 5.2 shows the proportions o f  persistently infected animals 
in vaccine groups and control groups for various studies. The individual parameters o f  
each experimental study must be taken into account in the analysis o f  the data 
produced.
Tables 5.1 and 5.2 were derived from a review o f FeLV vaccination by Sparkes 
[1997]. The various vaccines currently commercially available in the UK and USA  
are summarised in table 5.3.
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T ab le  5-1 V ira l ch a llen g e  param eters  u se d  in  F eL V  v acc in a tio n  stud ies
Study Age at 
challenge
Virus Dose o f virus (f.f.u.) Method o f  
challenge
Definition o f  PV % PV in 
controls
HaffercYrt/. 1990 17-25W FeLV-A/Rickard lO*" on day 1, 10^  " on 
day 2
O/N + S Antigenaemia at 12 W 
remaining for 6W
6/10(60% )
Clark e/fl/. 1991 16-19W FeLV-A/Glasgow 2 x  10' I/P viraemia 12W onwards 14/20
(70%)
HinescYa/. 1991 14-19W FeLV-A/Rickard Not specified O/N + S Antigenaemia at 12W 39/45
(87%)
Legendre et al. 
1991
16W FeLV-A/1161, 
FeLV-A/CT600 
and 2 FeLV-A 
field isolates
-1 0 ' on day 1 and 
again at day 7 
field isolates: 0.8ml 
blood day 1 + day 8
1/P + S 
or blood 
1/V
Viraemia 31W and for 8W 
prior to this
7/11 (64%)
Lehmann et al. 
1991
14-15M FeLV-A/Glasgow 10* I/P Consistently positive up to 
and including 24W
10/12
(83%)
Pedersen and 
Johnson, 1991
15-28W FeLV-A/CT600,
FeLV-A/Rickard
Not specified O/N + S Antigenaemia for more 
than 4W and at 16W
11/12
(92%)
Pollock et al. 
1991
Not
specified
FeLV-A/Rickard 1 q5.7 O/N + S Antigenaemia after 8W 50/81
(62%)
Pollock et al. 
1991
Not
specified
FeLV-A/NCE 10'-^ S/C Antigenaemia after 8W 3/5 (60%)
Sebring et al. 
1991
Not
specified
Not specified Not specified 1/P + S Not specified 4/4 (100%)
York et al. 1991 16-18W FeLV-A/Richard Not specified I/N + 1/M + 
S
Antigenaemia o f more than 
4W
14/22
(64%)
Pedersen, 1993 9-1 CM FeLV-A/CT600 4 x 1 0 “' T.C. infectious 
doses at day 1, 3, 5 
and 8
O/N + S Antigenaemia at 12W 10/10
(100%)
Lafrado, 1994 13W FeLV-A/Richard Natural exposure Natural
exposure
Antigenaemia at 12W 
onwards
1/26(4%)
Jarrett et al. 1996 14W FeLV- 
A/Glasgow-1
1 X 10' I/P Antigenaemia at 12 W and 
for at least 6W
7/8 (88%)
Jarrette/fl/. 1996 14W FeLV- 
A/Glasgow-1, 
FeLV-B/Sarma 
and FeLV- 
C/Sarma
2.2 X 10*, 2.2 X 10* 
and 6.5 x lO' 
respectively
O/N Antigenaemia at 12W and 
for at least 6W
5/6 (83%)
Gueguen et al. 
2000
14-15W FeLV- 
A/Glasgow-1
1.18 X 10* O/N Antigenaemic on 5 or more 
occasions or three 
consecutive tests
8/10(80% )
Hanlon et al. 2001 20-22 W FeLV- 
A/Glasgow- 1
2 x  10' I/P Viraemia at 15W 3/6 (50%)
Harbour et al. 
2002
15-17W FeLV- 
A/Glasgow- !
1 X 10* on day 0, 2, 4 
and 8
O/N Viraemia or antigenaemia 
for 3 consecutive weeks, or 
5 occasions between 3- 
15W post-challenge
10/12
(83%)
W -  weeks, M = months, O/N = oronasal, I/N = intranasal, I/P = intraperitoneal, S/C = subcutaneous, 
I/M = intramuscular, S = corticosteroid administration
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Table 5-2 Rate o f  FeLV infection in the vaccinates and controls o f  previous studies
VACCINATED ANIMALS CONTROL ANIMALS
Vaccine Study Number Combination of  
persistent and 
transient viraemia
Latent
infection
Number Combination of  
persistent and 
transient 
viraemia
Latent
infection
Leucocell 2 Ha (Ter et u/. 1990 25 16 (64%) NT 10 10(100%) NT
Legendre et al. 
1991
12 8 (67%) 11 (92%) 11 10(91%) 9 (82%)
Pollock et ai. 
1991
148 23 (16%) pers only NT 81 50 (62%) NT
Pollock et ai. 
1991
14 1 (7%) pers only NT 5 3 (60%) NT
Sebring et al. 
1991
4 2 (50%) pers only NT 4 4(100% ) NT
Tizzard et al. 
1991
10 4 (40%) pers only 18 13(72%)
Lafrado 1994 26 0 (0%) NT 26 5 (19%) NT
Jarrett É*/«/. 1996 12 10(83%) NT 8 8(100% ) NT
Leucat/VacSYN Legendre et al. 
1991
12 8 (67%) 10(83%) 11 10(91%) 9 (82%)
Pedersen and 
Johnson. 1991
18 10 (56%) pers only NT 12 11 (92%) NT
Sebring et al. 
1991
4 3 (75%) NT 4 4(100% ) NT
Jarrett ef o/. 1996 12 12(100%) NT 8 8(100% ) NT
York et al. 1991 43 2 (5%) NT 22 14(64%) NT
Fei-O-Vax Legendre et al. 
1991
12 0 (0%) 5 (42%) 11 10(91%) 9 (82%)
Sebring et al. 
1991
4 0 (0%) pers only NT 4 4(100% ) NT
Sebring et al. 
1991
90 4 (4%) pers only 58 53(91% )
Fevaxyn Hi nés et al. 1991 144 22(15% ) 10/96
transiently
or
aviraemic
animals
45 45 (100%) 6/8
transiently
viraemic
controls
Pedersen 1993 10 1 (10%) 0 (0%) 10 10(100%) 10(100%)
Leucogen C larke/a/. 1991 20 12 (60%) 3(15% ) 20 20(100% ) NT
Lehmann el al. 
1991
18 3(17% ) 1 (6%) 12 12(100%) 10(83%)
Jarrett e /a /. 1996 12 5 (42%) NT 8 8(100% ) NT
Jarrett e /a /. 1996 6 1 (17%) NT 6 5 (83%) NT
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5.1.3 Initial development of FeLV vaccine formulations
After the isolation o f FeLV, studies into transmission and immunity suggested that the 
development o f  a vaccine to the virus was feasible. Firstly it was shown that FeLV is 
transmitted mainly horizontally via contact with infected cats, rather than by genetic 
transmission [Hardy et al. 1973a]. Those cats that became immune to the virus were 
also shown to develop virus-neutralising antibodies (VNAb) [Jarrett et al. 1973]. In 
addition, kittens were shown to obtain maternally derived VNAbs from the milk, 
which conferred resistance to the virus [Jarrett et a l  1977].
The first vaccine strategy to be attempted involved the inoculation o f FeLV-infected 
FEA cells into uninfected cats. When large amounts o f  cells were administered, high 
antibody titres were elicited but these cats also demonstrated virus in the bone marrow 
at euthanasia. Lower levels o f FEA-infected cells produced a significant antibody 
response with no viral infection at necropsy [Jarrett et al. 1973]. Subsequent to this 
study, a feline lymphoblastoid cell line (FL74) infected with FeLV produced by 
Theilen et al. [1969], was inoculated into cats and found to elicit high anti-FOCMA 
antibodies and resistance to subsequent viral challenge. In addition, the virus 
produced from this cell line was shown to have very low infectivity and cats involved 
in the experiment were not infected at euthanasia [Jarrett et al. 1975].
The obvious problem with this vaccine strategy was the potential for the vaccine to 
infect the host with virus. The safer alternative was therefore the development o f  
inactivated vaccines. A  study was performed comparing the efficacy o f  live virus 
cultured from FL74 cells, formaldehyde-inactivated whole virus and formaldehyde- 
inactivated whole FL74 cells. Both inactivated vaccines were found to be safe but 
elicited no VNAbs, anti-FOCMA or resistance to infection. The live viral vaccine in 
this study was found to be safe, produce strong antibody responses and stimulate 
resistance to viral ehallenge [Pedersen et al. 1979]. However, the presence o f live 
virus in this formulation still had the potential risk o f  infection and disease in 
vaccinates even though it was found to be o f low infectivity [Jarrett et al. 1975]. 
When inactivated FeLV and inactivated whole FL74 cells were used as a combined 
vaccine, the anti-FOCMA antibody response was lower than if  inactivated whole cells
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were used alone [Olsen et a l  1977]. This suggested that FeLV components may have 
been inducing immunosuppression. One study showed that a vaccine o f killed FL74 
cells combined with purified p l5E  polypeptide was associated with an increased risk 
o f  developing progressive fatal fibrosarcoma following challenge with feline sarcoma 
virus (FeSV), which implicated this structural protein in immunosuppression [Mathes 
et ah 1979]. However, the suggestion that proteins associated with whole killed virus 
were immunosuppressive has been disputed by other studies o f inactivated virus 
vaccines. For example, cats inoculated with inactivated whole FeLV vaccine followed 
by challenge produced smaller tumours, a lower rate o f  persistent viraemia and 
increased protection compared to control animals [Pedersen et a l  1986]. As a result it 
has become generally accepted that FeLV pl5E  does not generate 
immunosuppression and may enhance efficacy o f  vaccines [Hoover et a l  1991]. This 
preliminary work into inactivated virus vaecines led to the first commercial FeLV 
vaccine.
5.1.4 The first commercial vaccine for FeLV
The first commercial vaccine was developed by refining the method used by Olsen et 
a l  [1977], to produce FeLV antigen from FL74 cells. Antigen was recovered from 
large volumes o f cell culture [W olff et a l  1979] by concentrating tissue culture fluids 
containing FeLV glycoproteins and tumour antigens in a serum-free medium. The 
vaccine was emulsified in Freund's adjuvant and inactivated by exposure to UV light. 
Eighty one percent o f vaecinated cats were protected against viraemia and high anti­
viral and anti-tumour antibodies were elicited [Lewis et a l  1981]. The vaccine 
contained protein from all three FeLV subgroups and a suitable vaccination regime o f  
three doses was initially found to be efficacious against viraemia and incidence o f  
tumour [Sharpee et a l  1986]. This vaccine, Leukocell (Norden Laboratories, 
Nebraska), became commercially available in 1985.
Subsequently, further work enhanced the antigenic content and therefore 
immunogenicity o f the preparation and produced the second-generation vaccine 
Leukocell-2. Studies demonstrated that a two-dose programme, three weeks apart 
provided an effective immunoprophylactic regimen [Haffer et a l  1990]. A degree o f
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controversy arose from this work regarding the efficacy o f this preparation. Several 
studies provided evidence in favour o f  the effectiveness o f  the vaccine. One group 
showed that Leukocell protected three times as many cats against viraemia than 
placebo-inoculated cats after natural challenge [Pollock and Scarlett 1990], and 
another showed Leukocell-2 proteeted 100% o f cats against viraemia [Lafrado et al. 
1994]. In the latter however, only 19% control cats (5 o f 26) tested positive for FeLV 
and 15% of these were transiently infected. In this case the preventable fraction (PF) 
was found to be 100%, as calculated by the following equation [Loar, 1993]:
PF (%) = % control cats with persistent viraemia (FY) - % vaccinates with PV x 100
% controls with PV
This value gives a measure o f the protective effect o f  a vaccine in excess o f natural 
immunity. In the study performed by Lafrado et al. [1994], although PF is 100% only 
1 o f  the 26 control animals were persistently viraemic. This study was therefore not 
an effective test o f the efficacy o f  the vaccine, despite an impressive PF valuation.
Other studies have strongly questioned the proficiency o f  this vaccine. One group 
showed Leukocell to only be 17% effective against viraemia [Pedersen and Johnson, 
1991] and another study using natural challenge, demonstrated 70% viraemia in 
Leukocell vaccinates compared to 64% unvaccinated animals [Legendre et a l  1990].
More recently a study was performed to ascertain the duration o f  immunity induced 
by Leukocell 2 vaccination. Animals were vaccinated at 9 and 12 weeks o f  age and 
were challenged a year later with oronasal inoculation o f virus. Fourteen out o f  
eighteen cats (80%) were protected from viraemia compared to 60% (nine o f  fifteen) 
control animals. It was concluded from this study that a significant proportion o f cats 
were protected using this vaccine a year after immunisation [Harbour et al. 2002].
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5.1.5 Whole inactivated viral vaccines
5.1.5.1 Leucat/VacSYN (Rhone-Merieux/Synbiotics)
Several vaccines comprising killed whole virus were developed and commercialised 
between 1989 and 1991. One vaccine, subsequently marketed as Leucat or VacSYN  
(Rhone-Merieux/Synbiotics), consisted o f  inactivation o f FL74 culture fluid by 
ethylenimine compound. In a study o f this vaccine, 2 o f 43 cats (5%) developed 
persistent viraemia after challenge compared to 14 o f 22 (64%) control animals [York 
and York 1991]. Another trial compared the efficacy o f Leucocell-2, Leucat and 
Leucogen, a recombinant subunit vaccine. O f twelve eats in each vaccine group, 10 
and 12 animals became persistently viraemic after challenge in the Leukocell-2 and 
Leucat groups respectively [Jarrett and Ganière 1996].
5.1.5.2 Fel-O-Vax (Fort Dodge)
In another study, a molecularly cloned FeLV-A virus was inactivated and an adjuvant 
included. This vaccine was used in an experiment alongside the original Leukocell 
commercial vaccine. The whole killed vaccine demonstrated 100% protection from 
viraemia whereas all control animals became persistently viraemic. The Leukocell 
vaccine only showed 43% protection from challenge [Sebring et a l  1991]. This whole 
killed vaccine was subsequently marketed in 1989 as Fel-O-Vax (Fort Dodge).
A natural challenge experiment comparing the efficacy o f Leucocell-2, Fel-O-Vax 
and VacSYN was performed. O f these preparations Fel-O-Vax showed complete 
protection from viraemia and was the only vaccine to demonstrate statistically 
significant protection from challenge. In addition, after 31 weeks o f  exposure to 
natural challenge, no cats were found to contain latent infection [Legendre et a l  
1991].
5.1.5.3 Fevaxyn FeLV (Solvay-Dulphar/Fort Dodge)
Similarly, Fevaxyn FeLV (Solvay-Dulphar/Fort Dodge), which came on the market in 
1991, comprises cell culture fluids from FeLV-A and -B infected feline cells. The
176
virus produced was inactivated, concentrated and adjuvanted. A study showed that 
this vaccine protected 92% vaccinates from viraemia where 87% o f the control group 
were persistently viraemic. When latency was investigated, 10% of vaccinates 
harboured FeLV infection compared to 75% o f  control cats [Hines et al. 1991].
A subsequent study found that Fevaxyn FeLV vaccine produced complete protection 
against viraemia and latency where all control cats became viraemic. Eight o f  the ten 
cats in the trial demonstrated virus neutralising antibodies to the virus at 5 weeks post­
challenge [Pedersen, 1993].
O f the three inactivated whole virus vaccines described, only Fevaxyn FeLV is 
currently available in UK.
5.1.6 Genetically engineered vaccines: recombinant gp70 subunit 
vaccine (Leucogen)
Prior to the early 1990s, several groups investigated the use o f a vaccine consisting o f  
envelope glycoproteins o f  FeLV, as antibodies to these proteins have been associated 
with protection from infection [Russell and Jarrett, 1978a; Lutz et al. 1980].
Although the use o f glycoproteins recovered from infected cell culture was associated 
with low immune protection [Salerno et al. 1978; Pedersen et al. 1986], the 
development o f  a pure recombinant gp70 subunit vaccine was pursued due to 
potential advantages over existing commercial vaccines at that time. Firstly the use o f  
a subunit vaccine excludes the infection potential that killed vaccines hold if  there is 
incomplete inactivation o f  virus. Vaccines such as Leukocell also have the theoretical 
potential to cause sensitisation and allergy as it is likely that they contain extraneous 
proteins. However, a recombinant vaccine o f  pure protective antigen eliminates this 
possibility.
Recombinant FeLV-A gp70 antigen was expressed in E. coli and purified by gel 
filtration chromatography and anion exchange chromatography. Aluminium 
hydroxide was used as a carrier o f the immunogen, which was combined with the
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adjuvant QS-21, purified from Saponin. A study o f the immune response to this 
vaccine in cats demonstrated significant levels o f virus-neutralising antibodies 
compared to control animals [Kensil et al. 1991].
In another study using this preparation, cats were immunised three times at 0, 3 and 8 
weeks and were ehallenged at 12 weeks by intraperitoneal inoculation o f  FeLV-A  
virus. After vaccination, all cats elicited anti-gp70 and anti-FOCMA antibody titres 
and two-thirds developed virus-neutralising antibodies. After challenge all cats 
produced a virus-neutralising immune response. None o f  the vaccinated cats 
developed viraemia compared to 3 o f  4 control cats [Marciani et a l  1991]. Studies 
using this recombinant gp70 with Freund's adjuvant produced much weaker immune 
responses in this study. The gp70 vaccine with QS-21 adjuvant was subsequently 
marketed as Leucogen (Laboratoires Virbae, Nice, France).
A similar study was performed using the QS-21 adjuvanted vaccine using a schedule 
o f  2 subcutaneous doses three weeks apart. Animals were challenged by 
intraperitoneal injection 2 weeks later. O f the vaccinated cats, 15% developed 
persistent viraemia, and 40% developed transient viraemia, which was cleared within 
12 weeks o f challenge, leaving 85% clear o f  viraemia. Latency o f  these cats was not 
measured in this experiment [Clark et a l  1991]. A field trial using pre-licenced 
vaccine at two 3 weekly doses were given to 1127 cats. O f 2234 doses, 150 post­
vaccinal reactions were noted, consisting o f small subcutaneous nodules at the 
vaccination site, or lethargy and anorexia for 24 hours post-vaccination [Clark et al. 
1991].
A comparison o f Leucogen, with Leukocell 2 or Leucat, both inactivated vaccines, 
showed that Leucogen was the only vaccine to produce signifieant protection against 
FeLV-A intraperitoneal challenge [Jarrett and Ganière 1996]. Five o f  the twelve 
kittens vaccinated with Leueogen became viraemic post-challenge while the rest 
developed virus-neutralising antibodies. All eight control animals were infected, one 
transiently. In addition, a study was conducted using an oronasal challenge o f FeLV- 
A, -B and -C . In the control group, 5 o f  6 kittens became persistently infected. p27 
antigen was detected in 1 o f  6 vaccinated kittens but unfortunately in these cases, no
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virus isolation was performed. Two kittens developed virus-neutralising antibodies 
[Jarrett and Ganière 1996].
More recently, an experiment was carried out to investigate whether Leucogen could 
be combined with the routine live vaccine for feline herpesvirus, calieivirus and 
parvovirus (Feligen RCP, Virbac). The combination vaccine was found to give similar 
protection against FeLV as found by Jarrett and Ganière [1996], and protection from 
herpesvirus and calieivirus was enhanced by this combination. It was therefore 
concluded that these vaccines were both efficacious if  coadministered [Guegen et al. 
2000].
5.1.7 ISCOM vaccines
The ISCOM or immunostimulating complex is a novel way o f presenting membrane 
proteins derived from enveloped viruses. Since its development the high 
immunogenicity o f  ISCOM formulations has led to the investigation o f many such 
vaccines, including FIV and HIV-1 [Sjolander et a l  1996; Tijhaar et a l  1997].
The complex consists o f a matrix combined with antigenic proteins o f  the pathogen. 
The matrix is made up o f glycoside Quil A which forms micelles, allowing interaction 
between membrane proteins and matrix by hydrophobic interactions. This forms a 
cage-like structure o f  around 35nm diameter [Morein et a l  1984]. This system was 
used to create a vaccine for FeLV using gp70 and gp85 subunit purified from FL74 
cell line supernatant. The purified subunits were shown to be shared by all subtypes o f  
FeLV. When used in a vaccination regime, 66% of cats developed virus neutralising 
antibodies and all vaccinates were protected from viraemia. O f the control animals, 
50% became viraemic post-challenge [Osterhaus et a l  1985].
This vaccine was further analysed by an experiment comparing the serological 
responses o f ISCOM FeLV vaccine to vaccination with Leukocell. Pet eats were used 
and tested for positive or negative antibody titres to FeLV prior to the trial. During 
this study all animals remained healthy and no virus was detected. Almost every cat 
immunised with ISCOM produced increased antibody titres by the end o f the
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experiment. 81% o f seronegative ISCOM eats displayed a rise in virus-neutralisation 
test compared to 6% in Leucocell group and 0% in control group. A similar pattern 
was observed in the seropositive cats. When the sera were analysed by 
immunoblotting, antibodies to gp70 and p l5E  were confirmed in the group vaccinated 
with ISCOM vaccine [Osterhaus et al. 1989]. However, antibodies to other proteins 
were also detected and the vaccine formulation was not highly purified. It would 
therefore be required to repeat this study using a purified version to confirm these 
results. Despite this, very few vaccines to FeLV have been found to induce virus- 
neutralising antibodies in this way [Jarrett, 1996], so these findings are o f particular 
interest.
5.1.8 FeLV live virus vector vaccines
Several studies have utilised viral vectors to deliver FeLV antigens to the host. These 
have included recombinant vaccinia virus [Gilbert et al. 1987], a feline herpesvirus 
type 1 (FHV-1) [Wardley et al. 1992; Willemse et al. 1996] and a recombinant 
canarypoxvirus [Tartaglia e/a /. 1993].
The use o f  a vaccinia virus was found to provide low efficacy [Gilbert et al. 1987], 
but the FHV-1 vector has demonstrated greater success. As infection o f  FHV takes 
place via the mucous membranes, it was thought this could be advantageous for the 
delivery o f FeLV genes as this pathogen also gains access to the host in this way. 
Wardley et a l  [1992], used various combinations o f  FeLV gag  and env in FHV-1 
vectors administered oronasally and intramuscularly. Administration o f  both FeLV 
constructs by both o f  these routes stimulated complete protection against challenge, 
but only when an additional injection o f  baculovirus constructs containing the same 
FeLV genes was given. FeLV gag  and env constructs administered alone did not 
produce the same protective effect [Wardley et a l  1992]. Another experiment 
described the use o f two vaccinations o f  FHV-1 vector containing gp70/pl5E o f  
FeLV. The vaccine protected 3 o f  4 eats from persistent viraemia where 5 o f  6 eats 
developed viraemia in the control group. In terms o f latency however, 3 vaccinates 
out o f four demonstrated detectable levels o f virus in the bone marrow [Willemse et 
a l  1996].
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The use o f canarypox vectors has been studied and an FeLV vaccine based on this 
work, Eurifel (Merial), became commercially available in 2002. An initial study used 
two recombinant vectors, one, ALVAC-FL expressed gag  and env genes o f FeLV-A, 
and the other, ALVAC-FL(dl IS) expressed gag  and an env gene deleted o f its 
putative immunosuppressive sequence in the TM (pl5E) coding region. ALVAC-FL 
vaccine produced 100% protection from persistent viraemia following challenge 
without the production o f virus-neutralising antibodies. ALVAC-FL(dl IS) produced 
only 50% protection from viral challenge [Tartaglia et al. 1993].
Table 5-3 FeLV vaccines commerciallv available in the UK and worldwide
Vaccine (Manufacturer) Vaccine type Subgroups o f  
FeLV
FOCMA
included
UK
Leukocell 2 (Pfizer) Produced from infected cell culture- mixed 
protein subunits. Inactivated and adjuvanted
A, B and C Yes Yes
Leucat /  VacSYN (Rhone 
Merieux/Synbiotics)
Inactivated whole virus. No adjuvant A ,B  and C Yes No
Fel“0-V ax (Fort Dodge). Inactivated adjuvanted whole virus A No No
Fevaxyn (Solvay-Duiphar/Fort 
Dodge)
Inactivated adjuvanted whole virus A and B No Yes
Leucogen/ Genetivac/Nobivac 
FeLV
(Virbac/Mallinckrodt/Intervet
Purified, recombinant non-glycosylated 
gp70. Adjuvanted
A No Yes
Eurifel (Merial) Recombinant canarypox vector containing 
gag  and env genes
A No Yes
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5.1.9 Immunisation using a FeLV DNA vaccine
5.1.9.1 Vaccine design and schedule
To date there is only one published study investigating the use o f a DNA vaccine for 
FeLV [Hanlon et a l  2001]. This study used a combination o f two plasmids, one 
encoding gag/pol and the other encoding envA o f  FeLV-A, each in a vector derived 
from pCI-neo (Promega). The efficacy o f  this vaccine was studied alone and with 
various combinations o f cytokine genes as adjuvants to the vaccine.
Five groups o f  10-12 week old cats were used and immunised three times at 2-week 
intervals with 100 p.g o f each vaccine construct. Animals were then challenged 3 
weeks later with an intraperitoneal injection o f  2 x  10  ^ f.f.u. o f FeLV-A/Glasgow-1 
virus diluted in endotoxin-free PBS [Hanlon, 1999; Hanlon et a l  2001]. The vaccine 
groups were arranged as follows:
Table 5-4 Immunisation groups o f FeLV DNA vaccine trial [Hanlon et a l  20011
Group Vaccine constructs Number o f  cats
1 Vaccine alone 6
2 Vaccine +  IFNy 5
3 Vaccine + IL-I2 6
4 Vaccine + IL-12 + IL-18 6
5 Empty vaccine vector 6
Animals were then blood sampled every three weeks until euthanasia, 16 weeks post­
challenge, where a sample o f  bone marrow was taken. Plasma was analysed for the 
presence o f p27 antigen, infectious virus and neutralising and non-neutralising 
antibodies. This was to detect the presence o f  viraemia and determine the immune 
response to the virus. Testing o f cultured bone marrow cell lysate and supernatants for 
p27 antigen and virus respectively was also performed to determine the presence o f  
latent infection in animals.
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5.1.9.2 Protection against FeLV viraemia
When the virus isolation (VI) results o f groups 1 (vaccine alone) and 5 (negative 
control) were compared, there was no statistical difference found between them. At 
euthanasia 3 o f 6 control cats were viraemic whereas 2 o f  6 cats from the vaccine 
alone group were viraemic. This showed that immunisation with the DNA vaccine 
alone did not provide significant protection against FeLV challenge.
O f the five cats in group 2 (vaccine + IFNy), two animals were viraemic at euthanasia. 
When these are compared with the control and vaccine alone group it showed that this 
vaccine combination did not produce immune protection and IFNy did not act as an 
effective vaccine adjuvant. A similar conelusion can be drawn from the vaccine 4- IL- 
12 group where 4 o f  6 cats were viraemic at euthanasia. This suggests that IL-12 
might even have inhibited vaccine efficacy.
In contrast, cats in group 2 (vaccine + IL-12 + IL-18) demonstrated significant 
protection from viral challenge. All o f the cats were free o f viraemia at euthanasia and 
significantly fewer were viraemic compared to control cats at 3, 6 and 9 weeks post­
challenge. It can be concluded, therefore, that the combination o f IL-12 and IL-18 had 
the potential to act as an adjuvant to this DNA vaccine.
5.1.9.3 Protection against persistent and latent FeLV infection
Unfortunately there were insufficient animals in each group to specifically analyse the 
efficacy o f  vaccines in protection against latency. Analysis o f the sum o f viraemic and 
latently infected cats in each group, however, allowed further comparison o f  vaccine 
groups.
A similar pattern was found as with protection against viraemia, in that neither the 
vaccine alone, vaccine + IL-12 nor vaccine + IFNy offered significant protection 
against viraemia and latency compared to the control group. However, only one cat in 
the vaccine + IL-12 + IL-18 group carried a latent infection which was only detected 
after subculture o f bone marrow supernatant. When compared with five control cats 
carrying both persistent and latent infection, this again is a statistically significant
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result. This suggests that this vaccine combination protected cats against both 
persistent and latent infection.
5.1.9.4 Analysis of antibody levels and immune responses elicited during trial
DNA immunisation induced neither neutralising nor non-neutralising antibodies at 
detectable levels between vaccination and viral challenge. Once cats were exposed to 
virus, protected cats tended to demonstrate a significant neutralising antibody titre 
whereas infected cats failed to elicit a FeLV-neutralising antibody response.
This display o f  immune protection in the absence o f  antiviral antibodies led to a study 
o f FeLV-speciflc CTL responses in these cats. It was found that vaccine-protected 
cats had higher levels o f  specific-CTLs in the peripheral blood and lymphoid organs 
compared to the unvaccinated persistently infected cats. Transiently infected cats in 
this study also had higher specific-CTL responses [Flynn et a l  2000a].
5.1.10 Design of current trial
The aim o f this work was to investigate further the data produced from this previous 
DNA vaccine study [Hanlon et ah 2001]. Preliminary work described in chapters 3 
and 4 involved the cloning o f refined constructs for IL-12 and IL-18 to be used in the 
DNA vaccine trial. Feline flexi-IL-12 comprised sequences derived from IL-12 p40 
and signal deleted-p35 linked by a synthetic polypeptide linker sequence [Anderson et 
al. 1997]. ILRAP-IL-18 was produced by cloning the signal sequence o f  human IL-lp  
receptor antagonist protein (ILRAP) as a secretory signal for mature feline IL-18 
[Wingren et al. 1996]. As mentioned in the respective chapters, each o f  these 
constructs has potential advantages over those used in the original trial. In vitro 
expression and bioactivity o f  flexi-IL-12 and ILRAP-IL-18 was demonstrated and in 
addition, secretion o f ILRAP-IL-18 from transfected cells was detected by Western 
blot and bioactivity o f  culture fluids.
Design o f the new trial focussed on establishing whether protection induced by the 
DNA vaccine, IL-12 and IL-18 was due to either cytokine alone, or a synergistic
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effect o f IL-12 and IL-18 [Hanlon et al. 2001]. The experiment was designed 
comprising the following groups; DNA vaccine alone, vaccine + IL-12 and IL-18, 
vaccine + IL-12 and vaccine + IL-18. In addition to these groups, two control groups 
were included. One group was inoculated with both cytokines and given the 
equivalent amount o f empty pCI-neo vector as DNA vaccine. This was to determine 
firstly if  the cytokines alone produce an immunostimulatory effect, and secondly to 
establish whether non-specific DNA affects the immune response. Finally a negative 
control group was injected with vaccine diluent alone (endotoxin-free PBS).
The final aim o f this experiment was to establish if  the vaccine was able to protect 
cats against a more natural viral challenge. Rather than an intraperitoneal challenge o f  
2 x 1 0 ^  f.f.u. used previously, a total oronasal dose o f  4 x 10  ^ f.f.u. was administered 
in four equal doses o f  10  ^ f.f.u. on days 0, 2, 4 and 8. This method o f  challenge was 
found previously to be sufficient to produce 82% persistent infection in kittens o f a 
similar age [Harbour et al. 2002].
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5.2 MATERIALS AND METHODS
5.2.1 Construction of FeLV DNA vaccine
Dr Derek Bain constructed the plasmid backbone for FeLV vaccine plasmids using 
the commercial plasmid pCI-neo (Promega). A mammalian expression series o f  
bicistronic vectors pUSE, pUSEL and pUSE2‘ were cloned using PCR and 
recombinant DNA technology. Included in these vectors were unique restriction sites 
for Asc I, Pac I, Pme I and Not I. These sites allowed efficient cloning o f reporter 
genes, promoters and insertion o f antigen-encoding gene into the empty plasmid 
backbone.
The FeLV DNA vaccine consisted o f  a combination o f two pUSEL plasmids 
containing a CMV-IE promoter. One plasmid contained the gene encoding FeLV 
gag/pol and the other contained the gene encoding env o f  FeLV-A.
5.2.1.1 Construction of pUSE1'CMVT(gag/po/) and pUSEI'CMVT(envA)
Figure 5-1 Structure o f pUSEl~CMVT(g<jg/poA
P m e  I
—  h C M V IE  —
synthetic Poly A
C h im e ric  intron: 5 ' is d o n o r s ite  fro m  th e  first intron  
o f th e  h um an  b e ta -g lo b in  and  the  b ran ch  and  3 ' -a c c e p to r  
o f a n  im m u n o g lo b u lin  g e n e  h e a v y  c h a in  v a ria b le  reg ion .
The structure o f  the plasmid is shown in the figure 5.1. The construct consists o f  
FeLV-A/Glasgow-1 gag/pol gene and a CMV promoter cloned into the Not I site o f  
pUSELCMVT to produce pUSE 1 CMVT(gag/po/).
Similarly, the env gene from FeLV-A/Glasgow-1 was cloned into pUSEl vector with 
a CMV promoter to produce pUSErCMVT(e«v/I) as shown in figure 5.2.
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P m e  I
synthetic Poly A
Figure 5-2 Structure o fp U S E l CMVT(gqg/poA
A s c I  A s c  I
1 1
—  hCM VIE —
N o t  I N o t  I
C h im e ric  intron a s  a b o v e
5.2.1.2 Expression of DNA vaccine plasmids using fixed cell immunofluorescence
293T ceils were seeded into 25 cm  ^ flasks and incubated for 24 hours at 37°C with 5% 
CO] until approximately 40% confluent. Transfections o f pUSErCMVT(gag//?o/)» 
pUSE 1 CMVT(cMv/t) and pCI-neo plasmid vector (Promega) were performed using 
LipofectAMFNE Reagent (Invitrogen Life Technologies) according to the instructions 
o f the manufacturer. For each transfection, 3 pg o f DNA was used and flasks were 
incubated for 24 hours at 37°C with 5% CO]. Each flask o f transfected cells was 
trypsinised using 1ml trypsin-EDTA, suspended in fresh medium, centrifuged at 1000 
rpm and then resuspended in tissue culture medium. Transfected cells were then 
transferred to the CC2 treated Lab Tek II chamber slide system consisting o f 8-well 
glass slides (Scientific Laboratory supplies, UK). Three wells were prepared for each 
transfection using 3 x 10"* cells per well in 200 pi culture medium. Alongside 
transfected cells, duplicate wells o f FEA cells and FEA cells infected with FeLV- 
A/Glasgow-1 virus (FeLV-A cells) were prepared as negative and positive controls 
respectively. All slides were then incubated for a further 24 hours as above.
Cell medium was removed from the wells and the cells were gently washed 3 times 
with PBS. Cells were fixed by adding 100 pi methanol to each well and incubating for 
1 hour at room temperature. The methanol was removed and cells were washed twice 
with PBS. Cells were then incubated with either 6-15 monoclonal antibody specific 
for FeLV gp70 antigen to detect expression o f pUSELCMVT(e«Vy4), PF12J-10A 
monoclonal antibody specific for FeLV p27 antigen to detect pUSErCMVT(gag/joo/) 
expression or PBS buffer as negative antibody control. These primary antibodies were
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used at a 1:50 dilution in PBS and all ceils were incubated for 1 hour at 37°C with 5% 
CO]. Wells were prepared as follows:
Table 5-5 Transfected cell lines and antibodies used for immunofluorescence
Well Transfected cell line Transfected DNA Antibody Antigen recognition
1 293T pUSE 1 'ChAVTigag/pol) PF12J-10A CA (p27)
2 293T pUSE 1 'CMVT(gag/pol) 6-15 SU (gp70)
3 293T pUSETCMVTfeag/po/) PBS None
4 293T pUSETCMVT(e/Jvzf) PF12J-10A CA (p27)
5 293T pUSETCMVT(e«v/l) 6-15 SU (gp70)
6 293T pUSETCMVT(e«v/l) PBS None
7 293T pCl-neo PF12J-10A CA (p27)
8 293T pCI-neo 6-15 SU (gp70)
9 293T pCI-neo PBS None
10 FEA none PF12J-10A CA (p27)
II FEA none 6-15 SU (gp70)
12 FeLV-A none PF12J-10A CA (p27)
13 FeLV-A none 6-15 SU (gp70)
Following incubation, primary antibody was removed and all wells were washed 3 
times with PBS. A secondary antibody was prepared in PBS using anti-mouse IgG 
(whole molecule) FITC conjugate (Sigma) at a 1:250 dilution and 0.5% Evans blue at 
a dilution o f 1:1000. A  volume o f 100 pi o f  this solution was added to all wells and 
slides were incubated for 1 hour at 3T C  with 5% CO]. After this incubation, the 
secondary antibody was removed and cells were washed 3 times in PBS. The wells 
were dried and kept in the dark until viewing under the UV microscope. Images o f  
cells undergoing fluorescence were captured using Fujichrome 400 film (H.A. West, 
Clydebank, UK) in a 35 mm camera attached to the microscope.
5.2.1.3 In vitro expression of gag/pol constructs using Western biot analysis
Previous work had failed to elicit in vitro expression o f pUSErCMVT(g«g/^o/) and 
pUSE 1 "CMVT(cMvW) by Western blot analysis [Hanlon, 1999]. An experiment was 
therefore performed to establish whether the level o f FeLV CA (p27) protein 
expression elicited by the gag/pol gene was affected by the plasmid expression vector 
used. Therefore gag/pol was cloned into the commercial expression vector pCI-neo 
(Promega) and the protein expressed from cell transfections were compared by
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Western blot analysis. The same cloning procedure was also performed using the 
envA gene but Western blot analysis o f SU (gp70) protein expression was 
unsuccessful and will not be detailed here.
5.2.1.4 Cloning of pCI-neo(gag/po/)
DNA encoding FeLV gag/pol was excised from pUSErCMVT(g«g/^o/) using a Not I 
bulk digest. A Not I bulk digest o f  pCI-neo expression vector opened the vector for 
insertion o f FeLV gag/poL Ligation o f digested vector and gag/pol fragment produced 
pCl-nQo{gag/pol). This ligation was transformed into MAX Efficiency STBL2 
competent cells (Invitrogen) using the instmctions o f  the manufacturer and bacterial 
colonies were selected into 3 ml o f  LB culture medium. These were incubated 
overnight at 37°C in an orbital incubator. DNA was prepared from these cultures 
using Qiaprep Miniprep Kit, (Qiagen) and positive clones were verified by restriction 
digestion. A positive clone was then sequenced using the ABI Prism system. T7 and 
M l3 reverse primers were used to verify the sequence and orientation o f  the inserted 
DNA.
5.2.1.5 Transfection and harvesting of pUSE1CMVT(gag/po/) and pCI-neo(gag/po/)
293T cells were seeded into 75 cm^ flasks and incubated for 24 hours at 37°C with 5% 
CO] until approximately 40% confluent. Transfections o f pUSELCMVT(gag/po/), 
pCI-neo(gag/po/) and pCI-neo plasmid vector (Promega) were performed using 
LipofectAMINE Reagent (Invitrogen Life Technologies) following the 
manufacturer's instructions. Flasks were then incubated for 48 hours at 37®C with 5% 
CO].
Supernatant fluids were decanted from the transfections and centrifuged at 1000 rpm 
for 5 minutes to remove any cell debris. The supernatant was then dispersed in 
aliquots and stored at -20°C until further use. Cells were removed from the bottom of  
the flask using a sterile scraper, suspended in 2 ml PBS and centrifuged at 1000 rpm 
for 5 minutes to pellet the transfected cells. The supernatant was discarded and cells 
were resuspended in 100 p.1 lysis buffer (1 M Tris pH 7.4, 1.4 M NaCl, 10 mM 
EDTA, 10% Triton X-100, 1% SDS, 5% deoxycholate, 10% Aprotinin) by pipetting
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up and down gently. Cellular debris was removed by centrifugation for 30 seconds at 
14000 ipm and the lysate supernatant was stored at -20^C until further use.
5.2.1.6 Western blot analysis of pUSE1CMVT(gag/po/) and pCI-neo(gag/po/)
A 15% SDS-PAGE gel was prepared using pUSErCMVT(gag/po/), pCI- 
v\.Qo{gag/pol) and pCI-neo supernatants and cell lysates. In the initial experiment, 20 
p,l o f each neat sample with 5 (xl protein loading buffer was used. A positive control, 
consisting o f  FeLV-infected F422 cell lysate, was kindly supplied by Mathew Golder, 
University o f Glasgow. A 5 |ll sample o f  1:20 F422 lysate dilution was run alongside 
transfection samples.
Protein from the gel was transferred to a PVDF membrane using a semidry 
immunoblotter as described in 2.2.11. The membrane was exposed to a 1:80 dilution 
o f PF12J-10A mouse monoclonal antibody specific to FeLV p27 antigen. The 
secondary antibody was anti-mouse HRP conjugate, used at a concentration o f  
1:2000.
On demonstration o f  in vitro expression o f  p27 antigen in both pUSEL  
CMW'I{gag/pot) and pCl-nQo{gag/pol), Western blot analysis was repeated using 1:2 
serial dilutions o f  each transfection supernatant to detect any difference in protein 
expression between the two expression vectors.
5.2.2 Preparation of DNA vaccine and cytokine DNA for immunisation
Once the plasmid vector for the DNA vaccine had been selected and the bioactivity o f  
flexi-IL-12 and ILRAP-IL-18 constructs verified, the vaccine components were 
prepared using large-scale DNA purification techniques.
Glycerols o f pUSErCMVT(g£7g/po/), pUSELCMVT(e«v^), flexi-IL-12, ILRAP-IL- 
18 and pCI-neo were streaked out onto separate LB-agar plates using a sterilised 
platinum wire and incubated overnight at 37°C. A single colony for each construct 
was selected and grown in 8 ml LB medium supplemented with 100 |ig/ml ampicillin
190
in a 15 ml Falcon tube. Tubes were incubated at 37°C with vigorous shaking at 225 
rpm for 6-8 hours. This starter culture was then inoculated into 2.5 litre LB medium 
with ampicillin, which was incubated overnight at 3T C  with vigorous shaking. Five 
2-litre glass flasks, each containing 500 ml o f culture, were used for this incubation.
Preparation o f  DNA from this large-scale culture was carried out using the Qiagen 
plasmid Endofree Giga Kit, (Qiagen) under the instructions o f the manufacturer. This 
kit is designed to purify up to 10 mg o f  low endotoxin, high-copy plasmid DNA in 
each batch. Endotoxins, or lipopolysaccharides make up a large proportion o f the cell 
membrane o f Gram-negative bacteria such as E. coli. It is crucial that endotoxin-free 
DNA is used in in vivo experiments as endotoxins can produce endotoxic shock 
syndrome, fever, and activation o f the complement cascade in both animals and 
humans [Vukajlovich c/a /. 1987].
In order to prevent contamination o f DNA preparations with endotoxin, pyrogen-free 
Rainin Greenpak filter tips (Anachem) were used and DNA was stored in 2 ml 
endotoxin-free Eppendorf tubes (Fisher Scientific). In addition, endotoxin-free water 
(Sigma) was used when necessary and DNA was resuspended in endotoxin-free PBS 
(Biowhittaker UK Ltd.). All tubes and pipettes used in the procedure were pyrogen- 
free.
The DNA pellet was generally resuspended in 1 ml endotoxin-free PBS and incubated 
overnight at 37°C in order to produce complete dissolution o f the DNA. Each batch o f  
DNA was then stored at -20^C prior to quantification, sequencing and endotoxin 
testing.
5.2.2.1 Quantification and sequencing of vaccine and cytokine DNA
Restriction digests o f each batch o f plasmid DNA were carried out as a preliminary 
measure to verify construct inserts. Quantification o f DNA was achieved by 
spectrophotometry and by comparison to standards on gel electrophoresis. Antigen or 
cytokine sequence in each batch o f  DNA was verified either partially or in full by 
sequencing using ABI Prism using appropriate primers.
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S.2.2.2 Endotoxin testing of vaccine and cytokine DNA
Each batch o f  DNA was tested for endotoxin using the Limulus amoebocyte lysate 
(LAL) assay. Batch samples were sent to Biowhittaker Europe, Verviers, Belgium for 
testing.
The concept behind this assay is the ability o f endotoxin to initiate clotting o f  Limulus 
polyphemus haemolymph. In its simplest form, the time taken for DNA samples to 
form a solid clot when mixed with LAL enzyme and substrate is a measure o f  
endotoxin present. This assay has been developed by replacement o f  clotting protein 
with a synthetic peptide. This peptide is covalently attached to para-nitroanilide, 
which on contact with endotoxin is cleaved and produces a colour change. This 
change is proportional to the amount o f endotoxin present and is measured by 
spectrophotometry at 405 nm [Novitsky, 1983]. The acceptable level o f  endotoxin 
allowed in each batch was taken as <50 EU/mg o f DNA [Schorr et a l  1995].
5.2.3 Virus used for challenge
The virus used for challenge was kindly provided by Mathew Golder. Wild-type 
FeLV-A/Glasgow-1 virus was cultured in the FEA cell line [Jarrett et a l  1973]. 
Before use, the virus batch was assayed using the QNIO cell line. Duplicate tests were 
carried out o f ten-fold dilutions o f virus from 10'  ^ to 10"^  and the mean o f  these values 
was taken as the viral titre. For the trial, batch 56 had a titre o f  4.2 x  10  ^ f.f.u./ml. The 
virus was stored at -80°C and thawed immediately before use.
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5.2.4 Design of DNA vaccine trial
5.2.4.1 Maintenance of experimental animals
Thirty-six specific pathogen free (SPF), 11-13 week old kittens were acquired from a 
commercial breeding establishment and housed in the isolation unit at the University 
o f Glasgow. They were arranged randomly on arrival, renamed L1-L36 and split into 
6 rooms o f 6 cats. Each experimental group was housed in a separate room within the 
isolation unit. Cat L7 was euthanased 11 weeks into the trial leaving one room 
housing 5 cats. L7 had displayed sudden onset anorexia, weight loss and ataxia and 
was removed from the trial and euthanased. On post mortem, a chronic fibrosing 
interstitial nephritis was identified with an accumulation o f crystals in the renal 
tubules. It was concluded that uraemia from renal disease had probably caused the 
neurological signs which were displayed.
Animals were fed according to weight with a commercial diet o f canned and dried 
food. All procedures were performed following Home Office regulations.
5.2.4.2 Vaccination groups
Each group o f cats was immunised with a different vaccine combination as follows: 
Table 5-6 Immunisation groups used for current DNA vaccination trial
Group Cats Vaccine combination
1 LI - L6 DNA vaccine + flexi-IL-12 + lLRAP-lL-18
2 L 8- L12 DNA vaccine + flexi-IL-12
3 L 13-L 18 DNA vaccine + ILRAP-IL-18
4 L 1 9-L 24 DNA vaccine
5 L25 - L30 pCI-neo vector + flexi-IL-12 + ILRAP-IL-18
6 L31 -L 36 PBS
The DNA vaccine in each case consisted o f  an equal combination o f pUSET 
CMNT{gag/pot) and pUSErCMVT(envH).
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5.2.4.3 Immunisation schedule
A diagram o f the vaccination schedule is shown in figure 5.3.
Figure 5-3 Vaccination schedule: parameters tested at each timepoint
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Once the animals had been separated into rooms they were allowed to acclimatise to 
their environment for 2 weeks before commencement o f the trial. Endotoxin-free 
vaccine DNA was prepared as described previously in 5.2.2. Cats were immunised 
three times at two-week intervals at weeks 0, 2 and 4. Each immunisation comprised 
100 pg o f each vaccine component suspended in 200 pi endotoxin-free PBS 
(Biowhittaker UK Ltd.). Cats were manually restrained and the vaccine was 
administered intramuscularly using a sterile insulin syringe and needle. The first and
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third vaccines were injected into the left quadriceps femoris muscle and the second 
vaccine into the right quadriceps femoris. For 24 hours after each immunisation, 
kittens were carefully monitored and no adverse local or systemic reactions were 
observed.
5.2.4.4 Viral challenge
Kittens were challenged with wild type FeLV-A/Glasgow-1 virus which had been 
previously assayed as mentioned earlier. They were challenged 3 weeks after the final 
immunisation at days 0, 2, 4 and 8 as performed in a previous study [Harbour et a l  
2002]. Each challenge consisted o f 1 x 10  ^ f.f.u. diluted to a total volume o f 1 ml in 
FEA cell medium, producing a total challenge to each kitten o f 4 x 10  ^ f.f.u. To mimic 
natural transmission o f FeLV via the saliva, virus was administered to the cats 
oronasally, 0.5 ml into the mouth and 0.25 ml into each nostril. Any cats that became 
persistently infected, usually after an incubation period o f 3-4 weeks, would 
subsequently be a source o f infection to other cats in the same room exposing them to 
an additional natural challenge. Again, cats were closely observed over the challenge 
period and no adverse local or systemic reactions were observed.
5.2.4.5 Blood sampling
Blood sampling o f kittens was performed in accordance with the guidelines o f the 
Home Office. Home Office regulations stipulate that the maximum volume o f blood 
that can be taken per 100 g bodyweight is 0.5 ml every two to three weeks. With this 
maximum volume in mind, blood for screening was taken as follows:
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Table 5-7 Quantities o f  blood taken during D N A  vaccination trial
Amount o f  blood (ml)
Blood sample Week p27, VI, VNAb, 
NNAb* (Heparin)
Haematology
(EDTA)
PBMC
(Alsevers)
PBMC
(Citrate)
Total
pre-immun 0 1 0.5 1 2.5
post-immun 2 1 2 3
post-immun 4 2 2 4
pre-challenge 7 2 0.5 3 5.5
post-challenge 11 2 4 6
post-challenge 14 2 0.5 5 7.5
post-challenge 17 2 6 8
post-challenge 20 2 0.5 7 9.5
euthanasia 23 2 1 3
p27 - FeLV p27 ELISA
VI - FeLV virus isolation
VNAb - FeLV virus neutralising antibodies assay
NNAb* - FeLV non-neutralising antibodies assay; this was performed at viral
challenge and at euthanasia
Cats were manually restrained and the jugular or cephalic vein area was shaved and 
prepared using Hibitane solution. Where necessary, cats were anaesthetised using a 
30% dose regimen o f a xylazine (Rompun, Bayer pic, Bury St. Edmunds, UK) and 
ketamine (Ketaset, Willows Francis Veterinary, Crawely, UK) combination according 
to the instructions o f  the manufacturer. Blood samples at euthanasia were collected 
from anaesthetised cats using intracardiac puncture.
S.2.4.6 Screening of blood samples
Screening o f blood for FeLV p27 antigen, virus isolation and antibodies
At every sampling point in the trial, heparinised plasma was screened for infectious 
virus by virus isolation (VI) and p27 antigen by ELISA. Antibodies produced to 
FeLV, both virus neutralising (VNAb) and non-neutralising (NNAb), were measured 
in each cat as shown in figure 5.3. Blood was collected in 2 ml heparin tubes and 
centifuged at 2000 rpm for 5 minutes. The plasma was removed, aliquoted and stored 
at -70°C until further use.
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The purpose o f  pre-immunisation screening was to establish the FeLV status o f cats 
and ensure no prior exposure to the virus. O f particular interest at this point was 
whether vaccination stimulated the production o f  anti-FeLV antibodies.
Sampling post-challenge was performed every three weeks until euthanasia. This was 
to establish the viral status o f  cats and to analyse any immune responses stimulated in 
response to viral challenge. These data were then used to compare the ability o f  
different vaccine combinations to induce protection against exposure to FeLV. Details 
o f  p27 ELISA, VI, VNAb and NNAb assays are described in detail later in 5.2.5.
Screening o f blood for haematology
At various points in the experiment, blood was collected into 2 ml potassium-EDTA 
tubes (Bibby Sterlin Ltd., Stone, UK) to establish the haematological status o f the 
cats. Cells were counted using an automated cell counter (Abbott, CELL-DYN 3500, 
Abbott Diagnostics Division, Abbott Park, IL 60064 USA) and differential cell counts 
were carried out manually using May-Grunwald-Giemsa stained smears.
The parameters measured were as follows: red blood cell count (RBC), haematocrit 
(HCT), mean cell volume (MCV), mean cell haemaglobin (MCH), mean cell 
haemaglobin concentration (MCHC), and white blood cell count (WBC). Proportional 
representation o f white blood cells into neutrophils, lymphocytes, monocytes 
eosinophils and basophils was also established. All o f  these levels were compared 
with normal parameters to confirm the health status o f the cats.
PBMCs collected from Alsevers solution
At each sampling point, PMBCs were extracted from blood collected in a 15 ml 
Falcon tube at a 1:1 ratio with Alsever's solution (Diagnostics Scotland, Edinburgh). 
Alsever's is a sterility tested solution with anticoagulant and preservative properties 
containing citrate and glucose. This blood/Alsevers mix was laid over an equal 
volume o f Ficoll-Paque PLUS lymphocyte isolation solution (Amersham Pharmacia 
Biotech AB, Sweden) contained in a 50 ml Falcon tube. Tubes were centrifuged 
without braking at 1500 rpm for 15 minutes. The PBMC interface layer was removed
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and diluted in 20 ml RPMI 1640 medium with L-glutamine, Cells were pelleted by 
centrifugation at 1500 rpm for 15 minutes without braking and the supernatant 
removed. The cell pellet was gently resuspended in freeze medium consisting o f  90% 
heat inactivated PCS and 10% DMSO (Analar, BDH Ltd) and transferred to a 2 ml 
cryogenic vial. These tubes were then stored at -70°C until further use.
PBMCs collected from sodium citrate anticoagulant
PBMCs were also collected from sodium citrate blood at the final sampling point o f  
the trial. These tubes were centrifuged at 2000 rpm for 5 minutes and the plasma 
removed and stored at -70°C. A small sample o f the buffy coat was then transferred 
into an Eppendorf tube, centrifuged for 5 minutes at 2000 rpm to remove any plasma 
and stored at -70°C.
5.2.4.7 Collection and analysis of bone marrow
At the end o f the trial, cats were anaesthetised using an intramuscular injection o f  
xylazine and ketamine and euthanased by an intracardiac injection o f pentobarbitone 
(Euthatal). All cats were euthanased except persistently infected cats in the control 
group, L31, L33, L34 and L35. These four cats were retained for an immunotherapy 
experiment described in chapter 6. Bone marrow was collected from all euthanased 
cats and bone marrow biopsy was performed on the remaining 4 cats in order to 
establish the presence o f  latent FeLV infection.
In euthanased cats, the femur was removed and bone marrow was taken aseptically 
using bone cutting forceps. Each sample was collected in a 5 ml bottle containing 
3 ml bone marrow transport medium. This medium consisted o f Alpha Minimal 
Essential Medium (Invitrogen), supplemented with 10% FCS, 2 mM L-glutamine, 
400U/ml penicillin/streptomycin, 10'  ^ M hydrocortisone succinate (AFC 10) and 50 
lU/ml preservative-free heparin (Pularin).
The four cats requiring bone marrow biopsy were anaesthetised using intravenous 
injection o f alphaxelone/alphadolone acetate (Saffan, Pitman-Moore Ltd., Crewe, 
UK) at a dose recommended by the manufacturer. The left gluteal area was shaved
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and prepared aseptically. The inter-trochanteric fossa was located and a small incision 
made over this region using a sterile scalpel. A bone marrow aspirate was taken using 
a 10 ml sterile syringe and a sterile disposable 18G Illinois Stemal/Iliac bone marrow 
aspiration needle (Pharmaseal, Allegiance Healthcare Corporation, USA.). Each 
aspiration was collected in bone marrow transport medium as described above. The 
preparation and culture o f  bone marrow samples is explained in detail in 5.2.5.5.
5.2.5 Feline leukaemia virus screening
5.2.5.1 FeLV p27 antigen ELISA
Greiner high-binding wells were used for this assay. Each well was prepared by 
coating with a mix o f 2 purified murine monoclonal antibodies, MCA 0022 and MCA 
0024, raised to p27 antigen. The protein concentration o f these antibodies was 
approximately 1 mg/ml suspended in PBS and the preparation contained azide. 
Antibodies were diluted 1:300 in coating buffer and added immediately to wells. Any 
delay in this addition brought about adhesion o f  antibody to the container in which it 
was diluted. Plates were covered and incubated on an orbital platform overnight 
-4°C and were washed 5 times in PBS/0.05% Tween.
Biotinylated sheep anti-p27 antibody was diluted at 1:4000 in PBS and 80 |il was 
added to each well. Twenty microlitres o f  sample or positive or negative control was 
then added to wells. The plates were covered and incubated at 37°C for 45 minutes 
with continuous shaking. A solution o f  streptavidin-alkaline phosphatase conjugate 
(Harlan) was prepared at a dilution o f 1:4000 in PBS and 100 \i\ was added to each 
well and wells were incubated with shaking at 37°C for 30 minutes. Plates were 
washed 5 times as before and 100 p.1 phosphatase substrate was added to each well. 
Substrate was prepared by dissolving a 5 mg p-nitrophenyl phosphate tablet in 5 ml o f  
alkaline phosphatase buffer (5.36 g diethanolamine, 2.92 g NaCl, 0.508 g MgCl in 
500 ml dH20, pH 9.5.). Wells were covered and incubated on an orbital shaker at 
37°C for 30 minutes. The reaction was stopped by the addition o f 50 p.l 0.5 M NaOH 
to each well. The optical density o f each well was then read immediately using a 
spectrophotometer (Ascent-AFVU) at 405 nm wavelength. A sample was taken as
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positive if  it gave an OD reading o f over 1.5 times the value o f the negative control 
reading for that batch o f  samples.
5.2.5.2 Virus isolation technique
This method o f virus isolation was described by Jarrett and Ganière, [1996]. QNIO 
cells were grown in 22 mm diameter, 12-well cluster plates. 5 x 10"^  cells in 1 ml 
culture medium were added to each well, supplemented with 4 |Lig/ml polybrene and 
incubated for 24 hours at 37°C with 5% CO]. At this time, 0.2 ml o f sample was 
added to each well using separate pipettes to avoid cross-contamination and plates 
were incubated for 2 hours at 37°C. The inoculum was then removed and replaced 
with 1.5 ml fresh medium and the plates were incubated for 3-5 days. Cells were 
examined for evidence o f morphological transformation. Positive control wells 
consisted o f ten-fold dilutions o f  FeLV-A. A negative control well using serum from a 
FeLV-A-free SPF cat was also included.
Samples with morphological transformation were diagnosed as positive for virus at 
this point whereas negative samples were subcultured. The reason for the subculturing 
step is that if  samples contain low levels o f FeLV there may be insufficient virus to 
produce a visual morphological effect. The wells o f these samples and controls were 
trypsinised using 250 fil o f  trypsin/versene mixture and left until the cells had 
detached. Cells were resuspended in 1 ml culture medium and added to a 5 cm plate 
containing 4 ml fresh medium. These plates were incubated for 3-4 days as before, 
viewed for morphological transformation and samples were scored positive or 
negative on this basis. Transfer o f  QNIO cells to 5 cm dishes at subculturing allows a 
faster rate o f cell division. This promotes visualisation o f transformation as FeLV 
replicates only in actively dividing cells.
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5.2.5.3 Assay for FeLV virus neutralising antibodies (VNAb)
Measurement o f  VNAb to FeLV in plasma was performed using a focus reduction 
assay previously described by Jarrett and Ganière [1996]. For each plasma sample, 4 
wells were prepared at 4 x 10"^  QNIO cells per well in 12 well cluster plates. These 
cells were suspended in 1 ml o f culture medium and were incubated overnight at 37°C 
with 5% CO].
Samples were diluted in Leibovitz medium from 1:4 to 1: 256 and 50 p.1 o f  dilutions 
were aliquoted onto 96 well plates. 50 \i\ o f  FeLV-A at a concentration o f  4 x 10  ^
f.f.u./ml was added to each well and incubated for 6 hours at 37°C with 5% CO]. O f 
the sample dilutions, 25 p.1 o f  1:4, 1:8, 1:16 and 1:32 dilutions were each added to a 
QNIO cell culture and incubated for 3-4 days at 3T C . The rest o f  the sample dilutions 
were stored at -70°C.
After incubation, QNIO cells were examined for the presence o f  foci o f  
transformation, which allowed quantification o f infectious virus levels. The reciprocal 
o f the plasma dilution which reduced the focal count o f  FeLV by 75%, was taken as 
the titre o f antibody present when compared with a virus control incubated without 
plasma.
5.2.5.4 Assay for FeLV virus non-neutralising antibodies (NNAb)
The presence o f non-neutralising antibodies was detected by Western blot analysis 
against complete viral lysate.
An SDS-PAGE gel was prepared as described in 2.2.10. Prior to running the gel the 
concentration o f p27 in the viral lysate was estimated by comparing the intensity o f  
p27 protein to an ovalbumin control o f  known concentration on a Coomassie blue 
stained gel. The total viral protein was then calculated as p27 accounts for about 30% 
o f total protein in the sample. Approximately 170 jig o f viral protein was added to 25 
jii o f  3 x protein sample loading buffer and protein was separated on an SDS-PAGE 
gel along with protein molecular weight standards.
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Protein was transferred to a nitrocellulose membrane using electroblotting equipment 
at 100 V for 1 hour and the membrane was removed and washed in TBS. It was then 
incubated on an orbital shaker for 3-4 hours in TBS/2% Marvel solution to block non­
specific binding sites. The membrane was washed in PBS/0.05% Tween 20 for 2 
hours, air dried at room temperature by placing on 3 MM paper between folded 
parafilm, and stored at -20°C in a sealed freezer bag until further use.
When required, the membrane was thawed at room temperature and cut into vertical 
strips each around 1 mm in width. Identical strips were cut for each cat serum sample 
as well as positive and negative controls. Individual plasma samples were incubated 
with a separate strip to identify any antibodies to FeLV proteins.
Any antibody bound to protein on the membrane was visualised using the streptavidin 
peroxidase method. In this protocol, strips were placed in individual compartments o f  
multi well dishes and solution A was prepared using 0.8 g Marvel in 20 ml TBS with 
100 |il Tween 20. A 20 \jâ plasma sample from each cat was made up to 200 |il with 
solution A containing 1 mM EDTA and added to a strip within a well. This was 
incubated at room temperature for 2 hours (or overnight at 4°C) and the strips were 
washed 3 times in PBS/0.05% Tween. Biotinilated protein A (Amersham Life 
Sciences) was diluted in solution A at a concentration o f 4 p,l/ml. 200 |il was added to 
each strip and incubated with gentle rocking for 1 hour at room temperature. Strips 
were washed again in PBS/0.05% Tween and 200 |il o f a 1:500 dilution o f  
streptavidin peroxidase in solution A was added to each strip. Wells were incubated at 
room temperature for 1 hour with gentle rocking and then washed 3 times with 
PBS/0.05% Tween.
At this point, substrate solution was prepared as follows: 10 ml o f methanol in a 
tightly capped universal, 30 mg o f 4-chloro-1 -napthol in a universal and a 15 |il 
aliquot o f H2O2 was placed on ice. A  volume o f 25 ml o f NT buffer (10 mM Tris, 
0.15 M NaCl, pH 8) was decanted into a 50 ml Falcon tube and placed on the bench 
until use. When the substrate was required, the methanol was added to the 4-chloro-1- 
napthol to make reagent A, and the H2O2 was added to the NT buffer to give reagent 
B. A. 5 ml aliquot o f  reagent A was added to reagent B to produce the active substrate.
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200 ]il substrate was added to each strip and the development reaction was stopped by 
removing the substrate and washing with dH20. Antibodies to specific protein 
antigens were then visualised on the nitrocellulose membrane according to molecular 
size o f protein.
5.2.5.5 Culture of bone marrow cells and viral screening
Bone marrow samples were diluted to 10 ml in bone marrow transport medium and 
passed first through a 21-gauge needle then a 23-gauge needle in order to produce a 
single cell suspension. The suspension was centrifuged for 10 minutes at 2000 rpm 
and the supernatant was removed and stored at -70°C until further use. Cells were 
resuspended in 10 ml 0.83% ammonium chloride and incubated on ice for 5 minutes 
to produce erythrocyte lysis. This solution was centrifuged again as above and the 
supernatant discarded. Pelleted cells were resuspended in 10 ml Alpha Minimal 
Essential Medium containing 20% FCS, 2 mM L-glutamine, 400 U/ml 
penicillin/streptomycin and 10'  ^ M hydrocortisone succinate (AFC20). Cells were 
cultured in 25 cm  ^ flasks with 10 ml AFC20 at 2 x 10  ^cells/ml. Flasks were prepared 
in duplicate for each sample and they were incubated at 3T C  with 5% CO2.
After 2 weeks o f culture, the cells consisted o f  an adherent confluent monolayer o f  
fibroblasts interspersed with large granulated cells and areas o f mature myeloid cells. 
At this time the bone marrow cells were split 1:2 in AFC20 medium and incubated for 
a further 72 hours. Cell suspensions were then centrifuged for 10 minutes at 2000 rpm 
and supernatants were removed and analysed for FeLV by virus isolation as described 
above. The pelleted cells were used in the p27 ELISA assay detailed earlier to detect 
the presence o f FeLV p27 viral antigen. An overview o f the culture o f bone marrow 
and viral screening is shown in figure 5.4.
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Figure 5-4 Overview o f  viral screening o f  bone marrow samples
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5.3 RESULTS
5.3.1 Construction of FeLV DNA vaccine
5.3.1.1 Expression of DNA vaccine plasmids using fixed cell immunofluorescence
In order to demonstrate in vitro expression o f  the FeLV DNA vaccine, pUSEL  
CMMTigag/poI), pUSErCMVT(e«V/4) and empty pCI-neo vector were transfected 
into 293T cells and cells were incubated with monoclonal antibodies specific for 
certain FeLV-A antigens. Antibody specific for p27 antigen detects cells expressing 
Gag protein and antibody specific for gp70 protein recognises cells synthesising Env 
protein.
Three cell samples o f  each transfection were transferred to an 8-well slide system. 
One well o f each transfection was incubated with gp70 antibody, p27 antibody or PBS 
buffer followed by incubation with IgG FITC conjugate secondary antibody. In 
addition, positive and negative controls o f FeLV-A infected and uninfected FEA cells 
were prepared alongside. Transfected cells incubated with specific monoclonal 
antibodies are shown in table 5.5.
Images visualised under UV light are shown in figure 5.5 (a) to (e). Positive and 
negative controls for antibodies using FeLV-A and FEA cells respectively, are shown 
in figures (a) and (b). Cells transfected with pUSELCMVTfgag/j^o/) demonstrated 
fluorescence when incubated with antibody specific for p27 antigen. No fluorescence 
could be detected on incubation with gp70 antibody or PBS buffer (d). Similarly, cells 
transfected with pUSE 1 "CMVT(e^vW) exhibited fluorescence on exposure to gp70 
specific antibody but not with antibody specific for p27 or PBS buffer alone (c). To 
rule out non-specific immunofluorescence, cells transfected with pCI-neo were 
incubated with the same antibodies. As the images demonstrate, none o f  these cells 
exhibited fluorescence (e).
In an earlier experiment, cells were transfected with pCI-neo(gag/^o/) and pCI- 
nQo{envA) and incubated with specific monoclonal antibodies as above. These 
constructs also displayed immunofluorescence at a similar level to constructs
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Figure 5-5 a) P ositive and negative  contro l for gp70 m onoclonal an tibody
F eL V  ce ll lin e
FFA cell line
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Figure 5.5 b) Positive and negative  contro l fo r d 27  m onoclonal an tibody
F eL V  ce ll lin e
FLA cell line
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Figure 5.5 c) Im m unofluorescence  pho to s o f  293T  cells transfected  w ith PU SEl~C M V T(ew v/41
g p 7 0  (S U ) m o n o c lo n a l a n t ib o d y  (x  I) n 2 7  (C A ) m o n o c lo n a l a n t ib o d y
gn7Q (S U ) m o n o c lo n a l a n t ib o d y  (x 2) PBS buffer
Figure 5.5 d) Im m unofluorescence  pho tos o f  293T  ceils transfec ted  w ith P U S E l~ C M V T (g g g /p o /)
d 2 7  (C A ) m o n o c lo n a l a n t ib o d y  ( \  1) gn7 0  tS U )  m o n o c lo n a l a n t ib o d y
d 27  (C A ) m o n o c lo n a l a n t ib o d y  (x  2 ) P B S  b u ffe r
Figure 5.5 e) N egative contro l im m unofluo rescence  pho tos o f  293T  cells transfec ted  w ith pC i-neo
g p 7 0  (S U ) m o n o c lo n a l a n t ib o d y
p 2 7  (C A ) m o n o c lo n a l a n t ib o d y
P B S  b u ffe r
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encoded by the pUSEl 'CMVT expression vector (data not shown), suggesting that the 
level o f antigen expression was unaffected by the plasmid vector used.
5.3.1.2 In vitro expression of gag/pol constructs using Western blot analysis
The pCl-neo{gag/pol) construct was cloned and the level o f protein expression from 
this construct was compared with pUSE 1C MVT(g<7g/^o/) by Western blot analysis o f  
transfection fluids. Previous in vitro work attempting to show protein expression o f  
pUSEl'CMVT plasmids had been unsuccessful [Hanlon, 1999]. Therefore the gag/pol 
and envA genes were cloned into pCI-neo and compared with pUSEl'CMVT  
construct expression to rule out any aberrent promoter sequence in the pUSEl'CM VT  
plasmids.
A Western blot o f 293T transfection products o f  pUSEl'CMVT(gag/po/), pCI- 
neoigag/pof) and pCI-neo vector was prepared.
Figure 5-6 Western blot o f 293T transfections o f sas/po l constructs
65kDa
25kDa
Lane 1 2 3 4 5 6
Autoradiograph o f  a 15% SDS-PAGE gel showing supernatants and cell lysates o f  
pU SEl“CMVT(gag/^o/) and pCI-neo (gag/pol) 293T cell transfections.
The lane order was as follows: lane 1: Novigen protein marker, lane 2: F422 cell 
lysate, lane 3: pUSET CMVT(gag/^o/) supernatant, lane 4: pCI-neo(gag/^o/) 
supernatant, lane 5: pCI-neo supernatant. lane 6: space, lane 7:
p U S E r CMVT(gag/^o/) cell lysate, lane 8: pCI-neo (gag/pol) cell lysate, 
lane 9: pCI-neo cell lysate.
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As shown in figure 5.6, the positive control FeLV-infected F422 cell lysate showed a 
strong band at approximately 27 kDa, indicating strong p27 expression and antibody 
specificity to this protein. Both pUSEl'CMVT(gag/^o/) and pCI-neo(g(7g/^o/) 
supernatants contained 27 kDa bands which was not evident in the negative control 
pCI-neo supernatant.
A similar sized protein band was also visualised in both pUSErCMVT(g«g//?o/) and 
pCI -neo{gag/pot) cell lysates but not in the pCI-neo cell lysate. In addition, two 
larger bands o f around 65 kDa were also present in both cell lysates.
Once p27 protein expression o f both constructs was demonstrated, an SDS-PAGE gel 
was prepared using T.2 serial dilutions o f supernatants o f each construct to an end 
point. This was to compare levels o f p27 expression o f pUSE I'CMVT(g^rg/^o/) and 
pC\-neo{gag/po[) in transfected cells.
Figure 5-7 Western blot o f  serial dilutions o f 2 0 2 /0 0 ! transfections
25kD a
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Lane 1: Novigen protein marker, lane 2: F422 cell lysate, lane 3: space, lanes 4, 6, 8, 
10, 12, and 14 are 1:2 dilutions o f  pUSE 1 " CMVT(gag/^o/) from neat to 1:32 
respectively. Lanes 5, 7, 9, 11, 13 and 15 are 1:2 dilutions o f pCI-neo(gag/^o/) from 
neat to 1:32 respectively.
As shown in figure 5.7, similar levels o f expression were evident in both supernatants 
and it was concluded that cloning FeLV gag/pol from pUSEl'CMVT into pCI-neo 
had no significant enhancing effect on protein expression o f  the antigen. Thus, 
pUSEl'CMVT constructs were used in the DNA vaccine trial.
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5.3.2 Concentration, purity and endotoxin levels of DNA vaccine 
batches
High-quality, low endotoxin plasmid DNA was prepared using the Qiagen plasmid 
Endofree Giga Kit. The concentration and purity o f  each batch o f  DNA was estimated 
by spectrophotometry. The purity o f samples was approximated using the ratio o f OD 
readings at 260 nm and 280 nm (OD26o/OD28o)- Pure DNA should have a ratio o f  
approximately 1.8. A lower ratio is suggestive o f  phenol or protein contamination. O f 
the batches o f DNA used, most ratios were in the region o f  1.9 and none had a value 
lower than 1.81 suggesting that the DNA was o f sufficient purity to be used in an in 
vivo experiment. The DNA concentration o f batches varied considerably according to 
the construct being prepared. pUSEl'CMVT(g<7g/^o/), pUSErCMVT(e«v^), ILRAP- 
IL-18 and pCI-neo plasmids produced relatively high yields, generally 4-9 |ig/p.l 
depending on the volume o f PBS in which they were suspended. Flexi-IL-12 
produced slightly lower yields requiring more batches o f DNA to be prepared. As 
mentioned previously, batches o f DNA were used only if  the concentration o f  
endotoxin was measured at less than 50 EU/ mg o f DNA. Details o f these levels are 
shown in the table below.
Table 5-8 DNA batches and endotoxin levels used in vaccination trial
Batch Batch volume Concentration DNA Purity o f DNA Endotoxin level
(Ul) (Ug/lil) (ODîûo/ODjso) (BU/mg)
ffOfi/pol 1 600 9.71 1.90 <0.51
f^af^/pol 2 1000 8.00 1.91 9.3
env A 1000 4.72 1.93 < 1.06
env 5 1000 5.88 1.93 8
ILRAP 1 600 9.44 1.81 < 5 .30
ILRAP 2 1000 3.07 1.92 < 1.63
Flexi 1 400 1.52 1.93 < 32.90
Flexi 2 1000 2.17 1.91 < 23.04
Flexi 3 1200 3.47 1.92 36.7
Neo 2 1000 3.53 1.92 < 1.42
Neo 5 1000 7.60 1.92 < 0.66
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5.3.3 Statistical analysis of parameters measured during the 
immunisation trial
Several parameters were measured during this experiment. Virus isolation (VI) and 
FeLV p27 antigen ELISA were performed on heparinised plasma at various time 
points throughout the trial. VI produced a positive or negative result depending on the 
presence o f morphological transformation o f QNIO cells. A positive value for VI was 
considered to be definitive for the presence o f FeLV viraemia. Animals were classed 
as persistently viraemic with the development o f a positive VI result which was still 
present at the end o f  the trial. Transient viraemia was defined as animals that were 
positive by VI at some point during the experiment but which eventually became VI 
negative and remained so until the end o f the trial.
The p27 ELISA produced an OD result, which was designated as either positive or 
negative. Empirical data has shown that a positive ELISA OD is a value greater than
1.5 the negative control OD. In addition the ELISA S/P ratio was calculated for each 
sample using the following equation:
ELISA S/P = OD sample -OD negative control
OD positive control - OD negative control
The purpose o f  this value is to take into account the positive and negative control 
values performed during each ELISA which allows for variation occurring between 
assays. A positive result produces an S/P ratio o f greater than 0.1.
The proportions o f cats positive and negative for VI and p27 antigen in each trial 
group were compared pairwise using Fisher's exact test. This test was used to 
establish whether the protection against viraemia afforded by vaccine groups was 
statistically significant compared to control groups.
5.3.4 Analysis of data produced from vaccine groups
The two main aims o f this vaccination trial were to establish the relative roles o f the 
cytokine adjuvants flexi-IL-12 and ILRAP-IL-18 in enhancing the protection o f a
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DNA vaccine to FeLV. Also, a previous trial investigating this DNA vaccine used 
intraperitoneal viral challenge, so the additional aim o f this experiment was to expose 
individuals to a more natural form o f FeLV challenge using oronasal inoculation 
[Hanlon et al. 2001]. The vaccine combinations used in each group o f  cats in the trial 
are shown below.
Table 5-9 Immunisation groups for current DNA vaccination trial
Group Cats Vaccine combination
1 LI -L 6 DNA vaccine + flexi-IL-12 + ILRAP-IL-18
2 L 8-L 1 2 DNA vaccine + flexi-IL-12
3 L 13-L 18 DNA vaccine + ILRAP-IL-18
4 L 19-L 24 DNA vaccine
5 L25 - L30 pCI-neo vector + flexi-lL-12 + ILRAP-IL-18
6 L31 -L 36 PBS
5.3.4.1 Haematological analysis of experimental animals
Haematology samples were taken from all animals before immunisation, on the day o f  
challenge, and 6 and 12 weeks after challenge. These results were generally 
unremarkable, most values within the approximate normal values for the age o f the 
animal [Jain, 1993]. Some cats displayed slightly high WBC counts, which may have 
been reflective o f  mild infection, however this did not seem to be related to viral 
challenge and the count returned to normal values in the subsequent sample. Five cats 
showed a neutropenia at six weeks post-challenge, three o f which, L8, L22 and L29 
were viraemic. In all cases however, these levels had returned to normal 12 weeks 
after challenge.
5.3.4.2 FeLV p27 antigen, VI and VNAb at time points pre-challenge
Virus was not detected by any o f these parameters in animals prior to viral challenge 
at week 7 (table 5.10). These data show that there had been no exposure o f these 
animals to FeLV prior to experimental challenge. It can therefore be concluded that 
excluding any antibody response to the DNA vaccine, the subsequent detection o f  
virus or antibody was the result o f viral challenge.
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Table 5-10 VI. p27 ELISA and VNAb results from start o f  trial until day o f  challenge
PRE IMMUNISATION 4 8 H POST 2ND  
IMMUNISATION
48H POST 3RD 
IMMUNISATION
DAY OF 
CHALLENGE
Cat p27 1 VI 1 VNAb p27 1 VI p27 1 VI p27 1 VI 1 VNAb
Croup 1 = DNA vaccine + flexi-IL-12 + lLRAP-lL-18
Li 0.14 - 0 0.15 - 0.13 - 0.13 - 0
L2 0.13 - 0 0.14 - 0.15 - 0.14 - 0
L3 0.14 - 0 0.15 - 0.13 - 0.13 - 0
L4 0.14 - 0 0.14 - 0.14 - 0.15 - 0
L5 0.13 - 0 0.14 - 0.14 - 0.14 - 0
L6 0.13 - 0 0.14 - 0.14 - 0.14 - 0
Group 2 = DNA vaccine + flexi-IL-12
L8 0.12 - 0 0.14 - 0.13 - 0.14 - 0
L9 0.12 - 0 0.14 - 0.14 - 0.12 - 0
LIO 0.12 - 0 0.14 - 0.14 - 0.13 - 0
LI 1 0.12 - 0 0.15 - 0.15 - 0.14 - 0
L12 0.13 - 0 0.15 - 0.13 - 0.14 - 0
Group 3 = DNA vaccine + ILRAP-IL-18
L13 0.13 - 0 0.14 - 0.14 - 0.14 - 0
LI4 0.12 - 0 0.15 - 0.14 - 0.14 - 0
L15 0.12 - 0 0.14 - 0.14 - 0.14 - 0
LI6 0.12 - 0 0.16 - 0.14 - 0.14 - 0
L17 0.12 - 0 0.14 - 0.14 - 0.14 - 0
L18 0.12 - 0 0.15 - 0.13 - 0.14 - 0
Group 4 = DNA vaccine
LI9 0.12 - 0 0.15 - 0.13 - 0.15 - 0
L20 0.13 - 0 0.18 - 0.14 - 0.14 - 0
L21 0.13 - 0 0.15 - 0.14 - 0.15 - 0
L22 0.13 - 0 0.14 - 0.15 - 0.15 - 0
L23 0.12 - 0 0.14 - 0.13 - 0.14 - 0
L24 0.12 - 0 0.14 - 0.14 - 0.13 - 0
Group 5 = 2 X pCI-neo + flexi-IL-12 + ILRAP IL 18
L25 0.13 - 0 0.14 - 0.13 - 0.15 - 0
L26 0.13 - 0 0.14 - 0.13 - 0.14 - 0
L27 0.13 - 0 0.14 - 0.14 - 0.15 - 0
L28 0.13 - 0 0.14 - 0.14 - 0.14 - 0
L29 0.13 - 0 0.14 - 0.15 - 0.14 - 0
L30 0.13 - 0 0.14 - 0.13 - 0.14 - 0
Group 6 = PBS buffer
L3I 0.12 - 0 0.15 - 0.14 - 0.15 - 0
L32 0.12 - 0 0.18 - 0.14 - 0.15 - 0
L33 0.13 - 0 0.14 - 0.13 - 0.15 - 0
L34 0.13 - 0 0.14 - 0.13 - 0.15 - 0
L35 0.13 - 0 0.15 - 0.13 - 0.14 - 0
L36 0.13 - 0 0.16 - 0.14 - 0.15 - 0
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S.3.4.3 Efficacy of oronasal challenge
One o f the main aims o f this experiment was to provide an effective viral challenge 
based on the natural pathway o f  infection in the field. FeLV is secreted mainly in the 
saliva and nasal secretions [Hoover et al. 1977] and is therefore spread mostly by 
socialisation o f infected animals with susceptible individuals [Hardy et al. 1973a]. 
The method o f challenge used here was based on an oronasal viral titration by 
Harbour et al. [2002], which successfully challenged 83% o f  15-17 week old cats, 
where 1x10^  f.f.u. was administered at day 0, 2, 4 and 8, producing a total dose o f  4 
X 10  ^ f.f.u. The proportion o f  latency produced by this dose was not established 
previously [Harbour et al. 2002].
In the current trial, FeLV virus was administered in 1 x 10  ^ f.f.u. doses at days 0, 2, 4 
and 8 to cats approximately 5 months o f age. O f the negative control cats inoculated 
with PBS buffer, 4 o f 6 cats were positive for p27 antigen at all timepoints between 3 
and 15 weeks post-challenge. Three o f  the cats were VI positive at 6 weeks post­
challenge which increased to 4 o f 6 cats (66%) at 9 weeks and remained until 
euthanasia at 15 weeks. In addition, bone marrow culture o f  the remaining two cats 
detected latent infection, producing a combined viraemia and latency total to 6 out o f  
6 cats.
It can be concluded from the data that this method o f viral challenge is a successful 
way o f  inoculating cats with FeLV, producing a high proportion o f  viraemic and 
latently infected cats by simulating a natural route o f administration.
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Table 5-11 FeLV p27 ELISA results at 3. 6 and 9 weeks post-challenge
3 WEEKS 6 WEEKS 9 WEEKS
CAT ELISA ELISA RESULT ELISA ELISA RESULT ELISA ELISA RESULT
O.D. S/P O.D. S/P O.D. S/P
Group 1 = DNA vaccine + flexi-IL-12 + ILRAP-IL-18
LI 0.13 -0.024 - 0.21 0 - 0.17 0.022 -
L2 0.13 -0.024 - 0.18 -0.029 - 0.15 0 -
L3 0.12 -0.048 - 0.17 -0.038 - 0.15 0 -
L4 0 13 -0.024 - 0.18 -0.029 - 0.15 0 -
L5 0.13 -0.024 - 0.17 -0.038 - 0.15 0 -
L6 0.14 0 - 0.18 -0.029 - 0.15 0 -
Group 2 = DNA vaccine + flexi-IL-12
L8 0.14 0 - 0.53 0.305 0.38 0.250
L9 0.13 -0.024 - 0.18 -0.029 0.15 0
LIO 0.22 0.190 0.70 0.467 0.41 0.283
L ll 0.13 -0.024 - 0.62 0.390 0.61 0.500
L12 0.13 -0.024 - 0.17 -0.038 0.15 0
Group 3 = DNA vaccine + ILRAP-IL-18
L13 0.13 -0.024 - 0.17 -0.038 - 0.15 0 -
L14 0.13 -0.024 - 0.18 -0.029 - 0.15 0 -
L15 0.13 -0.024 - 0.18 -0.029 - 0.15 0 -
L16 0.13 -0.024 - 0.18 -0.029 - 0.15 0 -
L17 0.14 0 - 0.19 -0.019 - 0.16 0.010 -
L18 0.13 -0.024 - 0.18 -0.029 - 0.18 0.030 -
Group 4 = t >NA vaccine
L19 0.44 0.714 0.67 0.438
L20 0.13 -0.024 - 0.17 -0.038
L21 0.13 -0.024 - 0.17 -0.038
L22 0.13 -0.024 - 0.26 0.048
L23 0.46 0.762 0.59 0.362
L24 0.26 0.286 0.51 0.286
0.46 0.310
0.15 0
0.15 0
0.27
0.71
0.48
Group 5 = 2 X pCI-neo + nexi-lL-12 + ILRAP-IL-18
0.120
0.560
0.330
L25
L26
L27
L28
L29
L30
0.13
0.50
0.14
0.27
0.44
0.14
-0.024
0.857
0
0.310
0.714
0
0.18
0.67
0.18
0.50
0.37
0.19
-0.029
0.438
-0.029
0.276
0.152
-0.019
0.15
0.37
0.16
0.42
0.52
0.17
0.253
0.010
0.313
0.434
0.012
L31 0.40 0.619
L32 0.13 -0.024
L33 0.34 0.476
L34 0.43 0.690
L35 0.58 1.048
L36 0.15 0.024
Group 6 = PBS buffer
0.54
0.19
0.54
0.68
0.50
0.18
0.314
-0.019
0.314
0.448
0.276
-0.029
0.33
0.16
0.27
0.58
0.32
0.15
0.205
0.010
0.133
0.506
0.193
0
2 1 8
T able 5-12 FeLV p27 ELISA results at 12 and 15 weeks post-challenge
12 WEEKS 15 WEEKS
CAT ELISA O.D. ELISA S/P RESULT ELISA O.D. ELISA S/P RESULT
Group I = DNA vaccine + flexi-IL-12 + ILRAP-IL-18
LI 0.18 0.018 - 0.20 -0.009 -
L2 0.16 0 - 0.19 -0.019 -
L3 0.16 0 - 0.18 -0.029 -
L4 0.16 0 - 0.17 -0.038 -
L5 0.15 -0.009 - 0.17 -0.038 -
L6 0.15 -0.009 - 0.18 -0.029 -
L8 0.35 0.168
L9 0.15 -0.009
LIO 0.40 0.212
LI 1 0.56 0.354
L12 0.15 -0.009
Group 2 = DNA vaccine + nexi-lL-12
0.46
0.18
0.36
0.49
0.18
0.238
-0.029
0.143
0.267
-0.029
Group 3 = DNA vaccine + ILI tAP-IL-18
L13 0.14 -0.011 - 0.17 -0.038 -
L14 0.15 -0.009 - 0.18 -0.029 -
L15 0.15 -0.009 - 0.18 -0.029 -
L16 0.14 -0.011 - 0.18 -0.029 -
L17 0.15 -0.009 - 0.20 -0.009 -
L18 0.15 -0.009 - 0.18 -0.029 -
L19 0.44 0.330
L20 0.15 -0.009
L21 0.14 -0.011
L22 0.32 0.193 1
L23 0.44 0.330
L24 0.38 0.261
Group 4 = DNA vaccine
0.79
0.18
0.552
-0.029
0.18
0.34
0.61
0.42
Group 5 = 2 X pCI-neo + flexi-IL-12 + ILRAP-IL-18
-0.029
0.124
0.381
0.200
L25
L26
L27
L28
L29
L30
0.15
0.47
0.15
0.49
0.73
0.15
-0.009
0.244
-0.009
0.260
0.443
-0.009
0.18
0.54
0.18
0.60
0.74
0.18
-0.029
0.314
-0.029
0.371
0.505
-0.029
Group 6 = PBS buffer
L31 0.32 0.130
L32 0.14 -0.011
L33 0.39 0.183
L34 0.44 0.221
L35 0.62 0.359
L36 0.15 -0.009
0.51
0.18
0.59
0.58
0.76
0.18
0.286
-0.029
0.362
0.352
0.524
-0.029
Table 5-13 Number o f positive d 27 ELISA results in vaccination groups post-
challenge
VACCINE GROUP 3 WEEKS 6 WEEKS 9 WEEKS 12 WEEKS 15 WEEKS
vaccine + flexi-IL-12 + ILRAP-IL-18 0/6 0/6 0/6 0/b 0/6
vaccine + flexi-IL-12 1/5 3/5 3/5 3/5 3/5
vaccine + ILRAP-IL-18 0/6 0/6 0/6 0/6 0/6
vaccine 3/6 4/6 4/6 4/6 4/6
2 X pCI-neo + flexi-IL-12 + ILRAP-IL-18 3/6 3/6 3/6 3/6 3/6
PBS 4/6 4/6 4/6 4/6 4/6
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Table 5-14 Virus isolation assay results post-challenge
C A T I 3 W E E K S  I 6 W E E K S  | 9  W E E K S  | 12 W E E K S  | 15 W E E K S
______________ Group 1 = DNA vaccine + llexi-IL-12 + ILRAP-IL-18__________
LI
L2
L3
L4
L5
L6
Group 2 = DNA vaccine + flexi-IL-12
Group 3 -  DNA vaccine + ILRAP-IL-18
L13
L I4
L15
L16
L17
L18
Group 4 = DNA vaccine
Group 5 = 2 X pCl-neo +  flexi-IL-12 + ILRAP-IL-18
Group 6 = PBS buffer
Table 5-15 Number o f positive VI results in vaccination groups post-challenge
V A C C IN E  G R O U P 3 W E E K S 6  W E E K S 9 W E E K S 12 W E E K S 15 W E E K S
vaccine + flexi-IL-12 + ILRAP-IL-18 0 /6 0 /6 0 /6 0 /6 0 /6
vaccine + flexi-IL-12 1/5 3 /5 3/5 3 /5 3/5
vaccine + ILRAP-IL-18 0 /6 0 /6 0 /6 0 /6 0 /6
vaccine 2 /6 4 /6 4 /6 4 /6 4 /6
2 X pCI-neo + flexi-IL-12 + ILRAP-IL-18 3 /6 3 /6 3 /6 3 /6 3 /6
PBS 3 /6 3 /6 4 /6 4 /6 4 /6
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Table 5-16 FeLV p27 ELISA and VI results on cultured bone marrow cells
CULTURED BONE MARROW 
CELL LYSATE
CULTURED BONE MARROW 
SUPERNATANT
CAT ELISA O.D ELISA S/P RESULT VI
Group 1 = DNA vaccine + flexi-IL-12 + ILRAP-IL-18
LI 0.41 0.365
L2 0.22 0.108
L3 0.14 0 - -
L4 0.14 0 - -
L5 0.14 0 - -
L6 0.15 0.014 - -
L8 1.48 1.444
L9 0.19 0.011
LIO 1.55 1.522
LI 1 1.50 1.467
L12 0.19 0.011
Group 2 = DNA vaccine + tlex i-IL -ll
Group 3 = DNA vaccine + ILRAP-IL-18
LI3 0.18 0
L14 0.18
L15 0.19 0.011
L16 0.18
L17
L18
0.19
0.19
0.011
0.011
L19 1.61 1.589 1
L20 0.19 0.011
L21 0.19 0.011
L22 1.77 1.767
L23 1.43 1.389
L24 1.68 1.667
Group 4 — DNA vaccine
L25 0.59 0.456
L26 1.73 1.722
L27 0.94 0.844
L28 1.23 1.167
L29 1.73 1.722
L30 0.20 0.022
Group 5 = 2 X pCI-neo + llexi-IL-12 + ILRAP-IL-18
L31 0.81 0.905
L32 1.03 0.944
L33 0.68 0.730
L34 0.75 0.824
L35 1.66 1.644
L36 0.23 0.056
Group 6 = PBS buffer
Table 5-17 Number o f positive p27 and VI results from bone marrow cell culture
VACCINE GROUP P27 ELISA OF BONE MARROW C/ L VI OF BONE MARROW S/N
vaccine + flexi-IL-12 + ILRAP-IL-18 2/6 2/6
vaccine + llexi-IL-12 3/5 3/5
vaccine + ILRAP-IL-18 0/6 1/6
vaccine 4/6 4/6
2 X pCI-neo + flexi-IL-12 + ILRAP-IL-18 5/6 5/6
PBS 5/6 6/6
C/L = cell lysate o f  cultured bone marrow cells 
S/N = supernatant o f  cultured bone marrow cells
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5.3.5 Assessment of DNA vaccines
It should be noted here that the small number o f  animals in each vaccination group 
restricted the statistical analysis o f the data produced. The efficacy o f the vaccine 
components were compared using p27 ELISA results shown in tables 5.11, 5.12 and 
5.13. The first two tables show the OD ELISA result o f each animal at sampling 
points post-challenge. The ELISA S/P ratio is also shown as well as an allocated 
positive or negative result. Table 5.13 shows the sum o f animals positive for p27 in 
each group at each time point.
Tables 5.14 and 5.15 show VI results between challenge and euthanasia. Table 5.14 
shows a positive or negative VI for each animal at each time point. Table 5.15 shows 
the number o f cats VI positive in each group at each time point.
Tables 5.16 and 5.17 show p27 ELISA and VI results performed on cultured bone 
marrow samples after euthanasia. Table 5.16 displays p27 ELISA OD, ELISA S/P 
ratio and an allocation o f a positive or negative result for ELISA and VI. Table 5.17 
shows the number o f  cats positive for p27 and VI o f cultured bone marrow cells in 
each vaccine group.
5.3.5.1 FeLV DNA vaccination alone does not protect animals from viral challenge
At 3 weeks post-challenge, plasma samples from group 4 (vaccine alone) and group 6 
(PBS buffer), demonstrated 2 out o f 6 and 3 out o f 6 virus positive cats respectively 
by p27 ELISA and VI. In both cases this increased to 4 cats by 6 weeks post­
challenge and remained at this level until the end o f the trial. Thus, group 4 
demonstrated the same level o f protection from challenge as the negative control 
group 6 animals. It can be concluded from this that the DNA vaccine when 
administered without adjuvants, did not produce any protective effect from viral 
challenge.
Neither o f the two remaining non-viraemic cats in group 4 (vaccine alone) was shown 
to harbour latent infection on bone marrow cell culture. However, both o f  the non- 
viraemic cats in group 6 (PBS) were latently infected. These results suggest that the 
vaccine may have stimulated an immune response sufficient to prevent viraemia in
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these cats. However, given the small number o f  animals involved in this experiment, 
no definite conclusions can be drawn from these data.
To conclude, the levels o f infection in group 4 suggest that the DNA vaccine alone is 
ineffective in providing protection against viraemia, but may stimulate sufficient 
immunity in some cats to prevent latent infection from developing into viraemia.
5.3.S.2 Cytokine constructs alone are not an effective FeLV vaccine combination
Animals in group 5 were each vaccinated with 200 pg o f  empty pCI-neo plasmid 
vector and 100 pg each o f flexi-IL-12 and ILRAP-IL-18. This group was therefore 
injected with the same vaccine combination as group 1 (vaccine + flexi-IL-12 + 
ILRAP-IL-18) apart from the cDNA encoding gag/pol and env antigens. This non­
specific vector DNA was included to establish whether the actual amount o f  DNA  
affected the magnitude o f the immune response stimulated. In addition, the vaccine 
combination o f group 5 was used to establish if  the cytokine constructs alone induced 
protection from challenge or whether their efficacy was via an adjuvant effect on the 
DNA vaccine with which they were administered.
Throughout the 15-week post-challenge period, 3 out o f 6 cats were viraemic in group 
5 with positive results for both VI and p27. Pairwise comparison with group 6 (PBS) 
shows that the cytokine constructs alone were not an effective vaccine against 
challenge even though there might have been a mild degree o f protection (3 o f  6 cats 
viraemic compared with 4 o f  6 cats). When group 5 was compared with group 1 
(vaccine + flexi-IL-12 + ILRAP-IL-18) where there was complete protection from 
viraemia, a statistical difference o f p=0.091 was detected. These results suggest that 
cytokine constructs flexi-IL-12 and ILRAP-IL-18 act by stimulating an adjuvant 
effect to the DNA vaccine with which they are inoculated. This potent effect is 
eliminated when the cDNA encoding the antigenic portion o f  the DNA vaccine is 
removed. These data also suggest that the actual amount o f  non-specific DNA used in 
the vaccine did not significantly affect the immune response elicited.
A similar pattern can be seen in the combination o f viraemic and latently infected 
animals where group 5 showed an infection rate o f 5 out o f 6 cats. When compared to
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group 6 (PBS) and group 1 (vaccine + flexi-IL-12 + ILRAP-IL-18) it is clear that the 
cytokines alone were not effective at protecting animals from challenge.
5.3.5.3 Flexi-IL-12 does not act as an adjuvant to FeLV DNA vaccination
Unfortunately one cat from group 2 (vaccine + flexi-IL-12) had to be euthanased 
during the trial leaving only 5 cats in this group. Of these animals, 1 cat became 
viraemic at 3 weeks post-challenge, which increased to 3 o f 5 cats for all subsequent 
time points until euthanasia. There was no statistical difference between this group 
and either group 4 (vaccine alone) or group 6 (PBS) at any time point.
At euthanasia, VI and p27 ELISA were performed on cultured bone marrow (BM) 
cells and cell lysate respectively in order to detect latent infection. As expected, bone 
marrow o f the 3 viraemic cats in group 2 produced virus. The 2 remaining non- 
viraemic cats, L9 and L I2, did not have latent virus suggesting that they were 
completely protected from infection. The combined total o f  viraemia and latency 
calculated for groups 2 (vaccine + flexi-IL-12), 4 (vaccine alone) and 6 (PBS), was 3 
o f 5 cats, 4 o f 6 cats and 6 o f 6 cats respectively. There was no statistical difference 
between group 2 and group 4 or 6 although the numbers suggest that vaccine + flexi- 
IL-12 may produce a mild degree o f  protection compared with inoculation o f PBS 
buffer alone.
These results show that in this experiment feline flexi-IL-12 did not act as an adjuvant 
to the FeLV DNA vaccine and the use o f  DNA vaccine with flexi-IL-12 did not 
produce effective protection against viraemia.
5.3.5.4 ILRAP-IL-18 Is an effective adjuvant to FeLV DNA vaccination
None o f the 6 animals in group 3 (vaccine + ILRAP-IL-18), showed any sign o f  
viraemia at any time point during the immunisation trial. Statistical analysis o f VI and 
p27 results by pairwise comparison o f  group 3 and group 4 (vaccine alone) at time 
points 6, 9, 12 and 15 weeks post-challenge gave a value o f  p=0.061. When the p27 
and VI results in group 6 (PBS buffer) were compared with group 3 (vaccine + 
ILRAP-IL-18) using the Fisher's exact test, a statistical difference was found at all 
timepoints for p27 and all timepoints after 9 weeks post-challenge for V.I (p=0.061).
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At the end o f  the trial, although no cats from group 3 (vaccine + ILRAP-IL-18) were 
positive for p27 ELISA on cultured BM cell lysate, one cat was positive for VI o f  the 
cultured BM cell supernatant. As mentioned previously, the combination o f  viraemia 
and latency in group 4 (vaccine alone) was 4 o f  6 cats. Pairwise comparison o f these 
groups 3 and 4 using Fisher's exact test did not produce a statistically significant 
result. However the relative number o f viraemic cats in each group does suggest that 
ILRAP-IL-18 functions as an adjuvant to the DNA vaccine. When the combined 
viraemia and latency o f  groups 3 and 6 (PBS) were compared using Fisher's exact 
test, a statistically significant result o f  p=0.008 was produced. This suggests that this 
vaccine combination o f DNA vaccine and ILRAP-IL-18 was effective at stimulating 
protection against viral challenge when compared with animals inoculated with 
vaccine buffer alone.
In conclusion, these data suggest that ILRAP-IL-18 plasmid acted as an adjuvant to 
the DNA vaccine, producing complete protection against viraemia and statistically 
significant protection against a combination o f viraemia and latent FeLV infection.
5.3.5.5 Flexi-IL-12 and ILRAP-IL-18 as adjuvants to FeLV DNA vaccination
Cats in group 1 were inoculated with vaccine, flexi-IL-12 and ILRAP-IL-18 plasmid 
DNA. During the 15-week post-challenge period, no cats in this group were positive 
for either p27 or VI. A pairwise comparison o f group 1 with group 4 (vaccine alone) 
and group 6 (PBS buffer) from 6 weeks post-challenge onwards produced a statistical 
result o f  p=0.061. This implies that the combination o f  flexi-IL-12 and ILRAP-IL-18 
acted as an adjuvant to the DNA vaccine and that the vaccine combination was 
effective in producing complete protection against persistent viraemia.
At euthanasia, latent infection was detected in 2 o f  the 6 cats in group 1 on both p27 
ELISA and VI. When combined viraemia and latency was compared with group 4 
(vaccine alone), the result was not found to be statistically significant although it does 
suggest that these cytokine constructs have an adjuvant effect on the vaccine. When 
the combined viraemia and latency o f group 1 and group 6 (PBS) were analysed, this 
produced a statistically significant result o f p-0.061. These results therefore suggest 
that the combination o f vaccine, flexi-IL-12 and ILRAP-IL-18 does show a degree o f  
efficacy against FeLV infection in this experiment.
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5.3.5.6 Clinical scoring system of vaccinated animals
A scoring system was devised to assess the efficacy o f  each vaccine combination 
using data produced from plasma and bone marrow samples. Each animal was given a 
score o f  either one or zero for seven different parameters depending on whether the 
result was positive or negative respectively. This produced a maximum score o f seven 
for each animal. The seven parameters were as follows: VI result on plasma at 3, 6, 9, 
12 and 15 weeks post-challenge, p27 ELISA result on cultured bone marrow cell 
lysate and VI result on cultured bone marrow supernatant.
The scores for each vaccination group were combined to give an overall score for 
animals in that group. This value represented the degree o f  viraemia and latent 
infection in each set o f individuals. These data are shown in table 5.18 and two bar 
charts were constructed (figures 5.8 and 5.9). Figure 5.8 is a bar chart comparing the 
overall clinical score for each vaccine group and figure 5.9 shows the mean clinical 
score in each group o f  animals along with the standard deviation for each group. As 
shown in the figures, the combined total clinical scores and the mean scores in group 
6 (PBS) was high and similar scores were produced in group 4 (vaccine alone), group 
5 (flexi-IL-12 + ILRAP-IL-18 alone) and group 2 (vaccine + flexi-IL-12). The clinical 
scores for group 3 (vaccine + ILRAP-IL-18) and group 1 (vaccine + ILRAP-IL-18 + 
flexi-IL-12) were significantly lower, indicating a lower level o f overall infection in 
these vaccine combinations. Pairwise comparisons o f total clinical scores were then 
made using Fisher’s Exact Test (table 5.19). The pattern o f  statistical difference 
between groups reflects comparisons o f  combined viraemia and latency. The vaccine 
with ILRAP-IL-18 and vaccine with ILRAP-IL-18 and flexi-IL-12 were statistically 
different to the negative control and the vaccine alone groups (p<0.001), whereas 
vaccine with flexi-IL-12 alone showed no statistical significance (p” 0.239 and 
p=0.485 respectively). Neither the vaccine alone nor the cytokines alone group 
demonstrated any statistical significance compared to the negative control group 
(p=0.817 and p=0.495 respectively), but the vaccine combined with cytokines was 
statistically significant compared with the cytokines alone (p<0.001). These data 
provide confirmation that neither DNA vaccine nor cytokines were effective vaccines, 
whereas vaccine in combination with ILRAP-IL-18 alone or ILRAP-IL-18 and flexi- 
IL-12 stimulated a high degree o f  protection against challenge.
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Table 5-18 Clinical scores o f  animals and groups in vaccination trial
VI POST-CHALLENGE BONE MARROW
CAT 3 WEEKS I 6 WEEKS | 9 WEEKS | 12 WEEKS | 15 WEEKS p27 C/L I VI S/N SCORE I TOTAL
Group 1 -  DNA vaccine + flexi-IL-12 + ILRAP-IL-18
LI - - - - - 2
L2 - - - - - 2
L3 - - - - - - - 0
L4 - - - - - - - 0
L5 - - - - - - - 0
L6 - - - - - - - 0 4
Group 2 = DNA vaccine + flexi-IL-12
Group 3 -  DNA vaccine + ILRAP-IL-18
6
0
7
6
0 19
L13 - - - - - - - 0
L14 - - - - - - - 0
L15 - - - - - - - 0
L16 - - - - - - - 0
L17 - - - - - - - 0
L18 - - - - - - 1 1
Group 4 = DNA vaccine
Group 5 = 2 X pCI-neo + flexi-IL-12 + ILRAP-IL-18
Group 6 — PBS buffer
27
2
7
2
7
7
0 25
7
2
6
6
7
1 29
C/L = cell lysate o f  cultured bone marrow cells 
S/N = supernatant o f  cultured bone marrow cells
Table 5-19 Pairwise comparisons o f  clinical scores using Fisher's Exact Test
Vaccine group vaccine alone flexi-IL-12 + ILRAP-IL-18 PBS
vaccine + flexi-IL-12 + ILRAP-IL-18 P<0.001 p<0.001 p<0.001
vaccine + flexi-IL-12 P=0.485 Not applicable p=0.239
vaccine + ILRAP-IL-18 P<0.001 Not applicable p<0.001
PBS P=0.817 P=0.495 Not applicable
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Figure 5-8 Barchart showing combined clinical scores for each vaccine group
35 I
I ■  Vaccine + flexl-L-12 + LRAP-IL-18
■  Vaccine + flexi- L -12 
30 I  H  V accine + ILRAP-L-18
■  Vaccine
□  2 X Neo + flexi-1-12 + ILRAP-IL-18 
B  PB S  buffer
Figure 5-9 Barchart showing mean clinical scores for each vaccine group
7- 1
n  Vaccine + llex)-L-12 * LRAP-L-18
■  Vaccine ♦ llexi-L-12 
■I Vaccine ♦ LRAP-L-18
■  Vaccine
□  2 x Neo ♦ llexi-L-12 ♦ LRAP-L-18 
n  PB S buffer
2 2 8
5.3.5.7 Virus neutralising and non-neutralising antibodies during trial
VNAb levels were measured before vaccination, on the day o f challenge and at the 
termination o f the trial. As detailed previously, there was no detection o f  antibodies 
up to and including the day o f  challenge indicating that the DNA vaccines failed to 
elicit VNAb prior to challenge. At week 15 post-challenge, the data shows that in 
general, animals negative for viraemia demonstrated the presence o f  VNAb and 
viraemic animals tended to be negative for VNAb (table 5.20). As recorded in table 
5.22, only one VI positive cat out o f 14 animals (7%) demonstrated VNAb and this 
was at a low level o f  16, whereas 18 o f  the 21 VI negative animals demonstrated 
VNAb (86%).
Western blot analysis o f complete viral lysate with plasma samples was performed to 
assess the presence o f  non-neutralising antibodies at day o f challenge and at the 
termination o f the trial. A scanned image o f the control and sample strips is shown in 
figures 5.10 and 5.11 respectively. As shown on the positive control strips, anti-p27 
(CA) and anti-gp70 (SU) antibody protein bands can be visualised. Some strips also 
demonstrate a smaller protein band which represents anti-pl5E ™ antibody.
Table 5.20 was assembled to assess the presence o f NNAb in each animal at the 
termination o f the trial. Also listed here was the viral status and level o f VNAb for 
each individual. A weak positive antibody band was represented by (+) and a strong 
band by +. Table 5.21 shows the number o f  cats in each vaccination group positive for 
each antibody. The percentage o f viraemic and non-viraemic animals positive for each 
antibody is listed in table 5.22.
It can be seen in table 5.21 that the vaccine combination administered to animals did 
not have any significant effect on the presence or the type o f antibody stimulated. The 
negative control group showed similar numbers o f  anti-gp70, p27 and p l5E  antibody 
positive animals compared to vaccinated animals. All cats inoculated with vaccine 
and ILRAP-IL-18 had anti-gp70 and p l5E  antibodies and all were protected from 
viraemia. This might be expected as VNAb are raised against these antigens and 
protected cats tend to demonstrate VNAb. However, all animals immunised with
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vaccine, ILRAP-IL-18 and flexi-IL-12 were protected from viraemia, but only 3 out 
o f 6 cats had anti-gp70 antibody.
When the proportion o f antibody positive viraemic and protected animals was 
compared (table 5.22), more protected animals had anti-gp70 antibody than viraemic 
animals (82% and 57% respectively). All protected cats were pl5E positive whereas 
only 64% o f viraemic animals demonstrated pl5E antibody. However, a higher 
proportion o f viraemic animals expressed anti-p27 antibody than protected individuals 
(79% and 52%).
Figure 5-10 Positive control western blot strips
Day o f challenge blot Euthanasia blot
I !
p27 gp70 p27 gp70
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Figure 5-11 Western blot strips o f  antibodies at day o f  challenge and euthanasia
D -  Day o f  challenge E = euthanasia
D E  D E  D E  D E  D E  D E
El L2 L3 L4 L5 L6
D E  D E  D E  D E  D E
L8 L9 LIO LU L12
D E  D E  D E  D E  D E  D E
L13 L14 L15 L16 L17 L18
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D E  D E D E D E D E D E
L19 L20
D E  D E
L25 L26 L27 L28 L29 L30
D E D E D E D E D E D E
L31 L32 L33 L34 L35 L36
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Table 5-20 Viral status and antibodies o f  animals at 15 weeks post-challenge
CAT
LI
L2
L3
L4
L5
L6
L20
L21
VI VNAb anti-gp70 Ab
Group 1 = DNA vaccine + flexi-IL-12 + ILRAP-IL-18
16
64
64
256
16
16
Group 2 = DNA vaccine + flexi-IL-12
0
64
16
1024
LI3 - 256
LI4 - 0
LI5 - 16
LI6 - 16
LI7 - 4
LI8 - 256
Group 3 -  DNA vaccine + ILRAP-IL-18
64
0
Grou p 6 = PBS buffer
1 0 -
1024
16
anti-p27 Ab anti-pl5E Ab
Group 4 = DNA vaccine
Group 5 = 2 X pC l-neo + flexi-IL-12 + ILRAP-IL-18
Table 5-21 Number o f animals antibody positive in each vaccine group
VACCINE GROUP VI VNAb anti-gp70 Ab anti-p27 Ab anti-pl5E Ab
vaccine + flexi-IL-12 + ILRAP-IL-18 0/6 6/6 3/6 5/6 6/6
vaccine + flexi-IL-12 3/5 3/5 3/5 4/5 4/5
vaccine + ILRAP-IL-18 0/6 5/6 6/6 2/6 6/6
vaccine 4/6 1/6 4/6 3/6 4/6
2 X pCI-neo + flexi-IL-12 + ILRAP-IL-18 3/6 2/6 5/6 3/6 6/6
PBS 4/6 2/6 5/6 5/6 4/6
Table 5-22 Antibody status o f VI positive and negative animals
VI STATUS % VNAb %  antigp70 % anti-p27 %  anti-pl5E
positive (14/35) 7(1/14) 57(8/14) 79(11/14) 64(9/14)
negative (21/35) 86(18/21) 82(18/21) 52(11/21) 100(21/21)
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5.4 DISCUSSION
5.4.1 In vitro expression of pUSE1'CMVT(gag/po/) and pUSE1 
CMVT(env>A)
As shown in 5.3.1.1, in vitro expression o f both plasmids comprising the FeLV DNA  
vaccine was demonstrated using fixed cell immunofluorescence. Only a very small 
proportion o f cells transfected with pUSE 1 'CMVT(gag/)9o/) or pUSErCMVT(e«Vy4) 
was found to express antigen by immunofluorescence. There are several reasons why 
this may have occurred. Firstly the 293T cells may have demonstrated an inefficient 
level o f  transfection. A transfection control o f  pEGFP-Cl plasmid DNA was carried 
out alongside the other transfections to monitor the transfection efficiency. The 
transfection efficiency was found to be at an acceptable level o f  between 20 and 30% 
so it is unlikely that the low proportion o f  cells expressing FeLV proteins was due to 
transfection efficiency. It is possible that either the plasmid constructs or the protein 
synthesised from them was toxic, leading to the death o f  potentially 
immunoflorescing cells. However, when transfected cells were viewed under the 
microscope there was no evidence o f  abnormal cell death. A likely alternative is the 
efficacy o f the monclonal antibodies used to detect the expression o f  FeLV proteins. 
The reason for this is that FEA cells infected with FeLV (FeLV-A cells) also 
demonstrated low levels o f immunofluorescence where all cells were infected with 
virus and contained large amounts o f both p27 and gp70 protein. Use o f  a higher 
concentration o f  monclonal antibody or a polyclonal antibody may have increased the 
level o f  immunofluorescence, but the quantity o f antibody available was severely 
limited preventing investigation o f  this problem.
5.4.2 in vitro expression of gag/poi constructs by Western blot 
analysis
The previous experiment using pU SE 1 "CMVT(gag/jc/oZ) and pU SE l‘CMVT(e«v^) in 
vivo, failed to demonstrate expression o f the vaccine in vitro [Hanlon, 1999]. It was 
therefore important that the expression o f  these plasmids was investigated prior to this 
in vivo experiment. If aberrant promoter sequence existed in these constructs, this
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could have an effect on the level o f protein expression. The gag/pol and envA genes 
were therefore cloned into pCI-neo and a comparison o f expression o f antigens by the 
different expression vectors was made by Western blot analysis.
The gag/pol and envA gene were cloned into pCI-neo and parallel transfections o f  
pCI-neo and pUSEl'CMVT constructs were performed. Expression o f  FeLV Env 
protein from either construct could not be detected by Western blot and therefore 
comparison o f  protein expression was not possible. The reason for this may have been 
that the level o f Env protein expressed by the cells was too low to be detected by this 
system. Alternatively as suggested above, the antibody concentration o f the gp70 
antibody may have been too low to detect Env protein. As a result, cloning o f  envA 
into pCI-neo is not discussed in this chapter.
Confirmation o f  p27 antigen expression by transfections o f both gag/pol constructs 
was demonstrated using Western blot analysis. This was initially attempted using 
streptavidin peroxidase method o f detection. Transfection supernatants and lysates 
were run on a nitrocellulose membrane, cut into strips and exposed to p27 specific 
monoclonal antibody. This method o f protein detection failed to demonstrate p27 
antigen expression, but the Western blot analysis system described in 2.2.11 was 
successful.
A 27kDa protein was evident in both transfection supernatants and cell lysates o f  
pUSE 1 " C M V T a n d  pC\-nQo{gag/pot). A glycosylated form o f  FeLV Gag 
protein is produced by initiation o f  translation upstream from the normal gag  
initiation codon. This produces Gag protein with an additional signal peptide, 
allowing protein secretion across the cell membrane [Dickson et a l  1985]. However, 
the p27 present in the transfection supernatant is not the glycosylated protein as the 
pUSErCMVT(g<3g/^o/) plasmid does not contain sequence upstream o f the gag  
initiation codon. In addition, secreted Gag protein is approximately 40kDa in size 
whereas this protein was 27kDa. This protein may represent the production o f  
recombinant retrovirus particles from gag/pol transfected cells. Env proteins have 
been shown to be unnecessary for virion assembly or budding, as normal appearing 
virions can be made and released in their absence [Dickson et al. 1982]. In addition, a 
previous study cotransfected pUSErCM VT(gag/^o/) and pUSE 1 'CMVT(e » ) into
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293 cells with a LacZ reporter gene. The transfection supernatant was harvested, 
filtered, and added to FEA cells. Recombinant virus was detected by LacZ expression 
using a p-galactosidase assay [Hanlon, 1999]. Therefore transfection o f cells with 
pUSErCMVT(gag4>o/) alone may allow the production o f recombinant retrovirus 
devoid o f Env proteins which would be detected as 27kDa protein using a p27 
monoclonal antibody.
In addition to the 27kDa protein band in the cell lysates, two large protein bands o f  
approximately 65kDa were also evident. Gag precursor molecules o f  approximately 
55kDa and 65kDa in size have been found to be synthesised in FeLV infected cells. 
p55 precursor consists p l2 , p l5  and p27 protein and p65 comprises plO, p l2 , p l5  and 
p27 protein [Meyer et al. 1995; Granoff and Webster, 1999]. The sizes o f the bands 
on the gel are difficult to estimate due to the large amount o f protein and low degree 
o f separation, but these bands may represent these Gag precursor molecules.
The amount o f p27 protein secreted into the culture fluid o f cells transfected by each 
construct was used as an indicator o f the level o f protein expressed from each gag/pol 
plasmid construct. One in two serial dilutions o f  supernatants from neat to 1:32 
showed no significant difference in protein expression o f each construct. This might 
be expected as the only difference between pUSELCMVT(gog/)9o/) and pCI- 
nQo{gag/pol) is in the plasmid backbone and pUSEl'CMVT expression vector is 
derived from pCI-neo. It was on this basis that pUSE 1 "CMVT(gag/^o/) and pUSEl" 
C M \T{envA ) plasmids were selected as the FeLV DNA vaccine in the immunisation 
trial. This is because these plasmids had been used successfully in a previous 
experiment [Hanlon et al. 2001], whereas there was no existing in vivo data o f the 
efficacy o f pCl-nQo(gag/pol) and pCl~x\&o{envA) as DNA vaccines.
5.4.3 Aims of the vaccination trial
The principal aim o f this study was to investigate further the role o f the cytokines IL- 
12 and IL-18 as vaccine adjuvants in vivo. Previous data had indicated that a 
combination o f plasmid constructs expressing IL-12 and IL-18 had provided a 
significant adjuvant effect when coadministered with a DNA vaccine for FeLV
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[Hanlon et al. 2001]. In that study, the DNA vaccine alone protected only 2 o f  6 cats 
from viraemia whereas the combination o f  vaccine with both cytokines elicited 
complete protection. The vaccine with both cytokines demonstrated latent infection in 
1 cat compared with 4 cats in the vaccine alone group. The vaccine with IL-12 alone 
was not found to be effective. These data suggest that either IL-18 was acting alone or 
that the combination o f both cytokines acted synergistically in providing an adjuvant 
effect to the DNA vaccine [Hanlon et al. 2001].
In that study, the lack o f a group injected with IL-18 alone in combination with the 
DNA vaccine prevented the relative role o f  each cytokine from being established. The 
current study used the same DNA vaccine with both cytokines alone and in 
combination in order to establish which component provided the biological effect in 
vivo. As described in Chapters 3 and 4, the cytokine constructs used in the previous 
trial have each been refined to overcome potential problems o f antagonism and 
secretion. In the case o f  IL-12, cDNA encoding subunits p40 and p35 were linked by 
cDNA encoding a synthetic polypeptide linker sequence. This was to prevent the 
formation o f  p40 homodimer molecules which theoretically can antagonise the 
biological effect o f  the heterodimer. With IL-18, cDNA o f  the mature molecule was 
fused to cDNA encoding the signal sequence o f  the human IL-ip gene, IL-ip receptor 
antagonist protein (ILRAP) to allow secretion o f protein from transfected cells. In 
both cases, in vitro expression was demonstrated using Western blot analysis and in 
vitro bioactivity was shown using bioassays specific to each cytokine.
5.4.4 Viral challenge
Several methods o f viral challenge have been used in FeLV vaccination experiments. 
Intraperitoneal inoculation o f  virus has the advantage o f overcoming the resistance to 
FeLV infection which develops with age [Hoover et al. 1976] and is therefore useful 
in older animals. Natural infection may be simulated by oronasal inoculation o f virus, 
as FeLV is mainly spread by saliva and nasal secretions [Hoover et al. 1977]. Field 
conditions o f FeLV disease are most effectively represented experimentally by 
exposing vaccinates to persistently viraemic cats. It is vital however that the correct 
proportion o f infected cats to vaccinates are used, to guarantee sufficient exposure to 
virus. Lafrado et al. used 5 viraemic cats with 26 vaccinates and produced only 4%
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persistent infection [Lafrado et a l  1994], The previous study used intraperitoneal 
viral challenge and one o f  the aims o f this experiment was to use a more natural form 
o f  viral exposure. Therefore to ensure each animal was exposed to a standard amount 
o f  virus, oronasal inoculation o f  virus was used as the route o f  administration.
As the low number o f  subjects in each group presented difficulties in statistical 
analysis, is was crucial that a high proportion o f  the negative control group became 
viraemic from challenge. In studies such as this, the dose o f  virus used for FeLV 
challenge is difficult to establish, as a standard protocol has never been described. To 
highlight this problem, table 5.1 shows previously performed FeLV vaccination 
studies and the protocols used to expose animals to virus after vaccination. These data 
show clearly that the efficacy o f  viral challenge varies widely according to dose, age 
o f exposure, type o f virus used, route o f  administration and the way viraemia is 
defined. This presents great difficulty, not only in selecting an appropriate method o f  
challenge and also comparing the efficacy o f  different vaccines in these studies.
The dose o f  virus for the current study was selected on the basis o f an experiment 
performed by Harbour et a l  [2002], where a dose o f 4 x 10  ^f.f.u. administered in four 
equal doses on days 0, 2, 4 and 8, produced persistent viraemia in 83% o f  15-17 week 
old kittens. In this study, 4 out o f  6 cats became persistently infected after challenge. 
This was considered a satifactory level o f viraemia and the remaining two cats were 
found to be latently infected at euthanasia.
In conclusion, the dose o f  virus administered by the oronasal route was found to be a 
simple, reliable and robust form o f  challenge. In future work, a slightly higher viral 
dose to ensure 100% persistent viraemia could be considered. This method o f  
challenge could also be combined with persistently infected challenge animals to 
provide an additional source o f natural infection to animals in the immunisation trial.
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5.4.5 The role of IL-12 as an adjuvant to DNA vaccination to FeLV
It is clear from the results produced from group 2 that IL-12 did not act as an adjuvant 
to the FeLV vaccine. As mentioned earlier however, the small number o f  animals in 
each vaccination group allowed only limited statistical analysis. The fact that one cat 
in this group also had to be euthanased during the experiment added further difficulty 
in the analysis o f the data produced.
However, o f the five animals in group 2, three were persistently viraemic at 15 weeks 
post-challenge compared to four out o f  six cats inoculated with vaccine alone (group 
4) and PBS buffer (group 6). In terms o f  viraemia combined with latency, group 2 
demonstrated 3 out o f 5, group 4 contained 4 out o f 6, and group 6 showed all 6 out o f  
6 cats to be infected. As in the previous study [Hanlon et a l  2001], the 
coadministration o f IL-12 plasmid with DNA vaccine appeared to produce no 
additional protective effect compared to the vaccine alone.
There have been many studies using IL-12 to either increase or modulate the immune 
response elicited to pathogens and vaccination against pathogen. The role that IL-12 
plays in upregulation o f the cell mediated immune response has been found to play an 
important role in defence against infection with pathogens. This stimulation o f  
immunity has led to the use o f IL-12 in combination with vaccination to both enhance 
and alter the nature o f the immune response elicited. This has produced successful 
immune responses in certain viruses, bacteria and protozoa.
However, some studies using IL-12 as an adjuvant have either failed to elicit any 
effect or have even produced adverse responses in vivo. One experiment used IL-12 
subunits encoded by separate plasmids in combination with an IL-18 plasmid, as 
adjuvants to a DNA vaccine to FIV. The same level o f  protection against FIV 
challenge was shown with both IL-12 and IL-18 together as with IL-18 alone. The 
virus-specific CTL responses were measured in each case and the inclusion o f IL-12 
was found to have no effect on the magnitude o f  the immune response produced 
[Dunham et a l  2002]. In another study, the immune response to a DNA vaccine for 
Leishmania major was not enhanced by the coadministration o f a plasmid encoding 
murine flexi-IL-12. In contrast, the use o f murine flexi-IL-12 alone stimulated a
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protective effect in mice [Noormohammadi et al. 2001]. The use o f  an IL-12 plasmid 
with a DNA vaccine increased the susceptibility o f cats to feline infectious peritonitis 
virus [Glansbeek et al. 2002]. Similarly, the use o f  a single chain IL-12 plasmid was 
also shown to elicit significant suppression o f  protective immunity to a DNA vaccine 
for Japanese encephalitis virus (JEV) [Chen et al. 2001].
It has been shown that IL-12 can elicit suppression o f  both humoral and cell mediated 
immunity. Further investigation by Chen et al. found that IL-12 cDNA produced a 
dramatic decrease in antibodies specific to JEV. This effect was dose dependent and 
the suppressive effect in mice was produced after a single inoculation at the initial 
priming stage o f  vaccination. The vaccine induced predominantly IgG2a antibodies 
with IM vaccination and IgGl following gene gun administration, both o f  which were 
abrogated by the coadministration o f  IL-12 cDNA [Chen et a l  2001]. Decreased 
levels o f antibodies were also observed with the coinoculation o f IL-12 cDNA with 
FIPV DNA vaccine [Glansbeek et a l  2002].
Cell mediated immunity was also shown to be suppressed in some o f  these cases. The 
coinoculation o f  IL-12 with JEV DNA vaccine decreased the proliferative response o f  
JEV-specific T cells and stimulated lower IFNy production compared with the vaccine 
alone [Chen et a l  2001]. Similarly, lower levels o f peripheral blood leucocytes were 
observed in kittens post-vaccination when IL-12 was included compared to when 
FIPV vaccine was given alone [Glansbeek et a l  2002].
Some studies have suggested that this immunosuppression may be related to the dose 
o f IL-12 plasmid used. High doses o f  recombinant murine IL-12 increased the 
susceptibility o f  mice to lymphocytic choriomeningitis virus whereas lower doses 
induced an enhancement o f the immune response to the virus [Orange et al. 1994]. A  
recombinant adenovirus expressing IL-12 was shown to potentiate the cell mediated 
immune response to a hepatitis C vaccine, but at higher doses o f IL-12 this adjuvant 
effect was abrogated. This immunosuppression was accompanied by a dramatic 
increase in IFNy, nitric oxide (NO) and apoptosis in the spleen [Lasarte et al. 1999]. 
A similar effect was observed using a recombinant vaccinia virus expressing the env 
gene o f HIV-1 and IL-12. When an additional booster o f IL-12 was given, the
240
impairment o f  immune responses was associated with an IL-12-stimulated increase in 
NO levels. This suppression was overcome by the use o f NO synthesis inhibitors 
[Gherardi et a l  2000]. The stimulation o f IFNy production by IL-12 has been shown 
to increase the levels o f  nitric oxide synthesis by macrophages [Waldburger et a l  
1996]. Nitric oxide inhibits the proliferation o f T cells by reducing tyrosine 
phosphorylation o f JAK3 and STAT5 molecules which may help to explain the 
immunosuppression induced by IL-12 [Bingisser et a l  1998].
Increased levels o f  IL-12 local to the area o f immunisation may have also contributed 
to an impaired immune response. High levels o f IL-12 have been associated with 
immunotoxicities corresponding to inhibition o f  T cell expansion and CTL activation 
[Orange et a l  1995]. In a study performed by Chen et a l,  IL-12 plasmid stimulated 
immunosuppression when coinoculated with JEV vaccine, but not when the vaccine 
and cytokine were administered simultaneously at different sites [Chen et a l  2001]. 
This suggests that a high level o f IL-12 in the local muscle may have had an 
inhibitory effect on the immune pathway at the site o f administration.
The timing o f IL-12 inoculation was in certain cases found to be crucial. 
Immunosuppression was induced when IL-12 was given before or together with JEV 
vaccine, but not if  administered after immunisation [Chen et a l  2001]. Further to this, 
Noormohammadi et a l  extended their study to show that administration o f IL-12 
cDNA 4 days after the DNA vaccine to L. major, decreased the immunosuppressive 
effect o f IL-12 [Noormohammadi et a l  2001]. This was associated with an increase in 
the level o f IFNy producing T cells.
One o f the major modifications to the previous FeLV DNA vaccination study was the 
use o f an IL-12 construct comprising the p35 and p40 subunits encoded by separate 
expression vectors [Hanlon et a l  2001]. The IL-12 construct in this case did not act as 
an effective adjuvant to the DNA vaccine and it was suggested that this may be due to 
p40 homo dimer formation which may have inhibited the action o f this construct 
[Hanlon, 1999]. It was for this reason that an alternative IL-12 construct was cloned. 
Flexi-IL-12 prevents the production o f  p40 homodimer formation by fusion o f  the two 
subunits using a synthetic polypeptide linker sequence [Anderson et a l  1997] and as
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described in Chapter 3, this construct showed in vitro protein expression and 
bioactivity. When used in this immunisation study in vivo however, this construct also 
failed to act as an effective vaccine adjuvant. This suggests that p40 homodimer 
formation in the previous experiment was not responsible for the lack o f in vivo 
efficacy o f  this construct.
To conclude, these data suggest that various parameters may have inhibited the 
adjuvant effect o f  feline flexi-IL-12 in this experiment. The timing o f IL-12 
administration may have affected both the magnitude and the type o f  immune 
response elicited. Also the response to the cytokine construct may have been affected 
by coadministration, administering the vaccine and flexi-IL-12 at different points may 
have altered the immune response. In addition, optimisation o f  the dose o f  IL-12 may 
also have enhanced the response, resulting in a higher level o f protection.
5.4.6 The role of IL-18 as an adjuvant to DNA vaccination to FeLV
Animals in group 3 were inoculated with FeLV DNA vaccine and ILRAP-IL-18 
plasmid construct. Throughout the post-challenge period all cats in group 3 were 
negative for viraemia, both on VI and p27 antigen ELISA. When the bone marrow o f  
animals was analysed, one cat o f six was harbouring virus from group 3 compared to 
all six animals from group 6 (PBS buffer). This result was statistically significant 
using the Fisher's exact test, suggesting that DNA vaccine together with ILRAP-IL- 
18 plasmid provides effective protection against FeLV infection in the bone marrow.
The biological functions o f  IL-18 make this cytokine an appropriate candidate for use 
in this in vivo situation. Overall, this pleotropic cytokine is an important mediator o f  
cell mediated immunity and Thl responses and these functions have great potential 
when applied to DNA vaccination. There are many examples demonstrating the 
success o f IL-18 cDNA as an adjuvant to DNA vaccination. The predominant effect 
o f  IL-18 as an adjuvant is the stimulation o f a Thl orientated response. This can be o f  
great value in vaccines against intracellular pathogens such as viruses, bacteria and 
protozoa. For example, intradermal injection o f  a plasmid encoding murine IL-18 and 
its natural signal peptide produced a lower humoral response but a greater cellular
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response to Mycobacterium bovis Bacillus Calmette-Guerin [Kremer et a l  1999], 
This construct was also used in a vaccine for Schistosoma mansoni, which requires a 
Thl response to elicit protection. A DNA vaccine to S. mansoni codelivered 
intradermally with IL-18 plasmid produced significant protection from challenge 
[Dupre et a l  2001]. Similarly IL-18 cDNA was shown to upregulate the cell mediated 
immune response to DNA vaccines for HIV-1. Coinjection o f  IL-18 decreased by 2 
weeks the time taken to induce a CTL response which corresponded to an 
enhancement in lymphoproliferative responses specific to the vaccine encoded 
antigen. In contrast, antibody titres against viral proteins were decreased, 
demonstrating a Thl biased immune response [Billaut-Mulot et a l  2001a].
The IL-18 plasmid used in this trial consisted o f feline mature-IL-18 cDNA fused to a 
signal sequence for the human IL-lp gene, IL-1(3 receptor antagonist protein 
(ILRAP). Preliminary work shown in chapter 4 confirmed strong in vitro expression 
and bioactivity o f this construct using Western blot analysis and a KG-1 assay 
respectively. O f particular importance was the evidence o f secretion o f  bioactive 
protein into the transfection supernatant which was not evident in feline mature IL-18 
alone. The in vivo data produced in this chapter implies that ILRAP-IL-18 also 
functions competently in a biological system, producing IL-18 protein capable o f  
stimulating the immune system.
O f interest was the comparison in expression and activity between ILRAP-IL-18 and 
PsecI-IL-18, a construct used in the previous DNA vaccination trial for FeLV. 
Western blot analysis using rabbit anti-equine antibody showed minimal levels o f  
PsecI-IL-18 protein expression within the cell and no evidence o f  protein in the 
supernatant, which corresponded with background levels o f bioactivity on the KG-1 
assay. In the previous study. Northern blot analysis demonstrated significant mRNA 
expression o f this construct [Hanlon, 1999] and when this plasmid was used in vivo, a 
significant biological effect was evident [Hanlon et a l  2001]. Unfortunately this 
previous vaccination study did not include a group immunised with vaccine and 
PsecI-IL-18 alone. However, when the group inoculated with vaccine and IL-12 was 
compared with the vaccine with the combination o f IL-12 PsecI-IL-18, the inclusion 
o f  the IL-18 plasmid appeared to induce an additional adjuvant effect.
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5.4.7 The role of the combination of IL-12 and IL-18 in FeLV DNA 
vaccination
Animals in group 1 (vaccine with IL-12 and IL-18) showed no evidence o f viraemia 
at any point post-challenge, detected by p27 ELISA and V I  However, animals 
injected with the vaccine and IL-18 also demonstrated complete protection against 
challenge. Therefore it was not possible to establish whether IL-18 was solely 
responsible for the vaccine adjuvant effect, or whether IL-12 enhanced the immune 
response even further, as both combinations were completely protective against 
viraemia. The fact that group 2 (vaccine and IL-12) displayed no statistical difference 
compared to the control group however, suggests that IL-12 was not an effective 
adjuvant. Therefore it is more likely that in group 1, IL-18 was an effective adjuvant 
and IL-12 induced no additional immune response.
Both IL-12 and IL-18 are cytokines which promote the cell mediated immune 
response by their separate ability to bring about the induction o f IFNy production. 
Both molecules alone are able to stimulate low levels o f IFNy production, but each 
can act with costimulatory factors to induce much higher levels. Binding o f IL-12 to 
its cell surface receptor stimulates the signalling pathway o f ST AT 3 and ST AT 4 
[Jacobsen et a l  1995] which then translocate to the nucleus and bind to promoter 
regions on the genome, including the IFNy promoters. IL-12 requires the presence o f  
costimulants to activate the AP-1 binding site o f  the IFNy promoter [Barbulescu et a l  
1998]. IL-18 is also able to augment the production o f IFNy from T cells and is more 
potent than IL-12 in stimulating its production [Okamura et al. 1995]. The signalling 
pathway o f this cytokine uses the adaptor molecule MyD88 which initiates the IRAK 
pathway, stimulates TRAF6 with the activation o f NF-kB and translocation to the 
nucleus [Robinson et a l  1997; Kojima et al. 1998; Takeuchi et a l  2000]. The 
production o f IFNy by IL-18 is also greatly enhanced by the use o f costimulants 
[Fantuzzi et a l  1998] but unlike IL-12, IL-18 alone produces strong activation o f the 
AP-1 site o f the IFNy promoter [Barbulescu et a l  1998].
These two cytokines via their separate pathways have been shown to act together in 
the synergistic production o f IFNy from both T cells [Micallef et al. 1996], and NK
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cells [Zhang et a l  1997]. Studies have also shown that B cells can also produce IFNy 
by stimulation with both IL-12 and IL-18 [Yoshimoto et a l  1997]. It has been 
demonstrated that IL-12-stimulated T and B cells show increased expression o f IL-18 
receptor, suggesting that IL-12 up-regulates the responsiveness o f cells to IL-18 in 
this way [Yoshimoto et a l  1998]. One study used murine mammary carcinoma cells 
expressing IL-12 and IL-18 by transduction with an 1RES IL-12 construct and murine 
mature-IL-18. Immunisation o f  these cells induced synergistic protection o f  70% mice 
from carcinoma cells inoculated at a distant site [Coughlin et al. 1998].
The results from this study however indicate that the DNA vaccine with ILRAP-IL-18 
alone (group 3) was able to provide protection from FeLV, without the requirement o f  
flexi-IL-12. It is possible that the inclusion o f  IL-12 upregulated the expression o f IL- 
18 receptor on cells, potentiating the activity o f IL-18 in vivo. From the viraemia data 
however, it is not possible to establish this, as both ILRAP-IL-18 alone and in 
combination with flexi-IL-12 induced complete protection from challenge.
5.4.8 Virus neutralising and non-neutralising antibodies produced 
against FeLV
Until the day o f challenge, there was no detection o f VNAb in any vaccinated cats. 
This confirms data produced in the previous trial where no VNAb were detected prior 
to inoculation o f virus [Hanlon et a l  2001]. As certain cats in this study were 
protected against challenge, this implies that an immune response was developed in 
the initial absence o f  VNAb.
The active stimulation o f  VNAb has been shown to have a strong correlation with 
resistance to infection with FeLV [Hardy et a l  1976]. Kittens can also be protected 
from infection by the passive transfer o f  VNAb from the mother's milk [Jarrett et 
a l\9 1 1 ] .  This however is not universal: VNAb have been shown not to be essential 
for FeLV protection and VNAb may be found in cats persistently infected with virus 
[Charreyre and Pedersen, 1991; Rojko and Hardy, 1994]. In addition, it has been 
noticed from monitoring VNAb test results that none o f the FeLV vaccines currently 
available in the UK induce consistent VNAb titres immediately after vaccination but
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only on recovery from challenge [Jarrett et a l  2001]. This suggests that the cellular 
branch o f  the immune response may play an important role in protection from 
infection. Confirmation o f this was seen in the previous DNA vaccine experiment 
where protected cats expressed higher FeLV specific CTLs than viraemic animals 
[Flynn et al. 2000a]. A previous study also showed that FeLV-specific CTLs were 
detected much earlier than VNAb in FeLV protected cats [Flynn et a l  2002].
When the VNAb levels at the termination o f  the experiment were analysed, it was 
found that o f  the 14 viraemic cats, only one, LI 1, demonstrated a VNAb titre. As 
mentioned, viraemic cats have been shown to demonstrate VNAb [Charreyre and 
Pedersen, 1991] and it may have been that the level o f antibody produced was 
insufficient to resist viral infection in this case. O f the 21 protected animals, 18 (86%) 
demonstrated detectable VNAb titres. This confirms the general correlation between 
FeLV protection and VNAb levels. However, as stated previously, VNAb are not 
essential for protection [Charreyre and Pedersen, 1991], and no VNAb was detected 
in cats LI4, L20 and L30, all o f  which were protected from viraemia. It is possible in 
these cases that cell mediated immunity may have contributed to protection, but it is 
not possible to confirm this hypothesis as samples to analyse virus specific CTL 
levels in animals were not collected.
Detection o f non-neutralising antibodies (NNAb) was carried out on plasma samples 
on the day o f  challenge and at the termination o f the experiment. On the day o f  
challenge there was no detection o f antibodies to any o f the viral antigens. However, 
at 15 weeks post-challenge, antibodies to gp70, p27 and p l5E  antigen could be 
visualised on Western blot analysis. It has been established that neutralising 
antibodies to FeLV are raised to the envelope proteins gp70 (SU) and p l5E  (TM) 
antigens [Rojko and Olsen, 1984; Rojko and Kociba, 1991]. It is difficult to compare 
VNAb and NNAb levels o f anti-gp70 and anti-pl5E due to the different systems used 
to assay each parameter. It might be expected that an animal with a high VNAb titre 
would demonstrate detectable gp70 and p l5E  NNAb levels as it is antibody to these 
antigens which confer neutralisation o f virus. However, the neutralising antibody 
level may be below the threshold o f sensitivity o f  Western blot analysis. This may be 
the case in cats LI, L5 and L6, where a low VNAb titre o f 16 was displayed with no 
antibody to gp70 visible by Western blot analysis. However all these cats
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demonstrated p l5E  antibodies which may have induced viral protection. The fact that 
more protected cats demonstrated gp70 antibody than viraemic cats (82% compared 
to 57%) might also be expected. However, non-neutralising antibodies raised to gp70 
also occur which makes this difficult to assess. Similarly, all protected cats showed 
detectable p l5E  antibody compared to 64% o f  viraemic cats. Again, the antibody 
detected may be neutralising or non-neutralising depending on the epitope to which 
the antibody is raised, which makes these proportions difficult to analyse.
Antibodies raised to p27 (CA) antigen were also detected on Western blot analysis. 
These antibodies are not thought to confer protection against FeLV and these results 
show that more viraemic cats were positive for p27 than those which were protected 
(79% compared to 52%). Viraemic animals will have had long term exposure to p27 
antigen, not only from viral infection but also from the release o f  p27 antigen into the 
blood. Therefore it might be expected that a larger proportion o f viraemic cats will 
show anti-p27 antibodies compared to non-viraemic animals.
5.5 Conclusion
In summary, the work in this chapter shows an in vivo study using IL-12 and IL-18 
cytokine constiucts which in vitro demonstrated protein expression, secretion and 
bioactivity. The constructs were used in combination with a FeLV DNA vaccine in a 
vaccine trial to investigate the ability o f  each cytokine alone and together to act as 
vaccine adjuvants. The ILRAP-IL-18 construct acted as an effective adjuvant, 
producing complete protection o f  animals against FeLV viraemia and protection o f 5 
out o f 6 animals against latent viral infection. The flexi-IL-12 construct was not found 
to act as an effective vaccine adjuvant. When both cytokines were inoculated together, 
this combination demonstrated complete protection from viraemia and protected 4 out 
o f 6 cats from latent infection. This beneficial cytokine effect was only produced 
when coinoculated with DNA vaccine, and the vaccine alone stimulated no protective 
effect. Overall, this is suggestive that ILRAP-IL-18 is initiating the dominant adjuvant 
effect when used in combination with flexi-IL-12 in this in vivo vaccination study.
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CHAPTER 6: IMMUNOTHERAPY TRIAL
6 IMMUNOTHERAPY TRIAL
6.1 INTRODUCTION
6.1.1 Immunotherapy of FeLV
As described in the previous chapter, the use o f an FeLV DNA vaccine with ILRAP- 
IL-18 was found to be highly effective at providing immune protection against viral 
challenge. It was therefore deemed worthwhile to investigate the effect o f this vaccine 
on the viral load o f persistently infected cats. Consequently, four persistently viraemic 
animals from the negative control group o f  the vaccination trial were inoculated three 
times at weekly intervals and the viral status o f the animals was monitored.
An immunotherapeutic agent for persistently infected animals must have the ability to 
overcome both the high level o f infection and the immunosuppression which is 
associated with this disease state. Persistently infected animals harbour high viral 
loads and a large proportion o f  cells are infected with virus. Furthermore, it is well 
documented that these individuals rarely develop virus neutralising antibodies 
[Russell and Jarrett, 1978b; Flynn et aL 2002], and that the virus specific CTL 
response is significantly lower when compared with recovered animals [Flynn et a l  
2002]. The observation that recovered cats express antibodies to envelope proteins but 
not Gag proteins, has led to the suggestion that viral immunoevasion may occur. 
Glycosylated Gag protein released from the cell may induce anergy, inhibiting a CTL 
response [Jarrett, 1999]. As yet, however, the mechanism behind this 
immunosuppression o f viraemic animals is unknown.
Several studies have adopted an immunotherapeutic approach to the treatment o f  
FeLV infection. One experiment used staphylococcal protein A columns in the 
removal o f IgG and circulating immune complexes from FeLV-infected cats with 
lymphosarcoma. Of the sixteen cats, complete viral clearance and long-term tumour 
regression was elicited in nine, and tumour regression without clearance o f virus was 
demonstrated in a further two cats [Snyder et a l  1989].
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Recent work has investigated the use o f immunomodulation therapy in the treatment 
o f clinically ill FeLV-infected cats. Animals were treated with Staphylococcus protein 
A (SPA), oral IFNa or a combination o f both therapies. Significantly more pet owners 
observed improvement in the animals’ health with SPA than control animals. 
However, other than subjective observation, no changes in the clinical parameters o f  
the cats were observed including FeLV status and survival time [McCaw et a l  2001]. 
A study using the combination o f IFNa, zidovudine (AZT) and lectin/IL-2 activated 
lymphocytes was found to clear viral infection in 4 o f 9 animals, despite the 
production o f anti-IFNa antibodies. Lymphocytes from this study were taken from 
putative histocompatible recovered cats that had been exposed to live FeLV virus. 
This effect was associated with the development o f VNAb and 3 o f  these cats 
remained virus negative until the end o f  the experiment, 95 days after treatment. This 
effect was not seen in animals exposed to activated lymphocytes without IFNa or 
AZT therapy [Zeidner et al. 1995]. Similarly, another study used autologous popliteal 
lymph node cells to treat persistently infected cats. Lymph node cells were cultured in 
vitro in the presence o f  IL-2 and were administered intravenously back into the same 
cat. Clinical improvement was recorded in nine o f sixteen animals and four o f these 
became FeLV antigen negative [Blakeslee et al. 1998]. Finally the use o f  a 
paramunity inducer consisting o f  inactivated parapox ovis virus is a commonly used 
drug for FeLV immunotherapy in Germany and other European countries. Several 
trials however have shown no statistical difference between this drug and a placebo in 
terms o f rate o f  viraemia in infected cats [Hartman et al. 1999].
These studies show that in a proportion o f cases, immunosuppression o f persistently 
infected cats can be overcome with the use o f immunotherapy. It has been postulated 
that since the FeLV DNA vaccine with ILRAP-IL-18 was effective in FeLV 
prophylaxis, it might also have a beneficial effect in viraemic cats through the 
appropriate presentation o f FeLV antigens to the immune system and the development 
o f a cell-mediated immune responses.
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6.1.2 Assessment of viral activity
In the previous chapter, the screening o f  plasma o f experimental animals used virus 
isolation as the definitive way o f identifying FeLV viraemia. The vaccination trial 
only required a positive or negative VI result to ascertain the ability o f  vaccines to 
protect against challenge. However, under certain circumstances the degree o f  
retroviral infection may be crucial. This is o f vital importance in research into the 
treatment o f  HIV, where assessment o f viral status is a reflection o f the efficacy o f  the 
antiretroviral therapy.
The evaluation o f viral status requires the measurement of parameters which relate 
accurately to the extent o f infection. This is reviewed in detail by Clementi [2000]. In 
the case o f retroviruses, several quantifiable parameters have been identified based on 
the dynamic processes o f productive infection. The extent o f infection may depend on 
the number o f  infected target cells, the level o f  viral production within those cells and 
the release o f  infective viral particles. Therefore infection may be measured by the 
proviral copy number or proportion o f  infected cells, the level o f  RNA transcription 
and the plasma viral load respectively.
6.1.2.1 Proviral copy number
The relationship between PBMC proviral copy number and level o f FeLV infection 
has been studied by Flynn et a l  [2002]. This work showed that proviral DNA was 
first isolated in animals 1 week after viral challenge and recovered cats had lower 
copy numbers o f  provirus than persistently viraemic animals. Interestingly, the 
proviral levels during the study were not found to correspond to the level o f p27 
antigen detected by ELISA [Flynn et a l  2002].
6.1.2.2 RNA transcriptional activity
One study measured the genomic RNA copy number o f  HIV-1 in plasma and the level 
o f  HIV-1 transcript copy numbers in peripheral blood CD4^ T lymphocytes in 
untreated patients and those using anti-HIV therapy [Bagnarelli et a l  1994]. Patients 
showed stable RNA levels in the latent clinical phase o f infection with dramatically
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lower levels in those who had undergone therapy. This suggests that as an indirect 
parameter, the transcriptional activity o f provirus in cells may also correlate with the 
level o f  viral infection.
6.1.2.3 Viral loads in plasma
The amount o f  virus present in the plasma has been shown in various studies to vary 
in different stages o f infection. The quantity o f  FIV RNA in the plasma was related to 
the clinical stage, rate o f progression and survival time in FIV infected cats [Goto et 
a l  2002]. Another study assessed the level o f  cytomegalovirus (CMV) in the plasma 
o f individuals with AIDS. Those testing positive for CMV were found to have a 3.4- 
fold higher chance o f developing clinical disease and a 2.5-fold increased rate o f  
death compared to CMV negative individuals. In virus positive cases, a 10-fold 
increase o f CMV in the plasma was found to have a 3.1-fold and 2.2-fold increase in 
disease rate and mortality respectively [Spector et a l  1998].
However conflicting studies have questioned whether these various parameters o f  
viral activity correlate with each other. One study found that the mean RNA HTV 
copy number per infected cell was constant, irrespective o f the viral load in the 
plasma, although a correlation was found between the proportion o f HIV-infected 
cells in the lymphoid tissue and the plasma viral load [Hockett et a l  1999].
6.1.3 Assays used to quantify viral status parameters
Assays used to quantify viral loads are reviewed by Clementi [2000]. These assays are 
required to be sensitive at both high and low virus levels, robust and reproducible, as 
well as rapid and easy to perform. In addition, absolute levels o f  virus must be 
determined rather than relative values between samples. There are very few assays 
which serve all o f these criteria and most are based on PCR amplification as 
summarised below.
2 5 1
6.1.3.1 Competitive PCR
Conventional PCR allows specific and sensitive amplification o f  nucleic acid 
fragments in samples. However, it does not allow the product to be quantified and as 
yields increase exponentially with each cycle o f amplification, small changes in 
variables can dramatically influence the amount o f  product generated.
Competitive PCR is a system that allows reasonable quantification o f  the RNA or 
DNA product. This technique employs a competitor DNA fragment that differs from 
the DNA o f  interest by including a small intron or a mutated enzyme site. Primers 
amplify constant ratios o f each fragment and these fragments can be quantified 
[Gilliland et al. 1990]. Competitive reverse-transcription PCR was used successfully 
to monitor the plasma viral loads o f  cats inoculated with a DNA vaccine against FIV 
env gene [Richardson et al. 1997]. However, this system is relatively complex and 
requires experienced operators to produce reliable results.
6.1.3.2 Branched-DNA in situ hybridisation
An alternative to competitive PCR is branched-DNA (bDNA) in situ hybridisation. 
This is a signal amplification system where target DNA or mRNA is hybridised in a 
microtitre plate well to a series o f  synthetic branched oligonucleotide probes. This can 
then be quantified by fluorescent or chromogenic signals via an alkaline phosphatase 
catalysed reaction. This assay has been shown to be sufficiently sensitive to detect one 
or two DNA copies per cell. The system was used in human papilloma virus-infected 
cervical biopsy samples and was found to be rapid, sensitive and highly specific 
[Kenny et a l  2002]. One potential disadvantage o f  this technique is the requirement 
for relatively large volumes o f sample. For example, one commercial bDNA assay for 
HIV-1 requires 1 ml o f plasma. This problem has has been overcome by the 
development o f  small-volume-format bDNA which uses 50 or 250 |il o f  sample with 
high correlation to the standard test [Yeghiazarian et al. 1998].
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6.1.3.3 Quantitative real-time PCR (Taqman)
Recently, a PCR method has been developed which measures the amount o f  product 
in real time (Taqman). This method uses conventional primers and, in addition, a 
fluorogenic probe is designed to anneal to the product between the forward and 
reverse primers on the DNA or cDNA o f  interest. The probe contains a reporter dye at 
its 5' end and a quencher at its 3' end. The 5' nuclease action o f  Taq DNA  
polymerase is then expoited so that cleavage o f the probe at its 5' terminus detaches 
the reporter dye, separating it from the quencher and allowing a fluorescence signal to 
be emitted (figure 6.1). The 3' end o f  the probe is blocked to prevent extension o f the 
probe during the PCR reaction. The level o f  fluorescence provides a direct 
quantification o f the PCR product amplified. This system has been shown to be as 
sensitive as the other techniques with a wide linear range o f amplification. It has the 
added advantage o f being rapid and simple for routine amplification o f both RNA and 
DNA. This is also a real-time system which allows the product to be quantified using 
the log phase o f amplification. The major disadvantage o f this system is that initial 
empirical data that must first be accrued in order to optimise the assay and the fact 
that sequence variations cannot be quantified.
This real-time quantitative PCR system has been used successfully to monitor the 
level o f  various retrovirus parameters. One study demonstrated the use o f  Taqman to 
detect the level o f  HIV-1 provirus in PBMCs and lymphoid tissue in individuals 
undergoing retroviral treatment. The assay was sufficiently sensitive to consistently 
detect a single proviral sequence and the system demonstrated 100% sensitivity for 
five copies o f  provirus [Désiré et al. 2001].
This type o f assay has also been developed for feline retroviruses. Several studies 
have successfully used Taqman assays to assess the viral load o f  FIV in vaccination 
trials. In one study, primers and a probe were designed from conserved sequence o f 
FIV gag  gene and used to measure the level o f viral RNA in plasma samples. The 
RNA loads were found to be significantly higher in animals in the AIDS stage o f FIV 
infection than in the asymptomatic stage and high viral loads tended to be associated 
with poor prognosis [Goto et al. 2002]. Quantitative real-time PCR was also used to 
assess the proviral DNA copy number in huffy coat cells o f cats challenged with
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FeLV. Copy numbers were found to be lower in recovered cats than those which were 
persistently viraemic [Flynn et al. 2002]. In addition, one study detected FeLV 
provirus from experimental infection, using two PCR methods, nested PCR and 
quantitative real-time PCR [Hofmann-Lehmann et al. 2001]. The diagnostic 
specificity o f both methods was found to be 100%. The nested PCR method was 
found to recognise all three FeLV subgroups, whereas real-time PCR detected FeLV- 
A/Glasgow and FeLV-B Gardner-Amstein but not FeLV-C Sarma. Both assays 
detected between 0.36 and 3.6 copies o f DNA and the assays were highly 
reproducible. There was also a general correlation between the level o f  p27 antigen in 
plasma and the mean proviral load in both experimental and naturally infected 
animals.
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Figure 6-1 Quantitative real-time PCR
1) Polymerisation of primers and probe to target cDNA
5*
3'
Reverse
2) Displacement of 5' end of probe allowing reporter detachment
3'
Reverse
3) Separation of reporter and quencher allows fluorescence 
of the reporter dye
5'
KEY
Reporter dye
Reverse
Quencher
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6.1.4 Immunotherapy of retroviruses
The use o f  DNA vaccination in the prevention o f infectious disease has been explored 
extensively. Effective DNA vaccines with adjuvants have been designed for several 
retroviruses such as HIV-1 [Kim et al. 1997], FIV [Hosie et al. 1998; Leutenegger et 
al. 2000] and FeLV [Hanlon et al. 2001]. However, fewer studies have investigated 
the use o f  DNA vaccines in the immunotherapy o f retrovirus infection. To date, no 
experiments have been published on the use o f DNA vaccines as immunotherapeutic 
agents for feline retroviruses. However, several trials have used DNA immunisation 
in the therapy o f  HIV-1 infection in both humans and primates.
A DNA vaccination experiment using a plasmid encoding HIV-1 env and rev was 
carried out on two HIV-1 infected chimpanzees. One animal was injected with the 
vaccine and the other with a control plasmid. The vaccinated animal produced an 
enhancement o f  humoral responses and a decrease in viral load at week 20 o f the 
study which persisted until the termination o f the study. The control chimpanzee was 
subsequently exposed to DNA vaccine and the same responses were produced [Boyer 
et al. 1997].
Some studies using DNA vaccination in HIV-1 infected humans have demonstrated 
beneficial responses to DNA vaccination. One experiment used nine patients all o f  
whom were symptom-free [Calorata et al. 1998]. After intramuscular injection at days 
0, 60 and 180 with plasmids expressing nef, rev or tat genes, all patients showed 
induction o f memory CTL responses and eight had antigen-specific CTL responses. In 
a third o f these patients however, the cellular response was transient and declined 
after the initial CTL stimulation. Further studies o f  these nine individuals showed an 
increase in antigen-specific T cell proliferation responses but no effect on the viral 
load or the CD4^ lymphocyte counts. Patients inoculated with HIV-1 nef cDNA  
induced the highest CTL responses, but all CTL levels in individuals decreased after 
the initiation o f highly active antiretroviral treatment. The increased humoral response 
elicited by DNA vaccination was also greatest in those injected with nef  HIV-1 
plasmid.
256
In another study, asymptomatic HIV-1 infected patients were inoculated 
intramuscularly with plasmids encoding env and rev o f  HIV-1 three times at 10 week 
intervals. DNA vaccination had no effect on either the viral loads, CD4^ or CD8^  
lymphocyte counts in any o f  these individuals, although some had increases in CTLs 
against gp l60 antigen. Those patients inoculated with larger amounts o f  DNA (100- 
SOOpg) showed increased antibody to gpl20. Importantly, the safety and 
immunogenicity o f vaccination was demonstrated and no local or systemic adverse 
reactions were detected. There was also no trace o f anti-DNA antibody in any 
individual [MacGregor e / «/. 1998],
6.1.5 Aim of this work
The aim o f this experiment was to establish the immunotherapeutic value o f  a DNA  
vaccine combination, which had previously been effective in protecting animals 
against FeLV infection.
The experimental trial described in chapter 5 found that the combination o f FeLV 
DNA vaccine with feline ILRAP-IL-18 induced complete protection against viraemia 
and significant protection against latent proviral infection. Of the control group, four 
animals became persistently infected. These animals were subsequently exposed to an 
immunotherapy vaccination schedule using the DNA vaccine with ILRAP-IL-18. 
Vaccination was carried three times at weekly intervals and blood samples were taken 
during this procedure and over biweekly intervals until week nine. Plasma was tested 
for VI, p27 ELISA, VNAb and NNAb. In addition, the proviral load in white blood 
cells and lymph node cells were established at the end o f the trial using a quantitative 
real-time PCR assay system [Flynn et a l  2002].
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6.2 MATERIALS AND METHODS
6.2.1 Immunotherapy protocol
6.2.1.1 Experimental animals
Four persistently infected cats from group 6 o f  the previous immunisation trial were 
used in this study. These animals had been injected intramuscularly three times at 2 
week intervals with PBS buffer, followed by oronasal administration o f 4 x 10  ^ f.f.u. 
of FeLV-A/Glasgow-1 at approximately 5 months o f age. This immunotherapy 
experiment commenced 15 weeks after viral challenge. All procedures in this study 
were carried out according to Home Office regulations.
6.2.1.2 Preparation of DNA for immunisation
The constructs used for immunotherapy were selected on the basis o f the previous 
vaccination trial. These data showed that the most effective vaccine combination at 
eliciting protection from viral challenge was the combination o f DNA vaccine 
plasmids and ILRAP-IL-18. Preparation o f  pUSE 1 " C M V T , pUSEL  
CMVT(e«V/4) and ILRAP-IL-18 constructs were carried out as described in 5.2.2, 
using the Qiagen plasmid Endofree Giga Kit, Qiagen (West Sussex, UK) under the 
instructions o f  the manufacturer. Each batch was tested for LAL endotoxin by 
Bio Whittaker Europe, Verviers, Belgium. All DNA used in vivo was verified as within 
the acceptable limits o f  less than 50 EU/mg o f  DNA [Schorr et al. 1995].
6.2.1.3 Immunisation schedule
The immunisation protocol is shown in figure 6.2. Animals were injected 
intramuscularly at weeks 0, 1 and 2 with 100 |ig each o f pUSErCMVT(g«gyj9o/), 
pUSE 1 "CMVT(gMV/4) and ILRAP-IL-18 plasmid constructs. Vaccine DNA was 
diluted in endotoxin-free PBS so that each inoculation could be administered in a 0.2 
ml volume. Vaccination at weeks 0 and 2 was administered into the left quadriceps 
femoris muscle and at week 1 into the right quadriceps femoris muscle. Animals were
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closely monitored after immunisation and no adverse effects to the injection were 
observed either locally or systemically.
Figure 6-2 Immunotherapv schedule: parameters tested at each timepoint
Intramuscular immunisation
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6.2.1.4 Blood sampling
Animals were manually restrained and blood was taken from either the jugular or 
cephalic vein. A total o f 2 ml o f blood was taken at each time point. Cats were 
sampled at week 0, 1, 2, 4 and week 6. An additional intracardiac blood sample was 
taken at week 9 from anaesthetised cats immediately before euthanasia.
O f the 2 ml o f  blood taken, 1 ml was collected into a 2 ml heparin tube and 1 ml into a 
2 ml sodium citrate tube. Each 1 ml sample o f  heparinised blood was centrifuged at 
2000 rpm for 5 minutes. The plasma was then removed, dispersed in aliquots and 
stored at -70°C until further use. Blood collected into sodium citrate tubes was 
centrifuged for 5 minutes at 2000 rpm and the plasma was removed and stored at 
-70°C until further use. A small sample o f the huffy coat was recovered using a
2 5 9
pipette and transferred to an Eppendorf tube. This was centrifuged at 2000 rpm for 5 
minutes, excess plasma was discarded and the pelleted cells were stored at -70°C.
At euthanasia, the same quantities o f  blood were collected by withdrawal from the 
heart. In addition, a sample o f  submandibular (peripheral) lymph node and mesenteric 
(deep) lymph node were collected separately from each cat into 5 ml bottles each 
containing 3 ml RPMI 1640 with glutamine and 400 U/ml penicillin/streptomycin. 
Each sample o f lymph node was placed into a Petri dish and 10 ml o f fresh medium 
was added. Cells were extracted from the node by gentle scraping with a sterile 
scalpel blade. The medium containing the cells was placed in a 15 ml Falcon tube and 
centrifuged for 5 minutes at 1000 rpm. The supernatant was removed and the pellet 
was transferred to Eppendorf tubes and stored at -70°C until further use.
6.2.2 Analysis of samples
6.2.2.1 VI, p27 ELISA and antibody analysis
Fleparinised plasma was screened for the presence o f FeLV by p27 antigen ELISA 
and VI. Plasma samples were assayed before the start o f  the trial, during vaccination 
and at three time points after vaccination. The methods used to perform these assays 
are described in detail in 5.2.4.6. The VI assay gave a positive or negative result for 
the presence o f virus in the plasma. The ELISA was given a positive or negative result 
based on whether the OD value was greater than 1.5 times the value o f the negative 
control OD value. The ELISA S/P ratio was calculated as described in 5.3.3.
The VNAb status o f each animal at each time point was established, and NNAb were 
detected pre-immunisation, immediately post-immunisation and at the end o f the trial. 
These assays are explained in detail in 5.3.3.
6 2.2.2 Quantitative real-time PCR
The purification o f total DNA from buffy coat and lymphocytes from cats at the six 
time points was carried out using the QIAamp DNA blood mini kit (Qiagen)
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according to the instructions o f the manufacturer. Each sample was eluted in 50 fxl o f  
Buffer AE and the samples were stored at -20°C until later use.
An initial real-time PCR assay was performed to establish the FeLV proviral DNA  
copy number per sample reaction. A ribosomal DNA (rDNA) assay was then 
performed to establish the number o f cells in each sample reaction. These two values 
were combined to produce the number o f copies o f proviral DNA per cell in each 
buffy coat or lymphocyte sample.
Assays were performed using an ABI Prism 7700 sequence detection system (Applied 
Bio systems, Warrington, UK). Forward and reverse primers and probes were 
designed using Primer Express software (Applied Biosystems, Warrington, UK). 
Primers for the detection o f FeLV provirus were specific for F eLV -A/Glasgow-1 env 
sequence as shown in figure 6.3 [Stewart et al. 1986]. These primers were selected to 
ensure minimal homology to feline endogenous retrovirus sequence [Pandey et al. 
1991; McDougall et al. 1994] and the primers were synthesised by MWG Biotech and 
were HPSF purified. The primers were as follows: 5' -GCC CCA A AC GAA TGA 
AAG C- 3' and 5’ -AAT CCG TTT GGG ACC CAT G -3 \  The probe was labelled at 
the 5' end with the reporter dye F AM (6-carboxyfluoroscein), and at the 3' end with 
the quencher dye TAMRA (6-carboxytetramethyl-rhodamine), and was phosphate 
blocked at the 3' end to prevent Taq polymerase extension. The probe sequence was 
as follows 5'- CCC AAG GTC TGT TGC CCC CAC C -3' (figure 6.3).
The standard for FeLV PCR was plasmid cDNA encoding the FeLV-A env gene 
[Stewart et al. 1986]. The copy number o f the DNA was quantified by 
spectrophotometry and from agarose gel electrophoresis as described in 2.2.8. Six 
standards were used o f  10  ^ to 10  ^ copy numbers in ten-fold dilutions in PCR grade 
water with 30 pg/ml calf thymus DNA (Invitrogen Life Technologies). A negative 
control containing no plasmid DNA was also included.
Fifty microlitre reactions were set up containing 10 mM Tris (pH 8.3), 50 mM KCl, 
200 nM dATP, dCTP and dGTP, 400 nM dUTP, 2.5 units o f Taq DNA polymerase, 
135 nM o f probe (Applied Biosystems), and 300 nM o f each primer. A 5 pi volume o f
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sample DNA and DNA standard was included in each reaction and all samples were 
assayed in duplicate. PCR conditions comprised an initial dénaturation step o f 95°C 
for 2 minutes followed by 40 cycles o f amplification o f 95°C for 15 seconds and 60°C 
for 60 seconds.
In order to estimate the cell number in each sample reaction, this assay was repeated 
using primers specific for rDNA [Klein et a l  2000]. The primers were as follows: 
rDNA343f: 5'- CCA TCG AAC GTC TGCCCT A -3' and rDNA409r: 5'- TCA CCC 
GTG GTC ACC ATG -3'. The probe for this assay was VIC labelled and was as 
follows: 5'- CGA TGG TGG TCG CCG TGC CTA -3'. The standards used for this 
assay consisted o f DNA prepared from MYA-1 cells. Quantification o f  DNA was 
carried out by spectrophotometry and a series o f  4 dilutions was prepared using PCR 
grade water with 30 pg/ml yeast RNA as a carrier (Roche Diagnostics Ltd., Lewes, 
UK). The MYA-1 cell number was derived from the quantity o f DNA on the 
assumption that 6 pg DNA represented one cell. A negative control reaction 
containing no DNA was also included. This assay was carried out under the same 
conditions as described above and all samples were assayed in duplicate.
Duplicate copy number values from the FeLV proviral DNA assay were used to 
produce a mean value for each DNA sample and the duplicate rDNA values generated 
the mean cell number per reaction. These data consequently allowed an estimation o f  
the proviral copies per cell over the course o f  the immunotherapy trial.
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Figure 6-3 FeLV-A env o f  quantitative real-time PCR primers and probe
Kev
Red text = Forward primer
Green text = Probe
Blue text = Reverse primer
1 ATGGAAAGTC CAACGCACCC AAAACCCTCT AAAGATAAGA CTCTCTCGTG
51 GAACTTAGCG TTTCTGGTGG GGATCTTATT TACAATAGAC ATAGGAATGG
101 CCAATCCTAG TCCACACCAA ATATATAATG TAACTTGGGT AATAACCAAT
151 GTACAAACTA ACACCCAAGC TAACGCCACC TCTATGTTAG GAACCTTAAC
201 CGATGCCTAC CCTACCCTAC ATGTTGACTT ATGTGACCTA GTGGGAGACA
2 51 CCTGGGAACC TATAGTCCTA AACCCAACCA ATGTAAAACA CGGGGCACGT
301 TACTCCTCCT CAAAATATGG ATGTAAAACT ACAGATAGAA AAAAACAGCA
3 51 ACAGACATAC CCCTTTTACG TCTGCCCCGG ACATGCCCCC TCGTTGGGGC
4 01 CAAAGGGAAC ACATTGTGGA GGGGCACAAG ATGGGTTTTG TGCCGCATGG
4 51 GGATGTGAGA CCACCGGAGA AGCTTGGTGG AAGCCCACCT CCTCATGGGA
501 CTATATCACA GTAAAAAGAG GGAGTAGTCA GGACAATAGC TGTGAGGGAA
551 AATGCAACCC CCTGGTTTTG CAGTTCACCC AGAAGGGAAG ACAAGCCTCT
601 TGGGACGGAC CTAAGATGTG GGGATTGCGA CTATACCGTA CAGGATATGA
651 CCCTATCGCT TTATTCACGG TGTCCCGGCA GGTATCAACC ATTACGCCGC
701 CTCAGGCAAT GGGACCAAAC CTAGTCTTAC CTGATCAAAA ACCCCCATCC
751 CGACAATCTC AAACAGGGTC CAAAGTGGCG ACCCAGAGOC CCCAAACGAA
801 TGAAAOCGCC CCAAGGTCTG TTGCCCCCAC CACCATOGQT CCCAAACGGA
851 TTGGGACCGG AGATAGGTTA ATAAATTTAG TACAAGGGAC ATACCTAGCC
901 TTAAATGCCA CCGACCCCAA CAAAACTAAA GACTGTTGGC TCTGCCTGGT
951 TTCTCGACCA CCCTATTACG AAGGGATTGC AATCTTAGGT AACTACAGCA
1001 ACCAAACAAA CCCCCCCCCA TCCTGCCTAT CTACTCCGCA ACACAAACTA
1051 ACTATATCTG AAGTATCAGG GCAAGGAATG TGCATAGGGA CTGTTCCTAA
1101 AACCCACCAG GCTTTGTGCA ATAAGACACA ACAGGGACAT ACAGGGGCGC
1151 ACTATCTAGC CGCCCCCAAC GGCACCTATT GGGCCTGTAA CACTGGACTC
1201 ACCCCATGCA TTTCCATGGC GGTGCTCAAT TGGACCTCTG ATTTTTGTGT
1251 CTTAATCGAA TTATGGCCCA GAGTGACTTA CCATCAACCC GAATATGTGT
1301 ACACACATTT TGCCAAAGCT GTCAGGTTCC GAAGAGAACC AATATCACTA
13 51 ACGGTTGCCC TTATGTTGGG AGGACTTACT GTAGGGGGCA TAGCCGCGGG
1401 GGTCGGAACA GGGACTAAAG CCCTCCTTGA AACAGCCCAG TTCAGACAAC
14 51 TACAAATGGC CATGCACACA GACATCCAGG CCCTAGAAGA ATCAATTAGT
1501 GCCTTAGAAA AGTCCCTGAC CTCCCTTTCT GAAGTAGTCT TACAAAACAG
1551 ACGGGGCCTA GATATTCTAT TCTTACAAGA GGGAGGGCTC TGTGCCGCAT
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1601 TGAAAGAAGA ATGTTGCTTC TATGCGGATC ACACCGGACT CGTCCGAGAC
1651 AATATGGCCA AATTAAGAGA AAGACTAAAA CAGCGGCAAC AACTGTTTGA
1701 CTCCCAACAG GGATGGTTTG AAGGATGGTT CAACAAGTCC CCCTGGTTTA
1751 CAACCCTAAT TTCCTCCATT ATGGGCCCCT TACTAATCCT ACTCCTAATT
1801 CTCCTCTTCG GCCCATGCAT CCTTAACCGA TTAGTACAAT TCGTAAAAGA
1851 CAGAATATCT GTGGTACAGG CTTTAATTTT AACCCAACAG TACCAACAGA
1901 TAAAGCAATA CGATCCGGAC CGACCATGA
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Table 6-1 FeLV p27 ELIS A  results before and during immunotherapy
Week 0 Week 1 Week 2
CAT ELISA
OD
ELISA
S/P
RESULT ELISA
OD
ELISA
S/P
RESULT ELISA
OD
ELISA
S/P
RESULT
L31 0.51 0.286 + 0.48 0.257 + 0.43 0.210 +
L33 0.59 0.362 + 0.68 0.448 + 0.82 0.581 +
L34 0.58 0.352 + 0.43 0.210 + 0.51 0.286 +
L35 0.76 0.524 + 0.79 0.552 + 0.88 0.638 +
Table 6-2 FeLV d27 ELISA results at three time points after immunotherapv
Week 4 Week 6 Week 9
CAT ELISA
OD
ELISA
S/P
RESULT ELISA
OD
ELISA
S/P
RESULT ELISA
OD
ELISA
S/P
RESULT
L3I 0.46 0.238 + 0.51 0.286 + 0.39 0.256 +
L33 0.86 0.619 + 0.79 0.552 + 0.69 0.605 +
L34 0.53 0.305 + 0.49 0.267 + 0.58 0.477 +
L35 0.73 0.495 + 0.64 0.410 + 0.54 0.430 +
Table 6-3 Virus isolation results o f  immunotherapy trial
CAT Week 0 Week 1 Week 2 Week 4 Week 6 Week 9
L3I + + -f + + +
L33 + + + + + +
L34 + + + + + 4-
L35 + + + + + +
Table 6-4 Non-neutralising antibody levels during immunotherapv trial
CAT Week 0 Week 2 Week 9
L3I No antibodies No antibodies No antibodies
L33 gp70 (+), p27 (+), pI5E (+) gp70 (+), p27 (+), pI5E (+) gp70 +, p27 (+), p l5E  (+)
L34 pl5E  + gp70 (+), p l5E  + pl5E  +
L35 gp70 +, p27 +, pI5E + gp70 +, p27 +, p l5E  + gp70 +, p27 +, pI5E +
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Table 6-5 Quantitative real-time PCR results o f  immunotherapv trial
WeekO Week 1 Week 2 Week 4 Week 6 Week 9 SMLN MLN
L31
Mean provirus copy 
number
1060811 517181 1020237 1675689 1815755 1013534 85409 49428
Mean cell number 96652 76624 658273 580406 116865 510055 140435 115332
Copy number/cell 10.976 6.750 1.550 2.887 15.537 1.987 0.608 0.429
L33
Mean provirus copy 
number
257983 269579 427709 318796 387816 417523 41089 47244
Mean cell number 1564872 185042 706973 832651 393276 1557837 185786 273245
Copy number/cell 0.165 1.457 0.605 0.383 0.986 0.268 0.221 0.173
L34
Mean provirus copy 
number
389761 83734 104208 54664 85247 229358 33570 16433
Mean cell number 3813909 140965 412030 138312 27228 476357 360160 111657
Copy number/cell 0.102 0.594 0.253 0.395 3.131 0.481 0.093 0.147
L35
Mean provirus copy 
number
35840 16184 16409 11010 22873 80091 2364 39023
Mean cell number 416118 23561 15761 56093 85339 204127 40823 114728
Copy number/cell 0.086 0.687 1.041 0.196 0.268 0.392 0.058 0.340
SMLN = submandibular lymph node 
MLN = mesenteric lymph node
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6.3 RESULTS
6.3.1 The effect of immunotherapy on FeLV viraemia
Heparinised plasma was used to establish the viral status and antibody response o f  
animals during the study. VI and p27 antigen ELISA assays were performed on 
plasma samples and each cat at all time points was found to contain p27 antigen (table
6.1 and 6.2) and infectious virus (table 6.3).
6.3.2 The effect of immunotherapy on FeLV proviral DNA
Quantitative real-time PCR was performed on duplicate DNA samples to estimate the 
mean FeLV proviral copy number per cell from buffy coat samples collected over all 
time points and lymph nodes collected at euthanasia. For each assay a standard curve 
was constructed using the standard reactions and the FeLV or rDNA copy number 
was calculated by interpolation o f the Ct value o f  the samples to the standard curve 
(figure 6.5). Primers designed to amplify FeLV-A env were used to approximate the 
FeLV copy number per reaction and primers for rDNA allowed the number o f cells 
per reaction to be estimated. This allowed an estimation o f the mean number o f  
proviral copies per cell sample (table 6.5). A graph was then constructed o f  logio o f  
proviral copy number for each animal for the duration o f the trial (figure 6.6).
The graph clearly shows that throughout the immunotherapy experiment, the proviral 
copy number per cell fluctuated randomly around a low general level. There was no 
overall increase or decrease in copy number in any animal over the study period. 
When the mean copy number per cell was calculated for each animal using the six 
buffy coat samples they were as follows L31=6.61, L33=0.644, L35=0.826 and 
L3 5=0.445 copies/cell.
There appeared to be little correlation between the copy numbers found in lymph 
node cells and the buffy coat samples, other than L31, which overall had much larger 
values than the other animals for all samples.
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In order to compare proviral copy number per cell and p27 ELISA values, a graph 
was constructed o f FeLV p27 ELISA S/P ratios at time points for each animal (figure 
6.7) and a correlation curve o f  ELISA S/P against proviral copy number was 
constructed using SigmaPlot 2001 (Windows version 7.0, SPSS Inc.). Proviral copy 
number was plotted on a log scale. The R value o f  points on the correlation curve was 
found to be R=0.433 which shows that there is no correlation between these values 
(figure 6.8). This suggests that the OD value produced from p27 ELISA does not 
necessarily reflect the degree o f proviral infection o f cells.
6.3.3 The effect of immunotherapy on anti-FeLV antibodies
The levels o f  VNAb and NNAb were analysed at various intervals during the study. 
VNAb was not detected in animals at any time point during the experiment. Detection 
o f NNAb carried out at weeks 0, 2 and 9 showed no significant change in the level o f  
NNAb (figure 6.4 and table 6.4). O f the animals, L31 showed no NNAb at any point, 
whereas L33 demonstrated low levels o f anti-gp70, p27 and p l5E  antibodies. The 
anti~gp70 antibody band for L33 became slightly stronger at each time point during 
the trial. L34 also displayed low levels o f  anti-pl5E and anti-gp70 antibody was 
detectable at week 2. L35 demonstrated all antibodies at all times with no consistent 
change in the strength o f antibody bands at the various time points. An interesting 
observation was that there tended to be an inverse relationship between proviral DNA  
copy numbers and the level o f  non-neutralising antibodies expressed by these animals.
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Figure 6-4 Western blot strins o f  non-neutralising antibodies
1 2  3 1 2  3 1 2  3 1 2  3
L 3 5L 31 L 3 3  L 3 4
1 =  p re -im m u n is a tio n  2  =  p o s t-im m u n is a tio n  3  =  e n d  o f tria l
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Figure 6-5 Quantitative real-time PCR Standard curves
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Figure 6-6 Logm o f  mean FeLV proviral copies per cell during trial
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Figure 6-7 ELISA S/P ratios for animals during immunotherapv trial
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Figure 6-8 Correlation curve o f  ELISA S/P ratio and proviral copy number values
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6.4 DISCUSSION
6.4.1 FeLV DNA vaccine and ILRAP-IL-18 as an 
Immunotherapeutic agent
The combination o f parameters measured during this study suggested that the use o f  
an FeLV DNA vaccine with ILRAP-IL-18 was an ineffective immunotherapeutic 
agent for persistently viraemic animals. This vaccine was, however, extremely 
effective in providing protection o f FeLV naïve cats against oronasal viral challenge, 
as shown in Chapter 5. In an attempt to explain this, a comparison must be made 
between the clinical and immune status o f  animals entering the vaccination trial and 
those used for immunotherapy.
Animals used for the vaccination trial were specific pathogen free cats which were 
exposed to a challenge o f  4 x 10  ^ f.f.u. in 4 equal doses over alternate days. As this 
challenge was applied oronasally, it is likely that only a proportion o f  the virus 
travelled across the mucous membranes and was exposed to the immune system o f  
vaccinated cats. Animals used in the immunotherapy experiment however had high 
FeLV viral loads disseminated throughout the body produced by cells undergoing 
replication: FeLV can be isolated from many systems in viraemic cats including nasal 
passages, trachea, pharynx, intestines, bladder, pancreas, oesophagus and salivary 
glands [Rojko et al. 1979a]. In addition, persistently infected cats are highly 
contagious and have been shown to release virus in large quantities [Hardy et al. 
1973a; Jarrett et al. 1973]. Therefore these viraemic animals would have been acting 
as a source o f infection to each other and would have produced a cycle o f  continual 
natural challenge. It is likely then, that a disseminated, constantly cycling infection 
with high viral load, would pose a greater challenge to the DNA vaccine than a series 
o f  low dose, isolated viral exposures administered in the vaccination trial.
Another important difference between these experiments is the timing at which 
immunisation took place. In the vaccine trial, animals were challenged three weeks 
after the last vaccination. This allowed time for priming o f the immune system with 
FeLV-specific antigen prior to viral exposure. The immune system in animals used in
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the immunotherapy study had already been exposed to viral challenge in the 
vaccination trial and had failed to eliminate the virus. Therefore as an 
immunotherapeutic agent, the DNA vaccine will have been confronted by an 
established infection.
It has been shown that immune protection using this DNA vaccine is associated with 
the development o f CTLs but not VNAb [Flynn et a l  2000a; Hanlon et a l  2001]. It 
follows therefore, that the vaccine may be effective against initial infection where 
CTLs are able to mount a response against a small number o f FeLV infected cells. In 
persistently infected animals however, a much larger number o f  FeLV infected cells 
are present, both in the blood and in a variety o f  other systems [Rojko et a l  1979a]. 
Also, a large amount o f  free virus is released, requiring the development o f  VNAb 
[Russell and Jarrett, 1978a]. This DNA vaccine is therefore less likely to be effective 
in persistently infected cats.
Persistent infection with FeLV has been shown to induce dysfunction o f the immune 
system. Studies have shown that kittens infected neonatally with FeLV, displayed 
atrophy o f the thymus and depletion o f  other lymphoid organs [Anderson et a l  1971]. 
Kittens infected with FeLV at birth were shown to have depression o f  cell mediated 
immunity, measured by allograft retention times [Perryman et a l  1972]. In addition, 
Flynn et a l  demonstrated a dramatically lower level o f humoral and cell mediated 
immune mechanisms in cats which became persistently infected after FeLV 
challenge. This study found that FeLV-specific CTLs were detectable in the blood as 
early as 1 week post-challenge in FeLV recovered cats whereas CTL activity was 
undetectable in persistently infected cats until between 4 and 7 weeks after challenge. 
This CTL response then declined in viraemic cats but persisted until recovery in 
immune individuals [Flynn et a l  2002]. Animals infected with FeLV were also found 
to have defects in T and B cells. T cell defects were demonstrated by a decline in 
mitogen-induced blast transformation beginning at 5 weeks post-challenge until death 
at 24 weeks [Cockerell et al. 1976]. It is therefore probable that the immune system o f  
the viraemic animals undergoing immunotherapy were compromised compared to 
those used in the vaccination trial despite the vaccinates having an immature, less 
developed immune system. Therefore, plasmid-encoded antigen may have been
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presented successfully to the immune system, but immunodeficiency may have 
inhibited any detectable change in viral activity.
6.4.2 Parameters used to assess viral activity
It is important in the development o f antiviral therapy that the viral status o f the host 
is measured to allow an assessment o f  drug efficacy. However the level o f viral 
infection comprises a combination o f  several dynamic processes, all o f  which should 
be taken into account when monitoring viral status. In the case o f  retroviruses, 
replication takes place once proviral DNA is integrated into the DNA o f the host. This 
is then transcribed to produce mRNA in the host cell, which is processed to allow the 
generation o f new virus and release from the cell [Fields and Knipe, 1990]. As 
described in 6.1.2, there are several ways in which this cycle can be quantified. 
Firstly, the proviral copy number per cell can be estimated [Flynn et al. 2002]. In 
addition, the level o f RNA transcription has been used as a measurement o f  viral 
activity [Bagnarelli et al. 1994]. Finally, a common method used to assess retroviral 
load is the quantification o f viral RNA in the plasma [Spector et al. 1998; Goto et al. 
2002]. In general, these parameters have been found to correlate with the clinical 
status. For example, persistently infected cats were shown to have higher proviral 
copy numbers per PBMC than FeLV-recovered animals [Flynn et al. 2002]. However 
some studies have demonstrated differences between the plasma retroviral load and 
the level o f viral RNA in virus-expressing cells [Hockett et al. 1999].
An assessment o f FeLV plasma load may be a more accurate method o f analysing the 
effect o f immunotherapy in persistently infected cats. A decrease in proviral copy 
number per cell reflects the death o f infected cells and replacement by healthy eells. 
This may be brought about by apoptosis from a cell mediated immune response, or 
cells reaching the end o f  their life span, which is dependent on the cell half life. This 
can be highlighted by data produced for HIV-1 where one study showed that the half- 
life o f  cell-free virus in plasma was approximately 6-fold less than the half life o f  
productively infected cells [Perelson et al. 1996]. Therefore plasma viral load will 
decrease more rapidly in response to a change in viral activity than the level o f viral 
infection o f cells. However, as samples were only taken at weekly intervals, it is
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unlikely that the assessment o f viral plasma levels would have made any significant 
difference to the data collected. The fact that plasma was collected as well as buffy 
coat cells at these times, would allow assessment o f  viral RNA load at a later date to 
compare these parameters.
The levels o f mean FeLV proviral copy numbers per cell varied between 15.537 and 
0.058. With the exception o f  animal L31, the proviral loads were extremely low and 
similar levels o f  provirus were demonstrated in a previous study [Flynn et a l  2002]. 
This could represent an overall low level o f integration in a high proportion o f cells, 
or a high integration rate in a small proportion o f cells. To investigate the frequency 
o f proviral integration further, a study into the proportion o f cells containing provirus 
could be performed.
6.5 Conclusion
This study was a preliminary experiment to assess the value o f immunotherapy o f  
persistently infected cats with a vaccine previously found to be efficacious in the 
prophylaxis o f  FeLV infection. A  protocol using three weekly immunisations o f DNA  
vaccine with ILRAP-IL-18 was found to have no effect on the parameters used to 
assess FeLV viral activity. However, in order to fully establish whether the pursuit o f  
immunotherapy in this system is worthwhile, a fully controlled experiment using 
larger group sizes should be carried out using a reliable assay to quantify the level o f  
FeLV in the plasma.
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CHAPTER 7: GENERAL DISCUSSION
7 GENERAL DISCUSSION
7.1.1 Introduction
The aim o f this project was to investigate further the role o f the feline cytokines IL-12 
and IL-18 as adjuvants to a DNA vaccine for FeLV. The previous study performed by 
Hanlon et a l  identified a successful vaccine combination which provided complete 
protection against viraemia and a significant degree o f protection from latent proviral 
infection. This combination comprised FeLV DNA vaccine in conjunction with feline 
IL-12 and PsecI signal feline lL-18 [Hanlon et a l  2001].
The work described here has involved the refinement o f  these constructs, potentially 
overcoming problems faced by both cytokines in their molecular structure. The 
development o f feline specific polyclonal antibodies allowed conclusive evidence o f 
in vitro protein expression o f  each cytokine. In addition, the development o f bioassays 
for both IL-12 and IL-18 permitted the in vitro activity o f  these molecules to be 
established prior to their use in an in vivo situation. These cytokines were then used in 
an experimental study to investigate the relative roles o f  each cytokine in providing an 
adjuvant effect to a DNA vaccine described previously [Hanlon et a l  2001]. The 
potential immunotherapeutic use o f  the successful vaccine combination was 
subsequently assessed using persistently viraemic animals.
7.1.2 [nterleukin-12
In recent years, the cloning o f  immune stimulating molecules such as IL-12 has 
facilitated a greater understanding o f  their function in the immune pathway and as a 
result their potential use in certain systems has been realised. As well as stimulating 
the proliferation and cytotoxicity o f  T and NK cells [Kobayashi et a l  1989; W olf et 
a l  1991; Chehimi et a l  1993], the most vital biological function o f IL-12 lies in its 
ability to stimulate the production o f IFNy from T cells [Marshall et a l  1995]. IFNy 
belongs to the interferon family, a group o f molecules related by their ability to 
protect cells from viral infection [Farrar and Schreiber, 1993]. IFNy induces the 
production o f  certain molecules which inhibit the lifecycle o f  viral pathogens. IL-12 is
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therefore able to induce a cascade effect which not only serves to enhance the cell- 
mediated branch o f the immune system, but also to inhibit the replication o f  the 
pathogens themselves.
The primary objective in the development o f  a vector expressing IL-12 was to 
produce a plasmid capable o f producing the bioactive heterodimer on transcription 
and translation. As described in 3.1.8, various constructs have been described 
including the use o f  separate plasmids encoding p35 and p40 [Hanlon et a l  2001], a 
single vector under the same or separate promoters [Tsuji et a l  1997; Yamakami et 
a l  2001], or the use o f an 1RES IL-12 construct [Zitvogel et a l  1994]. However, none 
o f  these vectors are guaranteed to prevent the overproduction o f  p40, which in 
homodimer formation is capable o f  inhibiting the activity o f the heterodimer 
[Gillessen et a l  1995; Ling et a l  1995]. Another construct which ensures equimolar 
subunit products has been cloned in the pig. Here the subunits are linked by cDNA  
encoding the FMDV self-cleaving peptide, 2A. This sequence allowed cleavage o f the 
polypeptide into separate subunits on translation and baculovirus vectors expressing 
this construct were found to produce bioactive IL-12 [Kokuho et al. 1999]. The 
presence o f free p40 subunit however still allows the possibility o f homodimer 
formation and antagonism o f  the bioactive molecule. The design o f flexi-IL-12 
ensures equimolar production o f  each subunit with the prevention o f free p40 and has 
been proven to be active in vitro and in vivo in several species [Foss et a l  1999; Lode 
et a l  1999; McMonagle et a l  2001]. In addition, this fusion protein reduces the size 
o f the construct required to deliver IL-12. This may be particularly advantageous in 
situations were the size o f vector is crucial, such as packaging into vaccine vectors. 
To the author’s knowledge, this is the first time that feline flexi-lL-12 has been 
described and this construct has the potential to be o f  value in the treatment and 
prevention o f feline disease.
Further to the cloning o f  cytokine constructs, in vitro bioactivity data is crucial. This 
is particularly relevant where commercial therapy is viable, where batch testing o f  
bioactivity would be required. The development o f a simple, robust and reliable 
bioassay for IL-12 allows confirmation o f  activity and is useful to compare activity o f  
new constructs in the field. In this work, an assay previously used for detection o f  
equine IL-12 [McMonagle et a l  2001], was also found to be sensitive to feline
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protein. This assay has proven to be relatively simple and reliable, relying on the dose 
dependent production o f IFNy from equine lymphocyte populations from lymph 
nodes collected at post mortem. A disadvantage o f this system is that lymphocytes 
collected from different individuals showed differential sensitivity to IL-12, so 
standardisation o f this assay was not possible.
IL-12 has been found to exert beneficial immune based effects in a variety o f systems. 
This cytokine can increase immunity and survival rates o f various pathogens such as 
Toxoplasma gondii [Khan et al. 1994], Mycobacterium tuberculosis [Cooper et al. 
1995], Leishmania major [Heinzel et al. 1993] and MuLV [Gazzinelli et a l  1994]. In 
all these cases, it is the stimulation o f  Thl responses and in some cases the inhibition 
o f Th2 responses which elicit the protective effects from the pathogens concerned. In 
the case o f  FeLV, although virus neutralising antibodies tend to correspond with 
immunity [Hardy et al. 1976], it is clear that cell mediated immunity is also 
important. The presence o f neutralising antibodies is not essential for viral protection 
[Jarrett 2001] and in the previous FeLV immunisation experiment, DNA vaccine 
immunisation did not produce neutralising antibodies but elicited protection from 
challenge. Additionally, protected animals showed increased levels o f FeLV specific 
CTLs compared to control animals [Flynn et al. 2000a; Hanlon et a l  2001]. It could 
be hypothesised then, that delivery o f  IL-12 would be beneficial in mounting an 
immune response against FeLV due to its ability to stimulate cell mediated immunity. 
Data produced from this in vivo study however suggests that in this system, IL-12 
does not enhance the level o f protection elicited in cats against a DNA vaccine for 
FeLV. A similar result was also produced in the previous trial, where the adjuvancy o f  
IL-12 was analysed using administration o f separate p35 and p40 plasmids [Hanlon et 
a l  2001]. This is suggestive that the IL-12 fusion protein does not in this case offer 
any significant advantage over separate plasmids in its in vivo adjuvant effect. As 
suggested in 5.4.5, it is possible that the dose [Orange et al. 1994], timing and site o f  
administration [Chen et a l  2001], may have affected the in vivo response to IL-12, 
parameters which have been shown to be important in other IL-12 studies.
2 7 9
7.1.3 Interleukin-18
IL-18 is another cytokine which has shown potential in the therapeutic manipulation 
of the immune response. Similar to IL-12 however, an IL-18 construct must bring 
about efficient bioactive protein production and successful secretion from the cell. As 
detailed in 4.1.3, pro-IL-18 construct produces the precursor protein which is inactive 
unless it is cleaved by natural caspase-1 and mature-IL-18 protein although bioactive, 
lacks the natural signal peptide for cell secretion. These problems were overcome 
using a synthetic signal peptide derived from the human signal sequence o f  the IL-ip  
receptor antagonist protein (ILRAP) gene which allowed feline mature-IL-18 to be 
transferred across the cell membrane. This construct showed superior levels o f  in vitro 
expression and bioactivity when compared with the previously used feline Psecl-IL- 
18 construct [Hanlon et al. 2001]. Again, this data is o f importance as IL-18 may be 
o f commercial value in feline medicine in the future.
As progress is made in terms o f investigation and clinical trials into IL-18, the 
specific quantification and activity o f  the molecule in blood and other tissues is a 
prerequisite to further development. Until recently, the dose dependent production o f  
IFNy from PBMCs was used to detect bioactive IL-18 [Ushio et al. 1996]. This 
system was not necessarily specific to IL-18 and was time consuming to perform. The 
KG-1 bioassay however [Konishi et al. 1997], proved to be simple and reliable, 
producing consistent results throughout this study. Its specificity was confirmed by 
the suppression o f bioactivity using IL-18 neutralising antibody. This antibody did not 
produce complete suppression o f IFNy production from cells whereas the negative 
control transfection samples demonstrated background levels o f bioactivity. This 
suggests that either the antibody level was not sufficiently high to bind all IL-18 
molecules, or that other factors, induced by IL-18 were stimulating IFNy production.
7.1.4 Vaccination trial
The use o f  IL-18 expression vectors in vivo have been found to be efficacious in a 
variety o f  systems including tumour therapy [Osaki et al. 1999], therapy against 
pathogens [Tanaka-Kataoka et al. 1998] and as adjuvants to DNA vaccination
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[Hanlon et a l  2001]. Similarly this project has demonstrated that the feline synthetic 
signal IL-18 dramatically increases the level o f immune protection to viral challenge 
compared to FeLV DNA vaccine alone. This experiment was designed to investigate 
the relative roles o f IL-12 and IL-18 constructs as adjuvants to a DNA vaccine for 
FeLV used previously [Hanlon et a l  2001]. The protective effect o f  each interleukin 
alone and in combination was analysed by its ability to protect animals from FeLV 
viraemia and latency. The DNA vaccine with ILRAP-IL-18 as an adjuvant stimulated 
complete protection from viraemia where 4 o f  6 control animals became persistently 
viraemic. Latency data demonstrated that only 1 o f 6 cats were latently infected in the 
vaccine and lLRAP-IL-18 group, whereas all animals showed bone marrow infection 
in the control group.
The gravity o f  this result can only be fully appreciated when comparisons are made 
with FeLV vaccines currently commercially available. Previous FeLV vaccine data 
shows that very few studies have shown complete protection o f animals against 
viraemia. Lafrado [1994] demonstrated complete protection in cats vaccinated with 
Leucocell 2, but only 19% o f control animals were viraemic, suggesting that the viral 
challenge used was not effective. An experiment elicited complete protection from 
viraemia using Fel-O-Vax [Legendre et al. 1991]. However at euthanasia 42% 
animals were latently infected with provirus. Sebring et al. [1991] also demonstrated 
complete protection using Fel-O-Vax, but unfortunately latent infection was not 
analysed in this study. The data produced from this study appears to be superior to all 
FeLV vaccine studies published to date.
The DNA vaccine combined with lLRAP-IL-18 and flexi-IL-12 also elicited complete 
protection from FeLV, but a higher proportion o f  these animals were latently infected 
with pro virus (2 o f 6 cats). A similar result was produced in the previous DNA  
vaccine trial using IL-12 delivered in separate plasmids and Psecl-IL-18, with 
complete protection from viraemia with one latently infected animal [Hanlon et al. 
2001]. Although this group displayed inferior protection in comparison to ILRAP-IL- 
18 adjuvant alone, the result still compares favourably with studies o f  the vaccines 
commercially available.
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In conclusion, this study shows that the use o f the feline lLRAP-IL-18 in combination 
with a FeLV DNA vaccine demonstrated potential as an effective vaccine against 
viraemia and latent infection, comparing favourably with the existing commercial 
vaccines currently available. This data confirms the result produced by Hanlon et 
a/. [2001], where complete protection against viraemia and some protection against 
latent infection were shown by the combination o f  DNA vaccine, IL-12 and IL-18. 
The development o f  improved constructs flexi-IL-12 and lLRAP-lL-18 did not 
improve the adjuvant effect o f  the previously used cytokine constructs. However this 
experiment identifies the IL-18 component as the important vaccine adjuvant, which 
alone can induce significant protection against challenge. Furthermore, this vaccine 
combination was shown to be efficacious against oronasal challenge with FeLV, a 
more natural form o f challenge than the intraperitoneal route used previously [Hanlon 
et a l  2001].
7.1.5 Immunotherapy trial
The FeLV vaccine with ILRAP-IL-18 was then used in an immunotherapy study, 
where four persistently infected cats were inoculated three times at weekly intervals. 
This was to establish if  immunisation could influence the viral load in tissues o f  
animals with established FeLV infection. The data produced suggested that 
immunotherapy with this vaccine combination had no beneficial effect on the viral 
status o f  persistently infected cats. Animals remained viraemic throughout the study 
and the level o f  FeLV proviral DNA levels in huffy coat cell samples after 
immunisation were similar to levels prior to inoculation.
7.1.6 Future work
This project has produced in vitro evidence which shows that both bioactive flexi-IL- 
12 and ILRAP-IL-18 are expressed at high levels within cells. These constructs were 
used as cytokine adjuvants to an FeLV DNA vaccine and were found to be highly 
efficacious in vivo. The combination o f DNA vaccine and ILRAP-IL-18 was 
particularly effective and compared extremely favourably to commercial vaccines 
currently available. A major constraint to this in vivo experiment however was the
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number o f animals used in each vaccination group, which limited statistical analysis. 
Therefore in order to examine the possibility o f  commercialisation o f this vaccine, a 
trial comprising larger vaccine groups should be performed. It would also be 
beneficial include the addition o f persistently infected animals from viral challenge 
onwards to reproduce natural FeLV infection as fully as possible. O f particular 
interest in this study would be the inclusion o f some o f  the most efficacious 
commercial vaccines which would allow a fair comparison o f each vaccine under the 
same conditions. Future work into feline flexi-IL-12 would require investigation in 
vivo into the dose, timing and site o f administration o f the IL-12 construct in 
comparison to the DNA vaccine.
In addition, the beneficial effects which the feline ILRAP-IL-18 construct has 
displayed in this experiment holds potential in other areas o f  feline medicine such as 
tumour therapy and immunotherapy against other pathogens.
This work combined with the previous FeLV DNA vaccination study [Hanlon et al. 
2001], shows great potential for the generation o f a new vaccine for FeLV. Factors 
which must be considered for commercialisation include the cost o f production and 
storage conditions. One o f the main advantages o f  DNA vaccines is their cheap, 
simple and efficient production. Furthermore, this type o f vaccine is heat stable and 
does not require the cold chain which is necessary for other more traditional vaccines. 
However, there are some potential problems which would have to be overcome in 
order to make commercialisation a viable option. The means o f delivery o f  DNA such 
as multiple administration and the requirement o f  naked skin in the case o f gene gun 
administration, poses a challenge in DNA vaccination o f domestic animals. In 
addition, the variability in the individual response and the issue o f  safety regarding 
DNA vaccination also needs to be addressed before DNA vaccines can become 
commercially available. However, if  future studies on this vaccine were to confirm 
the results produced in this work, then there would be a strong case for 
commercialisation o f this vaccine in the future.
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GENERAL ABBREVIATIONS
GENERAL ABBREVIATIONS
V degrees Celsius
1 1 1 microlitres
\iM micromolar
2-ME P-mercaptoethanol
A adenine or adenosine
aa amino acid
Ab antibody
AcPL accessory protein-like protein
AEBSF 4-(-aminoethyl)benzenesulphonyl fluoride
Ag antigen
AIDS acquired immunodeficiency syndrome
AML acute myeloid leukaemia
AP alkaline phosphatase
APC antigen presenting cell
APS ammonium persulphate
ATP adenosine triphosphate
BCG Mycobacterium bovis bacillus Calmette-Gi
Bas basophil
BGH bovine growth hormone
BM bone marrow
B Neut band neutrophil
bp base pair
BSA bovine serum albumin
C cytosine or cytidine
CB caspase buffer
cDNA complementary deoxyribonucleic acid
CMV cytomegalovirus
CO2 carbon dioxide
CSF colony stimulating factor
CTL cytotoxic T lymphocyte
Da dalton
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DC
DEPC
DMEM
DMSO
DNA
dNTP
dsDNA
DTH
EAE
EBV
EDTA
ELISA
enFeLV
Eos
EU
FBS/FCS
FeLV
FeSV
f.f.u.
FIV
FMDV
FOCMA
g
G
GCG
G-CSF
GM-CSF
HA
Hb
HCT
HEPES
HIV
HRP
HTLV
dendritic cells
diethylpyrocrbonate
Dulbecco's modified Eagle medium
dimethylsulphoxide
deoxyribonucleic acid
deoxynucleoside triphosphate
double stranded DNA
delayed-type hypersensitivity
experimental allergic encephalomyelitis
Epstein-Barr virus
ethylenediaminetetraacetic acid
enzyme linked immunosorbent assay
endogenous FeLV-related sequences
eosinophil
endotoxin units
foetal bovine serum/foetal calf serum
feline leukaemia virus
feline sarcoma virus
focus forming units
feline immunodeficiency virus
foot-and-mouth disease virus
feline oncornavirus-associated cell membrane antigen 
grams
guanine or guanosine
Genetics Computer Group
granulocyte-colony stimulating factor
granulocyte macrophage-colony stimulating factor
haemagglutinin
haemaglobin
haematocrit
V-2-hydroxyethylpiperazine-A^ -2-ethanesulphonic acid 
human immunodeficiency virus 
horse radish peroxidase 
human T-cell leukaemia virus
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ICE interleukin-ip converting enzyme
ICSBP interferon consensus sequence binding protein
ID intradermal
IFNa interferon alpha
IFNy interferon gamma
Ig immunoglobulin
IGIF interferon gamma inducing factor
IL-12 interleukin 12
IL-18 interleukin 18
IL-lRrp IL-1 receptor related protein
IL-12R IL-12 receptor
IL-18BP IL-18 binding protein
ILRAP IL-1 p receptor antagonist protein
IM intramuscular
IP intraperitoneal
IPTG isopropyl p-D-1 -thiogalactopyranoside
IRAK IL-1 receptor-activating kinase
1RES internal ribosome entry site
ISCOM immunostimulating complex
lU international unit
IV intravenous
JAK Janus-family kinase
JEV Japanese encephalitis virus
JNK c-Jun NH2-terminal kinase
kb kilobase
kDa kilodalton
L litre
LAL Limulus amoebocyte lysate
LB Luria Bertani medium
LPS lipopolysaccharide
LTR long terminal repeat
Lymph lymphocyte
M molar
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MCH
MCHC
MCV
ME
mg
MHC
MIDGE
mM
Mono
mRNA
Neut
NF-kB
NK
NP
NTP
OD
PAGE
PBMC
PBS
PCR
PF
PHA
PV
r
RBC
rDNA
RIM
RNA
RNAse
rpm
RSV
RT
mean cell haemoglobin
mean cell haemoglobin concentration
mean cell volume
mercaptoethanol
milligram
major histocompatibility complex
minimalistic immunogenic defined gene expression
vector
millimolar
monocyte
messenger ribonucleic acid 
neutrophil 
nuclear factor -kB 
natural killer cell 
nucleoprotein 
nucleoside triphosphate 
optical density
polyacrylamide gel electrophoresis
peripheral blood mononuclear cell
phosphate buffered saline
polymerase chain reaction
preventable fraction
phytohaemagglutinin
persistent viraemia
recombinant
red blood cell
ribosomal DNA
rapid immunomigration
ribonucleic acid
ribonuclease
revolutions per minute
respiratory syncitial virus, Rous sarcoma virus 
reverse transcriptase
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RT-PCR reverse transcriptase polymerase chain reaction
SC subcutaneous
SCID severe combined immunodeficiency
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel 
electrophoresis
SHIV simian-human immunodeficiency virus
SIV simian immunodeficiency virus
S/P sample to positive
SPF specific pathogen free
STAT signal transducers and activators o f transcription
SV40 Simian virus 40
T thymine or thymidine
TBE tris/borate/EDT A
TBS tris buffered saline
TBS-T tris buffered saline-tween solution
TCR T cell receptor
TEMED N ' -tetramethyl-ethylenediamine
Thl T helper cell, type 1
Th2 T helper cell type 2
TK thymidine kinase
TLR toll-like receptor
TMB 3.3', 5.5'-tetramethyl-benzene
TNFa tumour necrosis factor-alpha
TRAF6 tumour necrosis factor receptor associated kinase
TRAIL tumour necrosis factor-related apoptosis-inducing 
ligand
Tris tris(hydroxymethyl)aminomethane
Tris-HCl tris hydroxychloride
UV ultraviolet
VI virus isolation
VNAb virus neutralising antibody
NNAb non-neutralising antibody
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WBC white blood cell
X-Gal 5-bromO“4-chloro-3-indolyl-p-D-galactoside
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APPENDIX
APPENDIX: Haematology data
Abbreviations used in tables:
A B B R E V IA T IO N F U L L  N A M E N O R M A L  V A L U E
R B C T o ta l red  b lo o d  ce ll c o u n t x I 0 '7 l 5 .0 -1 0 .0  X 1 0 '7 L
H b H a e m a g lo b u lin , g /L 1 0 .0 -1 5 .0 g /L
H C T H a e m a to c r i t,  o r  p a c k e d  ce ll v o lu m e  (P C V ) 3 0 A 5 m l/L
M C V M ean  red  ce ll v o lu m e 3 9 .0 -5 5 .0 f l
M C H M ean  red  ce ll h a e m a g lo b in 1 2 .5 -1 7 .5 p g
M C H C M ean  red  ce ll h a e m a g lo b in  c o n c e n tra t io n 3 0 .0 -3 6 .0 g /d l
W B C T o ta l w h ite  b lo o d  ce ll c o u n t x lO’/L 5 .5 -1 5 .5  X 1 0 7 l
B N E U T Im m a tu re  (b a n d )  n e u tro p h il  c o u n t x lO’/L ra re
N E U T N e u tro p h il  c o u n t x lO’/L 2 .5 -1 2 .5  X 1 0 7 L
L Y M P H L y m p h o c y te  c o u n t  X lO’/L 1 .5 -7 .0  X 1 0 7 L
M O N O M o n o c y te  c o u n t  X lO’/L 0 .0 0 -0 .8 5  X 1 0 7 L
E O S E o s in o p h il c o u n t X lO’/L 0 .0 -1 .5  X 1 0 7 L
B A S B a so p h il c o u n t x lO’/L ra re
Pre-trial Haematologv results
C A T D A T E R B C H b H C T M C V M C H M C H C W B C B
N eu t
N e u t L y m p h M o n o E o s B as
LI 7 /1 /0 2 6 .1 8 9.3 2 4 .6 3 9 .9 15.0 3 7 .7 12.4 0.1 8 .3 0 8 3 .3 4 8 0 .4 9 6 0 0 .1 2 4
L2 7 /1 /02 6 .1 8 9 .8 25 .5 4 1 .2 15.9 3 8 .5 15.9 0 9 .6 9 9 4 .7 7 0 .3 1 8 1.113 0
L3 7 /1 /0 2 7 .3 9 10.1 2 6 .7 36 .2 13.7 3 7 .9 12.8 0 7 .8 0 8 4 .6 0 8 0 .2 5 6 0 .1 2 8 0
L4 7 /1 /0 2 6 .6 9 10.6 2 7 .8 4 1 .5 15.8 38.1 8 .5 4 0 5 .4 6 6 2 .1 3 5 0 .3 4 2 0 .5 9 8 0
L5 7 /1 /0 2 6 .4 4 9 .8 2 5 .9 4 0 .2 15.2 3 7 .8 14.6 0 8 .3 2 2 5 .2 5 6 0 1.022 0
L6 7 /1 /0 2 6 .1 6 9 .9 4 2 6 .3 4 2 .7 16.2 3 7 .8 13.7 0 9 .7 2 7 2 .6 0 3 0.411 0 .8 2 2 0 .1 3 7
L8 7 /1 /0 2 7 .5 4 12.1 31 .3 4 1 .5 16.0 3 8 .6 13.8 0 8 .9 7 4 .1 4 0 .4 1 4 0 .2 7 6 0
L9 7 /1 /0 2 7 .7 9 10.5 2 7 .6 3 5 .4 13.5 38.1 14.7 0 10.143 2 .7 9 3 0 .8 8 2 0 .8 8 2 0
LIO 7 /1 /0 2 6 .2 9 .2 4 2 4 .4 3 9 .3 14.9 3 7 .9 14.3 0 9 .4 3 8 2 .7 1 7 1.001 1.144 0
L I 1 7 /1 /0 2 6 .3 5 lO .I 26 .3 4 1 .4 15.9 3 8 .3 14.0 0 9.1 3 .7 8 0 .1 4 0 .9 8 0
L12 7 /1 /0 2 7 .0 2 9 .7 2 6 .0 3 7 .0 13.8 3 7 .4 18.9 0 13.041 5.481 0 .1 8 9 0 0 .1 8 9
L13 8 /1 /0 2 6 .9 3 9 .4 9 2 5 .9 3 7 .4 13.7 3 6 .7 10.5 0 5 .3 5 5 4.41 0.21 0 .5 2 5 0
L 14 8 /1 /0 2 7 .4 8 10.7 2 8 .8 3 8 .5 14.4 3 7 .3 9 .4 8 0 5 .4 0 4 2 .0 8 6 0 .1 9 1.801 0
L15 8 /1 /0 2 6.51 9 .8 8 26.1 40.1 15.2 3 7 .8 7 .4 7 0 3 .9 5 9 3 .1 3 7 0 .0 7 5 0 .2 9 9 0
L 16 8 /1 /0 2 6.41 10.0 2 6 .3 4 1 .0 14.7 3 8 .2 12.8 0 7 .6 8 3 .4 5 6 0 .3 8 4 1.152 0 .1 2 8
L17 8 /1 /0 2 6 .7 5 10.4 2 6 .2 3 8 .8 15.4 3 9 .7 8.91 0 4 .4 5 5 3.831 0 .2 6 7 0 .3 5 6 0
L 18 8 /1 /0 2 6 .4 4 10.0 2 6 .0 4 0 .3 15.6 3 8 .6 13.7 0 9 .1 7 9 3 .0 1 4 0.411 0 .9 5 9 0 .1 3 7
L 19 8 /1 /0 2 6 .6 4 9 .9 4 2 6 .0 39.1 15.0 3 8 .3 2 8 .5 0 2 3 .0 8 5 3 .7 0 5 1.425 0 .2 8 5 0
L 20 8 /1 /0 2 6.61 10.2 2 6 .8 4 0 .5 15.4 38.1 2 2 .7 0 15 .436 6 .1 2 9 0 .4 5 4 0.681 0
L21 8 /1 /0 2 6 .2 9 9 .7 4 25 .8 4 1 .0 15.5 3 7 .8 6 .8 4 0 2 .8 0 4 3 .2 1 5 0 .2 0 5 0 .6 1 6 0
L22 8 /1 /0 2 5 .7 5 9 .63 2 5 .7 4 4 .8 16.8 3 7 .4 12.9 0 7 .9 9 8 3 .4 8 3 0 .1 2 9 1.29 0
L23 8 /1 /0 2 7 .0 7 9 .3 7 2 4 .9 35 .2 13.2 3 7 .7 14.4 0 9 .0 7 2 3 .7 4 4 0 .4 3 2 1.152 0
L 24 8 /1 /0 2 6 .5 9 .6 6 26.1 40.1 14.9 3 7 .0 19.2 0 14.4 2 .8 8 0 .9 6 0 .5 7 6 0 .3 8 4
L25 9 /1 /0 2 7 .02 9 .4 2 25.1 3 5 .8 13.4 3 7 .5 6 .9 8 0 4 .2 5 8 1.605 0 .2 0 9 0 .8 3 8 0 .0 7
L 26 9 /1 /0 2 7 .83 9 .9 2 2 6 .8 34 .3 12.7 3 7 .0 13.6 0 7 .8 8 8 3 .6 7 2 0 1 .904 0 .1 3 6
L 27 9 /1 /0 2 5 .3 4 8 .93 2 3 .5 4 4 .0 16.7 3 8 .0 2 3 .3 0 17.242 3 .2 6 2 1.165 1.165 0 .2 3 3
L28 9 /1 /0 2 6 .5 4 10.1 2 6 .8 4 1 .0 15.5 3 7 .8 19.9 0 13.352 5 .3 7 3 0 .1 9 9 0 .5 9 7 0 .1 9 9
L 29 9 /1 /0 2 6 .3 2 9 .5 8 2 4 .8 39 .3 15.2 3 8 .5 13.7 0 7 .5 3 5 4 .6 5 8 0 .6 8 5 0 .8 2 2 0
L 30 9 /1 /0 2 6 .6 2 9 .5 4 2 5 .6 3 8 .7 14.4 3 7 .2 11.0 0 8 .25 1.65 0 .33 0 .7 7 0
L31 9 /1 /0 2 7 .0 8 11.2 2 9 .4 4 1 .5 15.9 3 8 .2 19.9 0 13.333 4 .9 7 5 0 .5 9 7 0 .7 9 6 0 .1 9 9
L32 9 /1 /0 2 6 .9 0 10.3 2 6 .5 3 8 .4 14.9 3 8 .7 14.6 0 8 .4 6 8 5 .4 0 2 0 0 .5 8 4 0 .1 4 6
L33 9 /1 /0 2 6 .0 4 9 .6 9 2 5 .0 4 1 .4 16.0 3 8 .8 13.8 0 7 .1 7 6 5 .3 8 2 0 .2 7 6 0 .8 2 8 0 .1 3 8
L 34 9 /1 /0 2 7 .2 2 10.1 27.1 3 7 .5 14.1 3 7 .5 13.9 0 6 .9 5 5 .1 4 3 0 .5 5 6 1.112 0 .1 3 9
L35 9 /1 /0 2 5 .8 6 9 .4 5 2 3 .5 40.1 16.1 4 0 .2 10.3 0 6 .1 8 2.781 0 .5 1 5 0 .8 2 4 0
L 36 9 /1 /0 2 7 .3 9 11.1 2 8 .4 38 .5 15.0 3 9 .0 11.0 0 0.11 6 .8 2 3 .1 9 0 .3 3 0 .5 5
3 3 4
H aem ato lo g v  re su lts  o n  d ay  o f  cha llenge
CAT DATE RBC Hb HCT MCV MCH MCHC WBC B
Neut
Neut Lymph Mono Eos Bas
LI 25/2/02 9.01 12.4 32,7 36.3 13.8 38,1 9.64 0 4,916 4,627 0 0.096 0
L2 25/2/02 7.15 11.5 29.2 40.8 16,1 39,5 14,2 0 7.81 3,834 0,568 1,846 0.142
L3 25/2/02 7.97 11.3 28.7 36,0 14,1 39,2 11.0 0 4.51 6,38 0 0.11 0
L4 25/2/02 6.81 11.1 28,9 42.4 16.3 38.4 7.02 0 3.721 2.948 0,07 0.281 0
L5 25/2/02 6.67 10.4 25,9 38.8 15.6 40.1 13,0 0 4,68 7.28 0 0.91 0.13
L6 25/2/02 7.30 12.3 31,1 42.6 16.9 39,7 11.9 0 6,902 3.808 0.357 0,833 0
L8 25/2/02 8.14 13.1 33.9 41.6 16,0 38.6 8,55 0 4,788 3.164 0.257 0.257 0.086
L9 25/2/02 7.79 11.0 27.3 35,0 14.2 40,5 11,6 0 6,264 3.944 0,58 0,812 0
LIO 25/2/02 7.71 11.1 28,2 39,4 15.5 39,2 6.80 0 3.4 2.992 0 0.408 0
L ll 25/2/02 7.94 11.2 29,2 36,8 14,1 38.3 7.35 0 7.579 6.006 0.429 0.286 0
L12 25/2/02 7.16 11,2 28.8 40.2 15,6 38,9 14,3 0 3.675 3.528 0.147 0 0
L13 26/2/02 8.18 11,0 29.8 36.4 13.5 37.0 7.53 0 4.141 2.937 0.151 0.226 0,075
L14 26/2/02 7.75 11,2 28,9 37.3 14,5 38.9 11,7 0 5.499 4.797 0.117 1.287 0
L15 26/2/02 6.91 10.4 27.4 39.6 15,0 37.9 10.3 0 4,944 4.841 0,206 0.309 0
L16 26/2/02 7.05 11,2 29,7 42.1 15,8 37.6 8.89 0 4.178 3.556 0.089 1.067 0
L17 26/2/02 7.66 11.2 30,0 39,1 14.6 37.3 12.0 0 6,36 5.28 0 0.36 0
L18 26/2/02 7.22 11.1 29,6 41,0 15.4 37.5 12.9 0 8,514 3.354 0.387 0.516 0,129
L19 26/2/02 7.56 11,3 30.0 39,7 15.0 37.6 14,1 0 7,191 6.345 0,282 0.282 0
L20 26/2/02 7.68 12,1 32.2 41.9 15.7 37.5 16,9 0 11,999 4.056 0.338 0.169 0.338
L21 26/2/02 7.22 10.7 28.6 39.6 14.8 37.5 13,3 0 6.783 5.719 0,266 0.532 0
L22 26/2/02 6.34 11,1 28.2 44.5 17.5 39.3 18.8 0 13,16 3.76 0,376 1.128 0.376
L23 26/2/02 7.78 11.2 28.8 37.0 14.4 38.9 18.8 0 12,22 3.572 0.188 2,632 0.188
L24 26/2/02 8.00 12.3 32.2 40.3 15.4 38.1 25.0 0 16 6 1.5 1,25 0.25
L25 27/2/02 8.04 10.9 29.9 37.2 13.6 36.4 11.6 0 6.496 4,176 0.232 0,696 0
L26 27/2/02 8.65 10.7 29.8 34.4 12,3 35.8 11.3 0 6.893 4.181 0 0,226 0
L27 27/2/02 6.84 10.9 30.1 44.0 16.0 36,3 19.7 0 13,79 4.728 0.197 0.788 0.197
L28 27/2/02 6.70 10.6 28.1 41.9 15,9 37.9 15.9 0 11.13 3,657 0 0.954 0.159
L29 27/2/02 7.46 11.1 29,4 39.4 14.8 37,7 11.7 0 6,201 4,563 0 0,936 0
L30 27/2/02 8.43 11.9 33,2 39.4 14.1 35.7 8.32 0 5,907 2,08 0.083 0.25 0
L31 27/2/02 7.97 12.6 33.3 41.8 15.8 37.8 16.1 0 8.694 6,762 0.322 0,322 0
L32 27/2/02 7.13 10.4 27,4 38.3 14.6 38.0 16.4 0 7,216 8.364 0.328 0.492 0
L33 27/2/02 6.38 10.3 26,5 41.5 16.1 38.7 14,6 0 7.008 6.132 0.438 1,022 0
L34 27/2/02 8.66 12,2 31,9 36.8 14,0 38.1 9.37 0 4,029 4.591 0.094 0.562 0.094
L35 27/2/02 7.19 10,9 28,7 40,0 15,2 38,0 21.8 0 14.17 5,45 0.436 1.744 0
L36 27/2/02 7.72 11,2 29.9 38.7 14,5 37,4 17,2 0 11.352 4,988 0.172 0.516 0.172
3 3 5
H a e m a to lo g v  re su lts  a t  6  w e e k s  p o s t-c h a lle n g e
CAT DATE RBC Hb HCT MCV MCH MCHC WBC B
Neut
Neut Lymph Mono Eos Bas
LI 15/4/02 7.78 11.2 28.5 36.6 14.4 39.4 12.6 0 8.316 3.654 0.504 0 0.126
L2 15/4/02 7.10 11.3 30.1 42.4 15.9 37.4 10.4 0 5.616 3,12 0.832 0.832 0
L3 15/4/02 7.96 11.3 30,2 37.9 14,2 37,3 11.8 0 5.546 5,31 0.472 0.354 0.118
L4 15/4/02 6.97 11.1 29.6 42.5 16.0 37,5 4,55 0 2.366 1.729 0.137 0.319 0
L5 15/4/02 6.83 10.4 27.8 40.7 15.2 37.4 15.8 0 7,268 7.9 0.316 0.316 0
L6 15/4/02 8.17 13.5 36.1 44.2 16,6 37.5 9,54 0 5,629 3,244 0.191 0.382 0.095
L8 15/4/02 8.10 13.6 35.2 43.4 16,7 38,6 5.04 0 0.655 4.284 0,101 0 0
L9 15/4/02 8.13 11,5 30.0 37.0 14.2 38,3 8,47 0 4.066 3.388 0,254 0.678 0.085
LIO 15/4/02 7,37 11,4 30.2 40,9 15.5 37.8 5,68 0 2,897 2,442 0,284 0.057 0
L ll 15/4/02 7.14 11.2 29.4 41.2 15,8 38,3 6.09 0 2,984 2.862 0.061 0.183 0
L12 15/4/02 8.05 11.2 29.5 36.6 13,9 37,8 13.5 0 6,345 7.02 0 0.135 0
L13 16/4/02 8.58 11.9 30.9 36.0 13,9 38,5 12,6 0 4.284 7,434 0.378 0.504 0
L14 16/4/02 7.44 11.1 29.5 39.6 15.0 37,8 6.36 0 3,371 2.671 0.064 0.254 0
L15 16/4/02 7.40 11.1 28.9 39.0 15,1 38,6 13.7 0 5,069 7.809 0.548 0.274 0
L16 16/4/02 8.06 13.0 33,6 41.7 16.1 38,7 13,8 0 6,624 5.658 0.552 0.828 0.138
L17 16/4/02 7.62 11,6 30,1 39.5 15.3 38,6 11.2 0 5,152 5.264 0.224 0.56 0
L18 16/4/02 8.15 12.7 32,6 40.0 15,6 38,9 11.4 0 5,358 5.472 0.114 0.456 0
L19 16/4/02 7.37 11.7 29,6 40,2 15,9 39,5 13,9 0 10,008 3.892 0 0 0
L20 16/4/02 7.58 12,5 31,7 41.8 16.5 39.5 16.0 0 10.24 4 0.8 0.96 0
L21 16/4/02 7.83 11.9 31.7 40,5 15,2 37.4 5.94 0 2.376 3.089 0.178 0.238 0
L22 16/4/02 6.03 10,7 27,3 45.3 17.8 39.3 4.37 0 2,229 1.486 0.044 0.612 0
L23 16/4/02 8.06 12.1 31,0 38,5 15.0 39.1 11.3 0 7,232 2.825 0.339 0.904 0
L24 16/4/02 7.79 12,6 33,3 42,8 16.2 37.7 5.84 0 2,57 2,57 0.409 0.292 0
L25 17/4/02 7.84 10.7 28,1 35.9 13,6 38,0 6.72 0 3,226 2.554 0 0.941 0
L26 17/4/02 8.32 10.3 28,0 33.6 12,4 36,9 12,5 0 5,875 5.875 0,5 0.75 0
L27 17/4/02 7.25 11,6 30,0 41.1 16.0 38.6 16.1 0 7,889 7.245 0.161 0.805 0
L28 17/4/02 6.91 11.2 28,8 41.7 16,3 38.9 10.8 0 5,508 4.644 0 0.432 0.216
L29 17/4/02 8.03 12,1 31,4 39,1 15.1 38,6 6.21 0 1.553 3.974 0.186 0.497 0
L30 17/4/02 8.45 12,3 32.7 38,7 14.6 37,7 10,2 0 6.732 2.652 0.102 0.714 0
L31 174/02 8.17 13,1 33,8 41,4 16.0 38.7 13,6 0 6,936 5.712 0.136 0.816 0
L32 17/4/02 7.69 11.2 28.8 37,4 14,6 39,0 13.7 0 6,576 6.85 0 0.274 0
L33 17/4/02 6.59 11.0 28.3 43,0 16.7 38,9 12,7 0 4,826 7.366 0.381 0.127 0
L34 17/4/02 9.32 13,1 33,4 35.9 14.0 39.1 10.2 0 6,018 3.06 0.306 0.816 0
L35 17/4/02 6.88 11,0 27,4 39,8 15.9 40.1 17.6 0 12.848 3.872 0.704 0.176 0
L36 17/4/02 8.28 12,4 32.2 38,9 15,0 38.6 8.85 0 5.045 3.275 0.088 0.443 0
336
H a e m a to lo g v  r e su lts  a t  12 w e e k s  p o s t-c h a lle n g e
CAT DATE RBC Hb HCT MCV MCH MCHC WBC B
Neut
Neut Lymph Mono Eos Bas
LI 27/5/02 8.81 13 33.5 38 14.7 38,7 12.2 0 5.612 6.344 0.122 0.122 0
L2 27/5/02 7.94 13.1 33,5 42,2 16.5 39.1 12.1 0 7,26 3.388 0.121 1.21 0.121
L3 27/5/02 9.05 13.4 33.7 37.2 14,8 39,9 10.7 0 3.852 6.206 0,107 0,428 0,107
L4 27/5/02 7.53 12.3 31.9 42.4 16,4 38,7 7.93 0 4.044 3,013 0,238 0,634 0
L5 27/5/02 7.62 12.1 30.7 40.3 15,9 39,4 14.4 0 5.328 8.352 0.288 0,432 0
L6 27/5/02 9.02 15.5 39.9 44.3 17.2 38.9 11.7 0 6.435 4,446 0 0.702 0,117
L8 27/5/02 7.5 13.1 33,1 44,1 17.5 39.7 12.4 0 4.464 6.944 0.372 0.62 0
L9 27/5/02 9.6 14 35,8 37,3 14,6 39.3 8.54 0 4,441 2.733 0.256 1.11 0
LIO 27/5/02 8.28 13.5 35,2 42,5 16,4 38.5 9.11 0 3,371 4.919 0.364 0.364 0.091
L ll 27/5/02 6.67 11.3 29,8 44,6 17.0 38.1 11,7 0 4.68 6.552 0.234 0.234 0
L12 27/5/02 8.89 12.7 33,1 37,3 14.3 38.4 8,57 0 4,114 4.028 0.343 0.086 0
L13 28/5/02 8.61 11.7 31.2 36.2 13.5 37.4 5,17 0.052 1.706 2.895 0.207 0.259 0,052
L14 28/5/02 7.67 11,3 31 40,4 14.8 36.6 10.1 0 4,848 4.141 0.101 1.01 0
L15 28/5/02 7.98 11.8 31.9 40 14.8 37 12,9 0 3.612 8.643 0.516 0.129 0
L16 28/5/02 7.96 12.7 34.3 43 15.9 37 12,4 0 6,448 4,588 0.372 0,992 0
L17 28/5/02 7.65 11.7 30.8 40.2 15.3 38.1 8.56 0 4,879 3,338 0.086 0.171 0.086
L18 28/5/02 8.39 13.1 34.4 40.9 15.6 38 8,97 0 4,395 3,947 0,09 0,538 0
L19 28/5/02 7.55 11.5 30.7 40.6 15.2 37.5 10.3 0 3.811 6,18 0.103 0.206 0
L20 28/5/02 8.18 13.2 34.2 41.8 16,1 38.4 12.4 0 7.44 4,34 0.248 0.372 0
L21 28/5/02 7.8 12.1 31.8 40.8 15.6 38,1 8.94 0 4,649 3.397 0.447 0,447 0
L22 28/5/02 7.16 12.9 35 48,9 18,1 36,9 8,13 0 2.52 4,878 0.244 0.488 0
L23 28/5/02 10.1 15.1 38,7 38.4 15.0 39 10.2 0 6,12 3,162 0.306 0.51 0.102
L24 28/5/02 7.78 14 36.4 46.8 18 38,6 8.72 0 5,494 2,442 0.262 0.436 0.087
L25 29/5/02 8.61 12 33 38.3 14 36.5 5,53 0 2.654 2,046 0,055 0,719 0.055
L26 29/5/02 8.44 11,1 30,1 35.6 13.2 37 11.8 0 5,664 5,546 0.118 0,472 0
L27 29/5/02 8.01 12.8 33,8 42.1 16 37,9 13.9 0 5.977 7,089 0,417 0,417 0
L28 29/5/02 7.5 12.7 33 44 16.9 38,4 11.5 0 5.635 5,175 0.115 0.46 0.115
L29 29/5/02 7.35 12,9 33,1 45 17.5 38,8 9.1 0 5.551 3.276 0.182 0.091 0
L30 29/5/02 9.81 14,8 38,9 39.6 15.1 38,1 8,76 0 5.081 2,978 0,088 0.613 0
L31 29/5/02 8.73 14.5 36,4 41.7 16,6 39.7 12.2 0 4,636 6.71 0.244 0.61 0
L32 29/5/02 7.42 11,8 29 39.1 15.8 40.6 6,18 0 2.781 3.028 0.062 0,247 0.062
L33 29/5/02. 7.51 12.8 32,5 43.3 17 39.3 13.5 0 2.565 10,8 0.135 0 0
L34 29/5/02 9.52 13.7 35,5 37.4 14.4 38.4 11.3 0 5,085 4,859 0.226 1.017 0.113
L35 29/5/02 8.05 13 32,7 40.6 16,1 39.6 9.03 0 2.619 5,508 0.09 0.813 0
L36 29/5/02 8.75 13.6 35,2 40.2 15,5 38,5 8 0 4.64 2.8 0 0.56 0
3 3 7 oiasgow
l i b e a r t
